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Abstract
Evaluation of patient reporting of adverse drug 
reactions to the UK ‘Yellow Card Scheme’: literature 
review, descriptive and qualitative analyses, and 
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Background: The monitoring of adverse drug reactions (ADRs) through pharmacovigilance 
is vital to patient safety. Spontaneous reporting of ADRs is one method of 
pharmacovigilance, and in the UK this is undertaken through the Yellow Card Scheme 
(YCS). Yellow Card reports are submitted to the Medicines and Healthcare products 
Regulatory Agency (MHRA) by post, telephone or via the internet. The MHRA electronically 
records and reviews information submitted so that important safety issues can be 
detected. While previous studies have shown differences between patient and health-
care professional (HCP) reports for the types of drugs and reactions reported, relatively 
little is known about the pharmacovigilance impact of patient reports. There have also 
been few studies on the views and experiences of patients/consumers on the reporting of 
suspected ADRs.
Objectives: To evaluate the pharmacovigilance impact of patient reporting of ADRs by 
analysing reports of suspected ADRs from the UK YCS and comparing reports from 
patients and HCPs. To elicit the views and experiences of patients and the public about 
patient reporting of ADRs.
Design: (1) Literature review and survey of international experiences of consumer reporting 
of ADRs; (2) descriptive analysis of Yellow Card reports; (3) signal generation analysis of 
Yellow Card reports; (4) qualitative analysis of Yellow Card reports; (5) questionnaire survey 
of patients reporting on Yellow Cards; (6) qualitative analysis of telephone interviews with 
patient reporters to the scheme; (7) qualitative analysis of focus groups and usability 
testing of the patient YCS; and (8) national omnibus telephone survey of public awareness 
of the YCS.
Participants: Patients (n = 5180) and HCPs (n = 20,949) submitting Yellow Card reports 
from October 2005 to September 2007. Respondents to questionnaire survey (n = 1362). 
Participants at focus groups and usability testing sessions (n = 40). National omnibus 
telephone survey (n = 2028).
iv Abstract
Setting: The literature review included studies in English from across the world. All other 
components included populations from the UK; the omnibus survey was restricted to 
Great Britain.
Interventions: None.
Main outcome measures: Characteristics of patient reports: types of drug and suspected 
ADR reported; seriousness of reports; and content of reports. The relative contributions of 
patient reports and of HCP reports to signal generation. Views and experiences of patient 
reporters. Views of members of the public about the YCS, including user-friendliness and 
usability of different ways of patient reporting. Public awareness of the YCS. Suggestions 
for improving patient reporting to the YCS.
Results: Compared with HCPs, patient reports to the YCS contained a higher median 
number of suspected ADRs per report, and described reactions in more detail. The 
proportions of reports categorised as ‘serious’ were similar; the patterns of drugs and 
reactions reported differed. Patient reports were richer in their descriptions of reactions 
than those from HCPs, and more often noted the effects of ADRs on patients’ lives. 
Combining patient and HCP reports generated more potential signals than HCP reports 
alone; some potential signals in the ‘HCP-only’ data set were lost when combined with 
patient reports, but fewer than those gained; the addition of patient reports to HCP reports 
identified 47 new ‘serious’ reactions not previously included in ‘Summaries of Product 
Characteristics’. Most patient reporters found it fairly easy to make reports, although 
improvements to the scheme were suggested, including greater publicity and the redesign 
of web- and paper-based reporting systems. Of the public, 8.5% were aware of the YCS 
in 2009.
Conclusions: Patient reporting of suspected ADRs has the potential to add value to 
pharmacovigilance by: reporting different types of drugs and reactions than those reported 
by HCPs; generating new potential signals; and describing suspected ADRs in enough 
detail to provide useful information on likely causality and impact on patients’ lives. These 
findings suggest that further promotion of patient reporting to the YCS is justified, along 
with improvements to existing reporting systems.
In order of priority, future work should include further investigation of: (1) the 
pharmacovigilance impact of patient reporting in a longer-term study; (2) the optimum 
approach to signal generation analysis of patient and HCP reports; (3) the burden of ADRs 
in terms of impact on patients’ lives; (4) the knowledge and attitudes of HCPs towards 
patient reporting of ADRs; (5) the value of using patient reports of ADRs to help other 
patients and HCPs who are seeking information on patient experiences of ADRs; and 
(6) the impact of increasing publicity and/or enhancements to reporting systems on the 
numbers and types of Yellow Card reports from patients.
Funding: The National Institute for Health Research Health Technology 
Assessment programme.
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Glossary
Adverse drug reaction (ADR) An ADR is a reaction to a drug, or a combination of drugs, which 
is harmful and unintended and that occurs at a dose normally used for prophylaxis, diagnosis or 
treatment. Sometimes the use of the term is restricted to reactions that have been shown to have 
a strong causal association with particular drugs; sometimes it is used for reactions that reporters 
consider might have been associated with a specific drug, for example reactions reported to 
pharmacovigilance schemes.
Black triangle drug Medicinal products that require a period of intensive monitoring by the 
Medicines and Healthcare products Regulatory Authority (MHRA) to further assess their risk–
benefit profile. 
Dictionary serious Reaction preferred terms (PTs) within the Medical Dictionary for 
Regulatory Affairs (MedDRA) dictionary are assessed by medically qualified personnel within 
the MHRA, and individually assigned a ‘dictionary serious’ status of either ‘Yes’ or ‘No.’ This 
classification is based on the MHRA’s own ‘in-house’ medical opinion.
Drug–adverse drug reaction (ADR) pair The occurrence of a specific drug associated with a 
specific ADR in Yellow Card reports.
Patient information leaflet (PIL) European and UK law requires all medicines to be 
accompanied by a PIL, setting out comprehensive information that is accessible to and 
understandable by those who receive it, so that patients can use their medicine safely 
and appropriately.
Patient reporter The patient who experienced and reported the suspected ADR or a patient 
representative who made the report on their behalf.
Pharmacovigilance Pharmacovigilance is the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects of drugs.
Signal Reported information on a possible causal relationship between an adverse event and a 
drug; the relationship being known or incompletely documented previously.
Signal of disproportionate reporting (SDR) A ‘statistical signal’, when the reporting rate for an 
ADR in association with a particular medicine is disproportionate to that of other products in 
the database.
Summary of product characteristics (SPC) A reference document in relation to a medicinal 
product, intended for use by health-care professionals (HCPs), which provides information on 
how to use/prescribe the medicinal product safely and effectively.
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List of abbreviations
ADR adverse drug reaction
ADROIT Adverse Drug Reactions Online Information Tracking
AME Adverse Medicine Events (Line)
APRIL Adverse Psychiatric Reactions Information Link
ATC Anatomical Therapeutic Chemical classification system for drugs
BMRB British Market Research Bureau
BNF British National Formulary
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CSM Committee on Safety of Medicines
dm+d Dictionary of Medicines and Devices
DSRU Drug Safety Research Unit
GP general practitioner
HCP health-care professional
HLGT high-level group term (MedDRA)
HLT high-level term (MedDRA)
IQR interquartile range
LLT lowest-level term (MedDRA)
MedDRA Medical Dictionary for Regulatory Affairs
MeSH medical subject heading
MHRA Medicines and Healthcare products Regulatory Authority
MSSO Maintenance and Support Services Organization
OR odds ratio
OTC over-the-counter
PIL patient information leaflet
PRR proportional reporting ratio
PT preferred term (MedDRA)
SD standard deviation
SDR signal of disproportionate reporting
SOC system organ class (MedDRA)
SPC summary of product characteristics
SSRI selective serotonin reuptake inhibitor
WHO World Health Organization
YCS Yellow Card Scheme
All abbreviations that have been used in this report are listed here unless the abbreviation is well 
known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only 
in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in 
the notes at the end of the table.
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Executive summary
Background
An adverse drug reaction (ADR) is a reaction to a drug and/or a combination of drugs, which 
is harmful and unintended, and which occurs at a dose that is normally used for prophylaxis, 
diagnosis or treatment.
The monitoring of ADRs through pharmacovigilance is vital to patient safety, as rare, serious 
and/or unexpected reactions often appear only when drugs are used in everyday practice by 
many people. Spontaneous reporting of ADRs is one method of pharmacovigilance, and in 
the UK this is undertaken through the Yellow Card Scheme (YCS). Since 1964, health-care 
professionals (HCPs) have been able to report ADRs and from October 2005 the Scheme was 
opened up to patients or their representatives.
Yellow Card reports are submitted to the Medicines and Healthcare products Regulatory Agency 
(MHRA) by post, telephone or via the internet. The MHRA electronically records and reviews 
information submitted, so that important safety issues can be detected.
Whereas previous studies have shown differences between patient and HCP reports for the types 
of drugs and reactions reported, relatively little is known about the pharmacovigilance impact 
of patient reports. There have also been few studies on the views and experiences of patients/
consumers on the reporting of suspected ADRs.
Aims
To evaluate patient reporting of suspected ADRs to the YCS in the UK by assessing the 
pharmacovigilance contribution of patient reports compared with those of health professionals; 
exploring the views of patient reporters and members of the public, and comparing study 
findings with those from existing schemes worldwide.
Objectives
To evaluate the pharmacovigilance impact of patient reporting to the YCS:
 ■ Main research questions:
 – What are the characteristics of patient reports to the YCS; what types of drug and 
suspected adverse reactions do they report and how serious are these?
 – What is the relative contribution to signal generation of patient reports compared with 
those made by health professionals?
 – What do patients’ descriptions of suspected adverse reactions add in terms of richness of 
data compared with those from health professionals?
To elicit the views and experiences of patients and members of the public regarding patient 
reporting of ADRs:
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 ■ Main research questions:
 – What are the views and experiences of patients reporting to the YCS?
 – What are the views of members of the public on the YCS including user-friendliness and 
usability of different mechanisms of patient reporting?
 – What is the level of awareness of the YCS amongst the general public in Great Britain 
and what are their views on the convenience of three different ways of reporting (online, 
telephone, completing and mailing a paper form)?
 – How might the reporting system be improved?
To offer recommendations for improvement to patient reporting based on our research findings 
and literature from other countries.
Methods
Literature review and international survey of patient reporting systems:
 ■ A range of methods was used to identify countries with patient reporting as part of their 
national pharmacovigilance activities, including a questionnaire to pharmacovigilance staff 
in 47 countries, personal communication with key contacts and literature review.
 ■ A literature review was performed to identify comparative studies of patient and HCP ADR 
reports. A search was conducted of MEDLINE (Ovid), EMBASE (Ovid) and Pharm-line 
databases using both medical subject heading (MeSH) and text search terms. The search 
dates were from 1996 to May 2009.
Evaluating the pharmacovigilance impact of patient reporting through analysis of reports of 
suspected ADRs from the UK YCS:
 ■ Anonymised data were provided by the MHRA for all patient and HCP reports received 
by the YCS between 1 October 2005 and 30 September 2007. To compare the two reporter 
groups, suspected adverse reaction terms were grouped within the hierarchical structure of 
the industry standard ‘Medical Dictionary for Regulatory Affairs’ (MedDRA, version 12) 
and suspect drug names were mapped to the most appropriate code within the Anatomical 
Therapeutic Chemical (ATC) drug classification system (2007 version).
 ■ Patient and HCP reports were compared for a wide range of characteristics including age 
and gender of the patient on whom the report was being made; numbers and types of 
drugs and ADRs reported; time taken from ADR to making the report, and the recorded 
seriousness of the reports (based on the classification of reaction terms by the MHRA and 
whether reactions were considered life-threatening by the reporter, or caused hospitalisation 
or death).
 ■ Signal generation analysis was undertaken on the whole database of patient and HCP 
reports. We identified signals of disproportionate reporting (SDRs) which are ‘statistical 
signals’ where the reporting rate for a suspected ADR in association with a particular 
medicine is disproportionate to that of other products in the database. We then investigated 
the effects (on SDRs) of including and excluding patient reports from the HCP database. We 
also did clinical causality assessments on selected drug–ADR pairs from patients and HCPs.
 ■ We undertook a qualitative analysis of reports from patients and HCPs and purposively 
selected a wide range of different types of report. Focusing on the free-text describing the 
ADRs we undertook a content analysis to describe the characteristics of 230 patient and 
179 HCP reports followed by a more detailed inductive qualitative analysis of the free text 
(which included 40 additional patient reports of drugs purchased over-the-counter and 
complementary therapies).
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Considering the views and experiences of patients and members of the public regarding 
patient reporting:
 ■ A questionnaire was developed for distribution by the MHRA to all patients reporting 
through the YCS between March 2008 and January 2009. The questionnaire elicited 
information on how patients found out about the YCS, their experiences of, and views on, 
reporting and their demographic characteristics.
 ■ Semistructured telephone interviews were conducted with a purposeful sample of 
patient reporters selected from those who had completed questionnaires and given 
consent to further contact by the research team. The interviews explored motivations for 
reporting, expectations of, and satisfaction with, the reporting system and suggestions 
for improvements.
 ■ Members of the public in Nottingham, UK, were invited to seven focus groups at which 
views on patient reporting of ADRs were explored. Participants were then observed 
completing Yellow Card reports for simulated ADR scenarios and detailed information was 
recorded on their experiences and suggestions for improvements.
 ■ Eight questions were added to a national omnibus survey, which was carried out by the 
British Market Research Bureau by telephone over two weekends in January 2009, using a 
database of residential telephone numbers in Great Britain. Questions were developed to 
assess public knowledge of the YCS, previous experiences of side effects from medications, 
previous reporting of ADRs and preferred methods for reporting ADRs.
Results
Literature review and international survey of patient reporting systems:
 ■ Forty-six countries were identified as having consumer reporting schemes. A number of 
studies of patient reporting of suspected ADRs were identified, including a recent systematic 
review. Since the time of that review, one large-scale comparative study from the Netherlands 
showed similarities in the classes of drugs most commonly reported by patients and HCPs, 
and similar proportions of reactions judged to be serious. Another large-scale comparative 
study from Denmark showed that compared with other sources, patients reported different 
types of medicines for categories of ADR. No large-scale studies were found investigating the 
impact of patient reporting on generating potential signals for suspected ADRs.
Evaluating the pharmacovigilance impact of patient reporting through analysis of reports of 
suspected ADRs from the UK YCS:
 ■ For the 2-year study period, 26,129 Yellow Card reports were received from the MHRA 
[5180 (19.8%) patient reports and 20,949 (80.2%) HCP reports]. Patient reports contained a 
significantly higher number of suspected ADRs per report than HCPs [median (interquartile 
range, IQR) of 3 (2 to 5) vs 2 (1 to 3), respectively; p < 0.001). A higher proportion of patient 
reports contained more than one suspect drug than HCP reports (16.1% vs 9%, respectively; 
p < 0.001). The median (IQR) word count (excluding reports with zero word counts) used 
to describe the suspected reaction was significantly higher for patient reports than for HCP 
reports [45.0 (22.0 to 74.0) vs 15.0 (9.0 to 26.0), respectively; p < 0.001).
 ■ Patients showed different patterns of reporting of drugs and ADRs compared with HCPs. 
Nevertheless, similar proportions of reports contained at least one reaction term that was 
classified as ‘serious’ by the MHRA (58.3% for patients vs 58.8% for HCPs; p = 0.58). The 
following were recorded more commonly in HCP reports than patient reports: ‘caused 
hospitalisation’ (18.8% vs 12.9%, respectively), ‘life-threatening’ (11.1% vs 6.2%, respectively) 
xvi Executive summary
and ‘caused death’ (2.6% vs 0.7%, respectively) (p < 0.001 for each comparison). Of the patient 
Yellow Card reports, 44.8% stated that the suspected ADR was bad enough to affect everyday 
activities. Patient reporters took a significantly longer time to report suspected ADRs than 
HCPs [median (IQR) of 104 (27 to 463) days vs 28 (13 to 75) days, respectively; p < 0.001], 
although there were missing data on ‘time taken to report’ for over 60% of patient reports.
 ■ For the signal generation analysis there were 16,566 drug–reaction pairs from patient reports 
and 28,775 from HCPs, with only 4340 (10.6%) pairs common to both groups. The HCP data 
set generated a significantly higher proportion of SDRs from the different drug–reaction 
pairs reported [1939 SDRs (6.7%) vs 649 (3.9%), respectively; difference in proportions 
2.8%, 95% CI 2.4% to 3.2%]. Also, a higher proportion of HCP SDRs were for reactions 
classified as ‘serious’ by the MHRA compared with patient SDRs (48% vs 28.5%, respectively; 
difference in proportions 19.5%, 95% CI 15.4% to 23.6%) or for drugs undergoing intensive 
surveillance (‘black triangle drugs’) (30.7% vs 10.9%, respectively; difference in proportions 
19.8%, 95% CI 16.6% to 23.0%). A similar proportion of SDRs in both groups (15%) were 
assessed as not being listed on the product’s summary of product characteristics (SPC) and, 
therefore, potentially providing new information.
 ■ After combining the patient and HCP data sets an additional 508 SDRs were generated that 
were not produced by either data set alone, although 186 SDRs generated by the HCP data 
set alone were no longer present. The combined data set identified 47 SDRs for reactions 
classified as serious by MHRA, which had not previously recorded on SPCs, while eight 
generated by the HCP data set alone were no longer present. Among the sample of individual 
reports assessed for causality, most were assessed as having a ‘possible’ causal association, 
regardless of reporter group.
 ■ The content analysis of text describing suspected reactions, showed that patient reports were 
more likely than those from HCPs to include information about symptoms (93% vs 78%) and 
to stress the extreme nature of these (47% vs 17% of reports). They were also more likely to 
highlight the impact of the reaction on the patient (47% vs 12%), particularly the emotional 
impact (34% vs 7%) or social impact (27% vs 7%). Patients commonly reported on temporal 
associations, with 61% stating that the suspected ADR had followed the administration 
of the drug; 26% that it had improved on stopping the drug; 22% that it had occurred on 
withdrawal of the drug, and 7% that it had recurred on restarting the drug.
 ■ The in-depth qualitative analysis demonstrated the richness of accounts from patients and 
provided numerous detailed and elaborate descriptions of suspected reactions. Patient Yellow 
Card reports also contained information on reasons for drugs being prescribed, reasons 
for reporting, how patients identified the ADR, and responses from HCPs. Particularly 
striking were reports, often in relation to central nervous system drugs, that were extremely 
distressing, and sometimes frightening, describing confusion, agitation, panic symptoms, 
mood swings, suicidal thoughts and electric shock sensations. Patient reports vividly 
described the effects of suspected ADRs on patients’ lives, illustrating impact in terms of 
serious disruption to social and occupational functioning and marked emotional effects. 
By contrast, where HCPs did comment on the effects of suspected ADRs on patients’ lives, 
the accounts were usually brief and rarely illustrated the profound impact recorded in 
patient reports.
Considering the views and experiences of patients and members of the public regarding 
patient reporting:
 ■ There were 1362 evaluable responses to the questionnaire sent to 2008 patient reporters 
(68%). The most frequent reporting method was postal (59.8%), followed by online (32.8%) 
and telephone (6.3%). Online reporters were younger (median age in years of reporters: 
online 50 years, postal 61 years, telephone 63 years; p < 0.001) with a higher education 
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level than those using other reporting methods (e.g. proportion of reporters with a degree: 
online 48%, postal 28%, telephone 32%; p < 0.001). Almost one-half learned about the YCS 
from a pharmacy (n = 667; 49.0%). In response to a closed question, most respondents 
1274 (93%) indicated that the report was ‘fairly’ or ‘very’ easy to complete, although in 
free-text comments 216 (15.9%) noted difficulties they had experienced. Suggestions for 
enhancements were made by 307 (22.5%). One-third (n = 448; 32.9%) expected feedback 
from the MHRA on their report and 828 (60.8%) would have liked feedback. Almost 
all respondents (n = 1302; 95.6%) would report again. Respondents indicated a need for 
increasing health professionals’ awareness of patient reporting. Some stressed the importance 
of having a reporting mechanism that is independent of health professionals, so that patients’ 
perspectives can be recognised.
 ■ Twenty-seven telephone interviews were conducted with patient reporters. Most became 
aware of the YCS by chance and many suggested that greater publicity was needed for patient 
reporting. Motivations for reporting included altruism and a desire to find out if others had 
experienced similar problems. Several suggestions were made for enhancements to reporting 
systems, including more space for writing free-text comments on the paper form.
 ■ Forty participants took part in seven focus groups. After hearing an introductory 
presentation, a number of suggestions were made about improving publicity for the YCS. 
Usability testing with the 40 participants indicated that telephone reporting worked well, but 
identified specific suggestions for enhancing online and paper reports.
 ■ From the national omnibus survey of 2028 adults, only 172 (8.5%) had heard about the YCS. 
The preferred method of reporting varied with the characteristics of respondents.
Conclusions
Patient reporting of suspected ADRs has the potential to add value to pharmacovigilance by:
 ■ reporting different types of drugs and reactions to reports from HCPs
 ■ generating new potential signals
 ■ describing suspected side effects in enough detail to provide useful information on likely 
causality and the impact of ADRs on patients’ lives.
These finding suggest that further promotion of patient reporting to the YCS is justified, along 
with improvements to reporting systems.
Implications for patient reporting
 ■ In the authors’ opinion, the following approaches may help to improve the timeliness and 
value of patient reporting for pharmacovigilance, increase the number of reports from 
patients, and improve patient experiences of reporting:
 – increase publicity for patient reporting
 – provide further guidance to reporters on what information to report
 – increase patient awareness of medicines for which the MHRA is undertaking 
intensive monitoring
 – change the design of paper reports and the online reporting system
 – provide general feedback to patient reporters on what the MHRA do with reports
 – explore possibilities for providing specific feedback to patients in relation to the 
medicines and suspected ADRs that they report.
xviii Executive summary
 ■ To aid future comparisons of reports submitted by patients and HCPs it important that 
similar information is collected from both groups, particularly with respect to categories 
of seriousness.
 ■ According to patient accounts, some HCPs seem to be unaware that patients can submit their 
own ADR reports, and some appear to be dismissive of patients who report suspected ADRs. 
Education at an undergraduate and postgraduate level might help address these issues.
Recommendations for research
In order of priority, these are investigation of:
1. the pharmacovigilance impact of patient reporting in a long-term study, including the 
identification and tracking of regulatory action taken as a result of the contribution of 
patient reports
2. the optimum approach to signal generation analysis of patient and HCP reports
3. the burden of ADRs in terms of impact on patients’ lives, and evaluating the extent to which 
patients’ views and experiences of the seriousness of ADRs concur with those of regulatory 
bodies, such as the MHRA
4. the knowledge and attitudes of HCPs towards patient reporting of ADRs, and evaluating 
approaches aimed at addressing any learning needs identified
5. the value of using patient reports of ADRs to help other patients and HCPs who are seeking 
information on patient experiences of ADRs
6. the impact of increasing publicity and/or enhancements to reporting systems on the numbers 
and types of Yellow Card reports from patients.
Funding
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Chapter 1  
Introduction
An adverse drug reaction (ADR) is a reaction to a drug and/or a combination of drugs that is harmful and unintended, and that occurs at a dose that is normally used for prophylaxis, 
diagnosis or treatment.1 It is widely acknowledged that ADRs ‘significantly diminish quality of 
life, increase hospitalisations, prolong hospital stay and increase mortality’.2 It has been estimated 
that 6.5% of acute hospital admissions are due to ADRs with an annual cost to the UK NHS (in 
2004) of £466M,3 and that one in seven hospital inpatients experience an ADR.4
Pharmacovigilance is the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects of drugs. The monitoring of ADRs through 
pharmacovigilance is vital to patient safety, as rare, serious and/or unexpected reactions often 
appear only when drugs are used in everyday practice by many people. Spontaneous reporting of 
ADRs is one method of pharmacovigilance. Other methods include postmarketing surveillance 
and interrogation of large electronic data sets.
In the UK, spontaneous reporting is undertaken through the YCS, which was established in 
1964 as a consequence of the thalidomide disaster.1 Since the 1960s, doctors were able to use 
this system to report suspected ADRs to the Medicines and Healthcare products Regulatory 
Agency (MHRA). From 1997, reports were also accepted from pharmacists. In 2002, the Yellow 
Card Scheme (YCS) was extended so that nurses, midwives and health visitors could also report 
suspected ADRs. An example of a health-care professional (HCP) report form is shown in 
Appendix 1.
The history of patient reporting to the Yellow Card Scheme
Patient reporting to the UK YCS was first considered by a working party of the Committee on 
Safety of Medicines (CSM) in 1983 following the withdrawal of benoxaprofen,5 but they decided 
against this and advised patients with suspected ADRs to consult their doctors in the hope that 
they would report appropriately.
The potential benefits of patient reporting were summarised at the First International Conference 
on Consumer Reports on Medicines in 2000 and included the promotion of consumer rights 
and equity, acknowledging that consumers have unique perspectives and experiences, and that 
health-care organisations would benefit from consumer involvement.6 It is widely recognised that 
there is substantial under-reporting of ADRs by HCPs; therefore, adding patients to the range 
of potential reporters may increase spontaneous reporting and earlier detection of important 
ADRs.2,7–9 Additional support for direct patient reporting came from the Metter’s report in 2004;1 
although, concerns were documented from some stakeholders.
In 2003, UK patients were able to report ADRs using the telephone helpline NHS Direct. There 
was a relatively low number of reports and there were criticisms that patients were not able to 
report to the MHRA directly.1
In 2004, the CSM approved the formation and membership of the CSM working group on patient 
reporting of ADRs (ADRWG). The ADRWG had representatives from patients and patient 
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organisations, academia, pharmacy, general practice and clinical pharmacology, and was chaired 
by Dr Patricia Wilkie, a lay member of the CSM. The first meeting was held in September 2004. 
The ADRWG held focus groups and recommended that a patient reporting system had to be:
 ■ accessible to patients and the public
 ■ easy to use
 ■ available in different reporting systems
 ■ able to provide information needed to effectively monitor medicines.
The first patient Yellow Card for use by the public was designed to include the important 
questions in the professionals’ Yellow Card and retained a similar format to the professional card. 
Consultations were held with patients and patient organisations and the first pilot of the patient 
Yellow Card was made available on the MHRA website in January 2005. A paper version was also 
distributed to 4000 general practices, representing some 30,000 general practitioners (GPs).
Between January and September 2005, over 650 patient reports were received. The reports 
contained detailed descriptions of suspected ADRs and were considered useful by the MHRA.
The ADRWG recommended that:
 ■ A range of methods, including paper, electronic and telephone, should be available to report 
suspected ADRs.
 ■ Yellow Cards be available in a variety of outlets, including pharmacies, general practices and 
voluntary organisations.
 ■ The report could be made by any member of the public who should provide name and 
contact details.
 ■ The MHRA would follow-up reports wherever necessary, but would not be able to give 
medical advice.
 ■ Reports could be made on any medicine on the market, including prescribed medicines, 
over-the-counter (OTC) products and complementary medicines including herbals.
Other recommendations included:
 ■ carrying out further evaluation into aspects of patient reporting
 ■ making Yellow Card information more widely available
 ■ making HCPs more aware of patient reporting
 ■ examining the possibility of one Yellow Card for all
 ■ informing patients when they are prescribed a drug that is undergoing intense monitoring by 
the MHRA.
Following the pilot, the forms were further adapted and a nationwide-direct patient reporting 
scheme was officially launched along with a media campaign in September 2005. An evaluation 
of 407 reports received in the first 6 months of the scheme suggested that patient reports were 
of a similar quality to HCP reports.10 Following the redesign of the paper-based reporting form 
and web interface for reporting, the scheme was launched again in February 200811 with another 
media campaign. On this occasion, community pharmacies received promotional literature, 
including display posters and credit card-sized information for informing patients about 
the scheme.
Examples of the patient report forms used from September 2005 to February 2008 and from 
February 2008 onwards are shown in Appendices 2 and 3, respectively. The reports can be 
submitted to the MHRA by post, telephone or via the internet.12,13 Patients are encouraged to 
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report suspected side effects of any prescribed, or non-prescribed, medicine or herbal remedy,14 
especially if:
 ■ it is not mentioned in the medicine patient information leaflet (PIL)
 ■ it causes problems bad enough to interfere with everyday activities
 ■ it happens when taking more than one medicine and could be caused by interactions.
The MHRA electronically records and reviews information submitted so that major safety issues 
can be detected using signal generation and additional methods.14 The UK scheme was one of the 
earliest to introduce patient ADR reporting and, as such, has generated considerable volumes of 
data to enable comparison between patient and ADR reports; by 2009 the MHRA had received 
around 9000 patient reports.11
In April 2006 there was a call for research to evaluate patient reporting to the YCS and our 
team was successful in bidding for funding. The aims, objectives and research questions of our 
evaluation are outlined below.
Aims
To evaluate patient reporting of suspected ADRs to the YCS in the UK by assessing the 
pharmacovigilance contribution of patient reports compared with those of health professionals; 
exploring the views of patient reporters and members of the public, and comparing study 
findings with those from existing schemes worldwide.
Objectives and research questions
The objectives and research questions relate to:
 ■ a review of the literature
 ■ studies based on the analysis of Yellow Card data for patients and health professionals
 ■ studies considering the views and experiences of patients and members of the public 
regarding patient reporting.
For ease of reference, we have numbered the separate studies as follows.
 ■ Literature review:
 – Study 1 Review of the world literature describing and comparing patient and HCP 
reporting of ADRs.
 ■ Evaluating the pharmacovigilance impact of patient reporting of suspected ADRs – analysis 
of reports of suspected ADRs from the UK YCS:
 – Study 2 Description of the characteristics of reports from patients and HCPs.
 – Study 3 Assessment of the pharmacovigilance impact of reports from patients and HCPs 
using signal generation analysis and clinical assessment of reports.
 – Study 4 Qualitative analysis of reports from patients and HCPs.
 ■ Considering the views and experiences of patients and members of the public regarding 
patient reporting:
 – Study 5 Questionnaire survey to capture the views and experiences of patients who have 
made reports.
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 – Study 6 Telephone interviews to explore further the views and experiences of patients 
who have made reports.
 – Study 7 Focus groups and usability testing with members of the public regarding 
patient reporting.
 – Study 8 Omnibus survey to assess public awareness of the YCS.
The objectives and research questions relating to these studies are listed in Table 1. These are 
derived from the original application.
TABLE 1 Original objectives and research questions
Study Objectives Research questions
Study 1 Review of the 
world literature describing 
and comparing patient 
and HCP reporting of 
ADRs
To review the published literature on patient and HCP-
reporting systems in different settings
How do the study findings compare with the literature?
Are there any recommendations that could be made to 
amend the UK system, derived from the literature?
Study 2 Description of the 
characteristics of reports 
from patients and HCPs
To identify the characteristics of patient reporting to the 
YCS
What are the characteristics of patients who report ADRs 
through the YCS?
To identify the types of drug, types of suspected adverse 
reactions and seriousness of suspected reactions 
reported by patients
What classes of drugs are most commonly reported by 
patients?
What categories of suspected adverse reactions are most 
commonly reported by patients?
What are the outcomes of suspected side effects and do 
these differ across reporter groups?
To determine whether there are differences in the time 
lag between ADR occurrence and reporting for patients 
and HCPs
Are there important differences in the time taken to 
report an ADR between patients and HCPs?
To investigate the factors associated with patient reports 
compared with those made by HCPs
Are patients more or less likely than HCPs to report 
serious reactions?
Are patients more likely than HCPs to report suspected 
adverse reactions to particular classes of drug?
Are patients more likely than HCPs to report suspected 
adverse reactions to newer drugs?
Are patients more likely than HCPs to report particular 
categories of suspected adverse reactions?
For children, are the events reported directly by parents 
different from those reported by HCPs, acknowledging 
possible small numbers?
Study 3 Assessment of 
the pharmacovigilance 
impact of reports from 
patients and HCPs using 
signal generation analysis 
and clinical assessment 
of reports
To explore the relative contribution of patient reporting to 
signal generation
Do patient reports add ‘weight’ to known signals or 
signals generated by reporting by HCPs?
Do patient reports generate ‘new’ signals?
If they do, are these signals for events which are 
expected to be of more concern to patients than HCPs?
Do patient reports generate new signals sooner?
To estimate the extent to which duplicate reporting 
occurs
What is the proportion of patient reports that also seem 
to have been reported by a HCP?
Study 4 Qualitative 
analysis of reports from 
patients and HCPs
To explore the richness of patients’ descriptions of their 
suspected adverse reactions compared with HCPs
How do patients describe suspected side effects?
How does the richness of patient reports compare with 
those of HCPs?
Are there similarities or differences between patient 
and HCP reports and between the three methods of 
reporting?
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Study Objectives Research questions
Study 5 Questionnaire 
survey to capture the 
views and experiences of 
patients who have made 
reports
To describe the views and experiences of patients 
reporting to the YCS
How did patients find out about the YCS?
How many times have they used the scheme?
What method of reporting did they use for their latest 
Yellow Card report (electronic, paper or telephone)?
Who did the report (the patient or the patient’s 
representative)?
How easy did they find it to make a report?
Were there any difficulties encountered in making 
reports, including whether patients needed additional 
help in completing the electronic- or paper-based forms?
Are there any suggestions for improvements in the 
reporting system?
Did reporters inform a HCP about the suspected 
reaction?
Were patients discouraged by HCPs from reporting?
What are the characteristics of respondents (age, gender, 
ethnicity and educational attainment) and do these 
influence reporting methods?
Study 6 Telephone 
interviews to explore 
further the views and 
experiences of patients 
who have made reports
To explore in detail the experiences and views of patients 
who have made reports to the YCS
Do reporters have difficulties in making Yellow Card 
reports, and suggestions for improving the reporting 
system?
What are patients’ motivations for making a report, and 
anticipated contribution of their report?
What are patients’ expectations about what would 
happen to their report?
Are patients satisfied or dissatisfied with making a 
report?
Are patients willing to report in future?
Study 7 Focus groups 
and usability testing with 
members of the public 
regarding patient reporting
To ascertain the views of members of the public on the 
YCS
What do members of the public think about the YCS?
To ascertain the views of members of the public on the 
user-friendliness, effectiveness and usability of different 
mechanisms of patient reporting
When given the opportunity to try out different methods 
of reporting in a simulated setting, what do members of 
the public think about these methods?
To obtain suggestions for potential ways in which the 
reporting system could be improved
What suggestions do members of the public have for 
ways in which patient reporting to the YCS could be 
improved?
Study 8 Omnibus 
survey to assess public 
awareness of the YCS
To estimate the percentage of the general public in Great 
Britain who have heard of the YCS for patient reporting 
of ADRs
What percentage of respondents have heard about the 
YCS?
To determine whether those respondents who believe 
they had experienced an ADR and who were aware of the 
YCS had made a report using the YCS
Have respondents used any types of medicines regularly 
or have taken any types of medicines in the last year? Do 
respondents believe that they have experienced a side 
effect from a medicine (or complementary therapies) in 
the past and, if so, have they told anyone about it?
For those respondents who have experienced side effects 
from a medicine in the past and who had heard about the 
YCS for patient reporting:
 Whether they made a report?
 If they did not make a report, why not?
To assess the views of members of the public on the 
convenience of the three different ways of reporting 
(online, telephone, obtaining a paper form from a GP/
pharmacy to fill in and post)
Which of the following ways of reporting suspected side 
effects might be most convenient to respondents:
 ■ telephone
 ■ online
 ■ obtaining a paper form from a pharmacy (chemist) or 
a general practice to fill in and post
TABLE 1 Original objectives and research questions (continued)
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Structure of the report
Each of the above studies is described in a separate chapter containing objectives, methods, 
results and a summary. In addition, a chapter is devoted to an explanation of data used for 
the studies evaluating the pharmacovigilance impact of patient reporting (see Chapter 3). The 
final chapter contains the discussion for all of the studies, including strengths and limitations, 
recommendations for patient reporting and recommendations for research.
Research team
The research was undertaken by a multicentre, multidisciplinary team coordinated by the 
University of Nottingham, Nottingham, UK.
In terms of main areas of responsibility:
 ■ The Drug Safety Research Unit from Southampton carried out the initial processing of 
Yellow Card Report data from MHRA and also undertook the signal generation analyses.
 ■ The University of Aberdeen undertook all of the other quantitative analyses in the study and 
led the literature review.
 ■ The Liverpool John Moores University undertook aspects of the qualitative analyses.
 ■ The University of Nottingham led on survey design and execution, interviews, focus groups, 
usability testing and qualitative analyses.
Advisory group
A multidisciplinary advisory group was set up 1 year after the start of the project. It was led by 
Millie Kieve, founder of the charity APRIL (Adverse Psychiatric Reactions Information Link; 
www.april.org.uk). The group commented on the design and progress of the study, advised on the 
qualitative analysis of Yellow Card reports and commented on drafts of the report. Membership 
of the group is shown in Appendix 4.
Medicines and Healthcare Regulatory Authority
The MHRA contributed to this study by providing data, administering the questionnaire and 
answering numerous queries from the research team. The MHRA did not, however, have a role in 
the interpretation of the findings and did not comment on the report before it was submitted.
Ethical approval
Our evaluation received a favourable opinion from:
 ■ Warwickshire Research Ethics Committee (07/H1211/117)
 ■ The Independent Scientific Advisory Committee of MHRA.
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Chapter 2  
Study 1: literature review on the 
international experience of consumer 
reporting schemes
Objective
To review the published literature on patient- and HCP-reporting systems in different settings.
Methods
A range of methods was used to identify countries with patient reporting as part of their 
national pharmacovigilance activities, including a questionnaire, personal communication 
with key contacts and literature review. The questionnaire (Appendix 5) was e-mailed to 
pharmacovigilance staff in 47 countries to obtain information on their ADR reporting schemes. 
The contact details were identified from the World Health Organization (WHO) Uppsala 
Monitoring Centre website (www.WHO-UMC.org). The questionnaire explored whether the 
national scheme permitted patient reporting and details about these schemes. The questionnaire 
was designed for rapid completion and the content was informed by the authors’ knowledge 
of the characteristics of previously identified national spontaneous reporting schemes. The 
questionnaire was not piloted prior to dissemination. One e-mail reminder was sent to non-
respondents. In addition, the authors liaised with key contacts in pharmacovigilance to identify 
relevant information.
A literature review was performed to identify comparative studies and reports of patient and 
HCP ADR reports. A search was conducted of the following databases MEDLINE (Ovid), 
EMBASE (Ovid) and Pharm-line using both medical subject heading (MeSH) and text search 
terms ‘ADR reporting’, ‘side effect reporting’, ‘pharmacovigilance’, ‘patient report’, ‘patient report’ 
and ‘public report’. Details of the search terms used are shown in Appendix 6. The search dates 
were from 1996 to May 2009. The searches were last run in May 2009. Only studies in the English 
language were included owing to financial and time constraints. Studies that included only HCP 
or only consumer reports were excluded. The reference lists of each included study were checked 
to identify additional studies. Personal reference lists were also searched. Internet searches were 
performed using similar search terms. The search results were checked by one individual (SA-U) 
for relevant studies. Data from the included studies were extracted using a data abstraction 
form. These data were synthesised by classifying the different types of study, and comparing and 
contrasting the findings.
Results
Table 2 shows the countries that, on the basis of the survey or literature review, were identified as 
having consumer reporting schemes. Appendix 7 shows the countries that did not appear to have 
consumer reporting based on the literature review or that did not respond to the survey.
8 Study 1: literature review on the international experience of consumer reporting schemes
TABLE 2 National pharmacovigilance schemes that include patient reporting
Country
Pharmacovigilance system 
(year of introduction)
Methods of report 
submission
Comparison 
of patient 
and HCP data 
available?
Feedback 
provided to 
patient reporter
Feedback to 
survey from 
pharmacovigilance 
contact 
Argentinaa
Armeniaa
Australia TGA (2003)
AME Line
Hard copy form ‘Blue card’, 
online, post, telephone
Yes17 Referred to 
TGA website 
for information 
requested
No comparisons 
made
bBelgium15 Test-Achats/Test-Aankoop (2006) Data from Herxheimer et 
al.15
Form downloaded from 
internet
No No response. Data 
from Herxheimer 
et al.15
Scheme run by 
Test-Achats/
Test-Aankoop, 
national consumer 
organisation
Botswanaa
Brazila
Burkina 
Fasoa
Canada Canada Vigilance Program (2003) Post, fax, telephone, online Yes18 Comparison made 
in 2008
HCPs 70% and 
patients 30% of 
reports submitted
Congoa, The 
Democratic 
Republic of 
The
Côte d’Ivoirea
Czech 
Republic
National Drug Information And 
Pharmacovigilance Centre
Online Unclear/unlikely Referred to website 
for information 
requested
Denmark Danish Medicines Agency (2003) E-mail, post, online, fax Yes19
Ghanaa
Guatemalaa
Iceland Iceland Medicines and Control 
Agency (2007)
(www.imca.is/Pharmacovigilance/)
Unclear – possibly only 
online
Not by telephone
No Unclear No comparisons 
made yet
Irana, Islamic 
Republic of
bIreland15 Irish Medicines Board
(www.imb.ie/default.aspx)
Online, freepost No Unclear No response
bItaly15 Italian Drug Regulatory Agency 
(2004) 
Data from Herxheimer et 
al.15
Form downloaded from 
internet; electronic form 
also available
No
Kenyaa National Pharmacovigilance 
Systems of Kenya (2009) (www.
pharmacyboardkenya.org/index.
php?id=2)
Hard copy forms, post, fax, 
e-mail, to local pharmacy
Unclear whether online 
or telephone submission 
possible
No Unclear Campaigns and 
programmes are 
being organised 
to create public 
awareness
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Country
Pharmacovigilance system 
(year of introduction)
Methods of report 
submission
Comparison 
of patient 
and HCP data 
available?
Feedback 
provided to 
patient reporter
Feedback to 
survey from 
pharmacovigilance 
contact 
Madagascara
Mexicoa
Moldovaa, 
Republic of
Myanmara
Namibia The Safety Yellow Form (2008)
(www.nmrc.com.na/PVSystem/
tabid/1347/language/en-US/
Default.aspx)
Form can be downloaded 
and submitted by post, 
e-mail or fax
Unclear whether online 
or telephone submission 
possible
No Unclear No comparison 
has been made as 
patient reports are 
low
Netherlands The Netherlands 
Pharmacovigilance Centre Lab 
(Lareb): government run (www.
lareb.nl) (2003)
IVM (Institute for Responsible 
Medicines Use): consumer run 
(www.medicijngebruik.nl) (2004)
Post, e-mail, fax, online, 
telephone
Yes20  
New Zealand Medicines and Medical Devices 
Safety Authority (< 1970)
Report forms available only 
or as hard copy.
For submission by freepost, 
fax or e-mail; telephone 
reports also accepted.
No Yes 
Acknowledgement 
and feedback 
letter sent to all 
reports
Letters include 
causality 
assessment, 
no. of similar 
reports in NHS, 
additional relevant 
information
No comparisons 
made yet
bNorway15 Norwegian Medicines Agency 
(2010)
(www.legemiddelverket.no/) 
No Unclear No comparisons 
made
Omana
Philippinesa
Saudi Arabiac
Sierra Leonea
Slovakia State Institute for Drug Control 
(NK) (www.sukl.sk/en)
Online, post No Unclear No comparisons 
made
South Africaa
Sri Lankaa
Saint Luciaa
Sweden Swedish Drug Information system
(www.kilen.org) (1978)
Forms, e-mail, electronic 
method launched in 2008
No Yes No comparisons 
made as reports 
received from 
patients are low
Switzerland Swiss Agency for Therapeutic 
Products (NK)
(www.swissmedic.ch/index.
html?lang=en)
Forms obtained online, or 
by telephone, post
Possibly only by post (online 
commencing soon for HCPs 
only)
No Yes
Primary reported 
receives a ‘brief 
evaluation’ within 
7 days
Referred to the 
website
continued
TABLE 2 National pharmacovigilance schemes that include patient reporting (continued)
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Sixteen countries responded to the questionnaire (response rate 34.0%). The characteristics 
of the longer-established European schemes were summarised in a report by Health Action 
International Europe,15 authored by one of the key contacts (Dr A Herxheimer). Since completion 
of the questionnaire, the results of a survey of low- and middle-income countries regarding their 
pharmacovigilance activities have been published.16 An additional 27 countries with consumer 
reporting were identified. Information was received that consumer reporting has been introduced 
in Saudi Arabia (Dr H Aljadhey, King Saud University, Riyadh, Saudi Arabia, 2010, personal 
communication). In total, 46 countries were identified as having consumer reporting schemes 
(see Table 2).
Findings from the survey and literature review
International experiences of patient reporting
Blenkinsopp et al.24 completed a systematic review of patient reporting of suspected ADRs, 
which was first published online in 2006. Seven studies were included, although none involved 
spontaneous reporting by patients. Where comparisons were available with HCP reports, quality 
of reports appeared to be similar. There was some evidence that patients were more likely to 
report ADRs if they felt their HCP had not acknowledged their concerns. We now report further 
on international experiences of patient reporting of ADRs drawing on literature from before and 
after this systematic review.
In Australia, patients have access to the ‘Adverse Medicine Events (AME) Line’,25 through 
which they can report ‘suspected AMEs, possible errors or “near misses” with their medicines’. 
Patients can also report to the Adverse Drug Reactions Unit (ADRU) of the Therapeutic Goods 
Administration (TGA).26 The AME Line is operated by the Australian Council of Safety and 
Quality in Health Care and was launched in 2003. Suspected errors and ADRs are reported 
using two different forms, therefore, reporting rates for each can be analysed separately. A recent 
case series of patient reports to AME relating to the use of zolpidem indicated that memory 
Country
Pharmacovigilance system 
(year of introduction)
Methods of report 
submission
Comparison 
of patient 
and HCP data 
available?
Feedback 
provided to 
patient reporter
Feedback to 
survey from 
pharmacovigilance 
contact 
United 
Republic of 
Tanzaniaa
Thailanda
Togoa
UK The YCS (2003, pilot; 2005, full 
introduction)
Hard copy form ‘Yellow 
Card’, post, e-mail, fax, 
telephone, online
Yes10,21,22 No  
Uruguaya
USA US Food and Drug Administration 
(~1960s)
Post, online, telephone Yes23  
Zambiaa
Zanzibara
Zimbabwea
AME, Adverse Medicine Events Line; NK, not known; TGA, Therapeutic Goods Administration.
a Data from WHO survey.16
b Data from Herxheimer et al.15
c Dr H Aljadhey, King Saud University, Riyadh, Saudi Arabia, 2010, personal communication.
TABLE 2 National pharmacovigilance schemes that include patient reporting (continued)
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disturbances, hallucinations and dependence were more common than was previously thought.27 
An audit of the use of the AME Line showed that 43% of the 3415 calls received in a 2-year 
period were prompted by media publicity.17 Females and older patients were more likely to call 
the line. One-fifth of ADRs reported by callers were previously unrecognised and 8% were related 
to complementary medicines. In total, 105 serious ADRs and drug-induced hospitalisations that 
callers reported had not been reported by health professionals.17 The case series and audit were 
reported as conference abstracts and as such very limited information is available regarding their 
methods and conduct.
The Canadian Adverse Drug Reaction Monitoring Program (CADRMP) at Health Canada is 
responsible for the collection and assessment of adverse reaction reports made voluntarily by 
health professionals and patients.28 In 2008, 20,360 adverse reaction reports were submitted, but 
these were not limited solely to medicines.18 The majority (72%) of these reports were submitted 
by the market authorisation holder. Of the 16,272 reports for which a reporter was identifiable, 
4851 (29.9%) were submitted by ‘consumers’ and ‘patients’, and 10,898 (67%) were submitted 
by health professionals. In total, 1719 (10.6%) reports were submitted solely by patients. The 
number of domestic reports for ADRs has nearly doubled between 2001 and 2008.18 A quarterly 
newsletter is produced for HCPs and patients; the former receive mailed paper copies, whereas 
the latter need to access the publication online. These data are presented as annual reports, which 
do not include detailed methodological information.
In Denmark, patient reporting of ADRs commenced in 2004 and the reports received from 
2004 to 2006 have been analysed.19 The analysis comprised 6319 reports and 15,531 ADRs 
in total, with 544 (8.6%) reports submitted by patients. This analysis focused solely on ADRs 
that were classified as serious. Highly significant differences were shown with reporter type 
(patient, physician, pharmacists, lawyers, other HCPs) and the total number of serious ADRs 
that were reported (p < 0.0001). Patients and physicians reported similar proportions of serious 
reactions (46% and 45%, respectively). Compared with all other types of reporters, patients 
were significantly less likely to report ADRs relating to the following: blood and lymphatic 
system [odds ratio (OR) 0.22, 95% confidence interval (CI) 0.08 to 0.59)]; hepatobiliary 
disorders (OR 0.14, 95% CI 0.04 to 0.57); infections and infestations (OR 0.45, 95% CI 0.23 to 
0.87); investigations (OR 0.71, 95% CI 0.50 to 0.99) and pregnancy, puerperium and perinatal 
conditions (OR 0.33, 95% CI 0.11 to 1.06). However, compared with all other types of reporters, 
patients were significantly more likely to report ADRs relating to the following: ear and labyrinth 
disorders (OR 2.09, 95% CI 1.01 to 4.30); nervous system disorders (OR 1.27, 95% CI 1.05 
to 1.53); psychiatric disorders (OR 1.70, 95% CI 1.31 to 2.20) and reproductive system and 
breast disorders (OR 2.02, 95% CI 1.13 to 3.61). Differences were also shown between patient 
and other types of reporter regarding the types of medicines for which they submitted ADR 
reports. Although patients were more likely to submit reports for medicines used to treat the 
nervous system and sensory organs, along with antiparasitic products, they were less likely than 
other types of reporters to report products for blood and blood-forming organs, anti-infectives 
for systemic use, antineoplastics and immunomodulating agents. In addition, it was noted 
that patients reported nine ADRs that had not been identified by other reporters, including 
dysgraphia, parosmia, and thromboembolic stroke, all of which are regarded as serious. As this 
study focused solely on ADRs that were classified as serious, it does not reflect the full range of 
ADRs reported by consumers (and HCPs).
In the Netherlands, patients can report suspected ADRs directly to the Netherlands 
Pharmacovigilance Centre (Lareb),29 a government-run organisation. Of the 6305 reports 
received in 2005, 819 (13%) were submitted by patients.29 A comparative study was conducted in 
the Netherlands of all suspected ADR reports from patients and HCPs, based on reports received 
between April 2004 and April 2007,30 i.e. the first 3 years of consumer reporting. A total of 2522 
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reports (5401 suspected ADRs) were received from patients and 10,635 reports (16,722 suspected 
ADRs) from HCPs. Patient reports were more likely to be submitted by females; the mean age of 
patient reporters was 48 years. The types of drugs most often reported by patients were statins, 
selective serotonin reuptake inhibitors, beta-adrenoceptor antagonists, anticoagulants and proton 
pump inhibitors. The drugs and ADRs most frequently reported by patients were similar to those 
reported by doctors, including the organ systems affected. No difference was found between 
patient and HCP reports in terms of overall seriousness, but some differences were reported 
between the type of reporter and different categories of seriousness, i.e. patients reported 
significantly more disability than HCPs (2.3% and 0.4%, respectively) and more life-threatening 
reactions (5.2% and 2.7%, respectively). The Lareb system accepts only electronic reports from 
consumers, whereas HCPs can submit online or using a paper form. This may limit the numbers 
of reports by consumers, especially those who have little or no access to the internet.
In addition to Lareb, a patient-run reporting scheme,31 has operated since 2004. Higher 
numbers of reports are made to this scheme than Lareb, but the amount and type of information 
recorded by the two schemes differs, and so the data are not entirely comparable. During the 
first 10 months of the scheme, 49% of reports related to side effects, of which 6% were severe 
and 30% were not mentioned on the PIL. A short report was published of a comparison of the 
reports associated with the use of paroxetine made with Lareb, with those reported to a free 
telephone medicines information service, introduced in 1990, which enabled patients to consult 
a pharmacist about the correct use of medicines and problems related to their medicine use.20 
Out of 23,625 calls from patients, 120 suspected ADRs were reported for paroxetine compared 
with 89 of the 7665 suspected ADRs from HCPs. Proportionally fewer reports were made about 
paroxetine via the telephone service compared with Lareb (0.5% vs 1.2%, respectively). However, 
suspected ADRs were reported sooner using the telephone service compared with Lareb (mean 
229 days, 95% CI, 160 days to 298 days). No difference was found between the two reporting 
systems in terms of new suspected reactions (i.e. those not included in the PIL). Nine new ADRs 
were identified by both systems. Each reaction was first reported using the telephone system 
for all nine reactions, with a mean time lag of 273 days (95% CI 89 days to 458 days) between 
the telephone and Lareb reports. Owing to this study being published as a short report, limited 
methodological data were presented. More recently, a comparative study was conducted using 
patient reports submitted to the patient-run reporting scheme for antidepressants,32 with HCP 
reports submitted during the same data collection period as Lareb. This study was published 
as an abstract, therefore only limited methodological information was available and there was 
limited interpretation of the results. In total, 258 reports were submitted by patients, most 
(72%) of whom were female. Of these reports, 217 were associated with side effects. Significant 
differences were shown between the ADRs reported by patients and HCPs. For example, the 
patients reported more sexual problems and weight gain, whereas HCPs reported more skin, 
muscle and joint complaints.
In the USA, the Adverse Events Reporting System (AERS) is the national database used by the 
Food and Drug Administration23 to support postmarketing drug surveillance. The MedWatch33 
programme is the reporting scheme for patients and HCPs to use to submit reports of serious 
problems associated with medicines or medical devices. All reports submitted to MedWatch are 
entered into AERS. The same reporting form is used for both types of reporters and reports can 
be submitted online, by post, fax or telephone. Reports submitted by patients are acknowledged. 
Patient reporters are also contacted by MedWatch if further information is needed. The scheme 
includes reports for serious adverse events, product problems and errors. Serious events are 
those that led to death, disability, congenital anomaly, hospitalisation, ‘other serious events’ 
or those that are life-threatening. In 2008, of the 226,647 reports received by MedWatch, 
46% were submitted by patients. The proportion of total reports submitted by patients has 
increased since the mid-90s.34 Relatively detailed annual reports were available regarding 
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patient and HCP reporting to this system in the 1990s,34 and these are now available from the 
AERS website.23 These data are presented as annual reports, which do not include detailed 
methodological information.
Overall, considerable variation exists across national schemes in terms of the proportion of total 
ADR reports submitted by patients and this is illustrated in Figure 1.
Other comparative studies of patient- and health-care professional-
suspected adverse drug reaction reporting
In addition to the comparative studies of spontaneous ADR reporting described above, several 
comparative research studies were identified which provide more information regarding the 
differences between these types of reporters, although they did not involve national spontaneous 
reporting. Only studies that have been published since the earlier review by Blenkinsopp et al.24 
are presented below. Studies were excluded if they were restricted to specific patient populations, 
for example children or the elderly.
A 6-month study conducted on medical wards in a university teaching hospital in north-east 
Thailand compared doctor and patient reporting of 13 new drugs newly introduced into the 
market in three medical wards.35 Patients who were either receiving one of the target drugs on 
admission or had one of these drugs prescribed during admission were included. Doctors were 
asked to report ADRs on forms attached to the patients’ records during the patient’s admission, 
or post discharge, on forms in the patient’s outpatient record. Patients were interviewed daily 
during admission and all reports recorded in the forms were attached to their records. The forms 
were also attached to outpatient records. During the inpatient phase, patients were interviewed 
and reported 28 suspected ADRs, whereas doctors reported 13, and in the outpatient phase, 
patients reported 88 suspected ADRs, whereas doctors reported five. Patients reported more 
ADRs than doctors, but doctors reported more serious ADRs than patients. Two methods of 
patient reporting were used: one for inpatients and one for outpatients. The effect of the two 
different methods of data collection was not assessed. Causality was assessed for ADR reports 
from doctors using validated criteria, although different criteria were used to assess reports from 
patients following discharge from hospital. It is unclear whether the latter were validated criteria.
FIGURE 1 Percentage of total reports submitted by patients by country.
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In 2009, a study was conducted with outpatients from one hospital in France, to determine 
whether they had experienced a suspected ADR and, if so, whether it had also been identified 
by their doctor(s).36 In total, 66 patients reported 91 ADRs. The majority (77%) of patients 
with ADRs were women. Reports of ADRs were included in the medical notes of 44% of these 
patients; however, it is unclear whether these were the same ADRs reported by the patient. This 
study was reported as a conference abstract and minimal data were presented regarding the 
methods used.
A second study in France, by Nasrallah-Irles et al.37 analysed patient reports of adverse events 
to health products submitted via patient associations. In the first year of the service, 200 reports 
were submitted by, or on behalf, of patients. Of these reports only 130 (65%) were evaluable 
(others had missing information or related to medical devices, which were excluded by the 
authors). More reports were received for female patients and the average age of the affected 
person was 54 years (range 0.5 to 90 years). With 93 reports, the adverse event was attributed 
with having a major effect on the patient’s well-being (physical, psychological and/or social). 
No direct comparison was made between reports received by this novel service and national 
pharmacovigilance statistics. Limited methodological information was presented. Validation of 
patient reports by their doctor was attempted, but achieved a response rate of only 40%. Overall, 
validation by HCPs of patient reports was achieved with 34.6% of all reports submitted. Although 
it is assumed that the 130 reports that formed the body of data for the analyses were associated 
with adverse events related to medicines, this is not described explicitly by the authors.
Summary
 ■ A range of methods was used to identify countries with patient reporting as part of their 
national pharmacovigilance activities, including a questionnaire to pharmacovigilance staff 
in 47 countries, personal communication with key contacts and a literature review.
 ■ A literature review was performed to identify comparative studies of patient and HCP ADR 
reports. A search was conducted of MEDLINE (Ovid), EMBASE (Ovid) and Pharm-line 
databases using both MeSH and text search terms. The search dates were from 1996 to 
May 2009.
 ■ Forty-six countries were identified as having consumer reporting schemes. A number of 
studies of patient reporting of suspected ADRs were identified, including a recent systematic 
review. Since the time of that review, one large-scale comparative study from the Netherlands 
has shown similarities in the classes of drug most commonly reported by patients and 
HCPs, and similar proportions of reactions were judged to be serious. Another large-scale 
comparative study from Denmark has shown that, compared with other sources, patients 
reported different types of medicines for categories of ADR. In this study consumers were as 
likely as physicians to report ADRs that were judged to be serious.
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Chapter 3  
Data used for the analysis of Yellow 
Card reports from patients and health-
care professionals
Introduction
This chapter describes the methods used by the MHRA when processing Yellow Cards, the data 
provided by the MHRA for the purposes of the project and the methods used by the project team 
when processing the data received from the MHRA. The data were used for the following studies:
 ■ the descriptive study comparing the characteristics of patient reports and HCP reports 
(see Chapter 4)
 ■ the study comparing signals generated by patient reports and HCP reports (see Chapter 5)
 ■ the clinical evaluation of signals generated by patient reports and HCP reports 
(see Chapter 5)
 ■ the qualitative study exploring the similarities and differences between patient reports and 
HCP reports (see Chapter 6).
Processing/coding of reports by the Medicines and Healthcare 
Regulatory Authority
Data capture and data entry by the Medicines and Healthcare 
Regulatory Authority
Yellow Card reports can be made on paper, by telephone and online.
Paper reports are optically scanned and the information is then entered manually into the MHRA 
database using a variety of coded and free-text fields.
For reports received by telephone, the MHRA staff member taking the telephone call records the 
relevant case information stated by the patient on to a Yellow Card, which is transcribed to the 
database in the first person.
Online reports were originally transcribed manually into the Adverse Drug Reactions Online 
Information Tracking (ADROIT) database that was used by the MHRA, but since 31 May 2006 
the MHRA changed to a custom database called ‘Sentinel’; this system allows for direct importing 
of data fields from reports completed electronically.
Data entry and quality checking is a four-step process involving different MHRA staff members:
 ■ Step 1 basic data entry (this requires the following minimum information: an identifiable 
reporter and patient, a suspected medicinal product and a reaction or event)
 ■ Step 2 full data entry
 ■ Step 3 checking the quality of the data before committing the report to the database
 ■ Step 4 a final check on the quality of data entry and initiation of follow-up, if appropriate.
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The MHRA performs a monthly audit on a sample of data entered.
Once a report is committed to the database, updates can be made if new information becomes 
available, for example if:
 ■ follow-up information has been received, either at the request of the MHRA or because the 
reporter spontaneously provided additional information for the case
 ■ a duplicate report for the same case has been received from another reporter (whereby 
additional details will be merged with the original report)
 ■ the classification of the report has been changed (for instance, if an error is identified 
through the MHRA’s internal quality audit procedures).
Reports are flagged by the MHRA if they have been updated, but this does not distinguish 
between reports updated with follow-up information and those updated on receipt of duplicate 
reports for the same case.
Coding of data by the Medicines and Healthcare Regulatory Authority
Reporter category
More than one reporter category may be coded for in an individual report if:
 ■ the MHRA receives the same report from different reporters – these are merged into one 
case folder and contact details retained from both reporters
 ■ follow-up information is obtained from a different HCP – again, the contact details for the 
new informant are retained in the same case folder
 ■ the patient is also a HCP.
Reaction terms
The description of the reaction is entered both as a free-text narrative and as coded fields. The 
MHRA code the reaction using the most appropriate lowest level term (LLT) in the Medical 
Dictionary for Regulatory Affairs (MedDRA). This is a hierarchical grouping dictionary 
structured at the highest level by system organ class (SOC) then high-level group term (HLGT), 
high-level term (HLT), preferred term (PT) and LLT. MedDRA is used widely for data processing 
and analysis by regulatory authorities and the pharmaceutical industry, and is clinically validated. 
It is maintained and updated by the Maintenance and Support Services Organization (MSSO).
Preferred terms within MedDRA may be mapped to more than one SOC. For example, the 
PT ‘dizziness’ may be mapped (via the corresponding HLT and HLGT) to ‘cardiac disorders’, 
‘vascular disorders’ or ‘nervous system disorders’ SOCs. This ‘multiaxiality’ allows for flexible 
analysis, depending on the research question or specific regulatory concern. However, within 
MedDRA a primary SOC is provided. For the example of ‘dizziness’ this would be ‘nervous 
system disorders’.
Seriousness
There are two ways in which seriousness can be coded: if ‘reporter considered serious’ has been 
flagged as ‘yes’ or the report contains at least one reaction term classified as ‘dictionary serious’. 
These terms are explained below.
‘Reporter considered serious’ flag
This relates to the report as a whole and is based on the response to the question regarding 
seriousness requested on the Yellow Card. The way in which this question is asked on the patient 
Yellow Card differs from that on the HCP Yellow Card. The HCP is asked ‘Do you consider the 
reaction to be serious?’ and is given a ‘yes’/‘no’ response option. If ‘yes’ is ticked then the HCP is 
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requested to specify one or more of six reasons for considering the reaction to be serious. These 
are based on Council for International Organizations of Medical Sciences (CIOMS) criteria as:
 ■ patient died owing to reaction
 ■ life threatening
 ■ involved or prolonged inpatient hospitalisation
 ■ involved persistent or significant disability or incapacity
 ■ congenital abnormality
 ■ medically significant (reporter asked to provide details).
If the ‘reporter considered serious’ question is not ticked, but one or more of the six CIOMS 
subcategories are set to ‘yes’ then the ‘reporter considered serious’ flag would nevertheless be 
coded as ‘yes’ by MHRA.
Patient reporters are not asked directly whether they considered the reaction to be serious. 
At the time of our study, they were asked ‘How bad was the reaction?’ and asked to select one 
option from:
 ■ mild or slightly uncomfortable
 ■ uncomfortable, a nuisance or irritation, but able to carry on with everyday activities
 ■ bad enough to affect every day activities
 ■ bad enough to be admitted to hospital
 ■ life-threatening
 ■ caused death.
If any of the last three of these options are ticked then the MHRA set the ‘reporter considered 
serious’ flag to ‘yes’.
‘Dictionary serious’ flag
The second method for classifying the seriousness is at the reaction term level using the flag 
‘dictionary serious’. Here, PTs within the MedDRA dictionary are assessed by medically-qualified 
personnel within the MHRA, and individually assigned a ‘dictionary serious’ status of either ‘yes’ 
or ‘no’. This is the MHRA’s own ‘in-house’ medical opinion and is independent of the CIOMS 
criteria. Where a reporter has not indicated any seriousness criteria, but at least one MedDRA 
reaction term is flagged as ‘dictionary serious’, the ‘medically significant’ CIOMS flag is set to ‘yes’ 
for that report.
Reaction outcome
Information on the outcome of the reaction is also requested in slightly different ways for patient 
and HCP reports. Table 3 shows the way in which the different options are coded by the MHRA.
TABLE 3 Coding of reaction outcome
Patient report options HCP report options Coded as
Recovered completely Recovered Recovered/resolved
Recovered, but with some lasting effects 
(details requested)
Recovered, but free text indicates sequelae Recovered/resolved with sequelae
Getting better Recovering Recovering/resolving
Still has the reaction Continuing Not recovered/not resolved
Other (details requested) Other Free-text field
Caused death Caused death Fatal
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Drugs
The MHRA code the name of the medicines involved in a suspected ADR as they are reported on 
the Yellow Card (after correction of spelling errors). Thus, the medicine may be named using the 
generic drug substance, its brand or proprietary name, the combination name (e.g. co-codamol) 
or the individual constituents of a product (including, in some cases, its excipients).
An internal drug dictionary is used by the MHRA to select the most appropriate medicine or 
product name. The medicine/drug/product is then classified as either the ‘suspect drug’ or ‘other 
drug’ based on the information specified on the report. The MHRA does not code suspected 
drugs into hierarchical therapeutic classes within the report.
Black triangle status
Drugs with ‘black triangle’ status are those that require intensive monitoring by the MHRA to 
further assess their risk–benefit profile. This occurs, for instance, if the product contains a new 
active substance, is a new formulation or combination of a previously licensed product or a 
significant new prescribing indication has been added to the product’s licence. The time period 
for black triangle status varies. The status is usually reviewed 2 years after the product has been 
on the market, although it may remain until the safety of the drug is more fully established. The 
MHRA allocates a black triangle flag to drugs specified on the Yellow Card report, according to 
the drug’s status at the time of the report. HCPs are made aware of black triangle drugs through 
publications such as the British National Formulary (BNF),38 but, currently, there is no system for 
informing patients.
Partial data entry
All data from online reports are imported into the database. For paper and telephone reports, all 
data are entered in to the database if the report is classified as ‘serious’ (as described above), but 
data from other reports are not always entered in full. The minimum information recorded for 
these other reports is the patient identifier, the suspect drug(s) involved and the coded MedDRA 
reaction terms. Hence, the data on the database may not always include, for example, the free-
text description of the reaction. Such reports are flagged as ‘partially classified’ on the database. 
Where more complete information is required for assessment of reports that have been partially 
classified, full data capture is carried out and the partial classification flag is updated.
Narrative field
When free-text descriptions of the reaction are entered by the MHRA in to the database, they 
are transcribed in a narrative field, generally verbatim. Sometimes, however, if certain elements 
have been coded in other fields, the narrative may be abridged, for example to remove personal 
information, dates, or information which can be recorded in structured fields elsewhere in the 
database. The narrative field is important in situations where the MHRA wishes to undertake 
detailed assessment of the potential causality and/or impact of a suspected ADR.
Data provision by the Medicines and Healthcare Regulatory Authority
The MHRA provided the Drug Safety Research Unit (DSRU) with anonymised data on all patient 
and HCP reports received between 1 October 2005 and 30 September 2007. Reports from the 
pharmaceutical industry were excluded.
The data were provided electronically in the form of several encrypted Microsoft excel 2003 
spreadsheets (Microsoft Corporation, Redmond, WA, USA). A case number was provided as a 
means of identifying unique patients and linking data between the different excel spreadsheets. 
The data fields available are shown in Box 1.
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BOX 1 Data fields available from Yellow Cards reports
Patient characteristics
Gender
Age
Weight
Height
Report/reporter characteristics
Reporter status:
•	 For patient reports: patient, carer or parent
•	 For HCP reports: qualification (e.g. doctor, pharmacist, nurse, other HCP, coroner)
Method of reporting (telephone, paper, internet)
Date report received by the MHRA
A flag to indicate, for example, that the report had been updated since first received
The opinion of the reporter (in the case of HCPs) as to the seriousness of the reaction
Various permissions requested by the MHRA from patient reporters:
•	 Permission to send a copy of the report to the reporter’s GP
•	 Permission to request follow-up information from the GP or reporter
Whether a patient reporter had informed a HCP of the ADR and whether the HCP had submitted a Yellow Card 
report
Reaction(s)
Free-text description of reaction experienced
MedDRA coded reaction terms: LLT and corresponding PT
Reaction start and end date
Onset of reaction from first and last dose of drug taken
Reaction duration
‘Dictionary seriousness’ (as noted above, this is a flag given by the MHRA to individual MedDRA terms and is 
independent from any opinion provided by the reporter as to the seriousness of the reaction)
Reaction outcome
Recovery time
Any specific treatment given
Reaction severity
Any sequelae
Suspect and concomitant drugs
Name of drug as reported
Prescribing indication(s)
Dose description as text (in various formats)
Dosage form and strength
Route of administration
Start and stop dates and/or duration of therapy
Status of whether drug was reported as the ‘suspect’ drug involved or an ‘other’ drug prescribed in the 
3 months prior to the reaction
A flag to indicate whether the drug was a ‘black triangle’ product (the MHRA reported some technical difficulties 
in the use of the black triangle flag in their database at the time of our study and this may have affected the 
quality of the data extracted)
A flag indicating evidence of rechallenge
continued
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Data processing
All data received from the MHRA were stored on a secure server network at the DSRU. Data 
were uploaded for data processing on to a Microsoft SQL Server database. Data were reviewed 
for initial exploratory analysis and logical checks using stata (version 10, StataCorp LP, College 
Station, TX, USA).
Data cleaning
It was not the purpose of this study to investigate the quality of the data coded by the MHRA. 
Various logical checks were performed, however, and any apparent anomalies or inconsistencies 
checked with the MHRA (see Appendix 8). Where appropriate (e.g. in the case of a coding error) 
the data were corrected, both by the MHRA at source and by the DSRU, manually, in the data 
obtained from the MHRA.
The MHRA have an automated method of identifying potential duplicate reports at the time 
of data capture (e.g. if a patient and his/her GP complete separate Yellow Cards). In these 
circumstances the electronic data are merged into one case folder allocated according to the 
‘primary’ reporter by the MHRA. Hence, if duplicate case numbers were identified in both the 
patient and HCP data sets received from the MHRA then these were checked at source by the 
MHRA in order to identify which reporter was the ‘primary’ reporter. Using this information the 
data from both reports were then merged into one record stored in the database of the ‘primary’ 
reporter. It should be noted that this occurred for only six of the patient reports and so the 
merging of records should not have skewed our findings.
The research team had originally planned to search systematically for duplicate reports, but 
we decided not to do this when we learned of the system used by the MHRA. We felt that the 
approach taken by the MHRA was more sensitive than anything that we could have done, 
Patient medical and drug history
MedDRA LLT terms and free-text description of medical conditions
Start/end dates or duration of these conditions and a flag to indicate whether ongoing
Name of drugs taken in the past (with dates)
Details of any deaths reported
Reported cause of death (MedDRA LLT term)
Certified cause(s) of death (MedDRA LLT term)
Flag to indicate if sudden death
Flag to indicate if post mortem on file at MHRA
Post mortem reported cause of death (MedDRA LLT term)
Test results
Name of tests performed (MedDRA LLT term)
Dates and results (with reference range)
Flag to show further information held at MHRA
Information on the parent (this may be requested by the MHRA where a reaction is reported in a child) including:
Details on the parent’s age, gender, weight, height, last menstrual period (details potentially relevant for 
medicines taken during pregnancy causing suspected ADRs to the fetus)
Parent’s medical and drug history including any dates and any previous parental ADRs
BOX 1 Data fields available from Yellow Cards reports (continued)
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particularly as the MHRA have access to full details on the patients (whereas we had only 
anonymised data). Hence, only limited checking for duplicates was undertaken by the research 
team as outlined below and as part of the qualitative assessment of potential signals detected by 
the disproportionality analysis (Chapter 5).
Grouping of reaction terms
The coded reaction terms were provided by the MHRA as LLTs and the corresponding PTs. 
The DSRU mapped the LLTs provided by the MHRA to the corresponding PTs, HLTs, HLGTs 
and SOCs using the database files for MedDRA (version 12). The ‘default’ SOC provided in the 
MedDRA database files was used where more than option was available (see Reaction terms, 
above).
Grouping of suspect drugs reported
As noted above, the data provided by the MHRA contained the name of the suspect drug as 
reported. To group drugs into categories, the drug name (as reported) was first converted to 
a generic equivalent and then mapped to the most appropriate code within the Anatomical 
Therapeutic Chemical (ATC) drug classification system.39 The ATC system is used worldwide to 
classify drugs into groups according to their therapeutic use.
A bespoke ‘matching tool’ was designed at the DSRU to enable each suspect drug to be mapped 
to the most appropriate ATC code. Data from the Dictionary of Medicines and Devices (‘dm+d’) 
was incorporated into this software (www.dmd.nhs.uk/). The dm+d database contains unique 
identifiers and descriptions for medicines and medical devices, and is used within the NHS for 
the purpose of procurement and reimbursement of medicines. Data from the dm+d were used to 
map brand names for proprietary products to generic equivalent drug names.
Having converted brand name to generic equivalent, the most appropriate ATC code was 
then selected by the DRSU researcher (LH, a pharmacist with experience of both community 
and hospital practice) for the generic equivalent. In some cases, there may be more than one 
ATC code for a drug, so the selection was based on assumptions taken from the contextual 
information provided on each report, such as prescribing indication, dose/strength, dosage form, 
administration route, other drugs prescribed and in some cases the free-text description of the 
reaction. In the absence of this contextual information, the ATC code was selected assuming the 
drug had been prescribed for systemic administration, unless this was unusual for the particular 
drug (e.g. salbutamol would be coded as an inhalation product). In addition, some drugs were 
mapped pragmatically, based on experience of the researcher involved in the mapping process, 
according to the most common prescription indication for the drug. For example, aspirin was 
coded as an antithrombotic agent rather than as an analgesic in the absence of other contextual 
information. Complementary therapies were identified as those containing herbal and/or 
homeopathic ingredients. These were not allocated an ATC code, but grouped as a separate 
category. An overview of the assumptions used in this mapping process is given in Appendix 9.
Identification of potential duplicate reports
The database was screened for patients with the same age, gender, suspect drug name and 
reaction term (as PT). This produced a list of 462 reports. Of these, 246 were related to fairly 
common reactions to immunisations, for example in babies of a similar age; 66 were unlikely 
to be duplicates as the reaction date or date of starting the suspect drug were different and 135 
potential duplicates had no information on dates to allow verification without viewing the source 
documentation held by the MHRA. The remaining 10 reports were reviewed more closely. Three 
appeared to be for different patients and seven were thought likely to include duplicate reports 
(relating to three patients). Hence, there appeared to be a few duplicate reports in the database.
22 Data used for the analysis of Yellow Card reports from patients and health-care professionals
Summary of differences between Yellow Card reports from health-
care professionals and patients
A number of differences between the data obtained from HCPs and patients have been noted 
above and Table 4 gives a summary of these.
TABLE 4 Main differences between the patient and HCP Yellow Card reports
Patient Yellow Card HCP Yellow Card
Current status of patient Reporter asked ‘How is the person feeling now?’ and 
selects one of:
 ■ recovered completely
 ■ recovered, but with some lasting effects
 ■ getting better
 ■ still has reaction
 ■ other – (there is space to give details)
Reporter selects outcome of the reaction:
 ■ has recovered
 ■ has recovered (but free text indicates sequelae)
 ■ is recovering
 ■ is continuing
 ■ other
Please note, that the MRHA recategorised these five options in the data set to make them comparable across 
reporter types. They were recorded as:
 ■ recovered/resolved
 ■ recovered/resolved with sequelae
 ■ recovering/resolving
 ■ not recovered/not resolved
 ■ free-text field
Is the reaction serious? Not asked Reporter asked ‘Do you consider the reactions to be 
serious?’ and selects ‘yes’ or ‘no’
How serious is the reaction? Reporter asked ‘How bad was the suspected side 
effect? (tick one)’ and selects from:
 ■ mild or slightly uncomfortable
 ■ uncomfortable
 ■ a nuisance or irritation, but able to carry on with the 
everyday activities
 ■ bad enough to affect everyday activities
 ■ bad enough to be admitted to hospital
 ■ life-threatening
 ■ caused death
After answering yes to the question above, the reporter 
asked to indicate why the reaction is considered serious, 
with the option of ticking any number of six boxes:
 ■ life threatening
 ■ hospitalised
 ■ caused death
 ■ congenital abnormality
 ■ involved persistent or significant disability or 
incapacity
 ■ medically significant (with request to give details as 
to why they felt this was so)
Height of patient Asked for Not asked for
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Chapter 4  
Study 2: descriptive study of Yellow 
Card reports
Objectives
This study was designed to provide important background information for evaluating the 
pharmacovigilance impact of patient reports of suspected ADRs. The objectives were to:
 ■ identify the characteristics of patients reporting to the YCS
 ■ identify the types of drug, types of suspected adverse reaction and seriousness of suspected 
reactions reported by patients
 ■ determine whether there are differences in the time lag between ADR occurrence and 
reporting for patients and health professionals
 ■ investigate the factors (see below) associated with patient reports compared with those made 
by health professionals.
Methods
After completing the data cleaning and processing, as described in Chapter 3, data analysis was 
undertaken at the University of Aberdeen.
Descriptive statistics were calculated for Yellow Card reports from patients and HCPs. 
Appropriate statistical tests compared the following factors across reporter type:
 ■ age and gender of patients
 ■ reported seriousness of the suspected ADRs (as coded by the MHRA)
 ■ types and number of suspected ADRs using MedDRA terms
 ■ word count used to describe the suspected reaction
 ■ number of suspect drugs per report and class of suspected drug using the ATC classification
 ■ time lag between suspected ADR and its reporting
 ■ reported outcome of the suspected ADR.
The time to report a suspected ADR for reactions occurring in the first and second year of the 
study period was also calculated by reaction outcome.
Reports with zero word counts were excluded when comparing word counts of reporter types 
because this provides the most valid comparison given that the MHRA do not always include the 
narratives in the database unless reports have been made online or are classified as serious.
Continuous variables were compared using an independent t-test if they were normally 
distributed, otherwise the non-parametric Mann–Whitney U-test was used. The median 
word count used to describe the suspected reaction for the different methods of reporting was 
compared using the Kruskal–Wallis test. Associations between two categorical variables were 
examined using Pearson’s chi-squared test. To minimise the chances of a type 1 error arising from 
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multiple comparisons, a p-value of ≤ 0.01 was used to denote statistical significance throughout. 
Multiple logistic regression models were fitted to quantify the ORs for reporting specific reactions 
(based on the system organ class of the MedDRA classification system) between reporter type. 
The ORs were adjusted for age and gender of the patient affected by the ADR. All statistical 
analyses were performed using sas (version 9; SAS Institute, Cary, NC, USA).
Results
Characteristics of those experiencing an adverse drug reaction
In total, 26,129 ADR Yellow Card reports were received from the MHRA for the 2-year study 
period. Of these, 5180 (19.8%) were patient and 20,949 (80.2%) were HCP reports. Significantly 
more Yellow Card reports were made for female patients, whether reported by the patient or via 
HCPs (both p < 0.001) (Table 5). The median age of patients, as reported by either patients or 
HCPs was similar (p = 0.06).
Method of reporting
The reporting method used was not documented for 22.7% of reports from patients and 29.3% 
from HCPs. Excluding these reports, the most frequent method used to report an ADR was the 
paper Yellow Card form for both reporter groups (79.0% of patients and 87.7% of HCPs); the 
internet was the next most frequent method (17.6% of patients and 12.3% of HCPs), followed by 
the telephone (3.5% of patients and 0.03% of HCPs). There was a highly significant association 
between the method of reporting used and reporter type (p < 0.001).
Reactions
Patients reported 20,358 ADRs in total, whereas HCPs reported 44,429 ADRs. Patients reported 
a significantly higher number of suspected ADRs per Yellow Card report than HCPs {median 
[interquartile range (IQR)] of 3 (2 to 5) vs 2 (1 to 3), respectively; p < 0.001 (Table 6)}. Almost 
one-half (45.2%) of HCP Yellow Card reports contained only one ADR compared with 21.6% of 
patient Yellow Card reports; only 3.3% of HCPs reported over five reactions per report compared 
with 21.8% of patient reports (p < 0.001 overall).
The most frequent LLT reaction reported by patients was nausea (n = 458; 2.2% of all patient 
reactions reported), followed by headache (n = 440; 2.2%) and dizziness (n = 334; 1.6%) (Table 7). 
Nausea (n = 987; 2.2%) and headache (n = 758; 1.7%) were also the two most frequently reported 
LLTs on the HCP reports, followed by vomiting (n = 647; 1.5%).
In Table 8, the number of patient and HCP reports are presented that had at least one of each 
type of reaction grouped according to the System Organ Classification of MedDRA. More patient 
reports had mention of a nervous system disorder problem (41.5%) than those of another organ 
TABLE 5 Characteristics of patients reporting through the YCS by reporter type
Characteristic
Patient report HCP report
Male Female All Male Female All
Age (years) Median (IQR) 57.0 
(40.0 to 69.0)
51.0 
(35.0 to 64.0)
54.0 
(37.0 to 66.0)
54.0 
(32.0 to 68.0)
53.0 
(34.0 to 68.0)
53.0 
(33.0 to 68.0)
Missing n (%) 402 (22.4) 723 (22.3) 1230 (23.7) 506 (6.2) 737 (6.2) 1371 (6.5)
Total N (%) 1796 (34.7) 3249 (62.7) 5180 (100) 8208 (39.2) 11935 (57.0) 20949 (100)
No gender was recorded for 3.9% of HCP reports and 2.6% of patient reports.
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system. This was followed by problems categorised as ‘general disorders and administration site 
conditions’ (39.8%), problems that were also the second most common organ system affected 
according to the HCP reports (23.1%). The most common category in the HCP reports was skin 
and subcutaneous tissue disorders (23.2%).
All of the age- and gender-adjusted ORs between patient and HCP reports by SOC were 
statistically significant except for vascular disorders, infections and infestations, and injury, 
poisoning and procedural complications (see Table 8). In general, patients tended to report more 
ADRs in each SOC, apart from cardiac disorders, where patients were significantly less likely to 
report a relevant ADR compared with a HCP.
TABLE 6 Number of reactions per report by reporter type
No. of reactions No. of patient reports (%) No. of HCP reports (%) p-value
Median (IQR) 3 (2 to 5) 2 (1 to 3) < 0.001a
1 1120 (21.6) 9475 (45.2) < 0.001b
2 1041 (20.1) 5405 (25.8)
3 812 (15.7) 3070 (14.7)
4 or 5 1076 (20.8) 2316 (11.1)
> 5 1131 (21.8) 683 (3.3)
Total (%) 5180 (19.8) 20,949 (80.2)
a Mann–Whitney U-test.
b Pearson’s chi-squared test = 2994.27, degrees of freedom = 4.
TABLE 7 The 20 most frequent LLT reactions by reporter type
No. of patient-reported reactions (N = 20,358) No. of HCP-reported reactions (N = 44,429)
LLT name
n (% of
reactions) LLT name n (% of reactions) Rank for patient reports
Nausea 458 (2.2) Nausea 987 (2.2) 1
Headache 440 (2.2) Headache 758 (1.7) 2
Dizziness 334 (1.6) Vomiting 647 (1.5) 6
Depression 300 (1.5) Rash 577 (1.3) 10
Diarrhoea 280 (1.4) Diarrhoea 479 (1.1) 5
Vomiting 242 (1.2) Dizziness 418 (0.9) 3
Tiredness 230 (1.1) Depression 273 (0.6) 4
Anxiety 196 (1.0) Abdominal pain 265 (0.6) 44
Itching 178 (0.9) Erythema 262 (0.6) 130
Rash 174 (0.9) Shortness of breath 256 (0.6) 49
Suicidal ideation 156 (0.8) Redness 252 (0.6) 108
Appetite lost 154 (0.8) Chest pain 249 (0.6) 28
Pain 148 (0.7) Pain 222 (0.5) 13
Muscle pain 145 (0.7) Itching 220 (0.5) 9
Joint pain 133 (0.7) Confusion 214 (0.5) 21
Shaking 133 (0.7) Swelling 213 (0.5) 47
Stomach pain 131 (0.6) Palpitations 212 (0.5) 22
Constipation 128 (0.6) Anxiety 211 (0.5) 8
Dry mouth 127 (0.6) Fever 206 (0.5) 55
Sweating 126 (0.6) Sweating 205 (0.5) 20
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The median (IQR) word count (excluding reports with zero word counts) used to describe the 
suspected reaction was significantly higher for patient reports [45.0 (22.0 to 74.0)] than HCP 
reports [15.0 (9.0 to 26.0); p < 0.001]. There was a significant difference between the median word 
count used to describe the reaction in each method of reporting (Table 9).
Seriousness of reaction
Similar percentages of both patient and HCP reports contained at least one reaction term coded 
as ‘dictionary serious’ by the MHRA (patients 58.3% vs HCPs 58.8%; p = 0.58).
Over one-half (55.5%) of HCP reporters stated that they considered their patient’s 
reaction serious.
Of the three subtypes of serious ADRs that were comparable between the two types of reporter, 
HCPs reported a higher proportion of each event than patient reports (caused hospitalisation 
18.8% vs 12.9%; life-threatening 11.1% vs 6.2%; caused death 2.6% vs 0.7%; p < 0.001 for each).
Nearly one-half (44.8%) of the patient Yellow Card reports said that the suspected ADR was 
bad enough to affect everyday activities, whereas 15.4% said it was uncomfortable or a nuisance 
and 2.6% said it was mild or slightly uncomfortable. Some patients appeared to have completed 
a HCP version of the Yellow Card or had a follow-up report by their HCP merged with theirs. 
Owing to the structure of the database these occurrences were difficult to quantify.
Drugs
A higher proportion of patient reports (16.1%) contained more than one suspect drug than 
HCP reports (9%, p < 0.001). The median (IQR) number of suspect drugs reported was 1 (1 to 1) 
TABLE 8 Comparison of the 15 most frequent SOC reaction groups by reporter type as a proportion of reporter type
Reaction
No. of patient 
reports (%)a No. of HCPb reports (%)a
Patient vs HCP: adjusted 
ORb (99% CI)
Nervous system disorders 1626 (41.5) 3912 (20.7) 2.72 (2.47 to 2.99)
General disorders and administration site conditions 1561 (39.8) 4371 (23.1) 2.20 (2.00 to 2.42)
Gastrointestinal disorders 1266 (32.3) 3722 (19.7) 1.95 (1.76 to 2.15)
Psychiatric disorders 1213 (30.9) 2312 (12.2) 3.22 (2.89 to 3.57)
Skin and subcutaneous tissue disorders 997 (25.4) 4391 (23.2) 1.13 (1.02 to 1.25)
Musculoskeletal and connective tissue disorders 766 (19.5) 1865 (9.9) 2.22 (1.97 to 2.50)
Respiratory, thoracic and mediastinal disorders 498 (12.7) 1598 (8.5) 1.58 (1.37 to 1.81)
Investigations 488 (12.5) 1713 (9.1) 1.43 (1.24 to 1.64)
Eye disorders 353 (9.0) 797 (4.2) 2.25 (1.89 to 2.67)
Metabolism and nutrition disorders 284 (7.2) 695 (3.7) 2.05 (1.70 to 2.47)
Vascular disorders 182 (4.6) 881 (4.7) 1.00 (0.80 to 1.23)
Renal and urinary disorders 176 (4.5) 609 (3.2) 1.41 (1.13 to 1.77)
Cardiac disorders 163 (4.2) 1025 (5.4) 0.76 (0.61 to 0.95)
Infections and infestations 141 (3.6) 711 (3.8) 0.96 (0.75 to 1.22)
Injury, poisoning and procedural complications 128 (3.3) 481 (2.5) 1.29 (1.00 to 1.68)
a The patient and HCP reports included in this table are those with data for age and gender, as this information was needed to adjust the ORs; 
reports with missing data for age or gender were excluded.
b ORs adjusted for age and gender of patient. The OR reference category is HCP.
Note: more than one reaction may be reported per report, so they are not mutually exclusive.
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
27 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
for both reporter types, although they were statistically different with the HCPs reporting less 
(p < 0.001). The 20 most frequent suspect drugs reported by patients and HCPs are presented in 
Figures 2 and 3, and substantial differences can be seen.
The ATC anatomical classification of suspect drugs on the patient and HCP reports is presented 
in Table 10. The most frequent category of drug suspected of being linked to an ADR was for 
the nervous system, for both patient (33.2%) and HCP (26.2%) reports. This was followed by 
cardiovascular system drugs from patient reports (21.8%) and anti-infectives for systemic use 
from HCP reports (19.4%). A statistically significant difference in the percentage of type of 
suspect drug between reporters was shown for drugs of the nervous system; cardiovascular 
system; systemic hormonal preparations, excluding sex hormones and insulin; antiparasitic 
products, insecticides and repellents; herbals/complementary medicine (which all had higher 
proportions in the patient than HCP reports); anti-infectives for systemic use; antineoplastic and 
immunomodulating agents; blood and blood-forming organs; and, ‘various’ (all of which had 
higher proportions in the HCP than the patient reports).
Patient Yellow Card reports were also split into those completed by patients themselves or by a 
representative (parent, carer, etc.) and HCP Yellow Card reports into those reported by doctors, 
pharmacists, nurses or another health professional (e.g. dentists). Among the patient reports, a 
higher proportion of patients reported drugs of the cardiovascular (p < 0.001) and genitourinary 
and sex hormone system (p = 0.003) than representatives who completed the patient report. 
In contrast, representatives reported a higher proportion of anti-infectives for systemic use 
(p < 0.001). Among HCP reports, there were significant differences in the proportion of drugs 
in each ATC anatomical category reported by the four HCP groups, except for antiparasitic 
TABLE 9 Median (IQR) word count used to describe the suspected reaction in the Yellow Card report by method of 
reporting used (excluding zero word counts)
Type of reporter and method of reporting n Median (IQR) Kruskal–Wallis p-value
HCP Yellow Card reporter
Internet 1231 17.0 (9.0 to 33.0) < 0.001
Paper 9012 14.0 (8.0 to 24.0)
Telephone 4 21.5 (10.5 to 36.0)
Not specified 5533 18.0 (10.0 to 29.0)
Patient Yellow Card reporter
Internet 607 94.0 (43.0 to 174.0) < 0.001
Paper 2718 42.0 (21.0 to 71.0)
Telephone 126 37.5 (19.0 to 64.0)
Not specified 1139 40.0 (19.0 to 64.0)
All Yellow Card reporters
Internet 1838 27.0 (12.0 to 69.0) < 0.001
Paper 11,730 17.0 (9.0 to 32.0)
Telephone 130 37.0 (18.0 to 61.0)
Not specified 6672 20.0 (11.0 to 34.0)
Reports with zero word counts were excluded because the MHRA do not always transcribe the narratives for HCPs reporting non-serious 
reactions. Including these reports would have led to bias in the word count when comparing patient and HCP reports.
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products, insecticides and repellents. A higher proportion of nurses reported a suspected 
ADR for anti-infectives for systemic use (41.8%) or respiratory system drugs (5.6%) than any 
other HCP. A higher proportion of pharmacists reported a suspected ADR for a drug for the 
cardiovascular system (17.2%), musculoskeletal system (11.8%), blood and blood-forming organs 
(10.8%), and systemic hormonal preparations (2.1%). Of all the HCP groups examined, doctors 
reported a greater proportion of suspected ADRs for drugs of the alimentary tract and metabolic 
drugs (10.5%) as well as genitourinary system and sex hormone drugs (6.4%).
Time lag between suspect adverse drug reaction and reporting
Patient reporters took a significantly longer median (IQR) time to report their reaction to the 
MHRA, compared with HCPs [104 (27 to 463) vs 28 (13 to 75) days, respectively; p < 0.001]. 
However, there was a higher percentage of missing data for the variable ‘time from reaction to 
report’ among patient reports (61.0% of such reports) compared with HCP reports (33.2%).
The median time to report a suspected ADR for reactions occurring in the first and second year 
of the study period is presented in Table 11, by reaction outcome. The median time to report an 
ADR among patients who were still recovering or whose reaction was resolving was significantly 
longer in year 2 than in year 1, regardless of who reported the ADR [patient (p = 0.01) and HCP 
FIGURE 2 The 20 most frequent suspect drugs reported by patients (by reporter type). Note: the rank of the drug for 
HCP reporters is shown to the right of the HCP bars.
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(p = 0.02) reports, respectively]. However, these data should be interpreted with caution as there 
were large amounts of missing data related to this issue, in both groups of reporter.
Reaction outcome
A significantly higher proportion of HCPs reported fatal outcomes to the reaction than patient 
representatives (2.6% vs 0.7%; p < 0.001). A significantly higher proportion of HCPs reported that 
the patient was recovering or that the ADR was resolving than among patient reports (28.4% vs 
16.8%; p < 0.001). More patients reported that they had not recovered or that the reaction had not 
resolved than HCPs (36.4% vs 22.2%; p < 0.001).
Yellow Card reports involving children
One of our objectives was to specifically examine Yellow Card reports involving children. 
The findings are shown in Appendix 10. The median age and percentage of females was 
similar between patient and HCP reporters. Patient reports contained more reactions per 
report and there were differences in the types of reactions reported. For example, in keeping 
with all patient reports, patient reports for children were more common for reactions in the 
following SOC reaction groups: nervous system, psychiatric, gastrointestinal, metabolism and 
nutritional disorders.
FIGURE 3 The 20 most frequent suspect drugs reported by HCPs (by reporter type). Note: the ordered rank of the drug 
for patient reporters is shown to the right of the patient bars.
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Summary
 ■ Anonymised data were provided by the MHRA for all patient and HCP reports received 
by the YCS between 1 October 2005 and 30 September 2007. To compare the two reporter 
groups, suspected adverse reaction terms were grouped within the hierarchical structure of 
the industry standard ‘Medical Dictionary for Regulatory Affairs’ (MedDRA, version 12) 
and suspect drug names were mapped to the most appropriate code within the ATC drug 
classification system (2007 version).
 ■ For the 2-year study period, 26,129 Yellow Card reports were received from the MHRA 
[5180 (19.8%) patient reports and 20,949 (80.2%) HCP reports]. Patient reports contained a 
significantly higher number of suspected ADRs per report than HCPs [median (IQR) of 3 (2 
to 5) vs 2 (1 to 3), respectively; p < 0.001]. A higher proportion of patient reports contained 
more than one suspect drug than HCP reports (16.1% vs 9% respectively; p < 0.001). The 
median (IQR) word count (excluding reports with zero word counts) used to describe the 
suspected reaction was significantly higher for patient reports than for HCP reports [45.0 
(22.0 to 74.0) vs 15.0 (9.0 to 26.0), respectively; p < 0.001].
TABLE 11A Descriptive statistics of time taken to report an ADR by outcomes of suspected side effects for reactions 
reported in the first and second year of the study: patient-reported ADR
Reaction outcome
 Time to report in first year (days)
No. of 
reports in 
first year
Time to report in second year (days) No. of 
reports in 
second 
year p-valuea
Median 
[IQR] Range
Missing 
(%)
Median 
(IQR) Range
Missing 
(%)
Not recovered/
resolved
195.0 
(44.0 to 
852.0)
2–14,994 675 (54.7) 1234 147.0 
(35.0 to 
644.0)
2–5389 441 (67.6) 652 0.08
Recovering/
resolving
51.0 (13.0 
to 212.0)
1–10,700 277 (49.2) 563 88.5 (27.0 
to 331.0)
2–4093 195 (63.9) 305 0.01
Recovered/resolved 
with sequelae
247.5 
(48.0 to 
670.0)
6–5986 52 (53.1) 98 306.5 
(77.0 to 
925.0)
9–2985 81 (61.8) 131 0.91
Recovered/resolved 68.5 (21.0 
to 305.0)
1–14,717 760 (52.8) 1440 88.0 (24.0 
to 352.0)
2–10,003 530 (71.3) 743 0.54
a The p-value from Mann–Whitney U-test.
TABLE 11B Descriptive statistics of time taken to report an ADR by outcomes of suspected side effects for reactions 
reported in the first and second year of the study: HCP-reported ADR
Reaction outcome
 Time to report in first year (days)
No. of 
reports in 
first year
Time to report in second year (days) No. of 
reports in 
second 
year p-valuea
Median 
(IQR) Range
Missing 
(%)
Median 
(IQR) Range
Missing 
(%)
Not recovered/
resolved
35.0 (14.0 
to 105.0)
0 to 4829 652 (27.7) 2354 34.0 (14.0 
to 98.0)
1 to 4328 1064 
(46.4)
2291 0.86
Recovering/
resolving
20.0 (10.0 
to 46.0)
0 to 5614 637 (20.3) 3135 21.0 (11.0 
to 52.0)
0 to 1642 960 (34.0) 2822 0.02
Recovered/resolved 
with sequelae
99.0 (41.0 
to 107.0)
7 to 203 2 (28.6) 7 90.5 (30.0 
to 167.0)
14 to 
1655
7 (28.0) 25 0.74
Recovered/resolved 33.0 (14.0 
to 81.0)
0 to 3971 987 (23.1) 4282 31.0 (14.0 
to 84.0)
0 to 3092 1725 
(39.7)
4350 0.77
a The p-value from Mann–Whitney test.
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 ■ Patients showed different patterns of reporting of drugs and ADRs compared with HCPs. 
Nevertheless, similar proportions of reports contained at least one reaction term that 
was classified as ‘serious’ by the MHRA (58.3% for patients vs 58.8% for HCPs; p = 0.58). 
The following were recorded more commonly in HCP reports than patient reports: 
‘caused hospitalisation’ (18.8% vs 12.9%, respectively); ‘life-threatening’ (11.1% vs 6.2%, 
respectively); and ‘caused death’ (2.6% vs 0.7% respectively) (p < 0.001 for each comparison). 
Of the patient Yellow Card reports, 44.8% stated that the suspected ADR was bad enough 
to affect everyday activities. Patient reporters took a significantly longer time to report 
suspected ADRs than HCPs [median (IQR) of 104 (27 to 463) days vs 28 (13 to 75) days; 
respectively; p < 0.001], although there were missing data on ‘time taken to report’ for over 
60% of patient reports.
© Adis Data Information BV 2010. All rights reserved.
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Chapter 5  
Study 3: pharmacovigilance impact 
of patient reporting: signal generation 
analysis
A large part of this chapter has been reproduced with permission from Adis, a Wolters Kluwer Business (see McLernon et al.40 for the final published version).
Introduction to signal generation analysis
An important objective in pharmacovigilance is the early detection of a potential signal of an 
ADR. Traditionally, this includes using observations by HCPs and patients, case reports in 
the literature, reports to spontaneous reporting systems and/or data from larger studies, such 
as clinical trials and observational studies. It is important to have robust systems that detect 
previously unsuspected problems, as well as those that are able to investigate emerging problems.
In order to further evaluate a signal of a previously unrecognised ADR, it is necessary to 
determine whether there is evidence of a causal relationship between the drug and the 
reaction. This will involve not only clinical evaluation of cases reported, but also a search for 
further information in the literature and an assessment of the pharmacological plausibility of 
a causal association.41 Causality assessment on individual or clusters of reports depends on the 
completeness of the information provided. It may require follow-up information from reporters. 
Particularly relevant are details on the patient’s medical history, concomitant drug therapies and 
the time course of the reaction in relation to the suspect drug therapy.
It is not practical to perform such assessments on all events reported to pharmacovigilance 
organisations. Triage methods may be applied.42,43 For example, the MHRA currently uses a 
system of filtering ADRs within their signal detection database so as to prioritise important ADRs 
for further clinical evaluation. Hence, ADR reports that have a fatal outcome, involve children 
or pregnant women, or include ‘alert’ terms (a list of reaction terms specified in-house by the 
MHRA) are regarded as high priority. In addition, reports relating to black triangle drugs that 
are regarded as serious by the reporter or that involve reactions coded as ‘dictionary serious’ by 
the MHRA are also prioritised for clinical assessment. For established drugs on the UK market, 
however, an additional filter is applied to serious reactions using quantitative signal detection 
methods. Essentially, these methods generate ‘statistical’ signals of ADRs using disproportionality 
analysis to identify drug–reaction pairs that are reported more frequently than expected, based 
on the background reporting rates for the drug and reaction of interest within the database.44 
The MHRA uses a method based on the Empirical Bayesian Geometric Mean (EGBM) method.45 
Vaccines are analysed in a similar way, but separately from other medicinal products.
Within the context of this project it was not feasible to analyse all reports meeting the high-
priority criteria outlined above. Hence, we have used disproportionality analysis as the primary 
means of identifying potential signals of ADRs, regardless of the patient’s age, seriousness of 
reaction, time of marketing of the suspect drug or the reaction outcome. In addition, reports 
relating to vaccines have been analysed together with drugs to maximise the size of our data sets.
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The method of disproportionality analysis used in our project was the proportional reporting 
ratio (PRR), in which the reporting rate for an ADR in association with a particular medicine 
is compared with that of other products in the database.46 This method is used by the 
EudraVigilance (European Union Drug Regulating Authorities Pharmacovigilance) Data 
Analysis System, which supports pharmacovigilance activities within the European Community. 
The system uses the term ‘signal of disproportionate reporting (SDR)’ instead of the more 
ambiguous term ‘signal’, as the latter term might be interpreted as implying a causal relationship 
between suspect drug and ADR.47
Unlike formal clinical trials or observational studies, disproportionality analysis within 
spontaneous reporting schemes does not provide an estimate of the frequency of ADRs (as 
it does not provide denominator information for drug exposure) and is subject to bias from 
under-reporting and selective reporting (e.g. when the media report a particular safety issue). 
The merits and limitations of different statistical methods for disproportionality analysis in 
the context of signal generation have been discussed elsewhere.44A key concept is that signals 
detected using any quantitative method indicate a higher proportionate reporting of a specific 
reaction for a specific drug than would be expected considering the whole ADR database; it does 
not necessarily prove causality. Further qualitative evaluation is essential when determining 
whether a real ADR is being signalled.
The SDRs identified by our analysis formed the sampling frame from which reports were selected 
for further evaluation. We did not plan to undertake an exhaustive signal assessment. Instead, we 
aimed to conduct an assessment of causality using information provided by patients and, where 
possible, compare this with similar assessments undertaken on information supplied by HCPs.
Aim
To investigate the relative contribution of patient reports to signal generation.
Objectives
The following objectives are more detailed than those in our original application and were:
 ■ Quantitatively:
 – to compare the types of SDRs generated by patient reports with those generated by HCP 
reports, in terms of their importance within the context of pharmacovigilance including:
 – the seriousness of the ADRs involved (using the MHRA’s ‘dictionary seriousness’ 
classification)
 – the time of marketing of the suspect drugs involved (black triangle drugs)
 – whether the ADR had been previously been documented on the summary of 
product characteristics (SPC) for the suspect drug involved
 – to investigate how SDRs generated in a spontaneous reporting database of HCP reports 
may be affected (statistically) by the inclusion of patient reports
 – to estimate the extent to which duplicate reporting occurs.
 ■ Qualitatively:
 – to investigate how the information provided by patient reports may contribute to the 
assessment of a causal association for selected drug–ADR pairs.
 – to identify problems incurred when assessing causality from patient reports.
© Adis Data Information BV 2010. All rights reserved.
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Methods
Data collection and processing
As described in Chapter 3, data were received from the MHRA containing details of patient and 
HCP reports submitted to the YCS during the 2-year period from October 2005 to September 
2007. Reports from the pharmaceutical industry were excluded.
Data synthesis
Following the initial data processing described in Chapter 3, three data sets of drug–ADR 
pairs were compiled: one for patient reports (‘patient-only’), one for HCP reports (‘HCP only’) 
and a combined data set for reports from both groups (‘combined’). For the purposes of the 
signal generation analysis the drug–ADR pair consisted of the drug name coded at the lowest 
hierarchical level within the ATC classification system for drug substances and the reaction term 
coded at the PT level within the hierarchical MedDRA dictionary.
Signals of disproportionate reporting were generated for each drug–ADR pair reported using a 
modification of the PPR, calculated by the formula:
PRR = A/(A+B)
C /(C+D)
 [Equation 1]
where:
 ■ A = the number of patients who had drug X and reaction Y
 ■ B = the number of patients who had drug X and did not have reaction Y
 ■ C = the number of patients who did not have drug X, but had reaction Y
 ■ D = the number of patients who did not have drug X and did not have reaction Y.
That is: 
Drug Reaction Y All other reactions Total
Drug X A B A + B
All other drugs C D C + D
Total A + C B + D N = A + B + C + D
For each drug–ADR pair, each patient contributes to only one of the four A, B, C or D cells, even 
if a report involved more than one suspect drug or reaction term. This maintains independence 
between the variables used to calculate the PRR, so that variance is not underestimated.
In order to improve statistical robustness of the PRR where few or no drug–ADR pairs were 
observed in the data set, a shrinkage method was adopted. Thus, the ‘PRRshrunk’ was calculated 
using a modification of the PRR formula:48
PRRshrunk = (‘observed’ + 0.5)/(‘expected’ + 0.5) [Equation 2]
where ‘observed’ = A and ‘expected’ = [(A + B)C/C + D].
For each PRRshrunk, 95% CIs were calculated using the formula:
Lower CI = PRRshrunk/exp(1.96s) and upper CI = PRRshrunk × exp(1.96s) [Equation 3]
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where:
s
A B A B C D
= + −
+
−
+
1 1 1 1  [Equation 4]
Within each of the three data sets the PRRshrunk was generated for each drug–ADR pair reported 
over the 2-year study period. Based on previously published arbitrary thresholds, drug–ADR 
pairs were flagged as SDRs, if at the end of the 2-year study period all of the following three 
conditions were fulfilled:46
 ■ the PRRshrunk was > 2
 ■ the number of reports for the drug–reaction pair (A) was ≥ 3
 ■ the lower 95% CI for the PRRshrunk was ≥ 1.
All PRR calculations were computed within a SQL Server (2000) database.
Quantitative analysis of signals of disproportionate reporting
Comparison of signals of disproportionate reporting generated by 
the patient and health-care professional data sets
The following descriptive statistics were calculated for the patient and the HCP data sets:
 ■ Number and proportion of SDRs generated in each data set.
 ■ Number and proportion of SDRs generated in each data set where the reaction preferred 
term was classified as ‘dictionary serious’ by the MHRA at least once (regardless of who 
reported such an event).
 ■ Number and proportion of SDRs generated in each data set where the suspect drug may 
have been available as a recently marketed product or formulation. For the purposes of 
this analysis drug–ADR pairs were flagged as ‘black triangle’ if any report relating to that 
drug, regardless of the brand or formulation reported, had been classified by the MHRA as 
‘black triangle’.
 ■ Number of SDRs that were documented, i.e. listed within section 4.8 (‘undesirable effects’) of 
the SPC for the suspect drug involved. It was not practical to evaluate whether all of the SDRs 
generated in this analysis had been previously documented on the SPC. Hence, a random 
sample of 300 SDRs from each data set was selected. This sample size would be sufficient to 
detect a 10% difference in proportion of SDRs that were not documented on the product’s 
SPC between the patient and HCP data sets, at the 5% significance level with 80% power. In 
addition, the SPC for a medicinal product changes over time, so it was not feasible within the 
context of the project to evaluate whether the SDRs generated had been documented on the 
SPC at the time of the individual report or reaction. Furthermore, the retrospective nature 
of our study meant that it was not always possible to identify when the SPC for a particular 
drug first recorded a particular ADR. In order to provide an estimate of whether new 
information about SDR/ADRs was being revealed by each data set, we referred to the version 
of SPC available at the beginning of the study period (2004) rather than estimate which 
version was available at the time of the report or reaction, or the first available SPC for drugs 
launched on the UK market during the course of the study.
 ■ Top five system organ classes for reactions and top five anatomical classes for drugs most 
commonly associated with the SDRs generated by each data set.
Univariate comparisons between reports from patients and HCPs were performed using Pearson’s 
chi-squared test for categorical variables, or the difference in proportions calculated with its 95% 
CI. These were computed using stata (version 10).
© Adis Data Information BV 2010. All rights reserved.
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Analysis of signals of disproportionate reporting generated after 
combining data from patients and health-care professional data sets
The following descriptive statistics were calculated:
 ■ Number of SDRs generated in the ‘patient-only’ and ‘HCP-only’ data sets that remained 
SDRs in the ‘combined’ data set.
 ■ Number of SDRs generated in the ‘patient-only’ and ‘HCP-only’ data sets that were no 
longer SDRs in the ‘combined’ data set, along with the proportion of these SDRs that were 
potentially serious, involved suspect drugs flagged as ‘black triangle’ and/or were not 
documented on the SPC.
 ■ Number of new SDRs in the ‘combined’ data set compared with those generated in the ‘HCP-
only’ data set, along with the proportion of these SDRs that were potentially serious, involved 
suspect drugs flagged as ‘black triangle’ and/or were not documented on the SPC.
 ■ Number of SDRs generated by the ‘HCP-only’ data set that were detected later or earlier after 
the combination with the patient data set.
Causality assessment in a sample of reports
Drug–ADR pairs identified as SDRs in the disproportionality analysis were first categorised 
according to whether the patient reports appeared to be adding, or taking away, information 
provided by the HCP reports (Table 12). This categorisation provided a sampling frame for the 
selection of reports for an assessment of causality.
Within each of the four categories, SDRs were subgrouped according to whether the ADR term 
was classified as ‘dictionary serious’ by the MHRA, whether the ADR (or similar term) was 
documented on the SPC and whether the suspect drug was available in a form or brand classified 
as a black triangle drug by the MHRA. Four SDRs were then randomly selected from the SDRs 
in each of the 12 subcategories. It is important to note that the categories in Table 12 were not 
mutually exclusive; if a randomly selected SDR had already been selected for one category it was 
replaced by another randomly selected suitable SDR.
The sampling frame was used to select SDRs that involved no more than 10 individual patient 
and/or HCP reports so that a variety of drugs (including OTC products and complementary 
therapies) and reactions could be assessed for causality. This number was chosen to give a range 
of reported problems while ensuring a manageable workload for the project.
An assessment of causality was made for each identified report, by two DSRU researchers (a 
pharmacist and a biomedical scientist). Conflicting assessments were discussed by the two 
researchers and where agreement could not be reached, a third member of DSRU staff (a 
medically-qualified doctor) arbitrated. The assessment involved reviewing all of the data provided 
TABLE 12 Categorisation of SDRs according to whether the patient reports appeared to add to, or lead to potential loss 
of, information provided by the HCP reports
Category Description
1 Potential new information provided by the patient report: drug–ADR pair identified as SDR in the ‘patient-only’ data set, but 
not identified as SDR in the ‘HCP-only’ data set, although drug–ADR pair in the HCP data set
2 Potential new information provided by the patient report: drug–ADR pair identified as SDR in the ‘patient-only’ data set, but 
drug–ADR pair not present in the ‘HCP-only’ data set (and, hence, could not be identified as an SDR in ‘HCP-only’ data set)
3 Potential new information from the addition of patient reports to HCP reports: new SDR generated in the ‘combined’ data set, 
which was not identified in the ‘patient-only’ or ‘HCP-only’ data sets alone, irrespective of whether the drug–ADR pair was in 
either data set
4 Potential loss of information from the addition of patient reports to HCP reports: SDR generated in the ‘HCP-only’ data set, 
which was no longer a SDR in the ‘combined’ data set
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by the MHRA. Each ADR was classified into one of four categories (Table 13). The process also 
enabled:
 ■ the identification of likely duplicates
 ■ the identification of limitations when making the assessment of causality for patient reports
 ■ an assessment of whether important information provided in the narrative description was 
lost by coding using MedDRA terminologies.
Results
Comparison of patient and health-care professional reports: overview
There were 5180 (19.8% of total) reports supplied by patients and 20,949 (80.2%) by HCPs. 
Table 14 shows the number of different reaction terms coded (at PT level), suspect drugs (at ATC 
code level) and drug–ADR pairs in the three data sets. The ‘patient-only’ data set contained less 
than one-half (approximately 40%) of all of the drug–ADR pairs reported in this study. Figure 4 
shows that most drug–ADR pairs were present in either the ‘patient-only’ or the ‘HCP-only’ 
data set – only 10.6% drug–ADR pairs were common to both data sets. This indicates marked 
differences between the two data sets in the identification of drug–ADR pairs.
Comparison of signals of disproportionate reporting generated by patient 
and health-care professional data sets
Figure 5 shows the number of SDRs generated using the PRRshrunk method in the ‘patient-only’ 
and ‘HCP-only’ data sets. A significantly higher proportion of SDRs were generated from drug–
ADR pairs contained in the ‘HCP-only’ data set than in the ‘patient-only’ data set (6.7% and 3.9% 
of pairs, respectively; difference 2.8%, 95% CI 2.4% to 3.2%). Only 136 drug–ADRs pairs (21.0% 
of those generated by the ‘patient-only’ data set; 7.0% of those from the ‘HCP-only’ data set) 
were generated as SDRs in both data sets. For these 136 SDRs, 56 (41.2%) were detectable earlier 
in the ‘patient-only’ data set, 71 (52.2%) were detectable later and for nine (6.6%) there was no 
difference in the time to reach SDR threshold.
TABLE 13 Causality categories
Causality Criteria
Probable An event that was clinically well defined, occurring within a reasonable time sequence to drug administration, more likely 
to be attributable to the drug than concurrent disease or medication and that followed a clinically reasonable response 
on drug withdrawal or dose reduction (dechallenge) or reintroduction of the drug or dose increase (rechallenge)
Possible An event with a reasonable clinical definition occurring with a reasonable time sequence to drug administration, but 
which could also be explained by concurrent disease or medication; information on dechallenge and rechallenge may 
have been incomplete or inconclusive
Unlikely An event with a temporal association to drug administration which makes causality improbable or in which an illness or 
another medication provided a more plausible explanation for the event
Not assessable Incomplete or conflicting information, which prevented an assessment of causal association
TABLE 14 Distribution of reaction terms, suspect drugs and drug–ADR pairs reported on each data set
Drug–ADR pairs, ATC codes and 
reaction terms
Exclusive to ‘patient-
only’ data set
Exclusive to ‘HCP-
only’ data set
Present in both the 
‘patient-only’ and 
‘HCP-only’ data sets In ‘combined’ data set
Drug–ADR pairs (% of row total) 12,226 (29.8) 24,435 (59.6) 4340 (10.6) 41,001
ATC codes (% of row total) 163 (11.6) 626 (44.4) 622 (44.1) 1411
ADR PTs (% of row total) 275 (9.6) 1514 (52.9) 1073 (37.5) 2862
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It would appear, therefore, that patient and HCP reports generate different SDRs, although 
this may partly be owing to differences in the way in which reactions are described and then 
subsequently coded at the MedDRA PT level. Further assessment of the 649 SDRs generated 
by the ‘patient-only’ data set revealed that, in addition to the 136 SDRs also generated by the 
‘HCP-only’ data set, another 88 used a reaction term for the suspect drug similar or related to 
that of some SDRs generated using the ‘HCP-only’ data set. For example, the ‘patient-only’ data 
set identified amlodipine and ‘heart rate irregular’ as an SDR, whereas the ‘HCP-only’ identified 
amlodipine and ‘palpitations’ as an SDR. Nevertheless, 425 of the 649 (65.5%) SDRs generated 
using the ‘patient-only’ data set were quite distinct and so unlikely be generated using the ‘HCP-
only’ data set.
FIGURE 4 Distribution of drug–reaction pairs across the patient and HCP data sets. aTotal: 41,001 pairs.
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FIGURE 5  Signals of disproportionate reporting generated from drug–ADR pairs in the patient and HCP data sets.
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Table 15 shows whether the SDRs generated by each data set involved reactions which were 
classified as ‘dictionary serious’, or involved a black triangle drug. Compared with those generated 
using the ‘patient-only’ data set, a significantly higher proportion of the SDRs generated using the 
‘HCP-only’ data set was classified as involving serious reactions (difference in proportions 19.5%, 
95% CI 15.4% to 23.6%) or a black triangle suspect drug (difference in proportions 19.8%, 95% 
CI 16.6% to 23.0%).
In both data sets the majority of SDRs generated were documented on the SPC, either specifically 
as described or using a similar or related clinical term for the suspect drug (Table 16). There 
was no significant difference between the two data sets in the proportion of SDRs which were 
regarded as not documented (difference in proportions 2.0%, 95% CI –3.7% to 7.7%).
Table 17 shows the top five most common system organ classes involved in SDRs generated 
by each data set and the top five anatomical drug classes involved. The same five system organ 
classes were involved when using each data set although their ranking differed (Table 17). Four of 
the five top anatomical drug classes were common to both data sets, although again the ranking 
differed (Table 18).
Table 19 shows the top 10 individual suspect drugs involved in the SDRs generated by each data 
set and Table 20 the 10 most common preferred terms for the SDRs generated. The drugs and 
preferred terms for SDRs generated by the two data sets tended to be different, with none of the 
drugs and only four of the preferred terms being the same. The drugs involved in SDRs generated 
by the ‘HCP-only’ data set tended to be for recently introduced (black triangle) drugs, whereas 
the drugs involved in the SDRs generated by the ‘patient-only’ data set were for older, more 
established drugs.
Analysis of signals of disproportionate reporting generated after the 
combination of data from patients and health-care professional data sets
Table 21 presents the number of drug–ADR pairs generated as SDRs before and after combining 
the patient and HCP reports and the number of drug–ADRs pairs no longer generated as SDRs in 
the ‘combined’ data set.
TABLE 15 Signals of disproportionate reporting in each data set classified as ‘dictionary serious’ reactions or involving 
‘black triangle’ drugs
Classification of SDRs ‘Patient-only’ data set ‘HCP-only’ data set
No. of SDRs generated 649 1939
No. classified as ‘dictionary serious’ reaction terms (% of SDRs generated) 185 (28.5) 931 (48.0)
No. involving a suspect drug flagged as ‘black triangle’ (% of SDRs generated) 71 (10.9) 596 (30.7)
TABLE 16 Signals of disproportionate reporting classified as potentially new information
Classification of SDRs ‘Patient-only’ data set ‘HCP-only’ data set
No. of SDRs generated 649 1939
Sample assessed 300 300
No. documented on SPC (%) 164 (54.7) 132 (44.0)
No. with similar clinical term documented (%) 73 (24.3) 80 (26.7)
No. not documented (%) 48 (16.0) 42 (14.0)
No. that were documented during or after the period of study (%) 11 (3.7) 33 (11.0)
No. of SDRs that could not be unclassified, e.g. non-specific terms such as ‘feeling 
abnormal’ (%)
4 (1.3) 13 (4.3)
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The majority of SDRs generated in the ‘patient-only’ and ‘HCP-only’ data sets remained 
SDRs after combining both sets of reports. However, 278 of the drug–ADR pairs generated as 
SDRs (approximately 11% of all SDRs generated by the ‘patient-only and ‘HCP-only’ data sets 
independently) were no longer generated as SDRs in the ‘combined’ data set, including SDRs 
TABLE 17 Top five reaction system organ classes for SDRs generated using the ‘patient-only’ and the ‘HCP-only’ 
data sets
‘Patient-only’ data set ‘HCP-only’ data set
SOC No. of SDRs (%)a SOC No. of SDRs (%)a
Psychiatric disorders 144 (22.2) General disorders and administration site 
conditions
319 (16.4)
Nervous system disorders 95 (14.6) Gastrointestinal disorders 234 (12.1)
Gastrointestinal disorders 94 (14.5) Nervous system disorders 228 (11.8)
Skin and subcutaneous tissue disorders 67 (10.3) Skin and subcutaneous tissue disorders 204 (10.5)
General disorders and administration site 
conditions
66 (10.2) Psychiatric disorders 194 (10.0)
a Percentage of all SDRs generated in each data set; n = 649 for ‘patient-only’ reports and n = 1939 for ‘HCP-only’ reports.
TABLE 18 Top five anatomical drug classes for SDRs generated using the ‘patient-only’ and the ‘HCP-only data sets
‘Patient-only’ data set ‘HCP-only’ data set
Anatomical drug class No. of SDRs (%)a Anatomical drug class No. of SDRs (%)a
Nervous system 253 (39.0) Nervous system 482 (24.9)
Cardiovascular system 124 (19.1) Anti-infectives for systemic use 452 (23.3)
Anti-infectives for systemic use 76(11.7) Cardiovascular system 207 (10.7)
Alimentary tract and metabolism 38 (5.9) Alimentary tract and metabolism 167 (8.6)
Genitourinary system and sex hormones 36 (5.6) Antineoplastic and immunomodulating agents 160 (8.2)
a Percentage of all SDRs generated in each data set; n = 649 for ‘patient-only’ reports and n = 1939 for ‘HCP-only’ reports.
TABLE 19 Suspect drugs most commonly associated with SDRs generated using the ‘patient-only’ and ‘HCP-only’ 
data sets
‘Patient-only’ data set ‘HCP-only’ data set
Suspect drug No. of SDRs (%)a Suspect drug No. of SDRs (%)a
Paroxetine 48 (7.4) Pneumococcal vaccine 46 (2.4)
Venlafaxine 23 (3.5) Rimonabant 41 (2.1)
Cyproterone and oestrogen 21 (3.2) Pregabalin 39 (2.0)
Citalopram 17 (2.6) Varenicline 38 (2.0)
Trimethoprim 16 (2.5) Duloxetine 34 (1.8)
Simvastatin 14 (2.2) Acetylsalicylic acid 32 (1.6)
Tramadol 14 (2.2) Bupropion 30 (1.6)
Atorvastatin 13 (2.0) Atomoxetine 27 (1.4)
Diclofenac 12 (1.8) Diphtheria–HIB–pertussis–poliomyelitis–
tetanus
27 (1.4)
Zopiclone 12 (1.8) Etonogestrel 26 (1.4)
a Percentage of all SDRs generated in each data set; n = 649 for ‘patient-only’ reports and n = 1939 for ‘HCP-only’ reports.
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involving drugs flagged as ‘black triangle’, potentially serious reactions or reactions that were not 
documented on the SPC of the suspect drug. Three of the drug–ADR pairs generated as SDRs 
by the ‘HCP-only’ data set that were no longer generated as SDRs in the ‘combined’ data set were 
potentially serious, involved a drug flagged as ‘black triangle’ and were not documented as a 
problem on the SPC (levetiracetam/drug interaction, pregabalin/overdose and rimonabant/blood 
pressure increased).
Of the 1753 SDRs generated in the ‘HCP-only’ data set that remained SDRs in the combined 
data set, 139 (7.9%) were detectable later in the combined data set, 247 (14.1%) were detectable 
earlier and in the remaining 1367 (77.0%) the month of detection was unchanged. This should be 
interpreted with caution, however, as this assumes that both patient and HCP reporting started at 
the same ‘day 0’, which is not true in practice (HCP reporting to the YCS commenced in 1964).
In practice, disproportionality analysis is not relied upon in signal detection for black triangle 
drugs. Instead, serious reactions to black triangle drugs are scrutinised on a case-by-case basis 
by the regulatory authorities. ‘Loss’ of SDRs, however, may be of concern for established drugs 
where disproportionality analysis is used to prioritise serious reactions for clinical assessment. 
Five of the SDRs generated when using the ‘HCP-only’ data set were ‘lost’ after combination 
TABLE 20 Preferred terms most commonly associated with SDRs generated using the ‘patient-only’ and ‘HCP-only’ 
data sets
‘Patient-only’ data set ‘HCP-only’ data set
Preferred term No. of SDRs (%)a Preferred term No. of SDRs (%)a
Diarrhoea 16 (2.5) Anaphylactic reaction 27 (1.4)
Anxiety 15 (2.3) Rash 26 (1.3)
Arthralgia 14 (2.2) Pyrexia 24 (1.2)
Weight increased 14 (2.2) Headache 22 (1.1)
Nausea 13 (2.0) Vomiting 22 (1.1)
Tremor 13 (2.0) Dizziness 21 (1.1)
Vomiting 13 (2.0) Urticaria 21 (1.1)
Dizziness 12 (1.8) Liver function test abnormal 20 (1.0)
Rash 12 (1.8) Dyspnoea 19 (1.0)
Dyspnoea 11 (1.7) Pruritus 19 (1.0)
a Percentage of all SDRs generated in each data set; n = 649 for ‘patient-only’ reports and n = 1939 for ‘HCP-only’ reports.
TABLE 21 Signals of disproportionate reporting generated before and after combination of patient and HCP data sets
Classification of SDRs ‘Patient-only’ data set ‘HCP-only’ data set
SDRs generated before data combined 649 1939
SDRs remaining after data combined (% of SDRs generated in each data set before 
combination)
557 (85.8) 1753 (90.4)
SDRs no longer present after data combined:
All (% of SDRs generated before combination) 92 (14.2) 186 (9.6)
Serious (% of all) 18 (19.6) 47 (25.3)
Flagged as ‘black triangle’ 10 (10.9) 69 (37.1)
Not documented on SPC (% of all) 14 (15.2) 32 (17.2)
Serious, black triangle and not documented (% of all) 0 (0.0) 3 (1.6)
Serious, established drug and not documented (% of all) 4 (4.3) 5 (2.7)
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of patient and HCP reports, involving established drugs, potentially serious reactions and 
reactions that were not documented on the product’s SPC (anastrazole/depression, citalopram/
hypoglycaemia, simvastatin/drug interaction, trimethoprim/chest discomfort and trazadone/
myalgia). Four of the SDRs generated by the ‘patient-only’ data set involved established drugs, 
potentially serious reactions and reactions that were not documented on the product’s SPC, 
which were ‘lost’ when the patient reports were combined with the HCP reports (citalopram/
aggression, doxazosin/muscular weakness, perindopril/hypertension and prednisolone/
face swelling).
The addition of patient reports to HCP reports generated an extra 929 SDRs for drug–ADR pairs 
that either had not been generated as SDRs when the ‘HCP-only’ data set was used (705 SDRs) 
or that were not present in ‘HCP-only’ data set (i.e. 224 SDRs that were only seen in the ‘patient-
only’ data set) (Figure 6). Of these 929 additional SDRs, 299 (32.2%) were classified as being 
potentially serious, 139 (15.0%) involved black triangle drugs and 222 (23.9%) involved reactions 
that were not documented on the SPC.
Of the 929 additional SDRs generated, 508 would not have been generated by disproportionality 
analysis in either the ‘patient-only’ or the ‘HCP-only’ data sets alone. Of these 508 extra SDRs, 
185 (36.4%) were classified as being potentially serious, 95 (18.7%) involved drugs flagged as 
‘black triangle’ and 137 (26.9%) involved reactions which were not documented as problems 
on the SPC. Ten of these additional SDRs were potentially serious, involved a drug flagged as 
‘black triangle’ and were not documented on the product’s SPC (see Appendix 11), whereas 37 
of the additional SDRs were potentially serious reactions involving established drugs that were 
not documented on the product’s SPC (see Appendix 12). Some of these SDRs were related to 
conditions that were prescribing indications for the suspect drug, for example diazepam/muscle 
spasms, chloramphenicol/eyelid oedema and donepezil/confusional state.
Causality assessment in a sample of reports
Overall, 41 drug–ADR pairs were randomly selected from the sampling frame for causality 
assessment, involving 199 patient reports and 184 HCP reports, to show the findings from the 
causality assessments performed within each category of drug–ADR pairs of interest. These have 
not been tested statistically owing to the small numbers within each category. The full breakdown 
of causality assessments is included in Appendix 13.
FIGURE 6 Additional SDRs generated after combining the patient and the HCP reports.
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In Category 1, 11 drug–ADR pairs present in both the ‘patient-only’ and the ‘HCP-only’ data sets 
but identified as SDRs only in the ‘patient-only’ data set, were selected from the sampling frame. 
The distribution of causality assessments, performed on the 56 patient and the 43 HCP reports 
involving these drug–ADR pairs was similar for both reporter groups (Figure 7). Most reports 
were assessed as ‘possible’ with a relatively small number assessed as ‘probable’. Slightly more 
patient reports than HCP reports could not be assessed.
In Category 2, 12 drug–ADR pairs identified as SDRs in the ‘patient-only’ data set but where 
the drug–ADR pair was not present in the ‘HCP-only’ data set were selected. Just under half 
of the 73 patient reports involved in these drug–ADR pairs were assessed as having a ‘possible’ 
causal relationship, with a minority assessed as ‘probable’. Compared with Category 1, however, 
a slightly smaller proportion was assessed as ‘probable’ or ‘possible’ and a higher proportion 
was assessed as ‘unlikely’ (Figure 8). In addition, almost a quarter of reports in Category 2 were 
regarded as ‘not assessable’.
In Category 3, 12 drug–ADR pairs were selected that were identified as SDRs only after 
combining the patient and HCP reports. The distribution of causality assessments performed on 
FIGURE 7 Category 1: drug–ADR pairs present in both the ‘patient-only’ and the ‘HCP-only’ data sets; SDRs generated 
only by the ‘patient-only’ data set (11 pairs selected).
FIGURE 8 Category 2: drug–ADR pairs only present in the ‘patient-only’ data set; SDRs generated by patient, but not 
the HCP reports (12 pairs selected).
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the 52 patient and the 46 HCP reports involving these drug–ADR pairs was again similar for both 
groups (Figure 9). Compared with the patient reports, a higher proportion of the HCP reports 
was assessed as ‘probable’ or ‘unlikely’ and a lower proportion was assessed as ‘possible’.
In Category 4, 12 drug–ADR pairs identified as SDRs by the ‘HCP-only’ data set were ‘lost’ 
when patient and HCP reports were combined and were selected for causality assessment. The 
assessment was performed on 84 HCP reports involving these drug–ADR pairs. Most reports 
were assessed as either ‘possible’ or ‘probable’, with few assessed as ‘unlikely’ (Figure 10).
A number of limitations to causality assessment were observed. These have not been 
systematically quantified and compared for each reporter group, but were observed when using 
both patient and HCP reports.
1.  Missing information In some reports, no narrative or relevant dates were given, preventing 
an assessment of temporality. In some cases only a list of symptoms/events was reported. 
Information on past medical history was generally sparse, making it difficult to assess 
whether there were other reasons for the reported event(s).
FIGURE 9 Category 3: drug–ADR pairs present in both the ‘patient-only’ and the ‘HCP-only’ data sets, but SDRs 
generated only after combining both sets of reports (12 pairs selected).
FIGURE 10 Category 4: drug–ADR pairs generated as SDRs in the ‘HCP-only’ data set, but no longer regarded as 
SDRs when patient reports were combined with the HCP reports (12 pairs selected).
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2.  Common or coincidental events Several events in the sample of pairs selected involved 
reaction terms that are common complaints in everyday life, making it difficult to determine 
whether these ‘reactions’ were in fact causal or coincidental, for example hair loss, cough, 
hypertension, weight gain, headache, diarrhoea or insomnia.
3.  Possible confounding by indication This limited the ability to determine causality for 
a number of drug–ADR pairs, for example pregabalin/convulsion, fluoxetine/anxiety, 
iofendylate/arachnoiditis, olanzapine/agitation, tiotropium/dyspnoea, atomoxetine/
depression and anti-malarial/vomiting or diarrhoea or pyrexia.
4.  Long time to onset of reaction It is difficult to assess causality in events or symptoms that 
develop or are recognised by the patient many months or years after starting the medication. 
There may be many other unknown or unreported events/factors that may have contributed 
over this time period. This was observed in assessing reports of ‘loss of confidence’ with 
cyproterone/oestrogen, many of whom also experience depression.
5.  The reporting of vague symptoms/less well defined terms These were difficult to assess, for 
example lack of confidence, anorexia, asthenia.
6.  In some cases a reaction was reported which was specific to the drug’s formulation or brand, 
or the medication was suspected as being counterfeit These reactions were regarded as ‘not 
assessable’ for this project.
7.  Multiple reaction terms/multiple suspect drugs In some reports a long list of reaction terms 
and/or suspect drugs was reported. It was not always possible to determine whether the 
information provided, regarding a possible temporal relationship or outcome, related to the 
specific reaction term or drug being assessed for causality. Patient reports tended to contain 
a larger number of coded reaction terms and were more likely to contain more than one 
suspect drug than HCP reports.
8.  Ambiguity of coded terms For each of the 383 reports sampled, the drug–ADR pair of interest 
was cross-checked with the free-text description of the reaction provided by the reporter. In 
the majority of cases (314; 81.9%) the MedDRA term used to code the reaction appeared to 
be appropriate; in one of these cases an appropriate coding term had been used for the drug–
ADR pair risperidone/musculoskeletal stiffness, but from the narrative the intended meaning 
of the reaction may have been an extrapyramidal side effect. In the remaining cases there was 
either no narrative (45; 11.7%) or the narrative did not contain any reference to the reaction 
of interest (24; 6.3%). Overall, however, there was little evidence to suggest that the intended 
meaning of the reporter’s description was lost in coding.
Finally, of the 383 forms evaluated, 18 were thought to be duplicate reports relating to the same 
nine patients: seven of these were detected twice in the ‘patient-only’ data set, one was detected 
twice in the ‘HCP-only’ data set and one was detected in both data sets. This suggests that the 
MHRA system to identify and merge reports about the same reaction in the same patient from 
different sources is not 100% effective.
Summary
 ■ Using the anonymised data provided by the MHRA for all patient and HCP reports received 
by the YCS between 1 October 2005 and 30 September 2007, signal generation analysis was 
undertaken on the whole database of patient and HCP reports.
 ■ We identified SDRs, which are ‘statistical signals’ when the reporting rate for a suspected 
ADR in association with a particular medicine is disproportionate to that of other products 
in the database. We then investigated the effects (on SDRs) of including and excluding 
patient reports from the HCP database. We also did clinical causality assessments on selected 
drug–ADR pairs from patients and HCPs.
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 ■ For the signal generation analysis there were 16,566 drug–reaction pairs from patient reports 
and 28,775 from HCPs, with only 4340 (10.6%) pairs common to both groups. The HCP data 
set generated a significantly higher proportion of SDRs from the different drug–reaction 
pairs reported [1939 SDRs (6.7%) vs 649 (3.9%) respectively; difference in proportions 2.8%, 
95% CI 2.4% to 3.2%]. Also, a higher proportion of HCP SDRs were for reactions classified as 
‘serious’ by the MHRA compared with patient SDRs (48% vs 28.5% respectively; difference in 
proportions 19.5%, 95% CI 15.4% to 23.6%) or for drugs undergoing intensive surveillance 
(black triangle drugs) (30.7% vs 10.9% respectively; difference in proportions 19.8%, 95% 
CI 16.6% to 23.0%). A similar proportion of SDRs in both groups (15%) was assessed as not 
being listed on the product’s SPC and therefore potentially providing new information.
 ■ After combining the patient and the HCP data sets an additional 508 SDRs were generated 
that were not produced by either data set alone, whereas 186 SDRs generated by the HCP 
data set alone were no longer present. The combined data set identified 47 SDRs for reactions 
classified as serious by MHRA which had not previously recorded on SPCs, whereas eight 
generated by the HCP data set alone were no longer present. Among the sample of individual 
reports assessed for causality, most were assessed as having a ‘possible’ causal association, 
regardless of reporter group.
 ■ Overall, patients appeared to have the potential to make a positive contribution to signal 
generation by:
 – reporting different drug–ADR pairs and generating different SDRs from HCPs
 – generating SDRs that may be considered important in the context of pharmacovigilance
 – generating additional SDRs when combined with data from HCP reports
 – providing information that may be valuable when assessing the likelihood of a causal 
association between a particular drug and reaction.
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Chapter 6  
Study 4: qualitative analysis of Yellow 
Card reports from patients and health-
care professionals
Objective
To explore the richness of patients’ descriptions of their suspected adverse reactions compared 
with health professionals.
Methods
Case selection
Following extensive discussions with the advisory group, and within the project team, a 
purposive sample was taken from a range of different categories of Yellow Card reports. The 
advisory group suggested sampling by reaction type as well as by drug and suggested we cover a 
wide range of different drugs and different types of reaction. The details of the approach taken to 
sampling are provided in Appendix 14. The reports were divided as follows:
 ■ drugs most commonly reported by patients
 ■ black triangle drugs
 ■ drugs purchased OTC
 ■ complementary therapies.
The original plan was to examine around 300 patient reports with 300 HCP reports for similar 
types of drug–ADR pairs. There were, however, marked differences in reporting between patients 
and HCPs (as described in Chapter 5) and this meant that it was not possible to obtain the same 
number of reports for each group. In addition, there were no drugs reported by HCPs that were 
purchased OTC and virtually no complementary therapy reports; we examined only the patient 
reports for these two categories.
The details of the final sample of reports are shown in Appendix 14, and are summarised in 
Table 22. In total, we selected 270 patient reports and 179 HCP reports. This is less than originally 
planned, but following discussion with the advisory group we judged that there were sufficient 
numbers of cases for the qualitative analysis.
Analysis
Descriptive analysis
Data were exported to spss (SPSS Inc., Chicago, IL, USA) for descriptive analysis of the reports to 
compare age, gender, total number of drugs reported, total number of reactions reported and the 
word count used to describe the reaction between the two reporter types. Association between 
gender of reporter and reporter type was tested using the continuity-corrected chi-squared test. 
The independent samples t-test was used to compare the continuous variables that were normally 
distributed for both reporter types. If data were skewed then the non-parametric Mann–Whitney 
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U-test was used. To minimise the chance of a type 1 error arising from multiple comparisons, a 
p-value of ≤ 0.01 was used to denote statistical significance throughout all analyses.
Content analysis
Following initial piloting using 10 patient reports and 10 HCP reports, a number of categories 
were identified from the descriptions given in the free-text field of the reports. These categories 
were identified inductively through iterative reading of the texts and discussion among 
researchers (CA and EM). Once the main data analysis began it was necessary to refine some 
of the categories in order to improve their precision or to widen the category definition. For 
example, in relation to text regarding clinical ‘signs’ we decided that it would be most appropriate 
to focus on ‘physical signs observed by a HCP’ as it was difficult otherwise to distinguish clearly 
between symptoms and signs. In relation to text indicating that an ADR improved when a drug 
had been discontinued, we found examples of improvement when a dose had been reduced, and 
so, widened the definition to include this possibility. The categories were stable at an early stage in 
the analysis to allow for quantification across the sample.
In broad terms, the categories covered the following:
 ■ description of the problem
 ■ impact of the adverse reaction on the patient
 ■ descriptions of the possible association between the drug and adverse effects
 ■ the patient's background medical history
 ■ actions taken by the patient
 ■ involvement of health professionals.
In addition, fields were created to allow for assessment of other features of the reports, such as 
whether there appeared to be ambiguities or possible recording errors. We made a qualitative 
judgement on how elaborate the accounts were and scored them as follows: 0, no narrative; 1, 
TABLE 22 Numbers of cases selected for patient reports and HCP reports for the qualitative analysis
Drug category Drug
Nos. of reports selected
Patients HCPs
Most commonly reported drugs by 
patients
Citalopram All 28 All 23
Co-cyprindiol (Dianette®, Bayer Schering) Randoma 30 All 3
Paroxetine Random 30 All 17
Simvastatin Random 30 Random 30
Venlafaxine Random 30 All 19
Subtotal 148 92
Black triangle drugs Insulin glargine All 13 All 9
Levetiracetam All 13 All 8
Olanzapine All 25 All 13
Pregabalin All 17 All 38
Proguanil with atovaquone (Malarone®, 
GlaxoSmithKline)
All 14 All 19
Subtotal 82 87
Drugs purchased OTC Subtotal 25 0
Complementary therapies Subtotal 15 0
All drug categories Grand total 270 179
a Where numbers of reports were ≥ 30, a random sample of 30 was selected.
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scant narrative; 2, moderately elaborate; and 3, very elaborate. We also recorded whether the 
presentation of symptoms stressed their extreme nature.
One researcher (VG) then read through each ADR report and noted the presence of information 
on a record sheet containing the categories of information shown in Appendix 15.
The researcher met regularly with the supervisor (AA) throughout this process to ensure 
accuracy of interpretation of information from the Yellow Card reports and accuracy of data 
extraction. Data from the record sheets were entered into excel by an administrator who then 
double checked all of the data entry. One in 10 reports were checked visually for accuracy of data 
entry (by AA) and no problems were detected.
For the content analysis of Yellow Card reports, data were analysed in excel. The number and 
percentage of reports containing each of the information items was calculated for patient reports 
and HCP reports.
In-depth qualitative analysis
Having developed the categories detailed in the previous section, the researchers then carried out 
a detailed qualitative content analysis by iterative reading of the data relating to each category, 
with particular reference to those categories where there were substantial differences between 
the frequency of use by patients and HCPs. The data were read by one researcher (CA), entered 
into the nvivo (QSR International Inc., Cambridge, MA, USA) software package and coded. 
The initial categories identified were checked and verified by two other researchers (AA and 
EM). Where there was not full agreement over the codes or the interpretation of the reports 
these were discussed and reviewed. The analysis used the technique of constant comparison 
and the identification of outlying cases. The transcripts were repeatedly read and discussed by 
the researchers in relation to the key categories identified. As well as looking for differences 
between patient and HCP reports we initially categorised those issues that had been highlighted 
in the content analysis of these data. Particular types of reactions that appeared to be reported 
at different rates by patients and health professionals were also categorised, for example electric 
shock sensations and suicidal ideation. In analysing and interpreting the data, we have tried to 
remain aware of the influence of the research process and the researchers’ backgrounds on the 
analyses produced. Factors, such as the researchers’ backgrounds as a pharmacist, a GP and a 
medical sociologist, are acknowledged.
Results
Description of the sample
In total, 449 reports were analysed, with 270 of these coming from patients and 179 from HCPs.
Descriptive statistics of the reports by patient (n = 230) and HCP (n = 179) reporters for the 
categories of ‘most commonly reported drugs by patients’ and black triangle drugs are presented 
in Table 23. Combining the data for these two categories, it can be seen from the table that the 
main differences between the patient and HCP reports were:
 ■ Mean age [standard deviation (SD)] in patient reports is slightly lower [44.2 (16.1) years vs 
47.8 (18.5) years].
 ■ The number of drugs that the patient was reported as taking was lower for patient reports 
[median 2 (IQR 1 to 3) compared with 2 (IQR 1 to 4) for HCP reports].
 ■ Median number of distinct reactions reported was higher for patient reports [5 (IQR 3 to 8) 
compared with 3 (IQR 2 to 5) for HCP reports].
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 ■ Median word count was greater in patient reports [58 words (IQR 29 to 121)] than in the 
reports from HCPs [16 words (IQR 9 to 31)].
 ■ Just over one-half (53.0%) of patient reports made using the paper form compared with 
81.0% of HCP reports.
There was no statistically significant difference between patient reports and HCP reports in the 
proportion relating to women.
The breakdown of HCP reporters was:
 ■ doctors (65%):
 – GP 51%
 – hospital doctor 8%
 – physician 6%
 ■ pharmacists (13%):
 – community pharmacist 6%
 – hospital pharmacist 5%
 – pharmacist – background not specified 2%
 ■ other health professionals (22%):
 – nurses (11%):
 – hospital nurse 8%
 – nurse background not specified 3%
 – other health professional – background not specified 7%
 – hospital health professional 3%
 – dentist 1%.
TABLE 23 Descriptive analysis of the reports used in the qualitative analysis
Characteristics
Drugs most commonly reported by 
patients (n = 240) Black triangle drugs (n = 169)
Combined categories of drug 
(n = 409)
Patient HCP p-value Patient HCP p-value Patient HCP p-value
No. of reports 148 92 82 87 230 179
Mean (SD) age (years) at 
time of reaction
42.8 
(16.6)
51.2 
(19.5)
0.001a 46.8 
(14.8)
44.3 
(16.7)
0.31a 44.2 
(16.1)
47.8 
(18.5)
0.04a
No. (%) of reports for 
women 
103 (70) 57 (62) 0.28b 53 (65) 54 (64) 0.93b 156 (68) 111 (62) 0.30b
No. of concurrent 
medications (median, 
IQR)
1 (1 to 3) 3 (1 to 5) < 0.001c 2 (1 to 3) 2 (1 to 4) 0.94c 2 (1 to 3) 2 (1 to 4) 0.01c
No. distinct reactions 
(median, IQR)
5 (3, 8) 3 (2, 5) < 0.001c 5 (3, 7) 3 (2 to 4) < 0.001c 5 (3, 8) 3 (2 to 5) < 0.001c
Word count (median IQR) 76.5 (32 
to 138)
16 (10 to 
28)
< 0.001c 46 (24 to 
68)
16.5 (9 to 
36)
< 0.001c 58 (29 to 
121)
16 (9 to 
31)
< 0.001c
Methods of reporting 
n (%)
Paper 77 (52) 76 (83) 45 (55) 69 (79) 122 (53) 145 (81) < 0.001d
Internet 68 (46) 7 (7) 16 (20) 3 (3) 84 (36) 10 (6)
Telephone 3 (2) 0 (0) 6 (7) 0 (0) 9 (4) 0 (0)
Not specified 0 (0) 9 (10) 15 (18) 15 (17) 15 (7) 24 (13)
a Independent samples t-test.
b Continuity corrected chi-squared test.
c Mann–Whitney U-test.
d Pearson’s chi-squared test.
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For patient reports, 216 (94%) were made by the patient themselves; 10 (4%) came from carers 
and four (2%) were from a parent.
Most commonly reported drugs category
A total of 240 reports were extracted for qualitative analysis with 148 of these coming from 
patients and 92 from HCPs. Descriptive analysis of these reports is shown in Table 23.
Black triangle drugs category
A total of 169 reports were extracted for qualitative analysis with 82 of these coming from 
patients and 87 from HCPs. Descriptive analysis of these reports is shown in Table 23.
Drugs purchased over-the-counter by patients
Twenty-five reports were extracted for qualitative analysis of drugs purchased OTC by patients. 
This number was lower than originally expected because of the large number of duplicates. The 
mean age of patients at the time the reaction was reported was 42 years (SD 20 years). Fifteen 
(60%) of the patients were female.
Nineteen (76%) patients reported by paper, four (16%) by internet, one by telephone and the 
source of the report was not classified for another patient.
Twenty-one reports (84%) were from the patients themselves, two from parents and one from 
a carer.
Complementary therapies reported by patients
Fifteen reports were extracted for qualitative analysis. The median age was 39 years (IQR 36 to 
56 years). Nine (60%) of the patients were female.
Eight of the patients reported by paper, four by internet, two by telephone and for one the 
method of reporting was not specified.
Qualitative analysis
Content analysis of Yellow Card reports
The content of Yellow Card reports in relation to the combined categories of ‘drugs most 
commonly reported by patients’ and ‘black triangle drugs’ were compared. Table 24 shows the 
findings of the content analysis.
We decided, on the advice of the lead statistician on the study (AL), not to statistically compare 
the patient reports and HCP reports, as it was felt this would give spurious precision to what was 
mainly a qualitative analysis. Nevertheless, it is apparent that patient reports were more likely to 
include information on:
 ■ symptoms
 ■ impact on the patient (particularly emotional and/or social impact)
 ■ comments on temporality (particularly in terms of text indicating that the ADR followed 
administration of the drug).
In addition, 56% of patient reports were judged to be at least moderately elaborate, whereas 61% 
of HCP reports were judged to have scant narrative. Furthermore, although we judged that 47% 
of patient reports highlighted the extreme nature of symptoms, this was the case for only 17% of 
HCP reports.
Health-care professionals were more likely to use medicotechnical language, although this was 
judged to be present in only 13% of their reports.
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Ambiguities were uncommon in the reports examined, and there were no apparent recording 
errors, for example patient reports appearing to come from a health professional or vice versa, or 
where the coding of reaction appeared to be based on misinterpretation of the text.
In-depth qualitative analysis of Yellow Card reports
When describing patients’ and health professionals’ reports, extracts have been quoted verbatim 
and identified by reporter type (patient or professional group), gender of patient, age of patient 
(years), suspect drug name and reporting method. A range of extracts from Yellow Card Reports 
have been used to illustrate our findings, representing different patients, reactions and drugs. 
TABLE 24 Summary of content of the free text from Yellow Card reports from patients and health professionals
Information categorya
Patient reports (total 230) HCP reports (total 179)
No. % No. %
1 Report no. 230 100 179 100
2 Suspect drug 230 100 179 100
3 Symptoms 214 93 139 78
4 Signs 1 0 8 4
5 Any impact 108 47 22 12
6 Emotional impact 79 34 12 7
7 Social Impact 62 27 12 7
8 Occupational impact 15 7 1 1
9 Involvement of health services 87 38 144 80
10 Investigations 17 7 17 9
11 Treatment 57 25 17 9
12 HCP advice 35 15 3 2
13 Past medical history 10 4 2 1
14 General health 11 5 3 2
15 Temporality 1: ADR followed administration of drug 141 61 48 27
16 Temporality 2: ADR improved when drug discontinued or dose was reduced 60 26 22 12
17 Temporality 3: ADR occurred on discontinuation of drug 50 22 16 9
18 Temporality 4: ADR recurred when drug started again 15 7 1 1
19 Dose relationship 13 6 5 3
20 Differential diagnosis 16 7 4 2
21 Past history 12 5 4 2
22 Causal theorising 7 3 6 3
23 Objective evidence 8 3 15 8
24 Endorsement by HCP of causal link 7 3 4 2
25 Self-management 13 6 6 0
26 Medicotechnical 0 0 24 13
27 Extreme nature of signs and symptoms 107 47 31 17
28 ‘Elaboration’ score
0 = no narrative 14 6 32 18
1 = scant narrative 86 37 110 61
2 = moderately elaborate 90 39 30 17
3 = very elaborate 40 17 7 4
29 Ambiguity 16 7 14 8
30 Apparent recording error 0 0 0 0
a Detailed descriptions of these information categories are provided in Appendix 15.
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Spelling errors in extracts were corrected for ease of reading, any emphasis in bold has been 
added by the researchers. A number of reports are written in the third person as someone else 
reported on behalf of the patient.
A number of major categories arose from the content analysis and these informed the in-depth 
qualitative analysis. We note, however, that some of the categories were linked or interrelated so 
that many text fragments could be related to more than one category. For example, there was a 
strong link between the categories of ‘symptom description’ and ‘extreme nature of symptoms’ 
and so these categories are not mutually exclusive. We have dealt with this issue by providing 
extensive detailed quotes so that the reader can see how these cover different categories, even 
when they have been used to highlight specific themes.
The main part of the results compares patient and health professional reports and examines 
in detail the characteristics of patient and professional reports with particular reference to 
those categories of content that patients use more frequently than HCPs, including symptom 
reporting, with emphasis on the extreme nature of these, and the impact of suspected ADRs on 
relationships, social life, occupation and emotions. The final part describes and discusses patient 
reporting of involvement of health professionals.
Symptom description
Both patients (93%) and health professionals (78%) described symptoms of ADRs. However, 
patients’ reports tended to be much more detailed and extensive, as reflected in the mean 
elaboration score (patients 1.68, health professionals 1.07) and the word count. Comparing the 
following two reports, one by a health professional and the other by a patient, relating to the same 
suspect drug but involving different patients, it can be seen that the HCP described the symptoms 
and what the patient had been advised to do to: withdraw from the medicine. In contrast, the 
patient not only listed the symptoms experienced, but also described their intensity. She refers to 
‘unbearable anxiety’, describing the current stage of dose reduction as ‘the worse stage so far’, and 
the medicine as ‘horrendous’. The symptom of headache is highlighted by repeating it and putting 
it in block capitals:
Dizziness, blurred vision, light headedness and electric shock sensations following 
withdrawal from Seroxat. These sensations are abolished by taking half a Seroxat tablet, 
but then recur after I switched him to Seroxat suspension 20 mg/10 ml and advised him 
to reduce dose in very small steps from 0.7 ml daily. Not seen since.
GP, male, 44 years, paroxetine, paper
Since beginning to reduce this medicine, I have had terrible withdrawal symptoms, 
these have included: sudden changes in emotion and mood, crying, insomnia, excessive 
anxiety and agitation, sweating and palpitations. There have also been bouts of stomach 
upsets, nausea, dizziness and headaches. Since reaching an amount of 5 mg I have had 
to use the liquid version with a syringe and make reductions of 1 mg per month, this 
has been the worst stage so far and I have been prescribed medication to alleviate the 
unbearable anxiety that this is causing! Still 2 mg to go before I am off this horrendous 
medicine! HEADACHE HEADACHE.
Patient, female, 46 years, paroxetine, paper
Similarly comparing two different reports for levetiracetam, the health professional report was 
very short and the patient report more elaborate and descriptive:
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Movements feel dull and heavy, tiredness, nausea and shaky.
Community Pharmacist, female, 71 years, levetiracetam, reporting method not specified
I couldn’t stay awake, sick, staggering, loss of balance, eyesight got worse. When I 
increased the evening dose, my knuckles got swollen and sore, then I had 5 weeks of 
sleeplessness nights with the agony of carpal tunnel syndrome in my right hand. A 
steroid injection helped, but I still have a sore hand. Keppra – pain in my feet, ankles, 
shins, knee, hips, thighs, fingers, hands and arms, I could hardly walk, also couldn’t sleep 
at night which made me tired during the day. Before taking the medication for epilepsy, 
I had no pain and could move freely. Since medication I have been in constant pain and 
hobble about like a crippled old woman. I can’t even sit cross legged any more.
Patient, female, 58 years, levetiracetam, paper
The patient quoted below gives an elaborate description of the history and symptoms of their 
hypoglycaemic reaction to insulin glargine, emphasising the unpredictability, rapidity of onset 
and associated dangers of the reaction:
Reaction started almost immediately. The analogue insulin made me have 
hypoglycaemic reactions that came upon me with little or absolutely no warning signs at 
all. Not only did this happen, but the window of opportunity of recognising a symptom 
to being too stroppy to do or have something done for me was less than 5 minutes – on 
Porcine I have at least 30 to 40 minutes. On top of this a hypoglycaemic reaction at night 
did not wake me up. Very dangerous and could lead to severe damage or even death if 
no one found me. This happened on several occasions, but fortunately others were with 
me. It did involve me going to A&E twice and having a doctor called out to house twice. 
Other times husband has given me 2 or 3 glucagons! I have after considerable difficulty, 
persuaded my Diabetic Consultant to put me back on to some porcine insulin – for the 
present only the neutral short acting, but as it is going so well, I am hoping to revert 
to the porcine long acting as well. It took me 5 months to get this to happen and that 
should not be the case. Stopped as soon as I switched back to porcine neutral insulin.
Patient, female, 54 years, insulin glargine, internet
In contrast, a GP report of a different patient’s reaction to insulin glargine is brief and to the 
point, but gives no history:
Erratic diabetic control.
GP, male, 36 years, insulin glargine, paper
Other health professional reports were equally brief:
Raised CK 350.
GP, simvastatin, paper
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Major withdrawal, panic attacks tremors, eye pain neck pain, leg pain, found it difficult 
to walk. Eye problems, sees floaters like looking through net curtain. Life threatening 
because depressed and anxious to end life.
Community pharmacist, male, 44 years, paroxetine, paper
Very few patients made short, unelaborated reports that were similar to those from HCPs, 
for example:
Severe depression with suicidal thoughts.
Patient, female, 30 years, Dianette, internet
On the other hand, there were very occasional elaborated reports from health professionals, such 
as the following, which describes the effect on the patient in great detail:
The patient was complaining that on a bad day she had palpitations, dyspnoea, 
nightmares, difficulty speaking, disorientation, difficulty walking with poor balance, a 
feeling as though she is drunk and feeling of cold alternating with episodes of sweating. 
The current symptoms are of difficulty focusing which varies from one eye to another 
on a daily basis, electric shock type symptoms shooting down her limbs periodically, 
poor balance, poor memory and word finding and severe insomnia. In addition, she has 
recently complained of heartburn and of extreme frequency of micturition. The patient 
tried a course of St John’s wort. This was to try and control the insomnia, electric shock 
and tremor symptoms. Approximately 2 weeks after starting this she had disturbing 
and visual hallucinations. She was agitated and felt driven to throwing herself off a roof. 
She discontinued the St John’s wort and did not seek medical attention at the time. Her 
mother observed her closely and after approximately 48 hours the symptoms resolved. 
Currently the patient continues with complaints of hallucinations, slurred speech and 
difficulty in word finding, intermittent blurred vision and intermittent dyspnoea which 
sounds like chest muscle spasms. She had a severe episode of abdominal discomfort last 
month which resulted in an attendance at the acute medical unit.
GP, female, 37 years, paroxetine, paper
Some patients stated why they were originally prescribed the offending medicine. The health 
professionals tended not to do this in the free-text, comments, but past medical history, which 
may include these details, is also recorded in coded fields as a MedDRA term in response to 
relevant questions on patient and HCP Yellow Cards:
I was first prescribed Seroxat as I was feeling low in mood …
Patient, female, 37 years, paroxetine, paper
I was prescribed this medication for mild sleeplessness. I became addicted to it and after 
18 months of severely debilitating symptoms, the principal symptom being persistent 
suicidal thoughts.
Patient, female, 31 years, paroxetine, paper
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Patients also described what their relatives and health professionals said about the adverse effect 
as if to confirm that it was real:
My daughter, my wife and a sister in a hospital said I looked dreadful in the face …
Patient, male, 61 years, simvastatin, paper
In addition to providing the expected details about the ADR, some patients also gave reasons for 
making the report, including a diagnosis or to find other people with the same reaction:
I am desperate to discuss my condition with someone who is prepared to listen. I don’t 
know where else to turn and a friend gave me the enclosed Yellow Card and suggested 
that I might get someone to diagnose and tell me which of the many diagnosis [sic] I am 
actually suffering from. I’m told I do not have the right to get advice from another doctor 
but I am sinking into depression now and feel there must be someone somewhere who 
can help me and not just leave me to it.
Patient, male, 61 years, simvastatin, paper
Emphasis on extreme nature of symptoms
Patients were much more likely than health professionals to discuss the extreme nature of 
signs and symptoms. Forty-three per cent of patients did this compared with 17% of health 
professionals. The following examples clearly illustrate how out of the ordinary and frightening 
the reactions could be. This patient discusses the extreme reaction he/she suffered after taking the 
complementary medicine Angelica sinensis:
Soon after taking the first dose of Tiao He Cleanse I got a severe headache, I had to take 
paracetamol which I continued to do until the following week in order to get through 
each day. I continued to take dose. The headache was just the beginning of a serious 
problem. Every internal organ became intolerably painful including my liver, kidney, 
stomach, I could scarcely move, sit, lie. I became dehydrated and took copious amount of 
water. I would wake at least four times in the night both to go to the toilet and to drink 
considerable amount of water. It would take me several minutes to work out how I could 
even move from the bed. Extraordinary heat came from the lower part of my body as if 
it was burning. I became bloated. I became constipated. My mouth became ulcerated. 
My teeth felt so on edge that I found them difficult to brush and could not eat all foods 
normally. I had to force myself to eat but maintained their recommended diet. I rang a 
Chinese herbalist practitioner and was advised to cease taking the medication (which I 
had already done) and to go to my doctor and get a liver enzyme test and to drink lots 
of water.
Patient, female, 61 years, Angelica sinensis, paper
The report below emphasises the extreme nature of this patient’s reaction to two selective 
serotonin reuptake inhibitors (SSRIs), citalopram and sertraline:
Became increasingly confused, violent and abusive towards his partner. Disorientated, 
and in his words thoroughly pissed off with life in total. Did not reach the point of 
suicidal thoughts, but had completely collapsed inside himself and unable to function 
or look at himself. He was re-prescribed sertraline which stabilised some of the worst of 
the above but not sufficiently enough to become fully effective. Citalopram and sertraline 
each caused mild to moderate involuntary muscle spasms, extreme libido problems 
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(impotency), extreme sleeping disorders (nightmares, early wakening, afternoon 
lethargy), extreme anxiety, moderate-to-severe loss of interest in basic personal hygiene.
Patient, male, 48 years, citalopram, paper
This patient discusses the extreme adverse effects suffered after taking levetiracetam and 
compares them with the single effect of weight gain caused by her previous antiepileptic 
medicines sodium valproate (Epilim, Sanofi-Aventis):
The first Keppra pill I took, I took at night, I was phasing off Epilim Chrono and coming 
onto Keppra – I have night time seizures, it just sent me to sleep automatically. It was 
like a really, really strong sleeping tablet, I’m not exactly tiny, so I was very surprised, I 
had to wait until the Christmas holidays before starting to take it during the day, as I felt 
I would end up like a narcoleptic otherwise, falling asleep at my desk in the middle of 
the day. Not only that over a period of time, I also got extremely agitated, stressed out, 
nervous, paranoid, leading up to a night where I honestly thought I was losing my mind 
totally. I’ve never, ever felt like this, I’m normally an extremely moderate and chilled-
out person, to feel like this was extremely worrying … I have been on Epilim for years 
previously and the only issue with Epilim is that it makes me put on weight when I start 
taking it! I’d rather be a few pounds heavier than risk losing my mental wellbeing!
Patient, female, 26 years, levetiracetam, internet
This report from a doctor describes a similar reaction to levetiracetam, but the report was more 
detailed and factual:
Levetiracetam introduced 500 mg twice daily. Sodium valproate reduced by 100 mg 
per week from 800 mg total/day. Patient very sleepy, slow eating, observed by staff to 
have tremors, head shaking no associated temperature, hands cold and slightly blue, 
very agitated, needing support from carers. Blood pressure, heart rate and respiratory 
rate normal. Vomited once. Levetiracetam stopped. Discussion with drug company 
recommend 250 mg twice daily introduction. Urine output and intake monitored 
throughout 5 days total. Gradual improvement over next 48 hours back to normal after 
1 week. Liver enzymes normal these checked pre levetiracetam and after patient had 
recovered as very difficult to obtain blood when having side effects.
Hospital doctor, levetiracetam, paper
This patient describes the severity of a reaction having taken the OTC antihistamine cetirizine for 
hay fever:
Soon after starting the medicine I experienced difficulty breathing, weariness, especially 
at night. This was so severe it affected a trip to [place name]. Had to stop taking the 
tablets, but still had trouble breathing at night and persistent cough.
Patient, male, 34 years, cetirizine, paper
A number of patients described their reactions as terrifying. The reports below illustrate just how 
frightening the patients felt their reactions were:
I have suffered horrific adverse reactions to venlafaxine for over two and a half years. 
I stopped taking the drug and the withdrawal effect has been the most terrifying 
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experience of my life. I could write a book – it has wrecked my life, my body, my mind. I 
have been unable to work for over eighteen months and started part time again, but have 
had another month of debilitating withdrawal. I shall attempt to describe the symptoms 
extreme drowsiness, exhaustion, severe heart palpitations, shakes, hypoglycaemia, 
diarrhoea up to three or four times a day, confusion – difficulty in thinking logically, 
orderly. Memory problems, electric shock sensations, and involuntary spasms. Severe 
dizziness, balance problems, co-ordination problems, weight/distance perception 
disturbed, feelings of waking drugged, insomnia, tinnitus, nausea, digestive problems 
– stomach ache, flatulence. Severe fogginess in head, horrendous concentration. 
Personality change (is the most unbearable effect – unable to think with my own mind), 
aggression, irritability, depersonalised feelings. This last week to 10 days I have literally 
felt like I have been physically hit over the head with a hammer – the symptoms are that 
severe and physical and tangible as well as mental. I almost feel a physical constricting 
sensation in my brain. At one point last year on the detox I even had trouble reading 
and interpreting English. I am staggered at how dangerous this drug is and how much 
it has the potential to destroy. It affects not only your mind, but brain function and your 
digestive system, central nervous system and much more. Still has not recovered – and is 
still suffering horrific side effects. The information on the PIL was not adequate enough.
Patient, female, 37 years, venlafaxine, paper
… The seizures with St John’s wort were happening totally unexpectedly, daily and were 
terrifying. I had to hang onto a lamp-post on my way into town to stop myself from 
falling. I could not read after the seizures, I could not count, I could not speak. My 
regular seizures do not have these effects. My doctor told me to come off the St John's 
wort straight away as there has been much speculation about the dangers. Other doctors 
I have spoken to said the same.
Patient, age and gender unknown, St John’s wort, internet
Took tablet at 14:00. Sleepy all evening … confusion, loss of memory, completely 
disorientated. Increased respiration, drowsy, unable to follow simple instructions, unable 
to recall recent events and past medical history … Able to read and write again … fully 
orientated. Nauseous, but able to tolerate clear fluids Monday. First time I was able 
to shower and dress since Thursday pm. Shaky, very scared by the reaction especially 
the confusion
Patient, female, 41 years, sumatriptan, paper
Twelve HCPs out of the 21 who had reported withdrawal symptoms mentioned the distress that 
withdrawal symptoms caused to patients, but these descriptions were never as elaborate as those 
reports patients discussed above:
Very severe withdrawal leading to severe distress.
Hospital doctor, female, 46 years, venlafaxine, not specified
Electric shock sensation
Twenty-three per cent of patient reports and 14% of HCP reports about citalopram, paroxetine 
and venlafaxine included descriptions of ‘electric shock sensations’ or similar reactions. Patient 
reports of this particular symptom exemplify the tendency among patients to stress the severity 
of the reaction, which was described above. Compared with the professional reports, patient 
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reports were particularly vivid, comparing this reaction to a range of other extreme experiences 
and stressing the intensity of the symptoms. These provide an important example of how, if such 
a serious and unpleasant adverse effect were to occur from another drug in the future, patients’ 
reports could contribute to pharmacovigilance and to understanding of the effects of an ADR:
Shocks these are like dropping out of an aircraft as a diver for the first time or a speeding 
car hitting a hill at speed then flying through the air. Your breath is taken away …
Patient, male 51 years, paroxetine, internet
… electrical zaps …
Patient, female, 32 years, paroxetine, internet
… ‘fireworks’ exploding in my head …
Patient, female, 50 years, venlafaxine, paper
… electric shock-like sensations also called brain shivers.
Patient, male, 27 years, venlafaxine, internet
One patient went to great length in her description of the adverse reaction:
First symptoms constant headache, extreme agitation, pressure inside head followed 
by sudden explosion inside head. Sensation of chemical being forcibly released from a 
particular area in brain, which then felt like a cold trickle down neck, across chest down 
spine. Neck went rigid and painful, cold shivers then feverishness, chest felt heavy, heart 
rate increased [although felt very calm and was not hyperventilating (this was not a 
panic attack)], legs then began shaking and convulsing uncontrollably for half an hour, 
accompanied by regular release of chemical in head symptoms subsided after an hour, 
but then began to reoccur approximately every 6 days in the same pattern, but with 
increasing severity. Arms and legs would convulse uncontrollably, arms and legs would 
be numb and pins and needles and loss of feeling, neck would go rigid and jaw clench, 
pressure inside head would rise and fall with each explosion. Symptoms would last for 
up to 3 hours each time. Headache would return once symptoms had subsided each 
time. After 3 weeks of this, I reduced the dosage of citalopram back to 10 mg, concerned 
that it was causing these symptoms
Patient, female, 34 years, citalopram, paper
A number of health professionals listed electric shocks as a reaction, but only one HCP in our 
sample described it in any more depth, quoting the patient’s own description:
… reported that her brain was fizzing like being connected to the national grid.
GP, female, 35 years, venlafaxine, paper
Impact on patients’ lives
Forty-seven per cent of patient reports discussed the impact of the reaction on their lives 
compared with only 12% of health-professional reports. Three types of impact were discussed: 
impact on relationships and social life, occupational impact and emotional impact.
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Impact on relationships and social life
Twenty-seven per cent of patients in the sample reported the social impact of their reaction, 
while only 7% of health professionals mentioned this. Not only were patients more likely to 
mention this effect, but also their accounts of the social impact of the reaction were much 
more elaborate and referred more to the feelings that this impact caused. These differences are 
illustrated by the extracts from professional and patient reports reproduced below. Professionals 
who did refer to the impact of the reaction tended to give brief, factual reports, for example:
Severe muscle pain restricting normal activities. Required analgesics four times a day.
GP, female, 56 years, simvastatin, paper
Somnolence. Odd visual effects. Difficult to drive.
GP, male, 61 years, pregabalin, paper
In contrast, a number of the patient reports vividly described the effect the ADR had on the 
patient’s normal functioning in society and the feelings which this generated. For example, they 
reported how they have been confined to their bed, how they could not go out at all and how the 
ADR was ruining their life. These extracts from reports by two patients who have suffered muscle 
pain as an ADR from simvastatin exemplify this:
… So many things have happened to me over the past year all originating from start of 
this medication. That is my opinion since I know how I feel and how my life has almost 
come to a standstill …
Patient, female, 71 years, simvastatin, paper
… but since starting simvastatin 10 mg, 1 at night, my life has been turned upside down. 
I can’t make any plans as I used to. Why do people force you to take cholesterol tablets 
because you are diabetic? If I did not get them I would not feel the way I feel now. I can’t 
eat my food like I used to, I look at food and am full up. I know I am 70 years old, but I 
only take the diabetic medication and am not even a problem to my family, I look after 
them and now this simvastatin ruins my life.
Patient, female, 72 years, simvastatin, paper
Other patients described how they could not function normally:
Two weeks into starting Dianette, started to feel depressed, anxious and low self esteem. 
After 3 weeks really depressed, felt suicidal, couldn’t function and couldn’t get out of bed. 
Was crying all the time and was very frightened. Stopped 3 days later and starting to feel 
better – though still feels wobbly.
Patient, female, 37 years, Dianette (Bayer plc), telephone
While the excerpts above refer to the direct impact of the drug, similar accounts were given in 
relation to the withdrawal of drugs:
After the dose drop to 10 mg, I had mood swings, palpitations and a weird head lagging 
behind sensation which I believe were withdrawal symptoms. Five weeks after the dose 
drop I got more symptoms – tiredness to the point of not being able to go to shops, 
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headaches, aching joints and muscles like having the flu, anxiety, sweating, finding it 
hard to speak, unable to cope with any stress, and feeling like I had been punched in the 
eyes. This belated effect is the bit I am worried about …
Patient, female, 30 years, citalopram, paper
In addition to the effects on functioning described above, some patients described the profound 
effect that the reaction had on their relationships with family and friends, as well as the impact of 
the reaction on others:
I feel so down a lot of the time I can’t even phone a friend as I’m afraid I’ll just cry 
down the phone. I have everything going for me and yet find it so hard to look on the 
bright side it’s a disgrace. So, I’ve decided to take a break from the pill altogether for a 
few months.
Patient, female, 30 years, Dianette, internet
The last year has been hell for me and has been awful for my parents who are 62 and 68 
respectively …
Patient, male, 31 years, paroxetine, internet
I don’t know why I was put on this medication either, as I have tonic–clonic grand 
mal seizures at night, which I don’t think they are for. I have never felt so odd on a 
medication and thank God I decided to come off it, I think my boyfriend and I would of 
split up otherwise, due to my change in mood.
Patient, female, 26 years, levetiracetam, internet
One patient reported harming herself, her pets and her husband:
Self harming myself, my pets and husband…
Patient, female, 54 years, pregabalin, paper
Occupational impact
Fifteen (7%) patient reports and one HCP in the sample commented on the effect of the 
suspected ADR the patient’s occupation. Only the health professional report mentioned how long 
the patient had been off work:
Reaction on withdrawal – headaches, nausea, vomiting, sweating, sleep disturbance, 
diarrhoea. Off work for 4 weeks.
GP, female, 49 years, venlafaxine, paper
Patients taking a number of different medicines portrayed how the ADR had affected their 
occupation – some had had to stop work, whereas others were able to work only part-time:
An increased heart rate, deep breathing and ‘rushes’ of sensation throughout body. 
Intense tingling in scalp, loss of spatial awareness and mild hallucinations. General 
mania, rambling of speech and difficulty stringing sentences together. Erratic behaviour, 
possibly a bit aggressive at times, although I don’t feel any animosity towards anyone. 
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I am a lab-based research student and the above symptoms make it unsafe for me to 
work …
Patient, male, 27 years, citalopram, internet
I would say that it was a gradual decline in my mental state within months whilst 
starting Dianette. I became extremely low and very unhappy, struggling with work, 
socialising, becoming withdrawn, distressed, short tempered and finding difficulty 
in coping generally (crying a lot, etc.). I didn’t talk to anyone over how I was feeling 
and issues at work worsened. I dealt with complaints within a hospital and very much 
struggled with the sensitive issues I was dealing with – anger, grief, bereavement, etc. I 
continued for a number of months until I could function no more and shared with my 
family how I was feeling.
Patient, female, 30 years, Dianette, internet
I was prescribed this medication for mild sleeplessness. However, a period of 18 months 
of severe symptoms has had a huge effect on my professional and personal life. I am now 
working part time, having lost fundamental confidence.
Patient, female, 32 years, paroxetine, internet
I have suffered horrific adverse reactions to venlafaxine. I have been unable to work 
for over 18 months and started part time again, but have had another month of 
debilitating withdrawal.
Patient, female, 37 years, venlafaxine, paper
One patient described the effect of the ADR on her work, stating that she had lost her edge:
It is the single most distressing experience. Anxiety, tearfulness/shakiness/feelings 
of panic/feelings of hopelessness, loss of cognitive function – can’t remember 
specific words, inarticulate, lose ‘edge’ at work as not thinking as sharply, 
gastrointestinal problems.
Patient, female, 43 years, venlafaxine, paper
Emotional impact
Thirty-four per cent of patient reports and 12% of HCP reports discussed the emotional impact 
of the ADR on the patient.
These patient reports clearly show how much emotional distress particular reactions cause:
Became increasingly confused, violent and abusive towards his partner. Disorientated, 
and in his words thoroughly pissed off with life in total …
Patient, male, 48 years, citalopram, paper
Become very anxious, sweaty and shaky 
Patient, female, 23 years, citalopram, paper
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I also get very confused, forgetful, mood swings, highs and very lows.
Patient, female, 54 years, pregabalin, paper
Nearly all the patient reports about reactions to Dianette in the sample vividly described their 
mood swings and depression, for example:
I had been suffering from violent mood swings for years, but had not linked it to the pill 
I was taking as I had always been told that the pill should help stabilise my moods. I had 
read the PIL however still did not link my mood swings to the pill. I just put it down 
to bad PMT. Then over the past couple of years I was getting quite depressed – crying 
all the time for silly reasons, not being able to cope with much at all, not being able to 
concentrate. Feeling pretty useless …
Patient, female, 29 years, Dianette, internet
Twenty-seven patients described how taking the antidepressants citalopram, paroxetine and 
venlafaxine and the acne treatment Dianette, had led them have suicidal thoughts:
This medication made me feel suicidal. Although I felt pretty bad anyway from my 
depression which was acute at the time, I experienced the effect of thinking in detail 
about how I could best kill myself. I thought about different methods and researched this 
on the internet. I have suffered depression for a long time and have often felt I wanted 
not to be alive any more but have never ever thought about ways of killing myself, much 
less researching them.
Patient, female, 45 years, citalopram, paper
I have noticed that the longer I have been taking the Dianette pill the more severe 
my depression has become. I cry about three to four times during the week and have 
thought about suicide.
Patient, female, 17 years, Dianette, internet
These two patients had suicidal thoughts on withdrawing from paroxetine and venlafaxine:
Side effects include not feeling myself, dizzy, agitated, sick, vertigo, harming myself, 
suicide thoughts, unbearable pains, muscle spasms, mental clicking inside head, 
headaches lasting weeks. I can only imagine it’s like the withdrawal from heroin. My son 
was also born with withdrawal symptoms shakes.
Patient, female, 26 years, paroxetine, paper
After tapering down as per doctor's instructions then stopping experienced nausea, 
ongoing irritable bowel syndrome, dizziness, fatigue, sweating, nightmares, electric 
shock-like sensations also called brain shivers, akathisia, abnormal vision, nervousness, 
panic attacks, depressed feelings, suicidal thoughts and confusion.
Patient, male, 27 years, venlafaxine, paper
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Some patients taking paroxetine, citalopram and venlafaxine described suicide attempts:
I tried suicide on several attempts and even attacked my father for no reason.
Patient, male, 31 years, paroxetine, paper
Two weeks after starting the medication, it caused me to have suicidal thoughts. On 
the first occasion I took 4 sleeping tablets on the second I took 6 sleeping tablets. The 
doctor then increased the dosage of citalopram and I had an uncontrollable desire to 
commit suicide. I took aspirin, Nurofen, Night Nurse and paracetamol. I was admitted to 
hospital and after 4 days of not taking citalopram all suicidal thoughts had disappeared.
Patient, female, 58 years, citalopram, paper
This patient made suicide attempts on withdrawal from citalopram:
Withdrawing from this drug caused me to feel suicidal. I made two suicide attempts 
during withdrawal. I am now on no medication at all.
Patient, female, 44 years, citalopram, internet
One patient complained of feeling suicidal following taking the OTC hay fever medicine 
cetirizine:
I took 2 cetirizine tablets in total over the space of approximately 1 week. On each 
occasion, within 24 hours of taking the tablet I was extremely depressed and felt suicidal. 
Have NEVER felt this way before. I woke in the night feeling that I might as well end it 
all. I have no previous history of depression. I stopped taking the cetirizine completely 
and preferred to suffer from the hay fever as I felt the tablets were responsible but was 
not sure.
Patient, female, 45 years, cetirizine, internet
Two HCP reports also mentioned patients’ suicidal ideation:
Suicidal thoughts and suicide attempt (potentially lethal paracetamol overdose). No 
recent suicidal thoughts prior to initiating citalopram, patient did not want to die.
Hospital pharmacist, female, 16 years, citalopram, paper
Brought out more thoughts of suicide especially in bed at night. She said they caused 
hallucinations as well. Stopped 2 days after stopping citalopram.
GP, female, 18 years, citalopram, paper
Causality
Patients commonly provided information that would be useful when assessing causal links 
between the suspect drug and the reaction. This will now be illustrated by discussing causality 
under a number of headings that have been derived from a series of questions designed for 
assessing the likelihood of an adverse reaction being related to the use of a medicine.49
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
67 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
Adverse drug reaction following administration of the drug
Patients often described reactions occurring after first administration of a drug or a particular 
formulation of that drug:
Suspected side effects (from the start of treatment), gastrointestinal problems, dizziness/
light-headedness on standing up, insomnia, weight gain, strange dreams, heightened 
awareness of colour.
Patient, female, 43 years, citalopram, paper
Started having leg problems shortly after start of simvastatin. I associate problem 
with medication because I had never had leg problems prior to starting medication. 
I pointed out to doctor that leaflet accompanying medication stated there could be 
muscle problems.
Patient female, 71 years, simvastatin, paper
Side effects immediate, chest pain worsened, couldn’t walk or talk, shaking, shock, ‘put 
myself in the recovery position and passed out’
Patient, female, 42 years, olanzepine, telephone
This patient’s reaction started on changing to a slow release formulation of tramadol:
I had two glasses of red wine per evening whilst on the tablets, contrary to what 
was recommended. This may have complicated the issue. However, having been 
on conventional tramadol, there had been no ill effects, and it was only when my 
prescription was changed to slow release tramadol that the seizures occurred. Two 
seizures within 3 hours of each other – the first at home the second in Accident 
and Emergency.
Patient, male, 51 years, tramadol, paper
This doctor related a reaction to insulin glargine to the administration of the drug:
Felt light headed after first dose also developed symptoms of the room spinning after 
subsequent doses.
GP, female, 70 years, insulin glargine, paper
Adverse drug reaction improved when drug discontinued
One-quarter of patient reports highlighted how a reaction improved on discontinuation of a 
drug. Patient reports about myalgia and arthralgia following simvastatin also give the history of 
the reaction as well as the effect of stopping the medicines:
My muscles became stiff in my neck, then in my arms a month later, then by 2 months 
later the muscles in my whole body were so painful I could not get out of bed and 
function. I thought it was from the simvastatin, but my doctor said no and told me 
to continue taking it as the symptoms got worse. I stopped taking simvastatin. Blood 
tests showed my sedimentation rates were very very high and I was diagnosed with 
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polymyalgia rheumatica (PMR). I am 100% convinced it was caused by simvastatin. It 
would not have progressed to PMR if I had stopped earlier.
Patient, female, 58 years, simvastatin, paper
This patient clearly links the start and finish of her problems to taking Dianette:
Unfortunately I had no indication that the contraceptive was having such an effect 
until I had been taking it for three years and decided to have a break. Of course I would 
not like to spur severe accusations about Dianette; however, I strongly believe that the 
contraceptive was affecting my mood, giving me anxiety and panic attacks and quite 
bad depression on occasions, it seems too much of a coincidence that the anxiety and 
depression began after a few months of taking the pill and then evaporated not long 
after stopping. During the time I was on Dianette, in one burst of depression I took an 
overdose, it is for this reason that I would like to report what I think were side effects of 
what is generally thought of as a harmless drug.
Patient, female, 19 years, Dianette, internet
Adverse drug reaction occurred on discontinuation of the drug
Patients (22%) were more likely than health professionals (9%) to discuss how the reaction had 
occurred on discontinuation of the drug. One of the reactions most dramatically described by 
patients was drug withdrawal; this was experienced whilst reducing the dose or stopping taking a 
number of medicines including the antidepressants citalopram, venlafaxine and paroxetine:
As I started to come off the medicine I started to feel anxious all over again despite 
feeling perfectly well prior to deciding to stop. Each time I have tried to come off the 
drug it has resulted in returning to the medication as the side effect s have too much 
impact on my daily routine. I have been taking the medicine again and plan to start to 
gradually withdraw using a liquid replacement of the tablet in the immediate future. 
Hopefully, this will allow me to reduce the quantity very gradually and have less effect.
Patient, female, 28 years, paroxetine, internet
Dizziness, nausea, alternate sweats and chills, unable to stand properly, balance affected. 
Dislike of bright lights, slurred speech, no appetite not even wanted liquids, pains in 
abdomen. Re-started medication, and symptoms increased in severity, vomited after 
36 hours, once after taking first capsule and soup, saw out of hours doctor as blood 
pressure was raised, heart rate fast and blood in urine – on test strip. Away from home 
for few days, forgot medication. After 48 hours from previous dose symptoms began. 
Continued to worsen. Family members called NHS direct helpline. Doctor contacted – 
advised withdrawal symptoms. Gave emergency prescription. GP said it was like ‘heroin 
cold turkey’. I thought SSRI’s were non-addictive, therefore I am very concerned about 
the severity of these symptoms and the duty doctor comparing it to a controlled drug 
withdrawal. 
Patient, female, 58 years, venlafaxine, paper
This GP also related the patient’s reaction to withdrawal:
Patient who received Efexor (venlafaxine hydrochloride tablet) therapy at 150 mg for 
3 years, reduced the dose to 37.5 mg for 1 month and then stopped therapy and after 
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24 hours of taking her last tablet the patient experienced withdrawal effects (drug 
withdrawal syndrome) and felt over stimulated (psychomotor hyperactivity), reported 
that her brain was fizzing like being connected to the national grid (paraesthesia) felt 
very sick (malaise) and heightened alertness (hypervigilance).
GP, female, 35 years, venlafaxine, paper
Adverse drug reaction recurred when drug started again
Seven per cent of patients and 1% of HCP reports discussed how the reaction started when 
the drug was restarted. This patient talks about how the reaction stopped within a few days of 
stopping their simvastatin but resumed on re-challenge:
Pain in right and left shoulder joint with lack of movement increasing, with constant 
pain in both upper arms and shoulders which becomes severe during night and early 
hours of morning. Diagnosed in November by GP as ‘Frozen Shoulders’. Further pain 
increase since December 2006 in neck and across top of both shoulders and down to 
upper arm as far as elbow joint. Link with Simvastatin identified when having course 
of physiotherapy and Simvastatin stopped in March after discussion with GP. Pain in 
neck disappeared within a 6 days of stopping Simvastatin, pain in arms no change or 
improvement with physiotherapy. Simvastatin resumed after 4 week break in dose and 
pains in neck re-appeared within 3 days, Simvastatin stopped after 7 days and pain in 
neck now subsided, Simvastatin dosage now ceased. Constant pain in both arms and 
‘Frozen Shoulders’ with lack of movement not improving despite intensive physiotherapy 
regime problem now existed for 13 months.
Patient, male, 48 years, simvastatin, internet
Dose relationship
The following quotes show how patient reports linked suspected ADRs to a change in dose:
I am presently taking 40 mg daily of this medication. On increasing the dose of 
citalopram, first to 60 mg and then reducing to 50 mg daily – I experienced severe 
agitation and a recurrent thought of ending my life. On 60 mg, I felt seriously suicidal, 
and had constant morbid thoughts and fixation. Increasing citalopram from 40mg 
daily to 60 mg daily made my depression and anxiety much worse, therefore having the 
reverse effect on my mood – inducing suicidal feelings.
Patient, female, 27 years, citalopram, paper
I have been taking simvastatin for a number of years, on doubling the dose 2 years 
ago to 40mg I developed severe muscle pains acute in arms, hands and shoulders. This 
was diagnosed as carpel tunnel both wrists, trapped nerves at both elbows and both 
shoulders frozen. I have been in severe pain for a long time. I stopped the simvastatin 
and felt a hell of a lot better (much less pain) to check that the simvastatin was 
intensifying the pain I started to take it again. One 20 mg tablet left me again in pain 
and feeling dreadfully confused and muddle headed. I therefore stopped taking the 
simvastatin and again felt better.
Patient, male, 55 years, simvastatin, internet
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These are examples of reported dose-related reactions from HCPs:
Patient had been on a small dose of Lyrica since last year for pain control. After 
increasing dose had an asthma attack followed by acute neurological symptoms – 
dysarthria, robotic speech, dizziness, drowsiness, ataxia, and difficulty controlling urine.
GP, female, 43 years, pregabalin, paper
This lady was in with a scalding injury and looked more depressed. Her paroxetine 
dose was increased to 20 mg daily from 10 mg and she was also prescribed tramadol for 
pain. She then started to hallucinate and developed myoclonic jerking and tremor with 
increased tone in all limbs. I think she had serotonin syndrome and as there were no 
other culprit drugs. Stopped her tramadol and paroxetine. All other tests normal and she 
improved rapidly.
Hospital doctor, female, 78 years, paroxetine, internet
Differential diagnoses
Patients sometimes provided information that showed they had considered different possible 
causes for their reactions. This patient tells of her reaction and how she decided it was due to 
Malarone and not due to food poisoning:
On day 10 of taking Malarone, one minute I was ok, next minute I was extremely dizzy 
and started to vomit, at 10 pm, within 3 minutes with severe diarrhoea. At the time I was 
sharing a meal with four others, none of whom were sick from the same food. I vomited 
several times in the night and had diarrhoea all night and all the following day. Next day 
I had severe flu-like pains in my whole body, particularly in my spine, and I was walking 
from my bed to the toilet like a woman of 100! I had to stay in bed the following day 
because I was very weak and slightly feverish. My arms and legs felt cold but my torso 
and neck felt hot to the touch. The joint pains moved into my wrists. My stomach and 
intestines felt tender to the touch. I could eat nothing for 60 hours, the thought of food 
was nauseating. My digestive system seemed to block up too when I started to eat again. 
I started to take Malarone again on day 12 but stomatitis started so I stopped taking 
Malarone altogether and will never use it again. Local people said Oh, you got Malarone 
malaria. One other detail: I noticed from the start of taking Malarone that my urine was 
extremely dark. It was clear that once I stopped taking the Malarone everything got back 
to normal.
Patient, female, 50 years, malarone, internet
This patient wondered if one or both of their drugs was causing their reaction:
Nose starts to tingle and the same effect moves down and around mouth and chin, 
it’s just like the feeling if you have injection in your gum at the dentist. Wonder if it’s 
a combination of both drugs – or one or the other – also it only happens when take 
medication late of forget.
Patient, female, 45 years, venlafaxine, paper
Involvement of health professionals
Many of the patient reports commented favourably on the advice and care they had received 
from HCPs, particularly that received from doctors. A small minority, however, reported that 
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their doctor had not understood them, not known about the existence of the side effect, ignored 
them or told them that they were wasting their doctor’s time:
… After 10 or more years on these pills I can feel my stomach isn’t right but have had 
to put up with it. I feel I’ve been lied to over the years even by the doctor who did my 
endoscopy who didn’t want to do it, I had to persevere to try and get to the bottom of 
this. Still haven’t. These drugs are evil.
Patient, male, 40 years, paroxetine, internet
A few of the patients who suffered from depression following taking Dianette complained that 
their doctor did not know that Dianette caused depression:
… My doctor suggested I take anti depressives just until my moods had become more 
stable but I refused. He never mentioned that my depression and anxiety could be linked 
to Dianette…
Patient, female, 29 years, Dianette, internet
Other patients described how they felt ignored by their doctor:
… I pointed out to doctor that leaflet accompanying medication stated there could 
be muscle problems. If experienced patient should discuss with doctor. I pointed out 
problem to my doctor and pain I was having all of which he chose to ignore. I’m told I 
do not have the right to get advice from another doctor but I am sinking into depression 
now and feel there must be someone somewhere who can help me and not just leave me 
to it.
Patient, female, 71 years, simvastatin, paper
One patient described a particularly unfortunate experience with their doctor over the adverse 
effects they had experienced from pregabalin:
Side effects started straight away, was violently sick, fit and blacked out. Dizzy head, 
tendency to fall over, itching, blurry eyes, swelling of the stomach, food tastes awful, 
mouth dry on waking and I feel like there is a heavy weight on my chest and I have to 
sit up to breathe. I can’t go about doing things and my husband has Parkinson’s disease. 
Five other women who suffer as I do and they had the same, and stopped them. I tell you 
this in confidence, my doctor was very rude to me, I had a couple of drugs that didn’t 
work, he prescribed the pregabalin. I went back to see him and he assured me of wasting 
NHS money and told me if I didn’t take them he would strike me off his medical list 
and I wouldn’t be seen again. He also wouldn’t believe me that I couldn’t use my arm, 
he grabbed hold of my finger, tugged my arm up into the air, let it drop down and it 
slammed down on to his desk, no apology. I was told I should have reported him, but I 
couldn’t have coped with the outcome it may have caused. I don’t see him anymore, I go 
to another one who is very nice.
Patient, female, 78 years, pregabalin, paper
Influence of reporting method
It was thought that the free text in patient telephone reports might differ from those reported on 
paper or via the internet because the report was transcribed during the patients’ telephone call by 
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a staff member at the MHRA, who may be selective in what they chose to record. Although a few 
telephone reports were short and more like health professional reports, a number of them were 
more elaborate, mentioning the impact of the reaction on the patients’ life and included what are 
assumed to be direct quotes from patients, as illustrated below:
Rigidity – not complete but a degree. Trembling feverishness – didn’t take temperature, 
loss of sleep, panic attacks, loss of concentration, depression worse, loss of sense of taste 
(partial), facial movements, blurred vision – more than usual, dizziness, agitation, feeling 
faint, weakness, confusion. Higher level of anxiety than usual – felt chemical in origin. 
Loss of initiative, being ‘full of words’ in minds ear, coupled with being ‘keyed up’ – not a 
good combination. Taken 2 months to die down since then.
Patient, male, 51 years, citalopram, telephone
One telephone report was written in the first person:
Twenty minutes in, as though I had been drinking – couldn’t stop laughing. I do not 
drink. Palpitations, very drowsy had to be prodded awake, slept till 11 pm. Arms ‘heavy’, 
nauseous, dreadful, slurry. Next day, violently sick. Went to GP next day, didn’t give 
anything as has had a mild antihistamine reaction. Tearful and aggressive/argumentative. 
Frightened. Feeling ill. Trying to disguise slurred speech. Headache.
Patient, female, 46 years, certrizine, telephone
Summary
 ■ We undertook a qualitative analysis of reports from patients and HCPs and purposively 
selected a wide range of different types of report. Focusing on the free text describing the 
ADRs we undertook a content analysis to describe the characteristics of 230 patient and 
179 HCP reports, followed by a more detailed inductive qualitative analysis of the free text 
(which included 40 additional patient reports of drugs purchased OTC and complementary 
therapies).
 ■ The content analysis of text describing suspected reactions showed that patient reports were 
more likely than those from HCPs to include information about symptoms (93% vs 78%) and 
to stress the extreme nature of these (47% vs 17% of reports). They were also more likely to 
highlight the impact of the reaction on the patient (47% vs 12%), particularly the emotional 
impact (34% vs 7%) or social impact (27% vs 7%). Patients commonly reported on temporal 
associations, with 61% stating that the suspected ADR had followed the administration 
of the drug; 26% that it had improved on stopping the drug, 22% that it had occurred on 
withdrawal of the drug, and 7% that it had recurred on restarting the drug.
 ■ The in-depth qualitative analysis demonstrated the richness of accounts from patients and 
provided numerous detailed and elaborate descriptions of suspected reactions. Patient Yellow 
Card reports also contained information on reasons for drugs being prescribed, reasons for 
reporting, how patients identified the ADR, and responses from HCPs. Particularly striking 
were reports, often in relation to central nervous system drugs, which were extremely 
distressing, and sometimes frightening, describing confusion, agitation, panic symptoms, 
mood swings, suicidal thoughts and electric shock sensations. Patient reports vividly 
described the effects of suspected ADRs on patients’ lives, illustrating impact in terms of 
serious disruption to social and occupational functioning and marked emotional effects. 
By contrast, where HCPs did comment on the effects of suspected ADRs on patients’ lives, 
the accounts were usually brief and rarely illustrated the profound impact recorded in 
patient reports.
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Chapter 7  
Study 5: questionnaire survey of 
patients reporting to the Yellow Card 
Scheme
Objective
To describe the views and experiences of patients reporting to the YCS.
Methods
Study population
The study population was all patients reporting an ADR to the MHRA via the YCS between 
March 2008 and December 2008.
Questionnaire development
A postal questionnaire was developed to explore patient reporters’ views and experiences of 
making a Yellow Card report. Members of the project team worked on several iterations of the 
questionnaire to ensure that it covered all key areas regarding reporters’ views and experiences, 
and that it had face validity. The questionnaire (see Appendix 16) asked about how patient 
reporters learned about the YCS, how often they had made reports, details of their most recent 
Yellow Card report, reasons for submitting a report, their experience of reporting the ADR 
and their sociodemographic characteristics. Most questions used closed formats, including 
some scaled responses. However, open questions were included to obtain views on problems 
with reporting, suggested improvements to the YCS, expectations and reasons for future use 
of the scheme. In addition, the patient reporters were asked if they would be willing to talk 
to a researcher about their report in a more detailed telephone interview (see Chapter 8 for 
further details).
For piloting, the questionnaire was distributed to a convenience sample of adults of varying ages 
and educational levels to assess ease of completion and identify areas for amendment. We did 
not assess test–retest reliability. A final version of the questionnaire was produced after taking 
account of feedback.
Questionnaire administration
To maintain confidentiality, the MHRA distributed the questionnaires on behalf of the research 
team with a covering letter (see Appendix 17). To minimise recall bias, the questionnaires were 
sent out within a week of a patient’s report being received by the MHRA. Only MHRA staff knew 
the identity of the reporters, and they assigned a unique identifier to each questionnaire holding 
the code separately. Completed questionnaires were returned directly to the researchers, who sent 
MHRA staff regular updates of identifiers for returned questionnaires. This enabled the MHRA 
to identify non-responders and send reminders (see Appendix 18), while maintaining anonymity. 
A single reminder was sent 3 weeks after the original mailing.
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Data management and analysis
Data from the questionnaires were entered into spss and validated by checking a 10% systematic 
sample against the original questionnaires. The medicine that the respondent suspected as 
causing their ADR was coded according to the ATC classification system.39 Categorical responses 
were described using frequencies and percentages. The distribution of respondent age was 
skewed and therefore was described using the median and IQR, and compared between groups 
using the Kruskal–Wallis test. Pearson’s chi-squared test was used to examine the associations 
between the method of reporting (online, postal, telephone) and the following responses to 
the questionnaire: where they learned about the YCS, the ATC anatomical classification of the 
suspect drug, how soon they reported ADR, ease of reporting using the YCS, whose idea it was 
to report the ADR, and whether they expected (and would have liked) feedback on their report. 
Associations between two categorical variables were examined using Pearson’s chi-squared test. 
To minimise the chance of a type 1 error arising from multiple comparisons, a p-value of ≤ 0.01 
was used to denote statistical significance throughout.
Each free-text question was analysed separately, using a thematic approach. All comments were 
read individually and sorted thematically using an iterative approach. For questions with large 
numbers of responses, two researchers initially independently read 100 responses to identify 
themes. Final themes were agreed and all responses were coded independently. Any discrepancies 
were discussed and agreed.
Results
The MHRA posted the questionnaire to a total of 2008 patient reporters and 1362 (68%) 
evaluable forms were returned and entered into the database. From a 10% systematic sample 
(n = 136), only seven minor errors were found relating to illegible handwriting on the 
questionnaire, misspelling, and data recording error, and these were rectified to reflect the 
original questionnaire.
Respondent characteristics
The respondents’ median (IQR) age was 56.5 years (43.0 to 67.0 years], 910 (66.8%) were female 
and 1274 (93.5%) were of white ethnicity (Table 25). Over two-thirds of respondents had been 
educated beyond 18 years. The Yellow Card report was submitted by post for 814 (59.8%), online 
for 447 (32.8%) and by telephone for 86 (6.3%) respondents. Respondents who made an online 
report were significantly younger (p < 0.001) and had a higher level of education than those using 
another method of reporting (p < 0.001). Only 105 (7.7%) respondents had sent in more than one 
Yellow Card report, and 133 respondents (9.8%) had submitted a Yellow Card report on someone 
else’s behalf.
How respondents learnt about the Yellow Card Scheme
Almost one-half of the respondents learnt about the YCS from a pharmacy (n = 667; 49.0%), 
followed by their GP (n = 220; 16.2%). Of those who learnt about the YCS from other sources 
not listed as options in the questionnaire (n = 252; 18.5%), the most frequent response was that 
they had a HCP background/professional knowledge (n = 88; 35.2%). A higher proportion of 
respondents reporting by post learnt about the YCS from a pharmacy or GP surgery than either 
of those using the other two methods (both p < 0.001; Table 26). One-hundred and thirteen 
(25.3%) patients reporting online found out about the scheme from an internet search, compared 
with only 24 (2.9%) and 7 (8.1%) of those reporting by post and telephone, respectively.
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Information regarding respondents’ Yellow Card reports
Table 27 presents the ATC anatomical classifications of the suspect drugs reported by the method 
of reporting used. Overall, the biggest percentage of reports was for a drug for the nervous 
system and this did not differ by method of reporting. However, there were some differences. 
TABLE 25 Sociodemographic characteristics of respondents by method of reporting
Characteristic
Method of reporting
All  
(n = 1362) p-value
Post  
(n = 814)
Online 
(n = 447)
Telephone 
(n = 86)
Median age – years (IQR) 61 (46 to 71) 50 (36 to 58) 63 (52 to 72) 56.5 (43 to 67) < 0.001
Gender
Female 534 (65.6) 310 (69.8) 56 (66.7) 910 (66.8) 0.31
Male 280 (34.4) 134 (30.2) 28 (33.3) 447 (32.8)
Education
I left school aged 16 years or younger and did no further 
education
222 (28.4) 58 (13.1) 24 (29.6) 309 (22.7) < 0.001
I left school or college aged 17 or 18 years and did no 
further education
48 (6.1) 34 (7.7) 7 (8.6) 90 (6.6)
I did a further education qualification beyond the age 
of 18
297 (37.9) 140 (31.5) 24 (29.6) 465 (34.1)
I did an undergraduate degree 131 (16.7) 127 (28.6) 17 (21.0) 277 (20.3)
I did a postgraduate degree 85 (10.9) 85 (19.1) 9 (11.1) 181 (13.3)
Ethnicity
White 758 (95.3) 427 (96.6) 75 (93.8) 1274 (93.5) 0.72a
Asian or Asian British 12 (1.5) 7 (1.6) 1 (1.3) 20 (1.5)
Black or Black British 10 (1.3) 2 (0.5) 1 (1.3) 13 (1.0)
Mixed 6 (0.8) 4 (0.9) 1 (1.3) 11 (0.8)
Chinese 2 (0.3) 0 (0.0) 0 (0.0) 2 (0.1)
Other 7 (0.9) 2 (0.5) 2 (2.5) 11 (0.8)
a Pearson’s chi-squared test was invalid as 55.6% of the cells had an expected count of < 5. However, when the test was repeated by 
combining all non-white ethnicities, the valid p-value was 0.40.
Figures shown are n (% of column total) unless otherwise reported.
TABLE 26 Source of how patients learned about the YCS by method of reporting
Source
Method of reporting
All  
(n = 1362) p-value
Post  
(n = 814)
Online  
(n = 447)
Telephone 
(n = 86)
Pharmacy 484 (59.5) 135 (30.2) 41 (47.7) 667 (49.0) < 0.001
GP surgery 167 (20.5) 45 (10.1) 8 (9.3) 220 (16.2) < 0.001
Other 109 (13.4) 114 (25.5) 29 (33.7) 252 (18.5) < 0.001
Internet search 24 (2.9) 113 (25.3) 7 (8.1) 145 (10.6) < 0.001
Family member or friend 46 (5.7) 34 (7.6) 7 (8.1) 89 (6.5) 0.32
Hospital 48 (5.9) 21 (4.7) 3 (3.5) 73 (5.4) 0.49
Magazine or newspaper 21 (2.6) 17 (3.8) 1 (1.2) 40 (2.9) 0.28
MHRA website 5 (0.6) 28 (6.3) 4 (4.7) 37 (2.7) < 0.001
Figures shown are n (%).
These sources are not mutually exclusive as respondents were asked to tick all that apply.
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Over one-quarter (n = 213) of respondents reporting by post reported a drug related to the 
cardiovascular system compared with 22.1% (n = 19) of those reporting by telephone and 17.2% 
(n = 77) of those reporting online (p = 0.001). A higher proportion of online users (n = 34; 7.6%) 
reported adverse events from drugs for the genitourinary system and sex hormones than users of 
other reporting methods [post n = 31 (3.8%) and telephone n = 2 (2.3%)] (p = 0.006).
Figure 11 shows that those reporting by telephone did so relatively sooner than those reporting 
by either of the other two methods, whereas those who reported by post took the longest time 
to report the event (p = 0.01). In total, 1304 (95.7%) respondents were at least fairly sure that the 
side effect was due to the medicine, with no significant difference between methods of reporting 
(p = 0.22).
Respondents’ views on submitting Yellow Card reports
Most respondents – 1274 (93.6%) – thought that the report was fairly or very easy to complete 
(Table 28), but in free-text comments 216 (15.9%) noted difficulties that they had experienced. 
A higher proportion of telephone reporters (6.8%) felt that it was ‘not very easy’ to report their 
ADR compared with those using other methods of reporting [online (3.4%); post (2.5%)] 
(p < 0.001).
Suggestions for improvements to the form or processes were made by 307 (22.5%) respondents. 
These included more space (n = 31), simpler questions or language (n = 18) and larger print 
(n = 7). Respondents who reported difficulties, included 39 who had general difficulties owing 
to problems with writing/poor sight, anxiety or confusion, 15 who indicated uncertainties about 
what to report and 10 who felt that some questions were missing or lacked relevant options. 
Several mentioned the inability to use imperial units for height and weight online.
TABLE 27 Anatomical Therapeutic Chemical classifications of suspect drugs by method of reporting
ATC class
Method of reporting
All  
(n = 1362) p-valuea
Post
(n = 814)
Online
(n = 447)
Telephone
(n = 86)
Nervous system 229 (28.1) 124 (27.7) 26 (30.2) 384 (28.2) 0.90
Cardiovascular system 213 (26.2) 77 (17.2) 19 (22.1) 311 (22.8) 0.001
Anti-infectives for systemic use 84 (10.3) 66 (14.8) 13 (15.1) 163 (12.0) 0.046
Alimentary tract and metabolism 74 (9.1) 33 (7.4) 6 (7.0) 114 (8.4) 0.51
Musculoskeletal system 52 (6.4) 22 (4.9) 5 (5.8) 79 (5.8) 0.57
Genitourinary system and sex hormones 31 (3.8) 34 (7.6) 2 (2.3) 68 (5.0) 0.006
Respiratory system 28 (3.4) 17 (3.8) 4 (4.7) 49 (3.6) 0.83
Blood and blood-forming organs 24 (2.9) 8 (1.8) 3 (3.5) 35 (2.6) 0.40
Antineoplastic and immunomodulating agents 21 (2.6) 10 (2.2) 2 (2.3) 33 (2.4) 0.93
Systemic hormonal preparations, excluding sex hormones and insulins 23 (2.8) 9 (2.0) 1 (1.2) 33 (2.4) 0.49
Dermatologicalsb 8 (1.0) 5 (1.1) 1 (1.2) 14 (1.0) –
Sensory organsb 10 (1.2) 1 (0.2) 1 (1.2) 12 (0.9) –
Antiparasitic products, insecticides and repellentsb 3 (0.4) 7 (1.6) 0 (0.0) 10 (0.7) –
Variousb 1 (0.1) 0 (0.0) 1 (1.2) 2 (0.1) –
a The p-value from Pearson’s chi-squared test to compare the proportion of suspect drugs in each reporting method.
b No chi-squared test performed owing to more than 20% of cells having an expected value of < 5.
Figures shown are n (%).
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Not much room on the form, not very well set out. I found it difficult the second time to 
fill in the form because I was suffering from severe anxiety which was the problem.
Female, 60 years, further educational qualification
There were 39 respondents who raised specific issues about internet reporting, many of whom 
gave up and reported via telephone or paper:
The proforma asked for the major symptoms. When I wrote paralysis, a long list of types 
of paralysis appeared – it needed medical knowledge to complete. I could not move past 
it. I gave up and sent a written report direct to your enquiry desk.
Male, 54 years, graduate
TABLE 28 Ease of completing the report by method of reporting used
Ease of completing the 
report
Method of reporting
All (n = 1362)Post (n = 814) Online (n = 447) Telephone (n = 86)
Very easy 577 (72.7) 245 (54.9) 44 (59.5) 874 (64.2)
Fairly easy 187 (23.6) 184 (41.3) 25 (33.8) 400 (29.4)
Not very easy 20 (2.5) 15 (3.4) 5 (6.8) 40 (2.9)
Very difficult 10 (1.3) 2 (0.4) 0 (0.0) 12 (0.9)
Total 794 (100) 446 (100) 74 (100) 1326 (100)
Figures shown are n (%).
Pearson’s chi-squared test showed a significant association between ease of completing the report and method of reporting used (p < 0.001).
FIGURE 11 Time the report was made after the side effect was first noticed by method of reporting. Note: Pearson’s 
chi-squared test showed a significant association between the time the report was made after the ADR and method of 
reporting used (p = 0.01).
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Seven raised issues relating to telephone reporting:
I first telephoned 08081 003 352 to be told by recorded message calls could only be taken 
between 10–2 Mon–Fri. The hours need to be extended. The Yellow Card says you can 
report suspected side effects by filling in Yellow form or by calling which I did first, but 
the person only asked for my name and address in order to send the Yellow Card and did 
not ask would I like to give details over the phone.
Female, 71 years, graduate
A total of 143 respondents suggested that greater publicity of the scheme, wider availability and 
accessibility of the reporting forms and encouragement to report were required. Twenty-three 
respondents indicated that health professionals lacked awareness of the patient reporting scheme, 
but should promote patient reporting. A substantial number suggested posters and leaflets should 
be available in GP surgeries, hospitals and pharmacies. Other suggestions included forms in post 
offices, libraries and local government offices or their issue with medicines:
My GP and receptionist did not know how to access a Yellow form! The hospital told me 
that a GP had to do it.
Female, 65 years, further educational qualification
A description of the scheme with the MHRA website should be (by law if necessary) 
included in the manufacturers’ information contained in the medicine packages.
Male, 69 years, graduate
Why the respondent made a Yellow Card report
Most respondents (n = 1098; 80.6%) said that making the report had been their own idea, with a 
significantly higher proportion of the online completers (86.4%; n = 386) stating this than postal 
(78.1%; n = 636) or telephone (77.9%; n = 67) reporters (p = 0.001). Among those reporting by 
telephone, 19.8% (n = 17) said that it was their pharmacist’s idea to report the event, compared 
with 17.4% (n = 142) of postal reporters and 6.9% (n = 31) of online reporters (p < 0.001). Only 
43 (3.2%) respondents were discouraged by someone from making a report. Of these, most were 
discouraged by their GP (n = 26; 60.5%). Fifty-six respondents (4.1%) stated that a HCP had 
refused to make a report on their behalf.
Respondent experiences and expectations of reporting
Some respondents (n = 104; 7.6%) had received help to make the report, with most assistance 
coming from a family member or friend (n = 56) or a pharmacist (n = 26). Almost one-third 
(n = 448; 32.9%) of respondents expected feedback from the MHRA and 828 (60.8%) said that 
they would have liked feedback. Of those reporting their suspected ADR by telephone, 42.7% 
(n = 35) expected feedback compared with 36.0% (n = 290) of postal reporters (p = 0.001) and 
26.2% (n = 117) of online reporters. A higher proportion of telephone reporters (74.3%; n = 55) 
would have liked feedback than other reporters [postal 67.3% (n = 495) and online 63.0% 
(n = 269)], although this difference was not statistically significant (p = 0.05).
Responses to open questions indicated that 134 respondents expected an acknowledgement 
of their report and 112 expected to receive information about the reaction or the medicine 
about which they had reported. Many of those who desired feedback (323/707) wanted specific 
information about the frequency with which other similar reports had been received, how 
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common the effect was or whether it was a well-known problem. However, 149 wanted to 
know whether any investigation or action would take place as a result of their report, including 
informing manufacturers or health professionals:
Would like to know how often this particular problem has been reported in the past and 
how well known the side effect is within the medical profession.
Male, 53 years, postgraduate
Tell me what you are doing with the information I give you and any action you plan to 
take to prevent others suffering as I did.
Male, 33 years, graduate
A minority (n = 24) had expected to be approached for further information or provided with 
advice on what action to take (n = 25); more (n = 84) wanted to receive such advice. There were 46 
respondents who wanted confirmation that the medicine and symptom were causally associated 
and 27 expected to receive this.
Almost all respondents (n = 1302; 95.6%) would make a report again if they, or someone they 
knew, had a suspected ADR. A similar number would encourage other people to report through 
the YCS (n = 1300; 95.4%).
The most frequently cited reasons for reporting again related to the need for collection of data 
on medicines (97 respondents), to help others (n = 57) or to improve the quality of medicines, 
medicines information or care (n = 51). The high prevalence of ADRs, the distress caused and the 
need to record patients’ experiences were also mentioned:
I think it is important to have reports from patients themselves as part of the post-
marketing surveillance. Patients’ experiences are very important. 
Female, 32 years, graduate
Some comments (n = 25) explained reasons for respondents not reporting again, 
including the time taken to make the report, the lack of feedback received and the 
perception that their report has little impact:
But think some feedback should be given, otherwise what’s the point? How would I 
know if it was making any difference?
Female, 50 years, further educational qualification
Although 23 respondents stated that they definitely would or indeed already had encouraged 
others to report, 22 provided reasons for not encouraging others and a further 34 indicated 
conditional encouragement only:
I wouldn’t want people to report unless they feel strongly that the product caused the 
effect, because it could reduce the value of these reports.
Female, 26 years, graduate
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General views on Yellow Card reporting
An open question ‘Why do you think it is important for people to report side effects from 
medicines using the YCS?’ elicited a total of 1802 specific comments from 1238 respondents, 
although 103 were judged to be unrelated to the question. The view most frequently expressed 
(by 355 respondents) illustrated an awareness of the purpose and importance of the scheme as 
a means of gathering data from a large population taking medicines. Respondents also cited the 
need to prevent others from suffering similar problems (n = 165) and to make the public or other 
patients aware of side effects from medicines (n = 152):
Might be small number of people scattered over country or something you think people 
are aware of but aren’t. Is good for someone to collate this info together to be able to see 
the whole picture and spot major problems with a particular medicine or any trends to 
stop others from suffering or make sure people are aware before they take them.
Female, 34 years, left school at 16 years
Others felt it was important to make MHRA or manufacturers aware of ADRs (n = 100), with 
many respondents expressing the hope that as a result medicines may be improved or PILs 
amended (n = 173) or products withdrawn from the market if necessary (n = 41):
This should ensure that drug companies are made aware of severe side effects so that 
they can issue appropriate warnings. They should also carry out further research to 
reduce the risks of side effects.
Female, 65 years, higher educational qualification
The view that health professionals need to be informed about ADRs and perhaps to change their 
practice was raised by 167 respondents. Others criticised government incentives to prescribe 
certain drugs and a number of respondents expressed distrust in the pharmaceutical industry, as 
well as in health care and government (n = 79):
Absolutely necessary to act as backup to clinical trials, plus acting as a brake on 
government instructions to issue pills on a one-size-fits-all basis, i.e. how many blood 
pressure and cholesterol tablets are issued to borderline cases in order to meet targets 
and gain bonuses?
Male, 72 years, left school at 16 years
For too long there does not seem to have been any method the general public can input 
side effects from their medication. It also means (hopefully) things can be collated, 
monitored, and fixed in shorter period of time.
Female, 38 years, higher educational qualification
The attitude of health professionals to suspected ADRs was raised by 106 respondents, who 
indicated both dismissive attitudes among HCPs and their failure to report ADRs. The need for 
a reporting mechanism which is independent of health professionals (n = 32) and for patients’ 
voices to be heard were also identified as issues (n = 49). A further 90 comments related to the 
importance of the patient’s perspective, indicating that side effects were, or could be, severe; may 
be perceived differently by patients or may be worse than the underlying medical problem:
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Because I feel if I told my doctor about my side effect, he would belittle it and I would 
wrongly feel I was making too much of a fuss, whereas the reality of my experience of the 
side effect was not wrong or little. I feel scared of my GP’s response. Being able to report 
side effects effectively anonymously allows side effects to be known by pharmacologists, 
which would otherwise remain unreported or lost in a GP’s database somewhere.
Female, 43 years, graduate
So the MHRA have independent information about prescribed drugs. Sometimes GPs 
may not believe patients reporting side effects. It helps patients recover from side effects 
‘getting it off your chest’. Patients hope that someone might take notice/make amends on 
patients’ suffering. People need to know they have a voice.
Female, 58 years, postgraduate
What doctors and nurses regard as a side effect worth reporting may differ from what 
the patient thinks. My mother has had a life changing experience that came out of the 
blue and is keen to ensure others don’t experience the same problem.
Female, 57 years, postgraduate
Some comments related to the need for research data on medicines, whereas others hoped that 
by drawing attention to problems, novel research would be initiated (n = 66). A wide range of 
other comments were received (n = 116), covering issues such as side effects arising from drug 
combinations or changes in brand, suggestions of ‘fake’ products, mistakes in production, or 
reactions to excipients. Criticisms of both health care and licensing were also raised:
Different (as far as I can tell) manufacturers may have different recipes. One may be okay 
and another not. I don’t know.
Female, 80 years, left school at 16 years
Because too many doctors prescribe inappropriately bowing to pressure from reps, 
patients and health authorities. In addition, a number of pharma companies tend not 
to look for AE data and so medicines are licensed on the basis of too small a safety 
database. Real life experience is the only way to build the database.
Male, 49 years, postgraduate
I think it is too easy for HCPs to go for the ‘quick fix’ if they know that a particular 
medication will ease a problem, but they don’t follow up often on repeat prescriptions 
and don’t really view subsequent problems holistically so can miss links to other reported 
problems. I see older people in relation to my work, they often have repeat prescriptions 
with many items on and some items are to deal with side effects of other meds. GPs don’t 
have time to follow through. I think we, as patients, should do more to raise awareness of 
these issues.
Female, 53 years, higher educational qualification
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Attribution of symptoms to medicines
The questionnaire also explored respondents’ views about what made them think that the 
medicine caused the side effect. There were 1348 responses to this question, 99% of all 
respondents. Of these, 181 (13.3%) were not analysable as 78 listed only symptoms and 103 were 
comments on other issues or inadequate descriptions. Of the remaining 1167 respondents, most 
(689; 59.0%) provided only one piece of information to explain causal association. However, 382 
(32.7%) respondents provided two pieces of information, whereas 87 (7.5%) provided three and 
nine respondents (0.8%) provided four.
Among these 1167 responses, 675 (57.2%) mentioned reasons relating to timing only. A further 
238 (20.2%) indicated using information sources and 145 (12.3%) mentioned both. Explanations 
included: symptom not present before medicine started (n = 195, 16.7%), symptom began soon 
after starting medicine (n = 320: 27.4%), symptom reduced on stopping (n = 275, 23.6%) and 
symptom re-occurred on re-challenge (n = 89, 7.6%). A further 37 noted symptom changes with 
dose changes, 25 noted symptoms started after medicine withdrawal and 29 on changing brand. 
In addition, 22 indicated it was a new medicine and 78 cited other timing-related issues:
Never had it before. Didn’t have it after stopped. Was worse on higher doses. Was better 
on lower doses.
Male, 32 years, graduate
I had been taking Pfizer’s Istin (amlodipine) for over six months and when I suddenly 
could not find it anywhere I was forced to take a generic version. Within half an hour 
of taking this I could feel symptoms which I had never experienced with Pfizers Istin. I 
reported them immediately to the doctor.
Female, 63 years, higher educational qualification
The most common sources of information used to associate the symptom with the medicine were 
HCP (n = 186; 15.9%), and information from the internet, information leaflet or books (n = 182; 
15.6%). A further 57 (4.9%) indicated other information sources:
Read about possible side effects on internet – commencement of taking medication 
coincided with my own medical problems. This was backed up by consultant.
Female, 65 years, postgraduate
The onset was a short time (few weeks) after commencing the drug. I looked it up in the 
literature and consulted several clinical friends.
Male, 77 years, postgraduate
In addition, 33 indicated previous reactions to the same or similar drugs, while 25 mentioned 
they or their doctor had seen similar effects in other people. A substantial number (n = 130) 
also felt that, for various reasons, no other explanation for their reaction was possible, including 
elimination of other possible causes. Other reasons/views were given by 27 respondents, 
including the severity of the event, interactions, specific excipients and confirmation by tests:
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Only medication at the time. Several of my friends on this drug have had similar 
side effects.
Female, 71 years, higher educational qualification
I know that I’m allergic to E104 and discovered after suffering severe migraines that this 
colouring was in some of my medication.
Female, 47 years, graduate
Summary
 ■ A questionnaire was developed for distribution by the MHRA to all patients reporting 
through the YCS between March 2008 and January 2009. The questionnaire elicited 
information on how patients found out about the YCS, their experiences of, and views on, 
reporting and their demographic characteristics.
 ■ There were 1362 evaluable responses to the questionnaire sent to 2008 patient reporters 
(68%). The most frequent reporting method was postal (59.8%), followed by online (32.8%) 
and telephone (6.3%). Online reporters were younger (median age in years of reporters: 
online 50, postal 61, telephone 63; p < 0.001) with a higher education level than those using 
other reporting methods (e.g. proportion of reporters with a degree: online 48%, postal 28%, 
telephone 32%; p < 0.001). Almost one-half learned about the YCS from a pharmacy (n = 667; 
49.0%). In response to a closed question, most respondents 1274 (93%) indicated that the 
report was ‘fairly’ or ‘very’ easy to complete, although in free-text comments 216 (15.9%) 
noted difficulties that they had experienced. Suggestions for enhancements were made by 
307 (22.5%). One-third (n = 448; 32.9%) expected feedback from the MHRA on their report 
and 828 (60.8%) would have liked feedback. Almost all respondents (n = 1302; 95.6%) would 
report again. Respondents indicated a need for increasing health professionals’ awareness 
of patient reporting. Some stressed the importance of having a reporting mechanism that is 
independent of health professionals so that patients’ perspectives can be recognised.
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Chapter 8  
Study 6: telephone interview follow-
up of patients reporting to the Yellow 
Card Scheme
Objective
To explore, in detail, the experiences and views of patients who have made reports to the YCS.
Methods
Semistructured telephone interviews were conducted with a theoretical sample of patients that 
was purposively selected from those who had completed questionnaires and had indicated a 
willingness to be approached for a telephone interview (Chapter 7). We aimed to interview 
around 30 people in order to gain a wide range of opinions and maximum variation sampling was 
used to do this in order to obtain a wide range of opinions. Factors that were taken into account 
in the sampling included: age, gender and educational attainment of patients, and the mode of 
reporting. In addition, we selected some patients based on issues raised in the questionnaire, 
such as the perceived ease of reporting. An iterative process was applied as we conducted the 
interviews to try to ensure that we interviewed people with different perspectives based upon the 
preliminary analysis and emergent themes.
Conduct and analysis of interviews
The semistructured telephone interviews were conducted by two researchers using an interview 
guide (Appendix 19) developed by the research team. The first three interviews were performed 
by one researcher (AG) and the remaining 24 by a second researcher (TP). The development of 
the guide was informed by a preliminary analysis of the questionnaire data and issues identified 
by the project team including:
 ■ exploration of any difficulties in making Yellow Card reports and suggestions for 
improvement in the reporting system
 ■ patients’ motivations for making the report and anticipated contribution of their report
 ■ patients’ expectations about what would happen to their report
 ■ patients’ satisfaction or dissatisfaction with the process of making a report
 ■ patients’ willingness to report in future.
The areas to be explored were reviewed and revised in the light of the data obtained from the 
initial interviews to ensure that the data obtained were relevant to the focus of the research. For 
example, in the early interviews respondents tended to focus on the story of their ADR rather 
than their experience of reporting it. So, in subsequent interviews we shifted the focus away 
from the reaction towards the reporting scheme. Interviews were audio-recorded digitally, with 
consent, and transcribed verbatim. The interview transcripts were analysed by an academic 
member of the research team (CA) and the analysis checked by another academic (EM). Data 
were analysed for both anticipated (based on the questions asked) and emergent themes using 
the constant comparison method. The researcher first read the interviews and noted the main 
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themes. The data were then categorised into the major themes, which were finding out about 
reporting, recognition of adverse effects, reason for reporting, involvement of others in decision 
to report, how patient reports might differ from health professional reports, ease of reporting, 
what people expected to happen following making their report, advertising the scheme, and 
reporting again and encouraging others to report. The researcher then identified from the data 
a number of subcategories for each of these themes. For example, under the major theme of 
‘reasons for reporting’ a number of subcategories emerged from the interview data, including 
altruism, solidarity and pharmacovigilance. Quotes are used to illustrate the themes, and for each 
quote the following information is provided: interview number, gender and age of reporter and 
mode of reporting, for example ‘interview 12, female 54 years, paper’.
Results
Twenty-seven telephone interviews were carried out; 23 interviewees had originally completed 
paper reports, two internet and two telephone reports. Two reports were done by parents on 
behalf of their children. A summary of the characteristics of the interviewees is shown in Table 29 
and more detailed information on each interviewee is shown in Table 30. All of the interviewees 
were of white-British ethnic origin.
Finding out about reporting
For the majority of people, awareness of the YCS was by chance either in the pharmacy, GP 
surgery or on the internet. One woman had found out about the YCS because her husband was 
a member of the Stroke Association and one from her diabetic nurse. Two interviewees already 
knew about the scheme because they were HCPs. Fifteen of the interviewees had found out about 
the scheme via the pharmacy because the cards were on display, they saw a poster or because 
pharmacy staff were proactive in encouraging people to report:
I think I was given that form in the chemist … No, well I’ve never been given cards 
before. She just said, ‘These forms now are given to people if certain tablets have not 
agreed with them. If you wish, fill it in’.
Interview 8, female, 66 years, paper
TABLE 29 Overall characteristics of telephone interviewees
Characteristics n (%) or median (IQR)
Gender of patient, n (%)
Female 19 (70)
Male 8 (30)
Educational attainment of patient, n (%)
Finished education at 15 years 2 (7)
Finished education at 16 years 5 (19)
Finished education at 18 years 1 (4)
Further education 9 (33)
Graduate 3 (11)
Postgraduate 3 (11)
Not stated 4 (15)
Age of intervieweea
Age (years): median (IQR) 60 (49 to 69)
a Includes two parents who submitted reports for their children.
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… I went and saw the doctor … and she referred me to a pharmacist. That’s when 
he said, ‘Well we can put you on a different variety and you can put in a Yellow Card 
Report’, which I’d never heard of at the time.
Interview 27, male, 61 years, internet
Others or their partners had seen the forms in the pharmacy:
And then I saw them, they were on the counter in [name and location of pharmacy] so I 
picked one up and thought well the reaction to this thing was so upsetting.
Interview 10, female, 75 years, paper
No, it was my wife that saw the card in the chemist and she brought one home for me.
Interview 22, male, 52 years, paper
Two interviewees had seen the scheme advertised on a poster in a community pharmacy. Others 
had found the forms while waiting at their GP surgery. However, in contrast with some of the 
TABLE 30 Characteristics of telephone interviewees
Interview no. Gender Age (years) Educational attainment
1 Female 74 Not stated
2 Female 72 Not stated
3 Female 30 (report on behalf of daughter aged 5) Not stated
4 Female 69 Graduate
5 Female 52 Finished education at 16 years
6 Female 60 Finished education at 16 years
7 Female 48 Postgraduate
8 Female 66 Finished education at 16 years
9 Female 47 Finished education at 16 years
10 Female 75 Further education
11 Female 57 Further education
12 Female 54 Further education
13 Female 32 Finished education at 16 years
14 Female 52 Graduate
15 Female 43 Further education
16 Female 60 Further education
17 Male 49 Not stated
18 Female 50 Graduate
19 Female 71 Finished education at 18 years
20 Female 36 Further education
21 Male 72 Further education
22 Male 52 (on behalf of son) Postgraduate
23 Male 61 Further education
24 Male 66 Finished education at 15 years
25 Male 64 Finished education at 15 years
26 Male 73 Further education
27 Male 61 Postgraduate
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interviewees’ experiences of a proactive approach in community pharmacies, there was no sense 
that GPs or their staff were playing an active part in facilitating reporting.
I, being the sort of person who, when I’ve been having difficulty sitting round in, down 
in surgery you know, I tend to stay on my feet and prowl, so I read everything on the 
wall that’s going er and go through the rack of whatever else is available and this is where 
I picked up the Yellow Card information on one occasion.
Interview 4, female, 69 years, paper
I had changed doctors and they have a load of those forms sitting there, I’ve never seen 
them before. So I just automatically picked a couple up and brought them home and read 
through them and just filled them in.
Interview 5, female, 52 years, paper
Others had found or ‘stumbled’ across the web-based form while looking on the internet:
It was actually, I think it was at the time when he was being poorly with it all, I think I 
just Googled the drug name and I don’t, I think there might have been some tag to your 
page but I’m sure that’s how I found out about the YCS anyhow … I kind of stumbled 
across it and I’ve never seen any leaflets in a surgery 
Interview 13, female, 32 years, internet
One interviewee heard about the YCS on the Radio 4 Today programme and had then obtained a 
Yellow Card form from a pharmacy:
Well I didn’t know there was such a thing as a Yellow Card. But then I heard a little, er 
a little bit on Radio 4, er in the Today programme it mentioned this Yellow Card and 
said you could get it in a chemists. And that is the first I heard of it. Yes, I went and got 
it from the chemists …Well they were out on display but not very visible so I had to ask. 
And then it was produced.
Interview 2, female, 72 years, paper
Another interviewee found out about reporting to the MHRA via a television programme:
It was a programme on the television about patients in hospital and this sort of thing 
and they had discovered through you know this information, that 300,000 people died 
last year from prescribed drugs and that didn’t include people who suffered damaging 
side effects, which damaged their internal organs in some way or another. Well when I 
saw this, at the end of the programme it said that if you think you have had a problem 
with drugs why not get in touch with the MHRA and it gave an address. So this is how I 
found out about it.
Interview 1, female, 74 years, paper
Recognition of adverse effects
Most interviewees were clearly able to link the ADR with taking a particular medicine, including 
making temporal links:
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I took this one capsule of the antibiotic and er I was talking to a friend on the phone and 
er within half an hour my tongue started to swell and I had to ring off because I couldn’t 
speak … and then I had mucous streaming from my nose and mouth. Oh it was awful, I 
felt sick and broke out into a rash all over my body which itched and felt hot.
Interview 2, female, 72 years, paper
… that was the Friday evening then on the Saturday morning I started to itch and 
noticed that I had a rash that was fairly extensive, pretty well covered in a very fine rash 
and didn’t feel very well at all and in the evening I just went to bed early. I didn’t take any 
more of the medication, I only had the one dose I think and it was because of the rash 
and feeling really sick and I think I felt very cold, I was very shivery.
Interview 11, female, 57 years, paper
For another reporter’s daughter, Stevens–Johnson syndrome started within 12 hours of 
starting penicillin.
Patients also noted a ‘dose response’. For someone who had taken pregabalin for pain, the 
reaction started the next morning after taking the first dose and became worse on the second 
dose. This patient recalled a previous similar experience:
Researcher: So how long had you been taking your medication before you realised that 
there was a problem?
Interviewee: Oh gosh erm, er a matter of days. Erm I sh’ it should be on the form.
Interviewee: Yes, it appeared following the morning after taking the dose the night 
before?
Interviewee: That’s right. Yeah.
Researcher: And then got worse after the second dose.
Interviewee: That’s right yeah because I’d had a similar reaction on, on meloxicam.
Researcher: Right so you phoned your GP who told you to …
Interviewee: Stop, stop!
Interviewee: within 24 hours I was feeling a lot better.
Interview 4, female, 69 years, paper
An interviewee who had been encouraged to fill in the report by a pharmacist at the store where 
she worked had been taking azathioprine for a flare-up of Crohn’s disease for 2 weeks when she 
started feeling sick. The doctor had asked her to take the azathioprine again as a re-challenge to 
ensure it was causing the ADR:
So I started taking that and about maybe two weeks into taking it and I started feeling 
sick. Reading on the instructions it just said that it can cause nausea but these are sort of 
like, when you read these instructions it’s maybe, you know, one in however many people 
90 Study 6: telephone interview follow-up of patients reporting to the Yellow Card Scheme
will have these … Yes, so I started feeling sick as I say and I thought right, that will be 
fine, I’ll just sort of ride through it and it just got worse until in the end I was being sick, 
violently sick. So I went back to my GP rather than the hospital because it was just every 
so often that I went to the hospital and he said, ‘Right let’s stop taking it.’ So I stopped 
taking it on a particular Wednesday and then he said, ‘Leave it a full week and then start 
taking the drug again and then we’ll know whether it’s that that’s actually making you be 
sick’. So I started taking it on the Wednesday morning and I remember taking it at half 
past 8 just before going into work and by 9 o’clock I was being violently sick again and I 
was being sick about every 5 minutes.
Interview 9, female, 47 years, paper
Another man had been taking a prostate medication and had experienced recurrence of 
symptoms on re-challenge:
I think it was one day, two days and it was most pronounced, the symptom was 
pronounced and definite and I was very surprised. Stopped taking it for I think a few 
days, repeated it and got exactly the same results much to my amazement. It was more 
pronounced, most definite and repeatable.
Interview 23, male, 61 years, paper
One man was convinced that his tablets for hypertension were causing the problem as all his 
adverse effects stopped when he ran out of tablets while on holiday, only to come back when he 
started to take extra tablets:
Well I had no problems up to start of taking the tablets and when I went abroad and ran 
out of the tablets everything returned to normal … But it was only when I came back, 
started retaking the tablets that the symptoms started to reappear and when I started 
taking the extra tablets the symptoms, they got extremely bad.
Interview 24, male, 66 years, paper
Why interviewees had made the report
Altruistic reporting
A number of interviewees had made their report because they thought that it might prevent the 
adverse effect from happening to someone else in the future:
It might help and it might save somebody going through the same symptoms because 
they’re so horrible.
Interview 4, female, 69 years, paper
I just thought he’d been in so much pain and I felt so frustrated because no-one had 
listened or no-one seemed to consider that it could be that and I just thought well it’s 
got to be logged for future because no doubt someone else in the country or the world 
will probably experience the same thing and … But I just thought, no I don’t want to 
see, or don’t want anyone else to be suffering like he did when there’s no need because 
if someone’s made aware of it then I just think it’s better to make sure that everyone is 
aware so if it does happen.
Interview 13, female, 32 years, internet
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There was a very strong sense of responsibility and duty that led some of the interviewees to 
report:
… it wasn’t making any difference to me one way or the other but I felt I had a duty.
Interview 13, female, 32 years, internet
Well I would really expect it to be sort of 50/50 as far as responsibility goes. Yes I do 
think that the GP or the pharmacist or whoever might just have a duty of care to report 
side effects like this in all instances. I also think that the people who, ie myself, who are 
swallowing all these nasty concoctions have got a duty to report back any untoward 
effects as well.
Interview 12, female, 54 years, paper
Others reported as they thought that as well as helping other people it would make the 
pharmaceutical manufacturer aware of the adverse effect:
And I did it because I thought well if this has happened to me there’s a good chance it’s 
going to happen to somebody else and I felt the company should be aware …
Interview 23, male, 61 years, paper
Solidarity and a desire for personal feedback
Some of the interviewees were keen to find out if other people had experienced the same thing 
and to find other people with the same problem. There was a strong sense that these interviewees 
had a different motive in reporting to that of others; they wanted something back. They also 
wanted to be reassured that they were not the only one who had suffered and wished to know 
how to alleviate their problem:
… thought well the reaction to this thing was so upsetting...that I felt perhaps it was 
worth sending it off just in case other people had experienced the same sort of thing 
… I had felt so unwell taking it that I just felt it justified giving a report. A degree of 
curiosity to know whether was I being neurotic or was it something that other people 
have experienced.
Interview 10, female, 75 years, paper
Well I just wanted, I felt as though it could be another outlet for easing this problem 
and also if other people had had the same problems they might have reported it and 
somebody somewhere might know what I can do to alleviate the problem.
Interview 24, male, 66 years, paper
Pharmacovigilance
Some of the interviewees showed some understanding of the pharmacovigilance process and had 
reported to help with this process:
Hopefully it can highlight more causes and erm more alerts for parents … 
Gathering information.
Interview 3, female, 30 years, telephone
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Mainly I hoped that it would, as I say, when the doctors look in the symptoms book in 
the future that if somebody came to them with similar side effects that we were having 
that they could actually see it straightaway because I think sometimes if it’s something 
that’s not in the book they just completely dismiss what you’re saying.
Interview 13, female, 32 years, internet
The following woman was against being ‘force fed’ with drugs and felt that if a lot of reports were 
coming through then the drugs should be taken off the market:
Because I mean all these things are force fed us as panaceas for this and that and the 
other and yes some of them are life savers, I’m not disputing that. What I am saying is 
that with some people the side effects are far, far worse than the actual illness that they 
may be experiencing at the time and I don’t think these drugs, if you’re getting a lot of 
reports about a certain drug it should be removed.
Interview 12, female, 54 years, paper
Involvement of others in decisions to report adverse drug reactions
A number of interviewees had been encouraged to report by their pharmacist. One woman who 
had been taking statins for 6 months was discussing her thinning hair with her hairdresser who 
asked her if she was taking any medicines. She then went to her pharmacist who confirmed the 
hairdressers’ diagnosis. This is the only example in our sample of a layperson identifying an ADR:
She said, ‘Are you on any new medications?’ But of course that was something I hadn’t 
considered and I told her about the statins and she said, ‘That’s funny’, and this girl that 
does my hair, she said, ‘My mum stopped taking statins for the same reason because she 
thought her hair was falling out’. So I filled it in. It was my pharmacist when I went to get 
a repeat prescription and she said, ‘Oh simvastatin’, and I said, ‘It’s making my hair fall 
out’. And she said, ‘Oh you should report that’, she said, you know, ‘they’re keen to know 
of any contra-indications sort of thing.’
Interview 7, female, 48 years, paper
Others said that they made their report because they did not think that they could rely on their 
GP to make a report on their behalf or could not rely on it being accurate. These interviewees felt 
that their report would compensate for their GP’s lack of commitment to reporting:
Yes. Because I’ve used it before. I’d reported pregabalin and meloxicam both of them I’d 
reacted badly to. I thought well if people don’t report you don’t know erm and I couldn’t 
rely on GP reporting.
Interview 4, female, 69 years, paper
If it had just been going to the doctor and reporting it I wouldn’t have gone to the doctor 
and reported it but the fact that this card was available, I filled it in. I gather from what 
I’ve read that a lot of GPs don’t bother reporting side effects anyway. I mean that’s just 
hearsay, I mean that’s what I’ve read but I don’t know if it’s true or not. Maybe that was 
the case 5 years ago, maybe it isn’t now.
Interview 23, male, 61 years, paper
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
93 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
How patient reports might differ from health professional reports
Three interviewees commented about how a patient report might differ from a HCP report, 
compensating for the perceived shortcomings of health professional reporting:
I think by the time it’s filtered through, through various other people it doesn’t actually 
go in the form in which the patient actually reports it … to, to make mine fairly specific 
erm and it was fairly specific and quite, and fairly detailed but I’m sure that anybody else 
would simply, a lot of health professionals would simply specify some general adverse 
symptoms and that would be it.
Interview 4, female, 69 years, paper
I think it is important that people do get the opportunity to report their own 
understanding of a problem which may be different from a professional’s understanding 
of a problem. And that, you know, some people just prefer to do things themselves than 
to have to go through an official course, you know, to have to go to the doctors and ask 
them to report it or, I think if people knew the reporting system was there and available 
more then they would use it.
Interview 11, female, 57 years, paper
I think it’s far better than reporting it to your GP because, you know, you have more 
time to sit and think about it and it doesn’t get filtered in the process if you know what I 
mean, you know what actually happened because you get so little time with the GP, you 
wouldn’t have time to think it through and put all the exact details down.
Interview 23, male, 61 years, paper
Ease of reporting
Although some of those interviewed found it straightforward to report, a number of difficulties 
were mentioned including lack of space on the paper form. Further details are not given here, as 
the issues concerning ease of reporting are covered more fully in Chapters 7 and 9.
What interviewees expected to happen after making their report
Eight interviewees had not expected a response to their report, although were pleased when they 
received one:
Nothing. I expected absolutely nothing and I was very surprised when I was informed 
that they’d received it and it had been noted and I thought well this is progress, most of 
the time things that you send off to official bodies just sort of disappear into the ether 
and you never hear about them again. So I was quite chuffed to hear back, feedback was 
the word I was looking for and yeah that was fine.
Interview 12, female, 54 years, paper
Well I did get a letter thanking me for the card, which I didn’t expect and that was nice 
because it made me feel that actually someone is taking notice there.
Interview 15, female, 43 years, paper
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Ten interviewees said that they had expected to receive an acknowledgement and or some action:
Well I don’t know, I suppose maybe an acknowledgement that somebody had received 
it but nothing particularly further than that other than it might be of some use to 
somebody who was monitoring different medications.
Interview 11, female, 57, paper
Others showed some understanding of the pharmacovigilance process, but were cynical as to 
whether anything would actually change as a result of their report:
Then I expected them to collect them and if there were more than a certain number of 
people report the side effect then it would get flagged up as a common one in the NHS 
or, I don’t know whether anything actually goes back to the manufacturers or if there are 
any studies that might come out of, you know, even if there might be something new that 
might put up a red flag, they might think well maybe we should look at this and find out 
what’s happening there and instigate some further research. That would be my hope but I 
tend to think that once something’s licensed and they’re making money then they’re not 
really interested in going back and doing further research
Interview 15, female, 43 years, paper
What was I expecting to happen? Very little, I suppose I expected, I hoped there’d be 
an acknowledgement because you’re never sure when you send something off it’s going 
to get there but I didn’t expect any benefit at all or anything to happen to me, I was just 
reporting what happened for some database somewhere really. I felt I wanted to be sure 
someone actually got it as an input.
Interview 23, male, 61 years, paper
One had not heard anything and felt ignored:
I take it from the fact that I’ve heard nothing is that I’m a maverick and they’ve ignored 
it, don’t worry about it, it’s not a significant problem so let’s not worry about it.
Interview 25, male, 64 years, paper
Advertising the Yellow Card Scheme
There was a general feeling amongst the interviewees that people ought to be aware of the scheme 
and not find out about it by chance, like they had. There was also a feeling that people should be 
encouraged to report as some people thought that they might not be believed:
… but one thing I do want to say is could the MHRA advertise more? The more they 
advertise it, the more people will be aware and the less people will suffer side effects.
Interview 1, female, 74 years, paper
Well I think the Yellow Card could be advertised better so people know what’s going on. 
I only heard about it by chance from the radio.
Interview 2, female, 72 years, paper
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Well I’m not sure that the little Yellow Card is the best way of bringing it to people’s 
attention. I think we’ve got some in our surgery but I think on the whole people are 
reluctant to report any side effects just in case they’re not believed.
Interview 10, male, 75 years, paper
The interviewees had a number of ideas as to how the scheme might be better advertised to the 
public. Interviewees suggested putting information on or in the pharmacy bag or on the medicine 
label:
Another thing I think you could do, you know on your pharmacy bag, you get another 
bag to put your tablets in, it could even be printed on the paper bags they put your 
medication in … Or even put a Yellow Card in with your medication to just say if these 
tablets have unforeseen, upset you in any way after two or three days, get back in touch 
with your doctor and tell them that you’re going to fill this form in or go back into the 
chemist and say, ‘Right they’re not agreeing with me, I’ve been in touch with the doctor, I 
want to fill this form in.’
Interview 8, female, 66 years, paper
In fact I would go so far as to say that in every single box of medication … there should, 
or information about the Yellow Card.
Interview 12, female, 54 years, paper
She also suggested running a television advertising campaign:
I mean why don’t they even do a TV ad. I bet a sort of TV ad when people are sat there 
in front of their tellies watching Coronation Street or something, I don’t know, look at 
everybody out there that takes medication, ‘Do you know there is a scheme that’s called 
the Yellow Card de da, de da, de da’ and make people aware that it’s out there.
Interview 12, female, 54 years, paper
Reporting again and encouraging others to report
The majority of interviewees were very positive about reporting again or encouraging other 
people to report ADRs:
Yes I think it’s a really good thing, I still think most people aren’t aware of it or really 
understand, I think lots of people who are on medication don’t even know what the 
YCS is or were aware of it even when it was just the GPs could fill them in…There were 
people I suggested it to.
Interview 15, female, 43 years, paper
A number of interviews had already actively promoted the YCS to others as a matter of course:
I run a shop in a village and I’ve heard of people who’ve had side effects and I’ve 
explained what the Yellow Card System is and I don’t know if it’s sinking in or not but it 
helps, it’s helpful. It’s not guaranteed that it helps for everything or they even fill it in.
Interview 22, male, 52 years, paper
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And I run a support group in [place name] for thyroid patients, when they’re having 
problems I’ll always mention the Yellow Card to them as well.
Interview 21, male, 72 years, paper
Because I can tell you, I have been in touch, with friends, colleagues, from the different 
organisations I belong to. I do a lot of charity work, you know, and people in the village 
here you know and it is amazing how many people are on prescribed drugs which are 
giving them dreadful side effects. I am trying to persuade them to get in touch you know 
on the YCS. So their information is recorded and some sort of investigation can be 
carried out, you know.
Interview 1, female, 74 years, paper
Some saw the importance of reporting for pharmacovigilance:
Well yes, I mean I suppose each individual is probably different aren’t they, maybe what 
one person suffers maybe the other person doesn’t … But, you know, occasionally there’s 
a pattern maybe there’s a lot of people have had the same thing …
Interview 17, male, 49 years, paper
Yes unless the public know about it people are going to be worried. I think it’s important 
to report as many side effects as possible so that they can list them then when people 
take the drug they know what to expect and they don’t think it’s their health.
Interview 18, female, 50 years, paper
Summary
 ■ Semistructured telephone interviews were conducted with a purposeful sample of 
patient reporters selected from those who had completed questionnaires and given 
consent to further contact by the research team. The interviews explored motivations for 
reporting, expectations of, and satisfaction with, the reporting system and suggestions 
for improvements.
 ■ Twenty-seven telephone interviews were conducted with patient reporters. Most became 
aware of the YCS by chance and many suggested that greater publicity was needed for patient 
reporting. Motivations for reporting included altruism and a desire to find out if others had 
experienced similar problems. Several suggestions were made for enhancements to reporting 
systems, including more space for writing free-text comments on the paper form.
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Chapter 9  
Study 7: focus groups and usability 
testing with members of the public
Objectives
To ascertain the views of members of the public on the YCS.
To ascertain the views of members of the public on the user-friendliness, effectiveness and 
usability of different mechanisms of patient reporting.
To obtain suggestions for potential ways in which the reporting system could be improved.
Methods
Recruitment
We planned to recruit six focus groups with up to eight subjects in each. For logistical purposes 
participants were recruited from only the Nottingham area and recruitment took place between 
June and November 2008. Although we recruited from only one area of the country, we aimed 
to recruit a broad demographic sample of people. Originally, we had planned to include patients 
who believed they may have experienced side effects from medications, but had not previously 
filled in a Yellow Card report. We decided, however, that this would make recruitment difficult 
and that there would be some advantages to widening our selection criteria to all adults. For 
example, this allowed us to recruit younger people, who might not have had side effects from 
drugs, but who might be more familiar with the use of online reporting systems. Three main 
approaches were used to recruit participants with a range of demographic characteristics.
Recruitment posters and leaflets were displayed in general practices, pharmacies, social centres 
and in the University of Nottingham. In addition, an article about the research study was placed 
in the local press. Finally, the pool of simulated patients utilised by the University of Nottingham 
Medical School for the purposes of supporting medical student training were invited by letter. 
Those interested in participating in the research were invited to contact the research team directly 
by telephone. Also, the simulated patients had the option of returning a consent form in a 
stamped addressed envelope provided.
All of those volunteering to participate in the research were offered a choice of dates for 
attendance at the focus group/usability sessions. The dates were confirmed by letter. Sessions 
were run on different days of the week and times of the day, to enable participants to attend at a 
time of their convenience. Volunteers were all offered a £25 inconvenience allowance. Sessions 
were conducted at the University of Nottingham where computer facilities were available. 
Refreshments were offered prior to the commencement of the focus groups.
Focus groups
The topic schedule for the focus group was developed by the research team, informed by the 
literature and project objectives. It included the participants’ thoughts about the YCS, whether 
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they felt they might utilise the scheme and how they felt the scheme might be improved. Finally, 
each participant was asked which method of reporting they felt that they would prefer to use. 
After completing the usability tests, participants were asked whether their views had changed.
A pilot focus group with members of the research team was conducted to confirm clarity and 
appropriateness of wording. As a result, the schedule was revised. The final version is shown in 
Appendix 20.
Before the focus group/usability session began participants were asked to complete a short 
questionnaire asking for basic demographic data and experience of using computers. These data 
were used to inform which of the usability tests participants were allocated to.
At the start of the focus group/usability session there was a 15-minute presentation, by a member 
of the research team, explaining the YCS and the research project. We felt it necessary to give a 
presentation to provide context for the focus group discussions and for the subsequent usability 
testing. At the end of the presentation, there was an opportunity for participants to ask questions. 
They were then asked to complete and sign a consent form to document their agreement to 
participate in the research and to the audio-recording of the focus group/usability session. 
The signed consent form was returned to the research team. Participants retained a duplicate 
copy. Once consent had been obtained from each participant, the focus group was conducted. 
Recordings of the focus group/usability sessions were transcribed verbatim. The focus group 
data were analysed thematically (by CA and AG), identifying the major predicted and emerging 
themes and ideas from the data.
Usability tests
Simulating the Yellow Card reporting scheme
Online reporting
In order to ensure that the online reporting system did not receive a number of ‘fake’ reports, the 
MHRA provided the team with access to a dummy system, identical to the real one, but which 
did not add reports to the database used for pharmacovigilance. The MRHA web address for the 
dummy system was used to ensure that the computers were logged onto the correct site and then 
left at the front page of the reporting system for participants.
Paper forms
Paper forms for reporting to the YCS were provided by the MHRA. These were the same as those 
available for members of the public through community pharmacies and GP surgeries.
Telephone reporting
The telephone reporting system at the MHRA is staffed between 10 am and 2 pm, Monday to 
Friday. As not all of the focus group/usability sessions were conducted during these times, the 
decision was made to use a member of the research team to replicate the telephone reporting 
system during the usability testing. In order to ensure that the participants’ experience of 
reporting using the telephone method was as realistic as possible, a pharmacist was used to 
answer the call, as the MHRA use science graduates (some of whom are pharmacists) to answer 
the telephone-reporting line. The MHRA provided their training materials for answering the 
telephone reporting line and these were used by our pharmacist to structure the telephone 
conversation. The research team pharmacist answered the usability test call and recorded notes of 
the conversation before completing a YCS paper report.
Adverse drug reaction scenarios
Six scenarios describing a patient experiencing an adverse effect to a medicine were developed 
by the researchers (Appendix 21). Each participant was given a randomly selected set of four 
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scenarios from which they chose two for use when completing two YCS reporting methods 
during the usability tests. The use of scenarios avoided the need for participants to disclose 
confidential medical information, allowed those who had not experienced a side effect to 
participate and gave consistency to data collection. Scenarios were provided in large print for 
participants who required them.
The participants were asked to read the scenarios then complete a report. Participants were 
given an opportunity to ask questions relating to the scenarios, to help clarify any issues arising. 
Each participant was assigned to two of the three possible reporting methods, informed by the 
demographic information collected prior to the focus group to ensure that only those familiar 
with the internet were given this option. In each group a maximum of two people were assigned 
to the telephone reporting system; numbers were limited by staff availability.
Participants were asked to think aloud as they completed the reporting process, highlighting any 
issues encountered. There was no time limit placed for completion of the report, but participants 
were told that if they felt that they would have given up completing the form at home, they 
should do the same during the usability tests. As the participants completed their report they 
were observed by a researcher to whom they had been previously introduced.
Observers made field notes and asked questions for clarification, and reminded the participants 
to keep talking if they stopped verbalising their thoughts. To aid analysis of the data, each 
participant and observer pair was digitally audio-recorded throughout the process. At the end 
of the session, the observer asked their participant which of the reporting methods they would 
choose to use if they were to report an ADR.
The observers were debriefed and their observation notes were transcribed, these were 
supplemented by further information and verbatim quotes from the audio recording.
The data from the field notes were analysed thematically by identifying the major themes 
and ideas emerging from the data by reporting method (telephone, internet and paper). A 
constant comparison comparative approach was taken and this was supplemented with relevant 
information from the audio recordings (these were not transcribed). For example, the major 
theme ‘ease of navigation of online form’ was sub categorised into ‘challenging’ and ‘easy’. The 
‘challenging’ theme subcategory was then further subdivided into, ‘drop-down menus’, ‘lack of 
understanding of medical terms’ and ‘saving data’. ‘Saving data’ was then further subcategorised 
into ‘losing information’ and ‘stopping reporting’.
Results
Characteristics of participants
Overall 40 participants took part in seven focus groups/usability sessions (22 recruited via the 
posters, 11 from the simulated patients and seven from the newspaper article). Table 31 shows the 
characteristics of participants.
Over two-thirds of the participants were female and most (74%) were aged 50 years or over. 
Despite widely publicising the project there were few men or younger people.
Two of the participants were hearing impaired and one had to use a magnifying glass with the 
large print materials in order to overcome his visual impairment.
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Thirty-seven people completed simulated online reports, 36 people completed paper reports and 
eight people completed telephone reports (81 reports in total).
Focus group findings
The focus groups lasted between 30 and 45 minutes. The main themes identified were awareness 
and value of the YCS, and direct patient reporting, identifying ADRs, issues regarding reporting 
and advertising the scheme, and these are discussed below.
Awareness and value of the Yellow Card Scheme and direct 
patient reporting
Of the 40 participants, two had previous knowledge of the YCS: one was a retired dentist, who 
knew of the scheme through his profession and another had heard of it on a radio programme.
After hearing the initial presentation introducing the YCS, all of the participants felt that it was a 
very worthwhile scheme and they could see the benefit of asking patients to report ADRs directly 
to the MHRA:
It’s very sensible, you don’t know that the general practitioners are going to complete 
the forms even if you go back to them, but this way they will get more information I 
TABLE 31 Characteristics of participants in the focus group/usability sessions
Demographic data Participant nos
Gender
Male 13
Female 27
Age (years)
18–29 5
30–39 1
40–49 5
50–59 5
60–69 15
70–79 7
80+ 2
Ethnic origin
White 34
Black 2
Asian 4
Other 0
Educational level achieved
Left school at 16 years 4
Left school at 18 years 2
Further education 17
Higher education 14
Postgraduate degree 2
Not stated 2
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suppose. Whether they can use the information or not I don’t know, or whether they get 
too much information or not, I don’t know. But at least they are getting information.
Female, 60–69 years
Several of the participants also commented that they had reported side effects from medications 
to their doctor previously and had felt that the doctor was disinterested or dismissive. They 
believed that direct patient reporting would avoid information being reported to the MHRA 
through a professional lens.
In two of the focus groups there was some discussion relating to the quality of data that would be 
reported by patients and the possibility that this could be influenced by varying levels of literacy 
and education.
Although most of the participants felt that it was a positive step to allow members of the public 
to make reports to the YCS, a few felt that the GP should still be informed about the potential 
adverse reaction. Three participants stated that it should remain their GP’s responsibility to 
report such ADRs to the YCS, as this would be the most appropriate way of screening out those 
problems that were minor and not worth reporting. One participant expressed concern that 
direct patient reporting could result in the patient not discussing the issue with the GP. Others 
saw direct patient reporting as an option in situations where the GP did not agree to report a 
suspected ADR. Nevertheless, several participants felt that it was a professional responsibility 
of HCPs to report ADRs. Some participants recognised that direct patient reporting provided a 
mechanism to report adverse events from medicines bought from pharmacies.
Identifying adverse drug reactions
One issue raised in all of the focus groups was the difficulty of determining whether the 
symptoms experienced were a side effect of the medicine, due to the patient’s illness, or unrelated 
to their health problems. In addition, several participants discussed the potential complexity of 
deciding which drug was causing an ADR if the patient was taking multiple drug therapies:
I think my problem would be on the complexity of it all. I wouldn’t be able to really 
say which drug it was coming from. I find it useless information to give as I have a 
mishmash. If you give them the wrong one it could be wrong.
Female, 70–79 years
Determining the severity of the adverse reaction was also discussed. There was great concern over 
what would constitute a side effect worth reporting; whereas some participants felt they would be 
keen to report any potential side effect, many feared that reports of minor or unimportant side 
effects would ‘waste’ the MHRA’s time. There was general agreement that participants would only 
report side effects that were serious enough to be debilitating:
I wouldn’t bother reporting it unless I thought it [the ADR] was serious.
Female, 18–29 years
If it was just a headache or something I wouldn’t make a report, but something life 
threatening I would.
Female, 40–49 years
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Participants also raised the issue of potential inter-patient variability on determining of 
the severity of ADRs:
How do I know, that, you know, my headache which I think is 8 on a scale of 1 to 10 is 
the same as yours (nodding at another participant) or yours?
Male, 50–59 years
The participants saw potential issues relating to the consistency of reporting of the severity of 
an ADR from members of the public, with no effective ‘filtering’ by a prescriber with greater 
medical knowledge.
Issues regarding reporting
Participants were informed that they would only receive an acknowledgement of their report 
from the MHRA. Concern was raised about this. Several participants felt that the lack of detailed 
feedback would potentially discourage them from completing a report:
If you are still suffering from the side effect, are still ill, er then I am not sure I would 
think it was worth the effort required to complete the form if I wasn’t going to get any 
advice or something, perhaps some personal feedback.
Female, 40–49 years
The majority of the participants felt that there ought to be more feedback provided to the 
reporter than a simple acknowledgement. It was suggested that this feedback might simply 
to give the reporter an idea of the frequency of the side effect reported for the drug involved. 
The participants felt that reporters would want to know how their experience of a side effect 
related to that of other people reporting side effects from the same drug. It was felt important 
that the reporting forms and information provided about the YCS made clear that feedback 
on an individual’s specific case and medical condition would not be possible. This would avoid 
disappointment or anger when reporters did not receive a more detailed response.
Advertising of the Yellow Card Scheme
None of the participants had seen a poster or leaflet relating to the YCS, despite some of those 
involved in the focus groups being individuals who attended regularly both GP and outpatient 
clinics and received regular prescriptions from their local pharmacy. A high level of concern was 
expressed by participants about this apparent lack of promotion of the scheme.
Advertising the YCS was discussed in some detail, with participants mentioning that there 
needed to be much wider awareness in order to ensure that the maximum volume of reports 
were obtained from the patient reporting system. Without extensive advertising, there would be a 
limited response from the public:
If you don’t know about it you can’t do anything can you? … I think the surgeries or 
pharmacies or whoever being more proactive in displaying all of this with posters and 
what have you so that the general public really do know what it is for. I don’t think that 
there is any other way that the general public are going to learn about it.
Male, 20–29 years
Several suggestions were made on how to improve awareness of the scheme among those most 
likely to suffer from ADRs. Simple measures, such as ensuring that posters are displayed in all 
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pharmacies, general practice surgeries and hospital outpatient departments were seen to be a 
good method for raising general awareness. To target those receiving prescribed medicines, it was 
suggested that there could be a leaflet included in the bag with repeat prescription items:
Mmm … would it not be better that any time you collect any medication or something 
from your chemist, then one of these little Yellow Cards are put in separately. Because 
then it’s, it’s in your face as soon as you open your bag …
Female, 50–59 years
However, some felt that the leaflet might be treated as ‘junk mail’, and so would be an expensive 
and inefficient method of raising awareness. Another suggestion was to include information 
about the YCS on the bottom of each PIL provided within the medicine packaging by the 
manufacturer. Participants suggested that even if people do not read these leaflets routinely, they 
were much more likely to go back and read them if they suspected that they were suffering from 
an adverse reaction. Therefore, this would be an appropriate place to site information on the YCS.
Another suggestion for raising awareness included advertising on radio stations, particularly 
those targeted at the older population, as this section of the population takes the largest 
proportion of prescribed medicines. Attempts could also be made to have the YCS discussed on 
popular television programmes that deal with viewers’ medically related issues.
Following on from the need to raise awareness of the system, participants felt there was also a 
need to ensure easy access to the reporting forms in surgeries and pharmacies, with forms being 
clearly displayed in both settings. The participants also felt that HCPs could play a more proactive 
role in encouraging reporting by patients, and suggested that GPs and pharmacists could hand 
out the reporting forms to all patients they saw.
Usability testing findings
The usability test data are presented below, with each reporting method discussed in turn.
Paper reporting
The form was generally well received, with many of the participants commenting positively:
This is an excellent form and with my own information I could er … fill it in easily.
Female, 60–69 years
Two participants with visual impairment found the font size too small. Several participants 
commented that they would not bother reading the information about the YCS provided within 
the integrated information leaflet and reporting form; they would just start filling in the form. It 
should be noted, however, that the scheme had been explained to participants in the focus group 
directly before they undertook the usability tests.
In some of the scenarios, details were provided about a number of drugs that were being taken 
by the fictional individual and some of the participants found it difficult to fit all the required 
information onto the form. Although the form suggests that further information can be provided 
on a separate sheet, participants were generally not keen on this:
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Having to attach extra sheets to give all the information would annoy me, so I wouldn’t 
bother!
Male, 70–79 years
I’m frustrated to have to add additional sheets.
Female, 70–79 years
And some felt that this part of the form was tedious and long winded:
I have lost the will to live (comment made when entering all details of the drugs).
Female, 50–59 years
Some individuals commented that they would struggle to remember the date on which their 
various drugs had started and finished and they would need to look up this information.
The layout of the form was commented on by some participants. Details about the reporter are 
asked for at the end of the report after details of the ADR and the severity of the side effect. This 
did not feel natural to some of participants, who felt that detailed ADR information should be 
requested after more basic information has been collected.
Whereas all the scenarios included the height and weight of the fictional character experiencing 
the side effect, some participants commented that they would not necessarily be able to provide 
these details, particularly their weight.
When participants tried to insert their completed form in to the reply-paid envelope, which is 
also part of the leaflet, they were disappointed to discover that the form did not slide neatly into 
it; instead, the form had to be folded:
The envelope is the same width as the form, so it doesn’t go in without folding. And the 
adhesive is not very good.
Male, 18–29 years
One participant commented that the use of a first-class reply-paid envelope made her feel that the 
MHRA was taking the whole system very seriously.
It was suggested that access to the system would be improved by making the paper-based and 
online forms available in languages other than English:
It might be useful to er you know, provide the service in other languages, er not 
only English.
Male, 60–69 years
Telephone reporting
The telephone reporting system was popular with all of those who used it. The interactive nature 
of the conversation with the person staffing the telephone was highlighted as a factor that made 
the process much easier for the reporter. Participants expressed concern that such a convenient 
method of reporting was only available for a limited number of hours, thereby limiting access. 
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They were pleased to be told that the reporting line has a direct-dial number which does not 
require reporters to enter a queuing system with an automated response menu:
I might be put off by having to pay for the phone call … the time restriction of the 
service might put me off too.
Female, 40–49 years
The only issue encountered with the telephone system occurred to one participant who had 
impaired hearing. He found that he was unable to hear the person taking the report because of 
background noise; the test had to be abandoned because of this. However, the participant stated 
that at home he would not have encountered this problem and he did not consider this to be an 
inherent problem.
Online reporting
The online reporting system received mixed comments from participants. There were a few who 
found the system easy to navigate, but many found it very challenging, even though they used the 
internet regularly and completed forms online.
When reporting the nature of the suspected ADR, there are a number of drop-down menus 
(dictionaries) that provide mixed-response options. However, the complexity of the terms used 
within these menus confused a number of participants. For example, entering an ADR term of 
‘rash’ produced over 70 medical terms for rash (such as ‘rash desquamating’, ‘rash morbilliform’). 
Participants were often unable to understand these terms, and many participants felt forced to 
choose the first term on the list (which is always a general term) or a term at random.
A number of participants did not see the drop-down menus appear, as they were concentrating 
on the next part of the form that they had to complete. This resulted in lack of further detail 
being provided.
There appeared to be no facility to save data at each stage of completing the online form. At least 
two participants had problems with losing information after taking some considerable time 
completing sections of the form. Having wasted their time, these participants told us that they 
would not have finished completing the form in real life.
One comment made by a number of participants related to the different ordering of questions 
on the online and paper forms. A consistent approach would make it easier for users who may 
use the paper form to collate their information, but then choose to submit the data using the 
online system.
The online system also asks for extra information to that requested on the paper form. It is 
important to consider whether this additional information is required and, if so, whether it 
should also be collected on the paper form.
Summary
 ■ Members of the public in Nottingham, UK, were invited to seven focus groups at which 
views on patient reporting of ADRs were explored. Participants were then observed 
completing Yellow Card reports for simulated ADR scenarios and detailed information was 
recorded on their experiences and suggestions for improvements.
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 ■ Forty participants took part in seven focus groups. After hearing an introductory 
presentation, a number of suggestions were made about improving publicity for the YCS. 
Usability testing with the 40 participants indicated that telephone reporting worked well, but 
identified specific suggestions for enhancing online and paper reports.
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
107 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
Chapter 10  
Study 8: omnibus survey
Omnibus survey
The omnibus survey is a multipurpose survey that was developed in the 1990s by the Office 
of National Statistics in the UK. It is most commonly used to measure the efficacy of publicity 
campaigns, assess awareness of new policies, test questions and provide a sample of respondents 
for follow-up investigations.50
The omnibus survey contains a set of classificatory questions, including socioeconomic status 
and ethnicity, and these can be supplemented to provide information on a range of health and 
health-related topics.51
Objectives
 ■ To estimate the percentage of members of the general public in Great Britain who had heard 
of the YCS for patient reporting of ADRs.
 ■ To determine whether those respondents, who believe that they have experienced an ADR 
and who were aware of the YCS, have made a report using the YCS.
 ■ To assess the views of members of the public on the convenience of the three different ways 
of reporting (online, telephone, obtaining a paper form from a GP/pharmacy to fill in and 
post).
Methods
Eight questions, three of which were contingent on answers to the other questions, were added to 
the national omnibus survey carried out by the British Market Research Bureau (BMRB) (www.
tns-ri.co.uk/what-we-do/6772.aspx) by telephone over two weekends in January 2009. Probability 
sampling was attained by using random digit dialling (RDD). This method ensures that numbers 
not listed in telephone directories are included in the sample. Each residential number has an 
equal chance of being dialled.
A UK database of residential numbers is the source of the master sample used by BMRB for 
its telephone omnibus service. New numbers are created by adding or subtracting up to 40 
from each original number. Duplicate numbers are removed from the listing. Samples for each 
omnibus survey are selected from the master sample using a random start and constant sampling 
interval. Any adult aged 16 years or above living in the household is eligible for interview. To 
ensure that the final sample does not over-represent groups that spend more of their time at 
home, criteria known to relate to an individual’s likelihood of being at home are used to control 
selection from the list of eligible adults. If no reply is received at the first calling, or if the 
respondent requests an appointment at a different time, the household is recalled.
Questions were developed to assess the public’s knowledge of the YCS and preference for different 
methods of reporting ADRs. We asked about respondents’ previous experiences of side effects 
108 Study 8: omnibus survey
from medications and whether they had ever reported these. In addition, respondents were asked 
to rank the convenience of each reporting method on a scale from 1 (very inconvenient) to 10 
(very convenient). The exact wording of the questions asked is shown in Appendix 22.
Demographic information was obtained for the sample about gender, age, geographical region, 
social grade, highest level of education, working status, ethnicity and internet use in the 
past month.
Analysis
Data were analysed using spss for Windows version 15.0. Data were described using frequencies 
and percentages. Original BMRB codes for ethnic background were combined into five major 
ethnic groups: (1) white Irish, white British and any other white background; (2) mixed African, 
mixed Caribbean, mixed Asian and any other mixed background; (3) Indian, Pakistani and any 
other Asian background; (4) African, Caribbean and any other black background; and (5) other 
ethnic background. The chi-squared test was used to compare the sociodemographic profile 
of our sample with UK general population figures of 2008. Similarly, the chi-squared test was 
used to examine sociodemographic variables across level of awareness of the patient reporting 
to the YCS. Multiple logistic regression was used to identify independent patient demographic 
predictors of awareness of the YCS. Mann–Whitney or Kruskal–Wallis tests were used to 
compare median convenience of reporting scores across sociodemographic factors. A p-value of 
≤ 0.01 was used to denote statistical significance throughout.
Results
Over the two weekends, 62,018 telephone calls were made, resulting in 31,390 contacts 
(50.6%) and 2028 responses (6.5% of contacts). The analysis was based on the 2028 subjects 
who responded to the survey. Demographic details of the respondents are shown in Table 32 
together with comparisons for the general population of England, Scotland and Wales in 2008 
unless stated otherwise. Compared with the general population in 2008, respondents were more 
likely to be female, of older age, living in London/south-east/south-west, of lower middle class, 
and economically inactive. It should be noted, however, that although all differences reached 
statistical significance, which was partly owing to the general population sample size; overall 
percentage differences were fairly small.
Table 33 reports the answers given to the eight questions. A total of 477 (23.5%) people said that 
they had suffered a side effect from a medicine, the majority of whom (408, 85.5%) had reported 
it to their GP or another HCP. The main reasons why respondents did not report it to a HCP 
were the side effect not being serious enough or respondents expecting or knowing about the side 
effect. Only 172 respondents (8.5%) had heard about the YCS and, of these, only three had self-
reported to the YCS the last time they had a side effect (two reported it online and one by post). 
Nearly 60% (n = 1295) of the sample had used the internet within the last month.
Table 34 shows that there was no significant association between awareness of the YCS and 
gender, age group, geographical region, working status and ethnicity (all p > 0.05). However, 
significantly more people who were aware of the YCS came from the upper or middle social 
grades compared with the skilled working and working class (p = 0.006). In addition, awareness 
of the YCS was associated with respondents having completed post secondary or university 
education (p < 0.001).
Multiple logistic regression with awareness of the YCS as the dependent variable and social grade 
or highest level of education as independent variables confirmed that people of upper and lower 
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TABLE 32 Demographic features of the sample and comparison with the general population of England, Scotland and 
Wales in 2008 (unless stated otherwise)
Factor Sample, % (n)
General population (2008, England, 
Scotland and Wales): % (n) p-value
Gender
Male 44.9 (911) 49.1 (29,280,500) < 0.001
Female 55.1 (1117) 50.9 (30,327,700)
Age group (years)
16–24 6.5 (130) 16.2a (7,956,200) < 0.001
25–34 9.8 (196) 15.6 (7,665,100)
35–44 17.4 (347) 18.1 (8,894,400)
45–54 20.2 (403) 16.1 (7,929,200)
55–64 20.3 (404) 14.4 (7,084,400)
65+ 25.8 (514) 19.5 (9,581,300)
Missing (n) 34 –
Geographical region
London/SE/SW 41.2 (836) 35.6 (21,209,100) < 0.001
Wales 5.1 (104) 5.0 (2,993,400)
E Anglia/E and W Midlands 22.1 (448) 26.1 (15,572,800)
Yorkshire/NW/NE/Scotland 31.6 (640) 33.3 (19,832,900)
Social gradeb
AB (upper middle) 22.0 (434) 22.0 (8,934,482) < 0.001
C1 (lower middle) 33.3 (657) 29.7 (12,065,333)
C2 (skilled working) 18.4 (363) 15.1 (6,149,928)
DE (working class) 26.3 (520) 33.2 (13,516,803)
Missing (n) 54 –
Highest-level education
None/primary/few years secondary 7.9 (153) c –
Secondary completed 35.6 (688)
High school/further education 31.9 (616)
University degree/doctorate 22.7 (438)
Still studying 2.0 (38)
Missing (n) 95
Working status
Full time 42.3 (846) 63.6d (31,220,000) < 0.001
Part time 13.2 (263)
Not working 14.7 (294) 36.4e (17,839,000)
Retired 29.9 (597)
Missing (n) 28
Ethnicity
White British/Irish/other 94.4 (1848) 89.0 (52,233) < 0.001
Mixed Caribbean/African/Asian/other 0.9 (17) 1.2 (677)
Indian/Pakistani/other Asian 2.1 (41) 5.3 (3107)
Black Caribbean/African/other 2.3 (45) 2.6 (1531)
Any other 0.4 (7) 1.9 (1160)
Missing (n) 70 –
E, east; NE, north-east; NW, north-west; SE, south-east; SW, south-west; W, west.
a Age group 15–24 years.
b England and Wales only.
c No comparable data available.
d Economically active.
e Economically inactive.
110 Study 8: omnibus survey
middle social grades were more likely to be aware of the YCS than those in the skilled working 
and working grades (overall p-value = 0.009). Those with further education were more likely to be 
aware of the YCS than the primary school-educated people (overall p-value = 0.001)
Table 35 suggests that perceived levels of convenience for online or telephone reporting of side 
effects were higher than those of a form from the local pharmacy or GP. Figure 12 shows that 
people felt that online reporting was either very inconvenient or very convenient. Telephoning 
was noted to be very convenient by the majority of subjects, whereas using a paper form from the 
pharmacy or GP was less favoured by some.
Subjects were not asked which of the three different forms of reporting they found most 
convenient – they were simply asked to rate each method separately. Therefore, they could 
give the same level of convenience to more than one method. Out of the 2028 subjects, 156 
(7.7%) answered ‘don’t know’ to one, two or three of the questions, whereas 1035 (50.8%) gave 
equal ratings to two or three of the questions. This meant that only 837 (41%) of subjects had 
TABLE 33 Reported answers to questions pertaining to the YCS
Question Response % (n)
Have you ever had side effects from any medicine? Yes 23.5 (477)
No 76.1 (1543)
Don’t know 0.4 (8)
If yes, did you tell your GP or other HCP about it? Yes 85.5 (408)
No 14.3 (68)
Don’t know 0.2 (1)
Question not applicable n 1551
If not, why not? Side effect not serious enough 25.0 (17)
Didn’t realise side effect due to medicine 7.4 (5)
Expected/knew about side effect 19.1 (13)
Stopped using medicine 7.4 (5)
I am a GP or HCP 4.4 (3)
Didn’t want to bother/unnecessary 7.4 (5)
Other (including ‘embarrassed’, ‘abroad’, ‘didn’t 
read instructions’)
22.1 (15)
Don’t know 7.4 (5)
Question not applicable 1960
There is a scheme called the ‘YCS’ that allows people who’ve had side 
effects from medicine to send a report about it to the Department of 
Health. Were you aware of this scheme before today?
Yes 8.5 (172)
No 91.5 (1856)
Thinking about last time you had side effect, did you report it yourself 
using YCS?
Yes 5.9 (3)
No 94.1 (48)
Not applicable (1977)
When you reported the side effects using the YCS, did you report it? Online 66.7 (2)
By filling out and sending in a form 33.3 (1)
By telephone 0 (0)
Not applicable (2025)
Have you used the internet in the last month? Yes 63.9 (1295)
No 36.1 (733)
HP, health professional.
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unique ratings to all three questions. Of these 837 subjects, 404 (48.3%) rated online as most 
convenient method of reporting, 287 (34.3%) the telephone and 146 (17.4%) a form from their 
GP/pharmacy.
TABLE 34 Level of awareness of YCS by patient demographics
Factor
Aware of YCS
p-valueYes (n = 172) No (n = 1856)
Gender
Male 41.9 (72) 45.2 (839) 0.399
Female 58.1 (100) 54.8 (1017)
Age group (years)
16–24 3.6 (6) 6.9 (124) 0.128
25–34 7.1 (12) 10.1 (184)
35–44 16.0 (27) 17.5 (320)
45–54 20.7 (35) 20.2 (368)
55–64 27.2 (46) 19.6 (358)
65+ 25.4 (43) 25.8 (471)
Geographical region
London/SE/SW 41.9 (72) 41.2 (764) 0.790
Wales 5.2 (9) 5.1 (95)
E Anglia/E and W Midlands 24.4 (42) 21.9 (406)
Yorkshire/NW/NE/ Scotland 28.5 (49) 31.8 (591)
Social grade
AB (upper middle) 27.2 (46) 21.5 (388) 0.006
C1 (lower middle) 37.3 (63) 32.9 (594)
C2 (skilled working) 8.9 (15) 19.3 (348)
DE (working class) 26.6 (45) 26.3 (475)
Highest level education
None/primary/few years secondary 6.6 (11) 8.0 (142) < 0.001
Secondary completed 23.5 (39) 36.7 (649)
High school/further education 35.5 (59) 31.5 (557)
University degree/doctorate 33.7 (56) 21.6 (382)
Still studying 0.6 (1) 2.1 (37)
Working status
Full time 40.6 (69) 42.5 (777) 0.575
Part time 15.9 (27) 12.9 (236)
Not working 12.4 (21) 14.9 (273)
Retired 31.2 (53) 29.7 (544)
Ethnicity
White British/Irish/other 94.7 (160) 94.4 (1688) 0.863a
Mixed Caribbean/African/Asian/other 1.2 (2) 0.8 (15)
Indian/Pakistani/other Asian 1.2 (2) 2.2 (39)
Black Caribbean/African/ other 3.0 (5) 2.2 (40)
Any other 0 0.4 (7)
E, east; NE, north-east; NW, north-west; SE, south-east; SW, south-west; W, west.
a ‘White British/Irish/other’ compared with other categories combined.
Values are column percentages (n).
112 Study 8: omnibus survey
There were significant associations between reported levels of convenience of each of the three 
methods of reporting and demographic factors.
Table 36 shows that respondents who thought that it would be convenient to report online were 
more likely to be male, younger, living in the Midlands/south, of middle social grade, have some 
form of further education and be working full time.
In contrast, those who thought that the telephone would be a convenient method of reporting 
were more likely to be female and of lower social grade.
Finally, people who thought that reporting via a paper form from their GP or pharmacy would 
be a convenient method tended to be female, older, of a lower social grade, have a lower level of 
completed education and be retired.
FIGURE 12 Level of convenience of reporting future side effects for (a) online reporting, (b) telephone reporting and (c) 
reporting by completing and posting a paper form, where 1 = very inconvenient and 10 = very convenient.
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TABLE 35 Overall reported level of convenience of reporting future side effects by different methods
Method of reporting Median (IQR) Missing (n)
Online 8 (1 to 10) 122
Telephone 8 (5 to 10) 80
Form from local pharmacy or GP surgery 6 (4 to 9) 77
On a scale of 1–10, where 1 = very inconvenient, 10 = very convenient.
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TABLE 36 Level of convenience of different reporting methods by patient demographics
Factor
Convenience of method of reporting
Online Telephone Paper
Gender
Male 8 (3 to 10) 8 (5 to 10) 5 (3 to 8)
Female 8 (1 to 10) 8 (5 to 10) 6 (4 to 9)
p-value 0.006 < 0.001 < 0.001
Age group (years)
16–24 9 (7 to 10) 7 (5 to 10) 5 (4 to 8)
25–34 10 (7 to 10) 8 (6 to 10) 5 (3 to 7)
35–44 10 (7 to 10) 8 (5 to 10) 5 (3 to 8)
45–54 8 (4 to 10) 8 (5 to 10) 6 (3 to 9)
55–64 7 (1 to 10) 8 (6 to 10) 6 (4 to 9)
65+ 1 (1 to 5) 8 (5 to 10) 7 (5 to 10)
p-value < 0.001 0.052 < 0.001
Geographical region
London/SE/SW 8 (2 to 10) 8 (5 to 10) 5 (3 to 8)
Wales 5 (1 to 10) 8 (5 to 10) 5 (3 to 9)
E Anglia/E and W Midlands 8 (1 to 10) 8 (5 to 10) 6 (4 to 9)
Yorkshire/NW/NE/Scotland 7 (1 to 10) 8 (5 to 10) 6 (4 to 9)
p-value 0.001 0.505 0.072
Social grade
AB (upper middle) 9 (7 to 10) 8 (5 to 10) 5 (3 to 8)
C1 (lower middle) 9 (4 to 10) 8 (5 to 10) 5 (3 to 8)
C2 (skilled working) 7 (1 to 10) 8 (5 to 10) 6 (4 to 8)
DE (working class) 3 (1 to 8) 9 (6 to 10) 7 (5 to 10)
p-value < 0.001 0.003 < 0.001
Highest level education
None/primary/few years secondary 1 (1 to 6) 8 (5 to 10) 6 (4 to 9)
Secondary completed 5 (1 to 9) 8 (5 to 10) 6 (4 to 9.8)
High school/further education 8 (2 to 10) 8 (5.5 to 10) 6 (4 to 8)
University degree/doctorate 10 (8 to 10) 8 (5 to 10) 5 (3 to 8)
Still studying 10 (7 to 10) 7.5 (6 to 10) 5 (4 to 7)
p-value < 0.001 0.134 < 0.001
Working status
Full time 9 (6 to 10) 8 (6 to 10) 5 (3 to 8)
Part time 8 (5 to 10) 8 (5 to 10) 5 (4 to 8)
Not working 8 (1 to 10) 9 (5 to 10) 6 (5 to 10)
Retired 1 (1 to 7) 8 (5 to 10) 7 (5 to 10)
p-value < 0.001 0.833 < 0.001
Ethnicity
White British/Irish/other 8 (1 to 10) 8 (5 to 10) 6 (4 to 9)
Mixed Caribbean/African/Asian/other 8 (5 to 10) 7 (2 to 8) 5 (4 to 8)
Indian/Pakistani/other Asian 8 (4 to 9) 7 (5 to 9) 5 (3 to 7)
Black Caribbean/African/other 9 (3 to 10) 7 (5 to 10) 5 (3 to 9)
Any other 10 (5 to 10) 9.5 (1.8 to 10) 5 (1 to 5)
p-value 0.224 0.071 0.154
E, east; NE, north-east; NW, north-west; SE, south-east; SW, south-west; W, west.
On a scale of 1–10, where 1 = very inconvenient, 10 = very convenient.
Values are median (IQR) level of convenience.
The p-values are from Mann–Whitney or Kruskal–Wallis test.
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Summary
 ■ Eight questions were added to a national omnibus survey that was carried out by the BMRB 
by telephone over two weekends in January 2009, using a database of residential telephone 
numbers in Great Britain. Questions were developed to assess public knowledge of the YCS, 
previous experiences of side effects from medications, previous reporting of ADRs and 
preferred methods for reporting ADRs.
 ■ From the national omnibus survey of 2028 adults, only 172 (8.5%) had heard about the YCS. 
The preferred method of reporting varied with the characteristics of respondents.
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Chapter 11  
Discussion
We have successfully completed a multifaceted evaluation of patient and HCP reporting of suspected ADRs to the YCS in the UK. In this chapter we begin by discussing the findings 
in relation to the first two objectives of the study, drawing on the literature where appropriate. 
The structure of these discussions reflects the authors’ views on the importance and significance 
of the findings, while addressing the original research questions set out in Chapter 1.
We then discuss the strengths and limitations of our studies in detail before offering 
recommendations for improvement to patient reporting based on our findings and those from 
the literature (our third objective). We end by providing suggestions for further research.
Evaluating the pharmacovigilance impact of patient reporting to 
the Yellow Card Scheme
How do patients describe suspected side effects, and how does 
the richness of patient reports compare with those of health-care 
professionals?
Patients gave detailed descriptions of suspected ADRs, attributed reactions to specific medicines 
and provided information useful for assessing causality. Patient reports often had richer 
narratives than those of HCPs and rarely provided irrelevant information or ambiguities. Patient 
reports also often contained detailed information about the impact of the suspected ADR on the 
patient’s life, thus providing insights that there were comparatively rare in HCP reports.
These findings are in keeping with analyses of consumer reports of reactions to paroxetine52 
compared with reports from HCPs to the YCS.52 The study authors noted:52
Our analyses suggest that reports from patients – in their own words – communicate 
essential information which professional reporters can never be expected to provide. 
In this case, patients provided reports that were much richer in their descriptions of 
behavioural phenomena and feelings than the YC [Yellow Card] reports, and often much 
better at explaining the nature, significance and consequences of adverse drug effects.
Medawar and Herxheimer52 also identified the potential for some terms used by patients, 
such as electric shock sensation associated with paroxetine, to be coded as less-specific terms, 
such as paraesthesia. In our study, we did not formally check the text from patients against 
coded reaction terms, but this information was readily available when selecting the cases for 
qualitative analysis. Our impression was that symptom descriptions were coded accurately 
and comprehensively. Nevertheless, if an entirely new symptom not listed in the MedDRA 
dictionary was to emerge in relation to a medicine, delays would occur in detection if there 
was an overemphasis on coding at the expense of careful reading and consideration of reports. 
Also, it is important to recognise that reports from either patients or HCPs will lose their 
richness when converted to symptom codes. Therefore, detailed reading of reports is still an 
extremely important task for regulatory bodies, particularly in relation to drugs undergoing 
intensive monitoring.
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In keeping with our findings, an earlier literature review of patient reporting of ADRs24 
concluded that none of the countries with patient reporting systems had identified poor quality 
of patient reports as an issue. Van Grootheest and colleagues53 state that the quality of the report 
should be distinguished from the quality of the clinical judgement. In terms of the quality of 
the report, they identified the following elements needed to make a report useful: description of 
the adverse reaction, time of onset of the reaction, the drug involved, concomitant medication, 
duration of drug use, including dates of initiation and discontinuation, and any other relevant 
information. Most of the patient reports in our qualitative study contained this information. 
Quality of the judgement, relates to whether patients can distinguish drug-related complaints 
from other problems, for example disease-related complaints.53 Many of the patients in our 
qualitative study appeared to be able to differentiate between symptoms of disease and ADRs, 
sometimes explaining their reasoning for this judgement.
The pharmacovigilance impact of suspected adverse drug reaction reports 
from patients and health-care-professionals
Spontaneous reporting of suspected ADRs by HCPs is a valuable pharmacovigilance 
tool1,54 and has contributed to the identification of major safety issues.1 There is general 
acknowledgement that patient ADR reporting is the right thing to do and that it will enhance 
pharmacovigilance,6,53,55 although the specific value of ADR reports from patients has not 
been clear.
Although proponents have highlighted potential benefits from patient reporting of ADRs,30,56,57 
others have expressed concerns. Many of these concerns have been highlighted already, including 
the capability of patients to distinguish between suspect ADRs and problems associated with 
the underlying condition being treated by the suspect drug;58 unclear ADR description;58 large 
numbers of reports of minor and well-known ADRs adversely affecting the ability to identify 
new drug safety issues;1 duplication of ADR reports;1 resources available to regulators;1 the 
potential influence of campaigning groups on signal generation;1 and perceived undermining of 
HCP status.59
Our qualitative findings should reassure those who worry that patients may not be able to give 
useful information for detailed pharmacovigilance assessment, such as the detailed reading of 
narratives required to assess the potential causality and impact of suspected ADRs. Other issues 
relevant to pharmacovigilance include:
 ■ seriousness of reports
 ■ outcome of the ADR
 ■ timeliness of reports
 ■ role of patient reports in the generation of new signals.
Seriousness of reactions and patient outcomes
In our study we found no significant differences between patients and HCPs in the proportion of 
reports containing at least one reaction term classified as ‘serious’ by the MHRA (58.3% vs 58.8%, 
respectively). The observation that such a high proportion of patient reports contained a reaction 
term classified as serious provides reassurance to those concerned that patients might report too 
many relatively minor ADRs.1
Studies from Denmark19 and the Netherlands30 also found that physicians and patients report a 
similar proportion of serious ADRs.
It was difficult to make a direct comparison of patient outcomes from suspected ADRs because 
of differences in the questions asked of patients completing a Yellow Card report compared 
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with those of HCPs. For those categories where direct comparison was possible, HCPs were 
more likely than patients to report that the suspected ADR had caused hospitalisation, was 
considered life-threatening or caused death. This difference may be because patients (or their 
representatives) are not in a strong position to make a report in such circumstances because of 
the physical and/or emotional impact of the illness or death (a point reinforced by our advisory 
group). Having said this, a Dutch study showed that patients reported a higher proportion of 
suspected ADRs for life-threatening events than physicians.30
Our content analysis of Yellow Card reports showed that patients were much more likely than 
HCPs to document the potential impact of suspected ADRs on their lives (47% vs 12% of 
reports) and a Dutch study showed that patients report higher proportions of ADRs associated 
with disability.30
Our qualitative analysis also highlighted the detailed descriptions that patients often gave for the 
emotional, social and occupational impact of suspected ADRs. Although this information would 
not be used in signal generation analysis, it could be extremely useful for regulators undertaking 
more detailed assessments of drugs that are being intensively monitored or investigating drug–
ADR pairings that have generated signals.
Our study has highlighted the burden of ADRs on patients’ lives and yet there may be a 
difference between what patients and regulatory authorities regard as serious. The concurrence, 
or disparity, of views between patients and regulatory authorities needs further exploration, we 
believe, because there is uncertainty about whether current regulatory approaches to assessing 
seriousness miss important reactions that may have very serious implications for patients’ lives. 
An example would be electric shock sensations associated with SSRI withdrawal, which was 
brought to prominence through analysis of patient reports to the media.52
Time taken to report reactions
In terms of the time taken to report reactions, it should be noted that over 60% of patient reports 
analysed had this piece of information missing. Where information was available, patient 
reporters took significantly longer to report their ADR than HCPs (median 104 vs 28 days). The 
situation did not change when the second year of patient reporting was compared with the first.
Our questionnaire survey of patient reporters to the YCS showed that those reporting by 
telephone did so relatively sooner than those reporting by either of the other two methods. Those 
who reported by post took the longest time to report. Our telephone interviews with patients 
who had reported an ADR, suggests that the main reason for delay is lack of knowledge of the 
reporting scheme. Lack of knowledge about the YCS was also found in our omnibus survey. 
Delays in reporting will inevitably delay signal generation and may affect the accuracy of recall 
of events relevant to the report. Therefore, it is extremely important to improve awareness of the 
YCS among the public and to ensure that access to the different reporting methods is made as 
easy as possible.
Do patient reports generate ‘new’ signals?
In Australia, 20% of patient reports were for previously unknown ADRs27 and there were 
conflicting results regarding whether patients were more or less likely to report these than 
HCPs. In the Netherlands, 30% of suspected ADRs reported by patients were not mentioned in 
the PIL.60
Our study went much further than previous published studies to examine the impact of patient 
reports on signal generation. We examined SDRs that are ‘statistical signals’, where the reporting 
rate for an ADR in association with a particular medicine is disproportionate to that of other 
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products in the database. We found that the ‘patient-only’ and ‘HCP-only’ data sets produced 
quite different findings in terms of reactions reported and suspect drugs, with only 10% of all 
reported drug–ADR pairs being present in both data sets.
The potential signals (SDRs) detected by disproportionality analysis of each reporter data set 
were also quite different. It should be noted, however, that this type of analysis relies heavily 
on the coding of reactions, so some differences may have arisen because of the way in which 
reactions were described by the two reporter groups, and, subsequently, coded using MedDRA 
terminology. For example, a patient may report a ‘seizure’ with metoclopramide, whereas a 
HCP may report an ‘oculogyric crisis’. These are subtle, but important differences. Nevertheless, 
comparisons using exact, similar or related terms for a particular reaction, still found that 
two-thirds of the SDRs generated by the ‘patient-only’ data set were not generated in the ‘HCP-
only’ data set. A similar proportion of SDRs generated in reports from either group (15%) were 
assessed as being ‘not documented on the product’s SPC’, suggesting that the identification of 
potentially important new information.
Do patient reports add weight to known signals or signals generated 
from reporting by health-care professionals?
Our study also found that combining patient and HCP data sets generated additional SDRs that 
were not generated by either data set alone (n = 508), although 10% (n = 186) of SDRs generated 
by the ‘HCP-only’ data set no longer appeared as SDRs. Forty-seven of the additional SDRs 
generated by the combined data set involved reactions that were classified as ‘serious’ and that 
had not been documented previously on the product’s SPC; 10 of these involved ‘black triangle’ 
drugs (for further details, see Appendices 11 and 12).
It would appear, therefore, that patient reports add weight to HCP reports by creating new 
and important SDRs. This is at the expense, however, of the loss of a smaller number of SDRs 
generated by HCP reports alone. SDRs for drugs labelled as ‘black triangle’ are unlikely to 
be missed in practice in the UK, as the MHRA would identify these using the traditional 
case-by-case approach. Five SDRs were ‘lost’ by the addition of patient reports to HCP reports 
for previously undocumented reactions to established drugs, compared with 37 being newly 
identified by the combination.
Those involved in the analysis of patient and HCP reports need to take these findings into 
account when considering how to maximise the pharmacovigilance benefit of using these two 
sources of information. For example, in addition to examining the combined data set, it might be 
helpful to conduct signal detection analysis on separate HCP and patient data sets to ensure that 
important new signals are not missed. Consideration of these issues will become more important 
over time as patient reports accumulate in national ADR databases and represent an increasing 
proportion of all reports available for analysis.
Recent analysis from the YCS has shown that patient reports do contribute to signal generation 
with examples including ‘varenicline and aggression, hyoscine and visual hallucinations and a 
food interactions between amlodipine and grapefruit’.61
Causality assessment of suspected adverse drug reactions
Our study showed that most of the reports assessed for causality were judged to have a ‘possible’ 
causal association between the drug and the suspected ADR, regardless of reporter group. This 
indicates that patients provide comparable information to HCPs with respect to its usefulness for 
causality assessment. It is noteworthy, however, that around one-fifth of both patient and HCP 
reports could not be assessed. This was because of missing, conflicting or too much information, 
for example multiple suspect drugs and reaction terms supplied. Providing further guidance to 
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reporters on what information to report may help strengthen the usefulness of both patient and 
HCP reports.
Other observations regarding patient and health-care professional reports
Demographic characteristics: age and gender
We found a similar median age of people included in patient and HCP reports as a Dutch 
study.30 In common with others,19,30 we found that more patient and HCP reports were submitted 
for females. The reasons for higher ADR reporting in women are not simply related to higher 
consumption of medicines.62 For example, a large hospital-based cohort study showed higher 
risk of ADRs in women than men, even when the number of drugs prescribed was taken into 
account.4,63 Women were found to be particularly at risk from dose-related ADRs and ADRs 
related to cardiovascular drugs.4,63 In a large hospital-based UK study, women were also found to 
be more susceptible to ADRs than men, although the number of medicines prescribed was the 
only significant predictor of ADRs when multivariate analysis was undertaken.4 However, women 
may not necessarily be at increased risk of ADRs for all types of drugs. One study of self-reported 
side effects to anti-hypertensive drugs64 showed no increased risk in women, in contrast with the 
cardiovascular drug findings of Zopf and colleagues.4,63 Clearly, the increased susceptibility of 
women to ADRs is not fully understood and is inadequately explained by current epidemiological 
studies.4,63 There is also bias against understanding female responses to medication as women are 
often excluded from phase I and phase II drug studies.65 Further studies are needed to help better 
understand the reasons for higher prevalence of ADRs in women.
Number and types of drugs and suspected adverse drug reactions 
reported
In our study, over 16% of patient Yellow Card reports contained more than one distinct suspect 
drug compared with 9% of HCP reports. This might be owing to patients being less able than 
HCPs to identify the drug(s) most likely to be associated with a particular suspected ADR.
When drugs were grouped into their ATC anatomical classifications, the three most 
frequently reported classes were the same for both patient and HCP reporters (nervous 
system, cardiovascular system, anti-infectives for systemic use), as in a Danish study.19 In the 
Netherlands, patients and physicians also reported similar types of drugs to each other.30 In our 
study, however, there were more marked differences between groups at individual drug level, with 
simvastatin and citalopram being the only two drugs in the top 10 suspect drugs for both patients 
and HCPs.
Health-care professionals were more likely than patients to report suspected reactions to newer 
‘black triangle’ drugs. Potential signals relating to ‘black triangle’ drugs were also more commonly 
identified when analysing the ‘HCP-only’ data set. This was not surprising given that HCPs are 
encouraged to report suspected ADRs to these drugs, whereas patients are not routinely told 
about drugs undergoing intense surveillance. Levels of patient reporting for ‘black triangle’ drugs 
may be raised if patients are given more information about which drugs are flagged as ‘black 
triangle’ products. For example, PILs could highlight the ‘black triangle’ status of the drug, and 
prescribers and pharmacists could encourage patients to report suspected ADRs for these drugs 
in particular. Patient reporters to the Australian national scheme were more likely to report new 
drugs compared with HCPs.27 It would be useful to explore why this might be the case.
In our study, patients reported significantly more suspected ADRs per Yellow Card report than 
HCPs. The reasons for this are not clear but may, in part, be related to patients writing more 
about their symptoms than health professionals (as demonstrated by our qualitative study and the 
three times higher word count in patient reports). A Dutch study also found that patients listed 
more suspected ADRs per report than HCPs.30
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The top two (LLT) reactions reported in our study by both types of reporters were nausea and 
headache. These reactions were in the top five in a Dutch study of patient reporting, with six of 
the top 10 reactions similar between patient reporters in the two studies.30
Our study showed that patients were almost three times more likely than HCPs to report ADRs 
categorised as affecting the nervous system, but the differences were less marked when examining 
SDRs. A Danish study also found that nervous system disorders were reported slightly more often 
by patients than other sources (i.e. HCPs, drug manufacturers and lawyers).19 Patient reports may, 
thus, be particularly valuable in helping to detect ADRs relating to the nervous system.
Word count
The median word count for patient descriptions of suspected ADRs was three times greater than 
that of HCPs. This may, in part, be owing to high motivation among patients to report in detail. 
In contrast, HCP reports may have been shorter because of limited time to complete the reports 
and HCPs having fewer details of the suspected ADR than patients. Another reason may be that 
the Yellow Card report form (in the BNF,38 which HCPs often use) has much less space for free 
text than either the paper YCS forms used by patients or the online Yellow Card system available 
to all reporters. Encouraging electronic reports by HCPs may result in more detailed reports 
being submitted.
Proportion of ADR reports coming from patients
Our study showed that over the period October 2005 to September 2007, patient reports 
constituted 19.8% of all reports from both patients and HCPs. This is comparable with published 
figures of 19.2% for the Netherlands.30 In the USA, the proportion of reports from patients has 
risen from 15% in 200424 to over 40% in 2010.23 Denmark and Canada have lower levels of patient 
reporting (see Figure 1), although the Canadian figures will be an underestimate because they do 
not contain reports categorised as ‘consumer and patient’.
Even though we have shown that public awareness of the YCS is low, there may be lessons that 
other countries can learn from the success of the Netherlands, the UK and the USA in facilitating 
patient reporting.
The views and experiences of patients and members of the 
public regarding patient reporting of adverse drug reactions
Awareness of the Yellow Card Scheme among patients and members of 
the public
Our national omnibus survey of 2028 adults showed that although one-quarter of the 
respondents had experienced a side effect from a medicine at some time, fewer than 10% had 
heard of the YCS and only three people had used it. Those who were aware of the scheme were 
more likely to be from upper or middle socioeconomic groups and to have completed education 
post secondary school. Most of those who had experienced a side effect had told a HCP 
about it (85.5%).
Our questionnaire survey of 1362 patients who had reported an ADR via the YCS found that 
the most likely source of information about the scheme was from a community pharmacy 
(49.0%) or general practice (16.2%). Most patients reported the ADR(s) by post, with a third 
reporting online.
Our finding that a higher proportion of respondents reporting by post learned about the scheme 
from a pharmacy or GP surgery probably reflects the main source of the forms. From our 
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
121 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
telephone interviews we know that some patients had seen posters about the scheme or displays 
of Yellow Cards in pharmacies. Some respondents commented that there appeared to be limited 
awareness of direct patient reporting among health professionals. Given that responses to our 
omnibus survey indicated that most of those experiencing a drug side effect told their HCP about 
it, it is important that HCPs are aware of patients’ ability to report ADRs directly and that they 
pass this information on to patients.
There are likely to be benefits from increasing public awareness of the YCS. These include 
increasing the volume of patient reports and reducing delays in reporting. Suggestions from 
participants about how to increase awareness of the YCS included advertising campaigns and 
provision of information when patients are issued with their medicines, for example by providing 
a leaflet with the drugs or information about the scheme on PILs. There may be a need to target 
publicity among minority ethnic groups and less educated members of the public, given their 
under-representation among reporters.
The MHRA had advertising campaigns about direct reporting to the YCS in 2005 and 2007. 
Information is also available on the MHRA website,14 including a video about patient reporting 
that can also be found on YouTube (www.youtube.com/watch?v=jExeaOpDRbE). There is 
some evidence from our findings that some patients heard about the YCS through television 
and radio, whereas others came across the MHRA website when searching the internet for 
information about their suspected ADRs. These results highlight the need to use multiple media 
for disseminating information about the scheme. Changes in awareness of the YCS following new 
publicity campaigns could be monitored by repeating the omnibus survey.
Patient and public views and experiences of reporting to the Yellow Card 
Scheme
Our questionnaire showed that although, in response to a closed question, most patient reporters 
found that it at least ‘fairly easy’ to make a report, some thought that the reporting systems 
could be improved. More detailed suggestions for enhancements arose from our usability 
testing sessions. In addition, the omnibus survey provided support for continuing with the three 
different methods of patient reporting.
Motivations for reporting
Several motivations for reporting were identified from the questionnaire survey and telephone 
interviews. Many patients reported for altruistic reasons accompanied by a sense that they did 
not want someone else to suffer like they had. Some recognised the importance of contributing to 
a database of reports so that adverse effects could be identified. A considerable number indicated 
the need for patients to be aware of possible ADRs, through the PIL or advice from HCPs, to help 
them make informed choices about whether or not to use medicines. A few had reported hoping 
that they would to be linked with similar sufferers.
Three of the telephone interviewees felt that patient reports would be different and more 
complete than HCP reports, thus supporting arguments made in the literature.52,66 They suggested 
that patient reports would show a better understanding of the effect of the ADR on a patient’s life 
and that a HCP report might just consist of a list of symptoms. Participants in our focus group 
study argued that direct patient reporting would avoid information being reported through a 
professional lens, and this was backed up by comments in response to the questionnaire. This 
supports Basch’s66 thesis that patient self-reports of ADRs provide valuable information and 
capture the subjective elements of patient experiences.
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Expectations and desire for feedback
Almost one-third of respondents to our questionnaire expected feedback from the MHRA 
and just over 60% said that they would have liked feedback. Currently, reporters do not receive 
individual feedback about their suspected ADR. In the Netherlands, every report submitted to 
the Pharmacovigilance Centre Lareb, including those made by the public, is assessed by a doctor 
and pharmacist before contacting the reporter with customised feedback on the ADR reported.30 
A similar system exists in Sweden, run by a non-profit organisation called Kilen.60
Though these systems are resource intensive, it might be worth considering methods of providing 
individual feedback in the UK. This could be partly automated by drawing on existing data that 
the MHRA have on frequency of reports on different drugs and the associated suspected ADRs. 
Alternatively, in order to ensure that those reporting suspected ADRs do not have unrealistic 
expectations, the MHRA could make it clear that no personal feedback will be provided. General 
information about how reports are dealt with could be supplied when acknowledging reports 
from patients and this might go some way to addressing patient-reporters’ desire for feedback.
Perceived attitudes of health-care professionals towards 
patient reporting
A small minority of respondents to our questionnaire survey stated that a HCP had discouraged 
them from making a report and some said that a HCP refused to make a report on their behalf. 
Furthermore, a total of 294 questionnaire respondents (21.6%) made at least one comment about 
HCP lack of awareness of ADRs, dismissive attitudes towards ADRs or the lack of awareness 
of patient reporting. These findings were further supported by comments from our focus 
groups indicating dismissive attitudes from some HCPs towards patients reporting side effects 
to them. Similar attitudes were noted in an American study which surveyed patients about 
their experiences of reporting ADRs associated with statin use to their physicians;67 physicians 
dismissed the possibility that the suspected ADR might be linked to the statin more often 
than they agreed that an association was possible. The authors noted ‘Rejection of a possible 
connection was reported to occur even for symptoms with strong literature support for a drug 
connection, and even in patients for whom the symptom met presumptive literature-based 
criteria for probable or definite drug-adverse effect causality’.
One-half of the patients who reported to the Netherlands Pharmacovigilance Centre Lareb53 
in the first 6 months of reporting stated that they did so because their health professional did 
not listen to their complaint about a possible ADR or they were not convinced that the HCP 
would report their experience. Although, a few similar reports were found in our results, these 
were uncommon.
Our study gives only the patients’ perspective on the attitudes of HCPs to patient reporting. 
Nevertheless, whereas clinicians need to make their own careful judgements about the possibility 
of ADRs in patients presenting to them, it is likely that some HCPs would benefit from learning 
more about side effects associated with drugs, how these present in patients and how they affect 
patients’ lives. As noted above, clinicians also need to be more aware of the availability of patient 
reporting and to be more proactive in informing patients about this. In addition, it would be 
helpful to explore in more detail, why some HCPs have dismissive attitudes towards patient 
reporting of suspected ADRs and whether these attitudes can be altered by exposure to the 
findings of studies that indicate the pharmacovigilance benefits of patient reporting.
Method of reporting
Our studies indicate that each of the three different methods of patient reporting of suspected 
ADRs suit different people. The omnibus data about perceived convenience of different reporting 
methods was particularly relevant. Given the continuing growth of internet access it is not 
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surprising that many respondents, particularly younger ones, considered this method to be a very 
convenient way of reporting ADRs. It is clear, however, that for many people (particularly the 
elderly) this method of reporting would not be useful or possible. It is important, therefore, to 
continue to make available the other methods of reporting, including telephone reporting, which 
many people considered very convenient.
Our usability testing study identified a number of enhancements that could be made to the 
paper-based and online reporting systems. Suggested changes to online reports included:
 ■ making it easier for users to navigate through the web pages
 ■ reducing the complexity of the drop-down menu options for ADRs
 ■ allowing users to save the report as they are going through it.
Our findings suggest that the frustration that occurs when data are lost by navigating backwards 
when trying to complete a YCS report online may result in the reporter abandoning their attempt 
at reporting. Changes to the online report forms could probably be made relatively easily. There 
are many good examples available of user-friendly online systems, particularly those that protect 
data with autosave functions and allow for easy navigation between screens.
With respect to reducing the complexity of the drop-down menu options for ADRs, we recognise 
the advantages to the MHRA of having MedDRA terms that can be imported directly to the 
MHRA database. Nevertheless, many of these terms are not easily understood by patients. It 
would help them if it was easier to record their ADR in free text, or using higher level terms such 
as ‘rash’ rather than having to select from a long list of different medical terms for rash.
One thing worth noting here is the importance of the interaction between users and the different 
systems of reporting. Not only did we identify technical issues, but also respondents’ motivations, 
expectations, willingness and ability to complete. Reporting systems are sociotechnical68 and 
there is a strong motivational component to their successful operation, which influences the 
willingness and decision to report.
Modifying the online form to fit more with patient requirements, while capturing similar data 
from both patients and HCPs, would probably be the optimal approach to allow for collection of 
comparable data, but in a way that patients find straightforward.
Suggested changes to paper reports included:
 ■ allowing more space for the recording of multiple medications
 ■ having a larger font size for people with visual impairment
 ■ redesigning the envelope so that the report fits within it more easily.
Changes to paper reports would require a redesign and we recognise that a balance is needed 
with respect to the amount of space provided for answers on the form. Nevertheless, on both 
patient and HCP forms, there is limited room for free text, and for recording multiple morbidities 
and multiple medications. Whereas the forms encourage reporters to add additional sheets of 
information if there is not enough space, members of the public involved in the usability testing 
were not keen to do this.
Although our usability tests identified no problems with telephone reporting, some concerns 
were expressed by participants about the limited hours of availability (10 am to 2 pm on 
weekdays). Given that telephone reporting was a popular option in our omnibus survey, 
particularly among older people and those of lower socioeconomic status, consideration should 
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be given to extending the hours of availability and increasing publicity about telephone reporting. 
It is noteworthy that posters previously available to promote the YCS did not mention the 
possibility of reporting by telephone. If it is not possible to staff the line for extended hours, then 
there does need to be a facility for patients to record their contact details so that their call can be 
followed up.
Harmonisation across reporting schemes
Our review of the literature has shown that spontaneous reporting schemes that include patient 
reports vary greatly. Some schemes involve government-funded organisations, for example 
MHRA in the UK and MedWatch in the USA, whereas others are patient organisations, 
for example Institute for Responsible Medicines Use (IVM) in the Netherlands (www.
medicijngebruik.nl). Some countries have multiple schemes, for example Australia and the 
Netherlands, thereby potentially creating a risk of duplication of reports and effort, and perhaps 
more importantly, creating databases that cannot be compared due to different information 
being collected. Some systems accept reports solely for ADRs, while others include medicine 
and product-related problems, including errors, for example AME Line in Australia and Health 
Canada. What is apparent from our review is the disparity that exists across and within schemes. 
Whereas the USA uses the same data collection form for patients and HCPs, the UK has two 
different versions, one for each type of reporter, with important differences in key information, 
for example, categories of ‘seriousness’ of ADR.
To maximise the value derived from patient reports, national patient and HCP schemes should 
at least be compatible with one another; ideally with other national schemes. At the time of 
preparing this manuscript, changes to legislation affecting pharmacovigilance were being planned 
in the European Parliament.55,69 It is timely for nations with existing patient reporting schemes 
to engage in a harmonisation process regarding data collection, analysis and dissemination to 
inform the future of patient reporting. Although the need for harmonisation in Europe has been 
recognised,70 a wider international approach should also be considered. There is also a need to 
promote pharmacovigilance in developing countries,71 preferably including patient reporting. 
This will require appropriate funding, training and public awareness for success.
Strengths and limitations of our studies
Success in addressing the objectives of the evaluation
Overall, we have been successful in addressing the main objectives of the evaluation and 
answering the research questions set out in Table 1 in Chapter 1 and in our original protocol 
(Appendix 23). We had only partial success in addressing our original plans for the following 
aspects of the work (more detailed explanations are given further below):
 ■ In the descriptive analysis of reports from patients and HCPs there were few categories on 
which we could directly compare the seriousness and outcomes of suspected side effects.
 ■ In the signal generation analysis:
 – It was difficult to assess whether new signals generated by patients were for events that 
are expected to be of more concern to patients than HCPs.
 – With only 2 years’ worth of data there was limited scope to make a valid judgement on 
whether patient reports generate new signals sooner.
 ■ When selecting cases for the qualitative analysis of Yellow Card reports:
 – We identified and analysed 449 reports, but did not reach our original suggested target 
of 600 reports.
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 – There were very few reports relating to OTC medicines or complementary therapies.
 ■ For the focus groups and usability testing, originally we had planned to include patients who 
believed they may have experienced side effects from medications, but had not previously 
filled in a Yellow Card report. We decided, however, that this would make recruitment 
difficult and widened our selection criteria to include all adults.
Literature review and survey of international experiences of reporting 
schemes
Although the literature review was conducted systematically, the searches were not exhaustive. 
Although only studies published in English were included, it is unlikely that any major 
comparative study (of patient and HCP reports) has been omitted, because most countries with 
longer established patient reporting schemes have already published reports or studies in English.
The online version of a major review of patient reporting of suspected ADRs was published 
in 2006.24 Our review has identified a number of papers published since then, including two 
large studies comparing patient and HCP reports from Denmark19 and the Netherlands.30 
Other studies we identified were of variable quality, with some being available only as 
conference abstracts.
The questionnaire was sent to 47 different countries using the pharmacovigilance contacts listed 
by the WHO Uppsala Monitoring Centre website (www.WHO-UMC.org). Nevertheless, there 
was a low response rate, despite a reminder e-mail being sent. From the responses received, 
however, and from the ‘15-country survey and literature review’ on direct patient reporting of 
ADRs,15 as well as the WHO survey of pharmacovigilance schemes in low- and middle-income 
countries,16 it is clear that patient reporting has been introduced to an increasing number of 
national pharmacovigilance schemes.
There is no single source of information showing whether a country has patient spontaneous 
ADR reporting. To allow for sharing of information and future comparisons, it would be helpful 
to have a centralised resource of all national patient reporting schemes, similar to that held by 
the WHO Uppsala Monitoring Centre. Nevertheless, when comparing information on patient 
reporting from different countries it needs to be recognised that there may be differences in the 
types of problems that can be reported, the available methods of reporting, the types of data 
collected and other context specific factors.
Analysis of reports of suspected adverse drug reactions from the UK 
Yellow Card Scheme
This is the first study in the UK to investigate large numbers of reports of suspected ADRs from 
patients and HCPs. Our descriptive analysis allows these reports to be compared with large 
retrospective analyses of other national reporting schemes. In addition, we undertook signal 
generation analyses, which enabled us to answer a number of questions raised in the literature 
regarding the pharmacovigilance impact of patient reports. Furthermore, our qualitative analyses 
of extracts from patient and HCP Yellow Card reports have provided useful information on the 
richness of patient reports, how patients describe ADRs, the impact of ADRs on patients’ lives, 
the clinical significance of patient reports and likely causality.
One strength of our study has been collaboration with the MHRA. This enabled us to obtain 
and analyse all ADRs reported over 2-year period, giving access to a database of > 26,000 reports 
including just over 5000 from patients. As a result, our study was larger than previously published 
major studies from Denmark19 and the Netherlands.30 This has also provided us with a sizeable 
database for signal generation analysis and for the sampling of reports for qualitative analyses.
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We worked carefully with the MHRA to ensure that, wherever possible, any anomalies in 
the database were corrected. This meant that, as far as we can tell, we had virtually complete 
information on key variables, such as the drugs and reactions reported by patients and HCPs. 
Nevertheless, many reporters failed to complete all fields and so data were missing for some 
variables, including indication for the drug, reaction outcome and time to report a reaction. 
Gender and age was missing for 3.6% and 10%, respectively, of all reports.
We noted several differences between the patient and HCP Yellow Cards. The most notable 
difference related to the perceived seriousness of the suspected reaction; only three of the six 
options were comparable. Nevertheless, we were able to directly compare the seriousness of 
suspected ADRs reported by patients and HCPs using the MHRA classification of seriousness 
based on the MedDRA dictionary.
For reasons outlined in Chapter 3, we were not able to calculate the frequency of duplicate 
reports in the database of patient and HCP reports. We found some evidence to suggest 
duplicate reports, but these appear to be uncommon; probably not at a level to invalidate the 
pharmacovigilance assessments.
The main limitation of our disproportionality analysis, was that the data were accumulated over 
only a 2-year period, soon after the launch of patient reporting. Reports from the pharmaceutical 
industry (normally around 40% of all reports received by MHRA each year) were also excluded, 
as the aim of the project was to compare direct reporting by patients and HCPs. Furthermore, as 
data from HCP reports received in the YCS before the study period were not included in our data 
set, it was not possible to analyse SDRs generated over many years. In addition, this meant that 
we could not investigate properly whether the introduction of patient reporting leads to earlier or 
later detection of signals.
In the database we used for our studies, patient reports comprised around one-fifth of all reports. 
In reality, the proportion of patient reports in the YCS database will be much smaller, as the data 
have accumulated since 1964. Hence, the contribution of patient reports to quantitative signal 
generation is likely to be smaller, although it will increase as patient reports accumulate.
We wished to investigate the relative contribution of patient reports to signal generation, and 
so we wanted every patient report to contribute as much information as possible, especially as 
it was clear that patient reports were different to HCP reports in terms of suspect drugs and 
reactions reported. The majority of the signals generated involved reactions that are not classed 
as ‘serious’ by the MHRA. In practice, these reactions would not routinely be prioritised by their 
signal detection system (unless they involved certain events on the MHRA’s ‘alert’ list or those 
involving a child). Nevertheless, we have shown the contribution that patient reports made 
to signals for reactions that are classed as ‘serious’ by MHRA. It is important to note that the 
signals ‘lost’ or ‘gained’ in this study were intended as examples to illustrate the potential effect 
of adding patient reporting to the spontaneous reporting database. It is difficult to say whether 
one ‘signal’ is more important than another. This would depend on a number of factors such as 
the level of use/exposure of the drug in the population, the type of population using the drug, the 
drug’s indication, the tolerability of the reaction. A detailed impact analysis for each of the drug–
reaction pairs in question would be required in practice, but was beyond the scope of this project.
Another possible limitation of our signal generation analysis was that it was based only on 
the proportional reporting ratio method (see Chapter 5 for further details). There are several 
methods for disproportionality analysis and different thresholds for filtering potentially 
important reactions. In order to maximise the size of the data sets in this study we analysed drugs 
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and vaccines together, rather than analysing these separately as the MHRA would do. Ideally, our 
results should be replicated by the MHRA using source data.
In our main qualitative analysis, we included many patient and HCP Yellow Card reports, looking 
at a range of purposively selected drug–ADR pairs. There was, however, sometimes an imbalance 
in the number of reports made by patients and HCPs available for comparison. We had planned 
to analyse around 600 reports in total, but the sample generated was smaller than anticipated 
(270 patient reports and 179 HCP reports) because although the database appeared to contain a 
very large number of suspect drugs and reactions that met our sampling strategy criteria, specific 
cases within the database were replicated many times if multiple drugs and multiple reactions 
had been recorded. Having completed the time-consuming process of selecting reports (which 
took several months) we did not have time to go back and select additional cases. Nevertheless, 
having undertaken the qualitative analysis of 449 reports, we judge that it is unlikely that our 
findings would have changed substantially with 600 reports.
We focused our attention on the medicines most commonly reported by patients and those that 
at the time of the study were classified by the MHRA as ‘black triangle’ drugs. For these groups of 
drugs we had relatively large amounts of data. For reports of medicines that were purchased OTC 
and complementary medicines, we had to focus on patient reports only because there were so few 
reports from HCPs; even then, the numbers of reports were few.
Our content analysis of reports was necessarily subjective and could have been biased because 
the researcher knew whether the reports were from patients or HCPs. Nevertheless, the work 
was checked carefully (by AA) throughout the process and very few misinterpretations, or 
inaccuracies in data entry, were apparent. For some categories, such as text indicating the 
impact of the suspected ADR on the patient, the contrast between patient and HCP reports 
was so marked that they clearly represent genuine differences. For other categories, such as text 
indicating temporal relationships between medicines and suspect ADRs, differences were less 
marked and did not take account of information available in other fields on the Yellow Card 
report database.
When considering different types of report, there was some concern among the research team 
that the meaning of patients’ concerns may be changed when telephone reports are transcribed at 
the MHRA. Reassuringly, the qualitative analysis indicated that telephone reports were not very 
different from internet and paper reports, often including information that was assumed to be 
direct patient quotes.
Our in-depth qualitative analysis of reports was, by its nature, subjective and could have been 
biased because we knew who the reporter was. Nevertheless, we checked the data carefully, 
rereading the reports several times and sought out divergent cases to counter possible biases.
Questionnaire of patient reporters and telephone interviews
Our questionnaire was the first large national study to follow-up patients or their representatives 
reporting via the YCS. The response rate of 68% was reasonably high; probably helped by 
distribution of the questionnaires directly by the MHRA. Although, we had no information on 
the characteristics of non-responders, the age and gender of respondents to our questionnaire 
was similar to those of all patient reporters in the MHRA database used for the retrospective 
analysis of Yellow Card reports. Therefore, it is likely that the findings are generalisable to all 
patient reporters at the time of our study. The high number of responses to open questions shows 
that reporters were willing to express their views in detail; this information has given us valuable 
insights into many aspects of patient reporters’ experiences of the YCS.
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These more in-depth comments were supplemented by telephone interviews, which allowed us 
to further explore issues regarding ease of reporting, motivations for reporting and promotion 
of the scheme. Of the 27 interviews, we managed to interview only two people who had reported 
by telephone and two who had reported via the internet, so our results are biased towards those 
who reported using the paper Yellow Card. This imbalance occurred because of difficulties 
arranging interviews with patients who had reported using the internet. In addition, because 
of circumstances beyond our control, the data were analysed by a third person (CA) who had 
not done the interviews. This may have led to misinterpretation of data, although the researcher 
listened to the tapes and repeatedly reviewed the transcripts. The proportion of women 
interviewed (70%) was slightly higher than the proportion of women in the questionnaire survey 
(66.8%) and the median age of interviewees was also slightly higher (60 years vs 56.5 years). It 
should be noted, that the interviewees are likely to have been a highly motivated group of people 
who not only completed a Yellow Card report and a questionnaire, but also who volunteered to 
take part in the interviews; not surprisingly, their views about ease of reporting were different 
from those in the usability study.
Usability study and focus groups
The participants recruited for the focus groups and usability testing covered a range of 
demographic characteristics, with a similar proportion of women (67.5%) to that found in our 
other studies, but they were slightly older and there was a higher proportion from minority 
ethnic groups (15%).
The scenarios for the usability tests were ‘hypothetical’. This may have introduced some 
artificiality as the participants may not have been familiar with the details contained within these 
scenarios. It might also have lengthened the process of completing the forms by any of the three 
methods. Conversely, the process may have been shortened as dates for starting and finishing 
the medicines were included in the scenarios, whereas in real life participants would have had to 
recall this information, look it up or ask someone else.
For practical reasons we recruited from the Nottingham area and decided to widen our selection 
criteria for the focus groups and usability testing to all adults. Even so, it was a challenge to 
recruit 40 participants and it is unlikely that we would have achieved this number if we had 
restricted entry criteria to people who had experienced ADRs. Although it is possible that we 
would have obtained different findings using members of the public from other parts of the 
country, we doubt whether any important additional issues would have been detected from the 
usability assessments.
Nevertheless, some of the findings from this part of the study are different from our studies of 
patient reporters, and this may, in part, have been owing to the sampling. For example, whereas 
some of our focus group participants say that they would have ‘given up’ trying to report because 
of difficulties they had experienced with the online reporting system, it is possible that people 
who had suffered a suspected ADR would have been more persistent.
National omnibus survey
The sample of > 2000 members of the British public was broadly representative of the general 
population, although they were different to patient reporters to the YCS. The response rate was 
very low, a common issue with this type of survey. We were aware of this issue at the time of 
planning our study, but judged that the advantages of being able to conduct a national survey 
at relatively low-cost outweighed the difficulties of using more rigorous techniques. Although 
it is possible that another type of survey might have revealed some different findings to those 
observed in the omnibus sample, we doubt that other methods would indicate a substantially 
higher level of public awareness of the YCS.
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One advantage of the omnibus survey was that it could be repeated at regular intervals and at low 
cost to track public awareness.
Conclusions
Patient reports gave detailed descriptions of suspected ADRs, attributed reactions to specific 
medicines and provided information useful for assessing causality. Patient reports often had 
richer narratives than those of HCPs and rarely provided irrelevant information or ambiguities. 
Patient reports also often contained detailed information about the impact of the suspected ADR 
on the patient’s life, thus providing insights that there were comparatively rare in HCP reports.
Patients showed different patterns of reporting of drugs and ADRs compared with HCPs. 
Nevertheless, similar proportions of reports contained at least one reaction term that was 
classified as ‘serious’ by the MHRA, demonstrating that most patients report clinically 
significant problems.
Signal generation analysis showed that patient reports were markedly different from those of 
HCPs in terms of the drug–ADR combinations reported. Patient reports add weight to HCP 
reports by creating new and important potential signals, although a smaller number of potential 
signals from HCP reports are ‘lost’ when the data sets are combined.
In relation to the existing literature, there are broad similarities between our study and large-scale 
Danish and Dutch studies comparing patient reports with HCP reports. In keeping with the 
literature, our study has also demonstrated the richness of patient reports. Whereas previous 
studies suggest that patient reports identify previously unknown ADRs, ours is the first large-
scale study, we are aware of, that has undertaken detailed signal generation analysis.
Most patient reporters found it at least ‘fairly easy’ to report, but many had suggestions for 
improvements in reporting methods and publicity for the scheme, and most would have liked 
feedback from the MHRA. Suggestions for improvements to publicity for the YCS, and detailed 
comments on the design of reporting methods, came also from members of the public involved 
in focus groups and usability testing. All of these studies identified the need to continue with 
the three different modes of reporting and to redesign the paper-based and internet reporting 
systems. A national survey demonstrated low levels of public awareness of the YCS.
This study has demonstrated the value of patient reporting to the YCS, and provides justification 
for further promotion of patient reporting, and for making improvements to existing 
reporting systems.
Implications for patient reporting
In the authors’ opinion, the following approaches may help to improve the timeliness and value 
of patient reporting for pharmacovigilance; increase the number of reports from patients; and 
improve patient experiences of reporting:
 ■ increase publicity for patient reporting by:
 – advertising campaigns targeted at the public and HCPs
 – encouraging proactive efforts by HCPs, particularly in community pharmacy and 
general practice, to publicise and promote patient reporting
 – providing information on patient reporting at the point of dispensing, ideally by 
incorporating this information within PILs
130 Discussion
 ■ provide further guidance to reporters on what information to report (this may help 
strengthen the usefulness of both patient and HCP reports)
 ■ increase patient awareness of medicines where the MHRA is undertaking intensive 
monitoring, for example by highlighting this on PILs
 ■ change the design of paper reports and the online reporting system, in line with suggestions 
made in this report, and increase the number of hours during which telephone reports can 
be made
 ■ provide general feedback to patient reporters on what the MHRA does with reports
 ■ explore possibilities for providing specific feedback to patients in relation to the medicines 
and suspected ADRs that they report.
To aid future comparisons of reports submitted by patients and HCPs, it important that similar 
information is collected from both groups, particularly with respect to categories of seriousness.
According to patient accounts, some HCPs seem to be unaware that patients can submit their 
own ADR reports, and some appear to be dismissive of patients who report suspected ADRs. 
Education at undergraduate and postgraduate level might help address these issues.
Recommendations for research
In order of priority these are investigating:
1. the pharmacovigilance impact of patient reporting in a long-term study, including the 
identification and tracking of regulatory action taken as a result of the contribution of patient 
reports, such as the addition of new ADRs to PILs, SPCs and the BNF
2. the optimum approach to signal generation analysis of patient and HCP reports. It is 
important to establish, in practice, the true extent to which important signals may be 
identified or missed by combining data from patient and HCP reports for data mining 
purposes and the feasibility of analysing the data separately by reporter group, in addition to 
analysing all reports combined
3. the burden of ADRs in terms of impact on patients’ lives, and evaluating the extent to which 
patients’ views and experiences of the seriousness of ADRs concur with those of regulatory 
bodies such as the MHRA
4. the knowledge and attitudes of HCPs patient reporting of ADRs, and evaluating approaches 
aimed at addressing any learning needs identified
5. the value of using patient reports of ADRs to help other patients and HCPs who are seeking 
information on patient experiences of ADRs
6. the impact of increasing publicity and/or enhancements to reporting systems on the numbers 
and types of Yellow Card reports from patients. This would be especially important if patients 
were to be provided with information on drugs undergoing intense monitoring, for example 
black triangle drugs.
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Appendix 1  
Yellow Card health-care professional 
reporting form
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Appendix 2  
Yellow Card patient reporting form 
used from September 2005 to 
January 2008
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Appendix 3  
Yellow Card patient reporting form 
used from February 2008
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Kathy Piccolo Royal College of Nursing, BSc Hons (Human Physiology).
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*Anyone wishing to contact members of the advisory group can do this through Millie Kieve, c/o: 
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Project team members on advisory group
Claire Anderson Professor of Social Pharmacy, University of Nottingham.
Tony Avery Professor of Primary Care, University of Nottingham.
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Appendix 5  
Questionnaire to countries regarding 
their adverse drug reaction reporting 
schemes
Name of country
Questions Consumer HCPs
1. Name of reporting system in your country
2. Year of commencement of the reporting system in your country
3. Products for which ADRs can be reported. Please tick all that apply:
 ■ Prescription drugs o o
 ■ OTC drugs o o
 ■ Medical devices o o
 ■ Other (please specify) 
4. What are the methods of report submission?
 ■ Post o o
 ■ E-mail o o
 ■ Online o o
 ■ Telephone o o
Other (please specify) 
5. Who can report ADRs in your reporting system?
Drug users o Doctors o
Family of drug user o Nurses o
Doctor of drug user o Pharmacists o
Other (please specify)
6. Has a scientific comparison been made between the reports from consumers 
and HCPs using your national reporting scheme?
Yes o o
No o o
If yes, please give details of the comparisons made and the results in the next 
column. If the results are published, we would be glad if you could provide us with 
a copy or give us the source of information/citation details so that we can retrieve 
them. If no, proceed to Q7.
7. What similarities occurred in the ADR reports from consumers and HCPs?
8. What was the time lag between the occurrence of ADR and the submission of 
the report?
9. Which systems affected by the ADRs were mostly reported?
 ■ Central nervous o o
 ■ Skin o o
 ■ Gastrointestinal o o
 ■ Respiratory o o
 ■ Other (please specify)
154 Appendix 5 
Questions Consumer HCPs
10. Which drugs were implicated in the reports?
 ■ Nervous system drugs o o
 ■ Cardiovascular drugs o o
 ■ Anti-infective drugs o o
 ■ Hormonal drugs o o
 ■ Other (please specify)
11. What were the ADRs reported?
Nausea o o
Vomiting o o
Rash o o
Depression o o
Anxiety o o
Itching o o
Other (please specify)
Which of the reporters were likely to report serious ADRs?
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Appendix 6  
Search terms for electronic databases
MEDLINE
# Search history Results
1 exp Adverse Drug Reaction Reporting systems/or adverse drug reaction reporting.mp. 3384
2 Exp Product Surveillance, post marketing/or exp Pharmacoepidemiology/or exp Adverse Drug Reaction Reporting Systems/
or pharmacovigilance.mp.
6844
3 Side effects reporting.mp 1
4 Consumer adj3 report$.mp 157
5 Patient adj3 report$.mp 18,752
6 Public adj3 report$.mp 937
7 3 or 2 or 1 6850
8 6 or 5 or 4 19,821
9 8 and 7 91
EMBASE
# Search history Results
1 Exp Adverse Drug Reaction Reporting Systems/or adverse drug reaction reporting.mp 6696
2 Exp Product surveillance, Postmarketing/or exp pharmacoepidemiology/or exp adverse drug reaction reporting systems/or 
pharmacovigilance.mp
10,438
3 Side effects reporting.mp 2
4 Consumer adj3 report$.mp 123
5 Patient adj3 report$.mp 18,874
6 Public adj3 report$ 704
7 3 or 2 or 1 10,472
8 6 or 5 or 4 19,675
9 8 or 7 85
Pharm-line
 ■ Simple phrase: Consumer OR public
 ■ Key words: adverse reaction monitoring, adverse reaction reporting, postmarketing 
surveillance and pharmacoepidemiology.
 ■ Number of hits: 189.
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Appendix 7  
National pharmacovigilance 
organisations with no patient-reporting 
or no response to questionnaire 
(n = 25)
Country Pharmacovigilance organisation contacted
Austria Austrian Agency for Health and Food Safety
Bulgaria Bulgarian Drug Agency
Colombia National Institute of Drug and Food Surveillance
Croatia Croatia National Centre for Adverse Drug Reactions Monitoring
Cyprus Ministry of Health
Estonia State Agency Of Medicines
Ethiopia Drug Administration and Control Authority
Finland National Agency for Medicines
Germany Federal Institute for Drugs and Medical devices
Greece National Organisation for Medicines
Hungary National Institute of Pharmacy
India Indian Pharmacovigilance Centre
Japan Pharmaceuticals and Medical Devices Agency
Korea Pharmaceutical Safety Bureau
Latvia Ministry of Health
Malaysia National Pharmaceutical Bureau
Malta Malta Medicines Authority
Nepal Department of Drug Administration
Nigeria National Agency for Food and Drug Administration and Control
Portugal National Institute of Pharmacy and Medicines
Romania National Medicines Agency
Singapore Health Sciences Authority
Spain Spanish Medicines and Health Products Agency
Uganda National Drug Authority
Ukraine Pharmacology Centre of the Ministry of Health
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Appendix 8  
Data cleaning checks performed by 
the research team on Yellow Card data 
from the Medicines and Healthcare 
Regulatory Authority
T able 37, below, outlines the data cleaning checks performed on the Yellow Card data from the MHRA. A number of inconsistencies and apparent anomalies were noted with the data 
from the MHRA. We explain here what action we took in relation to these.
With respect to the ‘reporter considered serious’ flag, for HCP reports this flag should be coded 
as ‘yes’ if the reporter specified one or more of the CIOMS flags for seriousness. This was not the 
case for 220 HCP reports. On the advice of the MHRA the absence of a flag was assumed to be an 
error and the ‘reporter considered serious’ flag was manually set to ‘yes’ for analysis purposes.
Apparent anomalies were also detected for seriousness classification in patient reports and the 
MHRA was contacted for clarification. For example, if one of the last three options in response 
to the question ‘How bad was the reaction?’ is ticked then the ‘reporter considered serious’ flag 
TABLE 37 Data cleaning checks performed on Yellow Card data from MHRA
Check performed
Action after checking with the 
MHRA
Patient reports HCP reports
No. of records 
checked
No. of changes 
made
No. of records 
checked
No. of changes 
made
Outliers of weight and 
height for age
Data updated in the case of coding 
errors, otherwise left as reported
104 87 77 35
Reports of gender-specific 
reactions among patients 
of the opposite gender
Data updated in the case of coding 
errors, otherwise left as reported
1 1 7 2
Date anomalies, e.g. 
reaction date after date 
report received or report 
signed by reporter after 
date report received
Data updated in the case of coding 
errors, otherwise left as reported
57 23 293 31
Missing data on reaction 
or drug name
Data updated in the case of coding 
errors, otherwise left as reported
23 23 81 73
Case number in both 
patient- and HCP-report 
data sets
Data from both data sets were 
merged and included in the data set 
pertaining to the primary report (as 
specified by the MHRA)
2 2 5 5
Duplicate reaction text 
found in reports with 
different case numbers
These were either deleted, merged 
to one report or retained as separate 
reports relating to two separate 
reaction experiences in the same 
patient
30 8 132 5
Reports coded as received 
from the pharmaceutical 
industry
These were removed from data sets 
or method of reporting updated in the 
case of a coding error
9 9 101 101
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should have been set to ‘yes’. On further inspection of the data, however, it was found that in 
75 reports this flag was set to ‘yes’, but without one of the last three options being ticked. The 
MHRA advised that it was possible for this flag to be manually set to ‘yes’ independently of the 
other seriousness options, but it is unknown whether this would have been done deliberately or 
in error. Without further information, the DSRU decided it should not update these records.
For 267 patient reports, the ‘reporter considered serious’ flag was set to ‘yes’ because one or more 
CIOMS flags for seriousness had been set to ‘yes’ despite the patient not being asked for this 
information on the Yellow Card. The MHRA were asked to check a 10% sample of these records 
and provided the following explanations:
 ■ In the database used before Sentinel, if the patient had chosen the third response to the 
question ‘How bad was the reaction?’ (i.e. ‘bad enough to affect everyday activities’) then, 
because this option was not available on the database at the time, this may have been 
recorded by setting the CIOMS flag ‘involved persistent or disabling incapacity’ to ‘yes’ and, 
hence, would have triggered the ‘reporter considered serious’ flag.
 ■ The patient had completed a HCP Yellow Card.
 ■ The case folder contained merged data from both a patient and HCP Yellow Card.
 ■ There was a coding error by the MHRA.
Given the complexity of these issues, the DSRU did not update the records before analysis.
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Appendix 9  
Rules and assumptions used in 
mapping suspect drug names to 
Anatomical Therapeutic Chemical 
classification system for drugs
Mapping rule for selection of ATC code No. of mappings
Only one ATC code considered appropriate 2098
ATC code selected based on the formulation/route of administration specified or the most common formulation/route of 
administration used in practice
141
ATC code selected based on the indication specified or the most common prescribed indication in practice 67
No ATC code selected – separate category for herbal or other complementary therapies 214
No direct map available, but mapped manually to closest matching ATC code (includes multiple ingredient products, 
excipients, non-specific drug name, e.g. ‘immunoglobulin’)
239
Unmapped 2
Total 2761
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Appendix 10  
Yellow Card reports for suspected 
adverse drug reactions in children
TABLE 38 Characteristics of children with suspected ADRs reported through the YCS, by reporter type
Characteristic
Patient report HCP report
Male Female All Male Female All
Age (years): median (IQR) 4.0 
(1.0 to 11.0)
4.5 
(1.0 to 10.0)
4.0 
(1.0 to 11.0)
4.0 (1.0 to 9.0) 3.0 (1.0 to 9.0) 4.0 (1.0 to 9.0)
Total: n (%) 74 (51.0) 68 (46.9) 145 (100.0) 1265 (51.9) 1080 (44.3) 2439 (100.0)
Note: no gender was recorded for 3.9% of HCP reports and 2.1% of patient reports.
TABLE 39 Number of reactions per report, by reporter type for children
No. of reactions No. of patient reports (IQR) or (%) No. of HCP reports (IQR) or (%) p-value
Median (IQR) 2 (2 to 4) 2 (1 to 3) < 0.001a
1 32 (22.1) 1022 (41.9) < 0.001b
2 41 (28.3) 667 (27.4)
3 24 (16.6) 411 (16.9)
4 or 5 28 (19.3) 287 (11.8)
> 5 20 (13.8) 52 (2.1)
Total (%) 145 (5.6) 2439 (94.4)
a Mann–Whitney U-test.
b Pearson’s chi-squared test = 2994.27; degrees of freedom = 4.
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TABLE 40 The 20 most frequent LLT reactions, by reporter type for children
No. of patient-reported reactions (N = 494) No. of HCP-reported reactions (N = 5176)
LLT name
n (% of
reactions) LLT name n (% of reactions) Rank for patient reports
Vomiting 12 (2.4) Redness 136 (2.6) 6
Diarrhoea 9 (1.8) Vomiting 131 (2.5) 1
High temperature 9 (1.8) Local reaction 111 (2.1) –
Rash 9 (1.8) Erythema 108 (2.1) 34
Nausea 8 (1.6) Rash 99 (1.9) 2
Crying 7 (1.4) Injection site reaction 82 (1.6) 34
Headache 7 (1.4) Swelling 79 (1.5) 6
Redness 7 (1.4) Fever 73 (1.4) 20
Swelling 7 (1.4) Injection site swelling 73 (1.4) 34
Appetite lost 6 (1.2) Injection site redness 71 (1.4) 84
Difficulty sleeping 5 (1.0) Diarrhoea 69 (1.3) 2
Hyperactive 5 (1.0) Swollen arm 64 (1.2) 84
Stomach pain 5 (1.0) Urticarial rash 57 (1.1) –
Drowsiness 4 (0.8) Pyrexia 55 (1.1) 34
Itching 4 (0.8) Crying 53 (1.0) 6
Personality change 4 (0.8) Headache 46 (0.9) 6
Screaming 4 (0.8) Swelling arm 43 (0.8) 84
Sleep disturbance 4 (0.8) Urticaria 39 (0.8) –
Unwell 4 (0.8) Injection site erythema 37 (0.7) 84
Allergic reaction 3 (0.6) High temperature 36 (0.7) 2
TABLE 41 Comparison of the 15 most frequent SOC reaction groups, by reporter type as proportion of reporter type 
for children
Reaction
No. of patient 
reports (%)a
No. of HCP 
reports (%)a
Patient vs HCP: adjusted ORb 
(99% CI)
General disorders and administration site conditions 65 (45.8) 1001 (42.7) 1.19 (0.76 to 1.87)
Skin and subcutaneous tissue disorders 53 (37.3) 829 (35.4) 1.12 (0.71 to 1.79)
Nervous system disorders 45 (31.7) 360 (15.4) 2.49 (1.51 to 4.12)
Psychiatric disorders 41 (28.9) 310 (13.2) 2.64 (1.59 to 4.38)
Gastrointestinal disorders 40 (28.2) 308 (13.1) 2.54 (1.53 to 4.23)
Respiratory, thoracic and mediastinal disorders 14 (9.9) 128 (5.5) 1.83 (0.85 to 3.94)
Metabolism and nutrition disorders 14 (9.9) 70 (3.0) 3.66 (1.66 to 8.08)
Musculoskeletal and connective tissue disorders 10 (7.0) 93 (4.0) 1.77 (0.73 to 4.32)
Eye disorders 8 (5.6) 67 (2.9) 1.89 (0.70 to 5.14)
Infections and infestations 7 (4.9) 161 (6.9) 0.74 (0.26 to 2.05)
Vascular disorders 6 (4.2) 85 (3.6) 1.14 (0.37 to 3.47)
Injury, poisoning and procedural complications 5 (3.5) 43 (1.8) 1.95 (0.56 to 6.75)
Investigations 4 (2.8) 118 (5.0) 0.52 (0.14 to 1.95)
Renal and urinary disorders 3 (2.1) 26 (1.1) 1.89 (0.39 to 9.24)
Cardiac disorders 2 (1.4) 63 (2.7) 0.51 (0.08 to 3.32)
a Numbers of patients and HCPs are lower owing to those having missing values for gender, which were used to adjust ORs.
b Odds ratios adjusted for age and gender of patient. Note: More than one reaction may be reported per report so they are not 
mutually exclusive.
Note: figures in italic text are statistically significant findings.
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Appendix 11  
Additional signals of disproportionate 
reporting (1)
The additional SDRs shown below were identified after combining the patient and HCP reports (they were not SDRs in either the ‘patient-only’ or ‘HCP-only’ data sets). The SDRs 
shown were classified as serious reactions, involving drugs flagged as ‘black triangle’ and not 
documented on the product’s SPC.
Suspect drug Preferred term
Adalimumab Deep-vein thrombosis
Aripiprazole Mania
Bisoprolola Arthralgia
Drospirenone and oestrogen Muscular weakness
Etanercept Emphysema
Fluoxetinea Hepatic failure
Paracetamola Haematemesis
Pregabalin Urinary retention
Strontium ranelate Asthma
Zoledronic acid Infection
a Drug–ADR pair flagged as ‘black triangle’ if any report relating to that drug, regardless of the brand or formulation reported, has been 
classified by the MHRA as ‘black triangle’.

© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
167 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
Appendix 12  
Additional signals of disproportionate 
reporting (2)
The additional SDRs shown below were identified after combining the patient and HCP reports (they were not SDRs in either the ‘patient-only’ or ‘HCP-only’ data sets). The SDRs 
shown were classified as serious reactions, not documented on the product’s SPC and involving 
established drugs.
Suspect drug Preferred term
Acetylsalicylic acid Blood pressure decreased
Amoxicillin and enzyme inhibitor Chromaturia, faeces discoloured
Atorvastatin Chromaturia
Cefalexin Chest discomfort, wheezing
Chloramphenicol Eyelid oedema
Cyproterone and oestrogen Paranoia, withdrawal syndrome
Diazepam Convulsion, muscle spasms
Dipyridamole Melaena
Donepezil Confusional state
Doxazosin Swelling face
Doxycycline Confusional state
Erythromycin Dysphagia
Influenza vaccines Lower respiratory tract infection, polymyalgia rheumatica
Lansoprazole Haemorrhage
Levothyroxine sodium Contusion
Loratadine Syncope
Losartan Ocular hyperaemia, skin exfoliation
Mirtazapine Coordination abnormal, dystonia
MMR vaccine Cellulitis
Natural opium alkaloids Muscle spasms
Nifedipine Dysphagia
Ofloxacin Arthralgia
Paroxetine Death, ocular hyperaemia
Ramipril Dysphagia
Simvastatin Muscle atrophy
Venlafaxine Paranoia, amnesia
Zopiclone Drug dependence, suicidal ideation
MMR, measles, mumps and rubella.
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Appendix 13  
Causality analysis
Category 3
Summary of causality assessments on drug–reaction pairs reported by both groups, but only 
generated as SDRs when data sets combined.
Drug Reaction Serious
Listed/
label
Black 
triangle
Patients HCP
DuplicatesNo. Causality No. Causality
Amlodipine Arthralgia Y Y N 9 Probable – 3 6 Probable – 2 No
Possible – 4 Possible – 2
Unlikely – 0 Unlikely – 1
Unassessable – 2 Unassessable –1
Alendronic 
acid
Myalgia Y Ya N 3 Probable – 1 6 Probable – 3 No
Possible – 2 Possible – 1
Unlikely – 0 Unlikely – 0
Unassessable – 0 Unassessable – 2
Risperidone Convulsion Y Nb Y 3 Probable – 0 3 Probable – 0 No
Possible – 1 Possible – 0
Unlikely – 1 Unlikely – 2
Unassessable – 1 Unassessable – 1
Paroxetine Hallucination Y Y N 4 Probable – 0 3 Probable – 0 One case 
reported by 
patient and 
HCP very 
similar 
Possible – 3 Possible – 2
Unlikely – 0 Unlikely – 1
Unassessable – 1 Unassessable – 0
Amlodipine Cough N N N 5 Probable – 4 Probable – 0 No
Possible – 2 Possible – 2
Unlikely – 2 Unlikely – 2
Unassessable – 1 Unassessable – 0
Atorvastatin Disturbance 
in attention
N N N 5 Probable – 1 3 Probable – 1 Yes – two 
patient 
reports 
similar
Possible – 2 Possible – 2
Unlikely – 2 Unlikely – 0
Unassessable – 0 Unassessable – 0
Erythromycin Chest pain N Nb N 4 Probable – 0 3 Probable – 1 No
Possible – 3 Possible – 2
Unlikely – 0 Unlikely – 0
Unassessable – 1 Unassessable – 0
Simvastatin Mobility 
decreased
N N N 3 Probable – 1 3 Probable – 1 No
Possible – 1 Possible – 1
Unlikely – 0 Unlikely – 1
Unassessable – 1 Unassessable – 0
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Category 4
Summary of causality assessments on drug–reaction pairs generated as SDRs by HCP diluted out 
in combined data set.
Drug Reaction Serious
Listed/
label
Black 
triangle
Patients HCP
DuplicatesNo. Causality No. Causality
Insulin 
glargine
Headache N Ya Y 4 Probable – 0 4 Probable – 0 No
Possible – 3 Possible – 2
Unlikely – 0 Unlikely – 0
Unassessable – 1 Unassessable – 2
Olanzapine Agitation N N Y 3 Probable – 0 4 Probable – 1 No
Possible – 0 Possible – 0
Unlikely – 1 Unlikely – 1
Unassessable – 2 Unassessable – 2
Risperidone Tremor Y Nb Y 6 Probable – 1 3 Probable – 1 Yes – two 
HCP reports 
likely 
duplicates
Possible – 3 Possible – 2
Unlikely – 0 Unlikely – 0
Unassessable – 2 Unassessable – 0
Proguanil, 
combinations
Vomiting N Ya Y 3 Probable – 0 4 Probable – 0 No
Possible – 3 Possible – 3
Unlikely – 0 Unlikely – 0
Unassessable – 0 Unassessable – 1
N, no; Y, yes.
a Similar term labelled on SPC.
b Summary of product characteristics has since been updated to include this reaction.
Drug Reaction Serious Listed/label
Black 
triangle
Patients
Reported by 
patients DuplicatesNo. Causality
Rimonabant Muscle 
spasms
Y Y Y 9 Probable – 3 Yes No
Possible – 5
Unlikely – 0
Unassessable – 1
Infliximab Arthralgia Y Y Y 10 Probable – 9 No (but flu-
like illness 
reported)
No
Possible – 1
Unlikely – 0
Unassessable – 0
Duloxetine Confusional 
state
Y Ya Y 9 Probable – 3 Yes No
Possible – 5
Unlikely – 1
Unassessable – 0
Atomoxetine Depression Y Nb Y 7 Probable – 0 No (suicidal 
attempt 
reported)
No
Possible – 7
Unlikely – 0
Unassessable – 0
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Signals of disproportionate reporting
Signals of disproportionate reporting generated in drugs classified by the MHRA (at least once in 
patient reports) as having been obtained OTC and SDRs involving complementary therapies.
Drug Reaction Serious Listed/label
Black 
triangle
Patients
Reported by 
patients DuplicatesNo. Causality
Hepatitis 
B, purified 
antigen
Chest pain N N N 6 Probable – 3 No No
Possible – 1
Unlikely – 1
Unassessable – 1
Ramipril Abnormal 
dreams
N N N 5 Probable – 0 No (sleep 
disorder 
reported)
No
Possible – 3
Unlikely – 0
Unassessable – 2
Rimonabant Blood 
pressure 
increased
Y N Y 5 Probable – 0 No No
Possible – 5
Unlikely – 0
Unassessable – 0
Tiotropium 
bromide
Dyspnoea N N Y 8 Probable – 1 No No
Possible – 2
Unlikely – 1
Unassessable – 4
Rimonabant Nightmare N Ya Y 9 Probable – 5 No (sleep 
terror, sleep 
disorder 
reported)
No
Possible – 0
Unlikely – 0
Unassessable – 4
Ezetimibe Asthenia N Ya Y 6 Probable – 1 No (apathy, 
fatigue 
reported)
No
Possible – 3
Unlikely – 0
Unassessable – 2
Pregabalin Gait 
disturbance
N Y Y 5 Probable – 2 No 
(coordination 
abnormal, 
dysstasia 
reported)
No
Possible – 3
Unlikely – 0
Unassessable – 0
Atomoxetine Insomnia N Y Y 5 Probable – 2 No No
Possible – 1
Unlikely – 1
Unassessable – 1
N, no; Y, yes.
a Similar term labelled on SPC.
b Summary of product characteristics has since been updated to include this reaction.
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Appendix 14  
Case selection for qualitative analysis 
of Yellow Card reports
The reports were divided into the following categories:
 ■ most commonly reported drugs
 ■ black triangle drugs
 ■ drugs purchased OTC
 ■ complementary therapies.
The Advisory Group suggested sampling by reaction type as well as by drug. Therefore, the 
DSRU was asked to provide data in a Microsoft access 2003 database (Mircrosoft Corporation, 
Redmond, WA, USA) containing tables that allowed this to be done. For example, for the ‘most 
commonly reported drugs’ category and the ‘black triangle drug’ category data were provided on 
the top five drugs in each of these categories. Separate tables giving reactions for these drugs that 
were either commonly reported by patients and/or deemed to be of importance to the project 
team or advisory group were also provided.
Tables 42 and 43 below show the numbers of complete reports provided in the ‘most commonly 
reported drugs’ category and the ‘black triangle drug’ category along with the different types of 
reactions that were looked at in detail.
TABLE 42 Numbers of drugs most commonly reported by patients in the database along with reactions that were 
purposely selected for those drugs
Reaction
Citalopram Co-cyprindiol Paroxetine Simvastatin Venlafaxine
Pt HCP Pt HCP Pt HCP Pt HCP Pt HCP
Anxiety 9 7 22 0 22 5 10 3a
Arthralgia 20 1
Depression 4 1 66 2 17 1 6 1a
Dizziness 11 4 41 3 18 8
Drug withdrawal 
syndrome
41 1 8 7
Myalgia 39 34
Paraesthesia 4 2 32 1 8 3
Suicidal ideation 10 7 20 1a 27 8 3 2
Tremor 11 3 20 4 13 3
Totalb 28 23 69 3 101 17 54 35 33 19
Pt, patient.
a Full details of report type not available for all of these cases.
b Patients may have several different reactions: the total row gives the total number of drugs on the database for the reactions considered.
Shaded cells imply that the reaction was not used for selecting cases for a particular drug.
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TABLE 43 Numbers of ‘black triangle drugs’ most commonly reported by patients in the database along with reactions 
that were purposely selected for those drugs (based on frequency of report by patients)
Reaction
Insulin glargine Levetiracetam Olanzapine Pregabalin
Proguanil with 
atovaquone
Pt HCP Pt HCP Pt HCP Pt HCP Pt HCP
Abdominal pain 3 1
Anorexia 3a 0
Anxiety 2 3
Arthralgia 2a 1 2a 1a
Balance disorder 2 0 1 1
Blister 2 2
Confusional state 2 0
Constipation 3a 0
Convulsion 3 3
Depression 2 2
Diabetes inadequately 
controlled
3 1
Diarrhoea 2 3 8 6
Disturbance in 
attention
3 1
Dizziness 1 2 6a 12 3 1
Dry mouth 2a 3
Dyspnoea 2 2 2 3
Emotional distress 3a 0
Fatigue 3a 1a
Headache 3 3 5 8
Hyperhidrosis 3a 0
Hypoaesthesia 2 0
Hypoglycaemia 4a 0a
Influenza-like illness 2 0
Insomnia 2 0 5 0
Malaise 5a 2a 3a 3 5 2
Memory impairment 4a 1
Nausea 3 0 2 2a
Pain in extremity 4a 0
Paraesthesia 2a 0
Pyrexia 3 2
Rash 4a 3a
Somnolence 5 1 3 13
Speech disorder 1 2a
Tremor 3 1 6a 1
Vision blurred 2 4
Weight increased 7a 0 13a 5
Totalb 13 9 13 8 25 13 17 38 14 19
Pt, patient.
a Full details of report type not available for all of these cases.
b Patients may have several different reactions: the total row gives the total number of drugs on the database for the reactions considered.
Shaded cells imply that the reaction was not used for selecting cases for a particular drug
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Complete cases were defined as those containing details of:
 ■ report type, for example paper, internet, telephone
 ■ suspect drug
 ■ description of the type of reporter – for example patient, HCP (and type of HCP)
 ■ reactions of interest (in terms of ‘most commonly reported drugs’ and the ‘black triangle 
drug’ categories)
 ■ age of the patient at the time of the reaction
 ■ gender of the patient.
These restrictions to selection were decided upon to enable description of each case in as 
much detail as was (potentially) available within the database and to allow for comparing and 
contrasting different types of report.
A total of 286 unique drug–ADR records were identified for patients and a total of 97 for HCPs.
There was a total of 82 unique black triangle reports for patients and 87 for HCPs.
In addition, all reports available for eight drug types that were purchased OTC and the 10 most 
commonly reported complementary therapies were requested. There was a total of 25 patient 
reports for drugs that were purchased OTC and 15 patient reports for complementary therapies.
The following approach to sampling reports for the qualitative analysis was taken. First, reports 
across the four categories were included. Second, for the ‘most commonly reported drugs’, where 
there were more than 30 reports for any particular drug, up to 30 cases randomly selected. Third, 
as far as possible, we tried to identify similar numbers of reports for specific drugs (and the 
selected ADRs) for both patients and HCP reports. It should be noted that the patient reports 
and HCP reports related to different cases, but the sampling strategy means that there were 
similarities in the types of drug–ADR combinations included in the samples from each group 
of reporters.
For the ‘drugs most commonly reported by patients’ 30 cases from HCPs for simvastatin and all 
cases available for the other drugs were randomly selected (where the total was < 30).
For black triangle drugs, patient reports were compared with all the HCP reports available for the 
ADRs selected.
It was not possible to find HCP reports for drugs purchased OTC and there were very few for 
complementary therapies. Therefore, for these categories of report only the patient reports 
were analysed.
Cases were selected in the following way:
 ■ First, cases were selected from each of the drug–reaction access tables on the basis 
of complete data being available (see above). For some of the HCP reports, however, 
where numbers were low, some reports that did not have full details of the reporter type 
were accepted.
 ■ Second, data from each of the drug–reaction tables were exported to excel, where data for 
each drug and drug category were combined and duplicates were removed (note: duplicates 
were sometimes common because the same report could appear in different tables within 
the database).
 ■ Third, in line with the sampling strategy outlined above, where necessary, cases were 
randomly selected using a web-based computer program (www.randomizer.org/form.htm).
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Table 44, below, shows the numbers of cases selected for the most commonly reported drug 
category and the black triangle drug category.
In addition, the tables below show the numbers of patient reports analysed relating to drugs 
purchased OTC (Table 45), and complementary treatments (Table 46).
It should be noted that the numbers of cases selected for drugs purchased OTC and 
complementary therapies is much less than was expected because of the large number of 
duplicates in the database.
TABLE 44 Numbers of cases selected for patient reports and HCP reports related to the most commonly reported 
drugs by patients
Drug category Drug
No. of reports selected
Patients HCPs
Most commonly reported drugs by 
patients
Citalopram All 28 All 23
Co-cyprindiol (Dianette®) Random 30 All 3
Paroxetine Random 30 All 17
Simvastatin Random 30 Random 30
Venlafaxine Random 30 All 19
Total 148 92
Black triangle drugs Insulin glargine 13 9
Levetiracetam 13 8
Olanzapine 25 13
Pregabalin 17 38
Proguanil with atovaquone (Malarone®) 14 19
Total 82 87
TABLE 45 Cases selected for patient reports of drugs that were purchased OTC
Drug name
Preparation name (for ‘other cold remedies 
and paracetamol combinations’) No. of patient reports
Cetirizine 4
Chloroquine 3
Fluconazole 1
Levonorgesterol 2
‘Other cold remedies’ Beechams Flu-Plus 1
Benylin Chesty Cough 1
Benylin 4 Flu Liquid 1
Day Nurse 2
Lemsip 1
Nirolex 1
Nirolex Night Cold and Flu Comfort 1
Paracetamol combinations Co-codamol 3
Medised 2
Proguanil 3
Sumatriptan 1
Total 25
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For example, for complementary therapies there appeared to be 163 entries in the database for 
the 10 preparations listed in Table 46, but a large number of these entries were multiple entries of 
the same record with different side effects.
TABLE 46 Cases selected for patient reports of complementary therapies
Complementary therapy No. of unique entries in the database
Agnus castus 2
Angelica sinensis 2
Arcitium lappa 1
Atractylodes macrocephala 2
Berberis aquifolium 1
Bupleurum chinense 1
Fructus lycii 3
Panax ginseng 3
Siberian ginseng 3
St John’s wort 8
Total unique entries for all the above complementary therapiesa 15
a Numbers of unique entries less than the total for individual complementary therapies because of duplicates.
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Appendix 15  
Yellow Card narrative codes and 
definitions
High-level 
category Code Definition
1. Report number ADR number
2. Suspect drug Drug suspected of causing reaction
Description of the 
problem
3. Symptoms Presentation of subjective symptoms. In the case of the patients this will often be of the form ‘and 
then I felt …’ In the case of HCPs it will often be of the form ‘the patient said she/he felt …’
4. Signs Physical signs observed by a HCP
Impact of ADR on 
patient
5. Any impact Any impact noted on the patient’s life (this includes categories 6–8 below)
6. Impact on daily life How the reaction made the patient feel (e.g. sad, scared, etc. – rather than sensory experiences, 
such as pain)
7. Social impact Impact of the reaction/s on the patient’s family and social activities
8. Occupational impact Impact on the patient’s work – absence, inability to fulfil duties, etc.
Involvement 
of health 
professionals
9. Involvement of health 
services
Visits by or to HCPs, ambulance called, A&E, admission, etc.
The HCP reports will almost always involve health services because in order to do a report the 
HCP will have been contacted about the problem leading to the report
10. Investigations Any investigations carried out
11. Treatment Any treatment carried out for the ADR (stopping the drug not included here)
12. HCP advice Any recording of advice given by HCP about what to do about ADR
Patient’s 
background
13. Past medical history Information about patient’s medical history
14. General health Information about the patient’s general health
Causality 15. Temporality 1 Text indicating that ADR followed administration of drug
16. Temporality 2 Text indicating that ADR improved when drug discontinued – or dose was reduced
17. Temporality 3 Text indicating that ADR occurred on discontinuation of drug (withdrawal)
18. Temporality 4 Text indicating that ADR recurred when drug started again
19. Dose relationship Discussion linking increasing severity of reaction to changing dose of suspect drug
20. Differential 
diagnosis
Consideration/discussion/rejection of possible alternative causes for reaction. Where evidence is 
adduced to indicate grounds for believing that the signs and symptoms were/were not the result 
of the drug rather than the underlying condition, some new condition or other factor. Please also 
tick this box where there is reference to possible alternative explanations, even when reporter 
does not come down on one side or another
21. Past history Reference to any similar reactions to drugs in the past
22. Causal theorising Discussion of possible causal pathways, e.g. possible drug interactions, change in form of drug 
(e.g. from injected sumatriptan to oral sumatriptan), faulty batch of drug, interaction between drug 
and concurrent illness, etc.
23. Objective evidence Confirmation of adverse event by objective evidence
24. Endorsement by 
HCP of causal link
Where HCP is quoted as agreeing that drug may have caused reaction. This may also apply 
where a HCP is making the report if s/he cites another HCP as supporting the view that the 
reaction was caused by the drug
Patient actions 25. Self-management Text indicating patient self-management in response to the reaction
180 Appendix 15
High-level 
category Code Definition
Presentation of 
report
26. Medicotechnical Where reporter uses technical language (e.g. tachycardia, pyrexia, etc.) rather than lay terms
27. Extreme nature of 
signs and symptoms
Please tick this box where the presentation of signs and symptoms stresses their extreme nature
28. ‘Elaboration’ score Please make a judgement about how elaborate the account is (which includes the extent to which 
the text tells the story of the suspected ADR)
0 = no narrative; 1 = scant narrative; 2 = moderately elaborate; 3 = very elaborate
29. Ambiguity Please tick this box if the account is confused or has conflicting information
Coder’s remarks 30. Apparent recording 
error
Please tick this box if there’s reason to think that a recording error has been made, e.g. if the 
report clearly comes from a physician but has been recorded as a patient report; or where the 
coding of a reaction appears to be based on a misinterpretation of the narrative
31. Worth reading the 
text in more detail?
Please tick box if the text appears to provide particularly useful text for the in-depth qualitative 
analysis
32. Comment Any other comment you wish to make about the report
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Appendix 16  
Questionnaire and letter
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Appendix 17  
Initial covering letter sent out by 
Medicines and Healthcare Regulatory 
Authority for the questionnaire survey
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Appendix 18  
Reminder letter sent out by Medicines 
and Healthcare Regulatory Authority 
for the questionnaire survey
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Appendix 19  
Interview schedule for telephone 
interviews
The interviewer will set the scene regarding audiotaping, confidentiality, etc:
 ■ story of illness/event
 ■ story of treatment
 ■ story of suspected side effect
 ■ story of decision to report
 ■ story of process of reporting.
Story of illness/event
1. You’ve all ready told us a little bit about the side effect that you have reported to the 
MHRA using the YCS. I want use this opportunity to get you tell me a bit more about the 
circumstances that lead up to you reporting.
2. Firstly, can you tell me a little bit about how you came to take the medicine that caused the 
problem:
 – Reason for medicine (symptoms, etc.) and how you came to take it.
 – Prescribed or OTC.
 – How long had you been taking the medicine before you realised there was a problem?
 – Tell us about the side effect. Description of symptoms, etc.
 – What was the problem? Did you stop taking the medicine?
 – Straight away? If you didn’t stop, why not?
 – What made you think the symptoms were related to medicine? How certain were you? 
Did you talk to anyone about it, if so who? What did they say?
3. Was this the first time you have ever experienced a side effect from a medicine you have 
taken?
4. On this particular occasion, how easy did you find it to link the particular side effect you 
experience to taking a particular medicine?
Story of decision to report
 ■ Can you tell me a bit more about what made you decide to report this side effect using the 
YCS?
 ■ When you experienced [the suspected side effect] did you discuss this with anyone?
 ■ If so what advice did they give you?
 ■ Were you aware of the YCS and/or the fact that patients can report before you recently 
experienced [the suspected side effect]?
 ■ How did you know about the YCS?
 ■ What made you decide to use paper/internet reporting?
 ■ How easy did you find the reporting process you used (i.e. questionnaire or internet)?
 ■ Did you experience any specific difficulties in using this process?
 ■ How easy did you find it to describe the side effects you had experienced?
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 ■ Were you able to provide all the information that the report form asked you for?
 ■ How much time did it take you to fill in the form?
 ■ Did you need additional help in completing the form? If so, from whom did you get this 
help?
 ■ Were you contacted following your report?
 ■ What was the nature of the contact?
 ■ Was this what you were expecting? What else were you expecting, if anything?
 ■ Would you have liked to have had any further contact? If so what would you have liked?
 ■ Until recently, reports to the YCS could only be made by professionals, such as doctors, 
nurses and pharmacists. Do you think it’s a good idea to expand the scheme so that patients 
are now able to report side effects of medicines?
 ■ Which do you think is likely to be more useful – when patients make the reports to the 
scheme or when health professionals, such as doctors, pharmacists and nurses, do?
 – What makes you say that?
 – What do you think is the advantage of each?
 ■ What do you think is the point of reporting side effects?
 – Who do you think will benefit? HCPS and/or patients?
 – In what way(s) might they benefit?
 ■ Do you think the reporting system could be improved in any way?
 ■ Having made this report, would you consider reporting again if you experienced side effects 
from another medicine?
 ■ Would you encourage others to fill in a report if they experience a side effect from a 
medicine?
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Appendix 20  
Focus group schedule
1. Presentation about ADRs and the YCS.
2. How do you feel about reporting side effects in general?
3. What would make you report a side effect?
4. Do you think people ought to report side effects or leave it to health professionals?
5. What might put you off reporting?
6. Discuss initial preferences for paper or internet reporting.
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Appendix 21  
Usability scenarios
Scenario 1
Here are the details for the patient for scenario 1. Please note that this is not a real patient and all of 
the contact details are made up. In this scenario you are the patient.
Mr John Smith is a 56-year-old gentleman.
His address is 42 Long Acre, Beeston, Nottingham NG9 4EG. Tel: 0115 9286695. E-mail address 
at work: john.smith@notts.ac.uk
The doctor started him on a new medication to help with his angina in early May 2008. The drug 
was simvastatin 40 mg at night.
He started to get pains in the muscles in his legs and arms a few weeks after taking a new tablet. 
He noticed an aching in his muscles most of the time and he wasn’t able to get around quite as 
well as normal. The problem went away about a week after stopping taking the medicine. He tried 
taking paracetamol for the pains but this was not very helpful. He stopped taking the medicine 
after discussing the pains with his doctor.
He also uses a salbutamol inhaler for his asthma, takes aspirin for his angina and St John’s wort 
for low mood.
He has had angina since 2007 and has been an asthmatic since the age of 5 years.
He is allergic to penicillin.
Mr Smith weighs 13 stone and is 5 feet 9 inches tall.
His GP is Dr Mayberry, Middle Vale Surgery, Beeston, Nottingham NG9 7ET.
Scenario 2
Here are the details for the patient for scenario 2. Please note that this is not a real patient and all of 
the contact details are made up. In this scenario you are the son of the patient.
Mr Gerald Carr is a 52-year-old gentleman, who is concerned about the side effects that his 
elderly mother has had to a medicine the GP recently started her on.
His mother, Mrs Elsie Carr, is 93 years old.
She lives at 25 Main Street, Long Eaton, Derbyshire DE45 2LL. Tel.: 0116 255822.
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Mrs Carr has a number of medical conditions. She has suffered from heart failure since 2002, 
hypertension since 1995 and she had an operation for cataracts in 2000. In 2006 she was also 
diagnosed with glaucoma.
Mrs Carr was given perindopril for her heart condition in February 2008, and a few days later she 
developed an irritating dry cough, which kept her up for much of the night. She tried a number 
of cough mixtures that her son bought from the chemist, but none were successful. On the fourth 
visit to the pharmacy, at the beginning of May 2008, the pharmacist asked Gerald about his 
mother’s other medication and suggested that the perindopril might be the cause of the cough.
Mrs Carr spoke to her GP who gave her an alternative to the perindopril and her cough went 
away about a week after stopping the medication.
The perindopril dose was 2 mg daily for heart failure.
Mrs Carr also takes:
 ■ bendrofluazide 2.5 mg daily
 ■ atenolol 25 mg daily
 ■ latanoprost eye drops for glaucoma
 ■ multivitamin supplement for elderly people – since January 2008.
She weighs 9 stone 2 pounds and is 5 feet 2 inches tall.
Her GP is Dr Linton, Green Lane Surgery, Long Eaton.
Mr Gerald Carr, the son, lives at 22 Fletcher Street, Spondon, Derbyshire DE55 6TH. Tel.: 01332 
222664. E-mail: Gerald.Carr7974@hotmail.com
Scenario 3
Here are the details for the patient in scenario 3. Please note that this is not a real patient and all the 
contact details are made up. In this scenario you are the patient.
Your name is Ms Phoebe Foster.
Your address is 2 Church Street, Selston, Derbyshire DE56 3SS. Tel: 01773 566566. E-mail: 
Phoebe.Foster@hotmail.com.
You are a 32-year-old woman who has suffered from bouts of depression since having your 
second child in 2003.
In April 2008, you went to see your doctor again as you were feeling very low and unable to cope. 
She suggested you should go back on to an antidepressant. She prescribed Prozac (fluoxetine) 
20 mg in the morning.
Two weeks later you developed a rash that spread over most of your body and itched dreadfully. 
You stopped the Prozac as it was the only thing you could think might have caused the rash, and 
the rash went away a few days later after using hydrocortisone cream.
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Before you saw the doctor for your depression, you had taken St John’s wort for 2 months, but it 
had had no effect.
Additional information:
 ■ Your GP is Dr Shah, 10 Penny Lane, Selston.
 ■ You are 165 cm tall and weigh 65 kg.
Scenario 4
Here are the details for the patient in scenario 4. Please note that this is not a real patient and all the 
contact details are made up. Please do the report as if you are the patient.
Your name is Alan Partridge.
Your address is 12 Main Street, Long Eaton DE12 2PS. Tel.: 0115 234234. E-mail: apartridge@
btinternet.com
You are a 54-year-old man and you are generally fit and healthy.
Last week, July 2008, you returned from a business trip to India and within 2 days you had 
diarrhoea and stomach cramps. You went to see your doctor and he prescribed an antibiotic, 
ciprofloxacin, which you were to take 500 mg twice a day for 5 days.
After 3 days you noticed your toes were tingling, but as you were wearing a new pair of shoes you 
assumed these were causing it. However, it continued and you mentioned it to the pharmacist 
2 days later when you went to buy some paracetamol. They suggested that the antibiotic may have 
caused it, but you had finished the course the day before. When the tingling stopped two days 
later you realised it had probably been the tablets.
You are still taking the antimalarial tablets from your trip, which are proguanil two tablets daily 
and nivaquine two tablets weekly.
Additional information:
 ■ Your GP is Dr Walker, Green Lane Surgery, Long Eaton.
 ■ You are 5 feet 10 inches tall and weigh around 14 stone.
Scenario 5
Here are the details for the patient in scenario 5. Please note that this is not a real patient and all the 
contact details are made up. In this scenario you are the patient’s mother.
Your name is Clare Strand.
Address: 3 Queen Lane, West Bridgford, Nottingham NG24 3RR. Tel.: 0115 856767. E-mail: 
Clare.Strand@nottingham.ac.uk
You are concerned about a side effect suffered by your 3-year-old son.
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On the 28 June your son Nathan Strand had a fever and headache, and you treated him with 
Nurofen syrup, using 5 ml three times a day. The next day he was coughing badly and when you 
took him to the doctor they prescribed amoxicillin syrup, one 5-ml spoonful three times a day.
The next day, on 30 June, he was covered in a rash when he woke up and then you noticed his 
face and fingers swelling. You phoned the doctor who suggested you take him immediately 
to casualty.
They treated him for an allergic reaction, stopped both of the syrups and gave him paracetamol 
and another antibiotic. He stayed in hospital over night, but came home with just the remains of 
the rash the next day (1 July). The rash cleared over the next few days.
Your son suffers from asthma and has to use a salbutamol inhaler occasionally.
Additional information:
 ■ The GP is Dr Shah, West Road Surgery, West Bridgford NG24 6TT.
 ■ Your son is 3 years and 5 months old and weighs 38 lbs. He is 3 feet 3 inches tall.
Scenario 6
Here are the details for the patient in scenario 6. Please note that this is not a real patient and all the 
contact details are made up. In this scenario you are the patient’s husband.
Your name is Roger Manning, and you live at Lilac Cottage, Lant Lane, Wollaton NG3 4FT. Tel.: 
0115 9896662. E-mail: Roger.Manning@egg.com
You are reporting a side effect suffered by your wife, Jenny Manning. Jenny is 64 years old. In 
the middle of June, Jenny was started on metformin tablets, 500 mg twice a day, as she had been 
diagnosed with diabetes. She was also started on atenolol 50 mg in the morning as her blood 
pressure was high.
After 2 days Jenny complained she had a funny metallic taste in her mouth and her hands and 
feet were cold. Then within a week she was having nasty stomach pains.
She went back to the doctor who stopped the metformin and gave her gliclizide instead, and 
within a week, by the end of June, most of the symptoms had stopped, although she still has cold 
hands and feet.
Additional information:
 ■ The GP is Dr Joan Grieve, East Road, Wollaton NG3 5GF
 ■ Your wife is 162 cm tall and weighs around 70 kg.
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
203 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
Appendix 22  
Omnibus questions
204 Appendix 22
 
 
 
  
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
205 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
 
  
206 Appendix 22
 
 
 
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Avery et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
207 Health Technology Assessment 2011; Vol. 15: No. 20DOI: 10.3310/hta15200
Appendix 23  
Protocol, version 3: 7 June 2007 
(version produced following response 
to referees’ comments)
Protocol for evaluation of patient-reporting to the Yellow Card 
System (RM05/JH30)
Version 3: 7 June 2007 (version produced following response to referees’ comments)
Summary of research
Abstract of research
Objectives
 ■ Evaluate the pharmacovigilance impact of patient-reporting to the Yellow Card System (YCS)
 ■ Report on patient experiences of the YCS
 ■ Assess public awareness of being able to report
 ■ Offer recommendations for improvements to patient-reporting based on our research findings and literature from other countries
Methods
We plan to address our objectives by undertaking:
 ■ quantitative analyses of the pharmacovigilance impact of the YCS comparing reports from patients with health professionals using univariate and 
logistic regression analyses
 ■ qualitative analyses of approximately 300 Yellow Card reports from patients and a similar number from health professionals using clinical 
assessment of pharmacovigilance impact and comparative documentary analysis to explore the richness of reports
 ■ a national questionnaire survey of patient experiences of reporting to the YCS (n = 1200)
 ■ a national telephone interview survey to explore the experiences of patients who have reported to the YCS (30–50 interviews)
 ■ a national survey of public awareness of being able to report (n = 2000)
 ■ usability testing of different methods of Yellow Card reporting (six groups of eight participants)
 ■ literature review
Timescale
Proposed starting date: 1 September 2007
Proposed duration: 2 years 0 months
Cost
Total research grant: £249,811
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Details of proposed research
Evaluation of patient reporting to the Yellow Card System
Introduction
The call for an evaluation of patient reporting to the UK Yellow Card System (YCS) provides 
a tremendous opportunity to learn more about the role of patients in reporting suspecting 
adverse reactions.
In this document we present:
 ■ background literature on the UK YCS and its use by patients
 ■ background literature on other patient-reporting systems throughout the world
 ■ our research objectives
 ■ proposed methods for six studies and a further literature review aimed at addressing our 
research objectives and the questions raised in the National Coordinating Centre for 
Research Methodology (NCCRM) call for research
 ■ scheduling of the studies and responsibilities of coapplicants
 ■ proposals for the management of the project
 ■ justification for costings
 ■ references.
Background
An adverse drug reaction (ADR) is a reaction to a drug or combination of drugs that is harmful 
and unintended and which occurs at a dose normally used for prophylaxis, diagnosis or 
treatment (Metters 2004). The primary system for reporting suspected ADRs in the UK is the 
‘YCS’. As a result of a Health Committee report (House of Commons Health Committee 2004–5), 
patients (or consumers) in the UK have been able to submit Yellow Card reports since 2005. The 
potential benefits of patient reporting were summarised at the First International Conference 
on Consumer Reports on Medicines in 2000, and included: the promotion of consumer rights 
and equity; acknowledging that consumers have unique perspectives and experiences; and, that 
health-care organisations would benefit from consumer involvement (World Health Organization 
2000).
It has been suggested that direct consumer reporting avoids the filtering effect of reporting via 
health professionals, and that the former could contribute to drug surveillance when reports from 
the latter are declining (Hammond and Rich 2005), as is the situation in the USA. Consumer 
reporting of ADRs has also been suggested as a method of hypothesis generation that could be 
used in addition to health professional reports (Fernandopulle and Weerasuriya 2003).
International experience of consumer reporting systems
Other countries with consumer reporting of ADRs include the USA, Australia, Canada, 
Denmark, Sweden and the Netherlands. The characteristics of the European schemes are 
summarised in a report by Health Action International Europe (HAI 2005).The reporting 
schemes differ in terms of whether they are government supported or run by consumer groups.
MedWatch is the adverse event reporting system in the USA, which is provided by the US Food 
and Drug Agency (FDA). The scheme includes reports for adverse events, product problems 
and errors. Reports can be submitted by consumers either using mailed or faxed report 
forms, by telephone, or online (www.fda.gov/medwatch/report.htm). The number of reports 
from consumers has been increasing since 1993, while the number and proportion of reports 
from health-care professionals (HCPs) has been decreasing. In 1996, 41% and 58% of reports 
originated from consumers and health professionals, respectively (FDA 1997).
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In Australia, consumers have access to the ‘Adverse Medicine Events (AME) Line’ to which they 
can report ‘suspected AMEs, possible errors or “near misses” with their medicines’ (www.mater.
org.au/ame/HomeAME1.htm). [Consumers can also report to the Adverse Drug Reactions Unit 
(ADRU) of the Therapeutic Goods Administration (TGA) (Hill and Tan 2006).] The AME Line 
is operated by the Australian Council of Safety and Quality in Health Care. Suspected errors and 
ADRs are reported using two different forms, therefore, reporting rates for each can be analysed 
separately. A recent case series of consumer reports to AME relating to the use of zolpidem 
indicated that that memory disturbances, hallucinations and dependence were more common 
than was previously thought (Moses and McGuire 2006). An audit of the use of the AME Line 
showed that 43% of the 3415 calls that were received in a 2-year period were prompted by media 
publicity (McGuire and Moses 2006). Females and older consumers were more likely to call the 
line. One-fifth of ADRs reported by callers were previously unrecognised and 8% were related 
to complementary medicines. In total, 105 serious ADRs and drug-induced hospitalisations that 
were reported by callers had not been reported by health professionals (McGuire and Moses 
2006).
The Canadian Adverse Drug Reaction Monitoring Program (CADRMP) at Health Canada is 
responsible for the collection and assessment of adverse reaction reports made voluntarily by 
health professionals and consumers. A public opinion survey on postmarketing surveillance, 
conducted on behalf of Health Canada, showed that consumers were more likely to believe in 
the safety of prescribed medicines than non-prescription medicines and natural health products 
(Health Canada 2003). The authors stated that reported ADRs in general (i.e. not solely ADR 
reports by consumers to CADRMP) were more likely to be reported by women, older consumers 
and by consumers with lower household incomes. Few health professionals who were surveyed 
had reported an ADR in the past year, and of those who had, they were more likely to be a 
pharmacist or a nurse compared with other health professionals. In terms of reporting ADRs, the 
majority of pharmacists (92%) stated that they knew how to make an ADR report, compared with 
63% of physicians, 44% of nurses, 19% of naturopaths and 13% of dentists (Health Canada 2003). 
Over 80% of consumers believed that there should be a legal requirement for health professionals 
to report ADRs.
In the Netherlands, consumers can report ADRs directly to the Netherlands Pharmacovigilance 
Centre (Lareb) – a government-run organisation. Of the 6305 reports received in 2005, 819 (13%) 
were submitted by patients (Lareb 2005). As a result of greater emphasis on patient reporting, the 
number of reports received from patients in 2005 was 87% higher than in the previous year. In 
addition, there is a consumer-run reporting scheme (DGV: www.meldpuntmedicijnen.nl), which 
has operated since 2004. Higher numbers of reports are made to DGV compared with Lareb, 
however, the amount and type of information recorded by the two schemes differs, therefore the 
data are not entirely comparable. During the first 10 months of the DGV scheme, 49% of reports 
were related to side effects (HAI 2005), of which 6% were severe and 30% were not mentioned on 
the patient information leaflet (PIL).
A comparison was made of the reports associated with the use of paroxetine made to the 
Netherlands Pharmacovigilance Foundation (NPF), with those reported to a telephone medicines 
information service, which enabled patients to consult a pharmacist regarding the correct use of 
medicines and problems related to their medicine use (Egberts et al. 1996). Proportionally fewer 
reports were made about paroxetine via the telephone service compared with the NPF (0.5% vs 
1.2%, respectively). However, ADRs were reported sooner [mean 229 days (95% CI, 160 to 298)] 
using the telephone service compared with the NPF. No difference was shown between the two 
reporting systems in terms of new suspected reactions (i.e. those not included in the PIL). Nine 
new ADRs were identified by both systems. Each reaction was first reported using the telephone 
system for all nine reactions, with a mean time lag of 273 days (95% CI, 89 days to 458 days) 
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between the telephone and NPF system reports. The authors concluded that consumer reporting 
might assist in the earlier detection of both known and unknown ADRs, but that data from 
consumers alone were insufficient due to their ‘crude and incomplete’ nature.
Sweden also has a non-government consumer reporting system, known as KILEN (www.kilen.
org). This system has been available since 1978. The HAI report (HAI 2005) states that the data 
collected by KILEN differ from data collected from health professionals. The KILEN system also 
provides feedback to individuals who submit reports.
Jarernsiripornkul et al. (2003) reported that the frequency of consumer reports for ADRs with 
tramadol was similar to spontaneous reports but higher than prescription event monitoring 
studies. Van den Bemt et al. (1999) compared doctor, nurse and patient reporting of ADRs for 
hospitalised patients. Patients were more likely to report ADRs with new drugs than doctors and 
nurses. Doctors reported more serious reactions. Fromme et al. (2004) compared patient reports 
using a specific instrument, with doctor reports of ADRs associated with chemotherapy. Patients 
reported more ADRs than doctors. There was little agreement between patient and doctor 
reporting. A qualitative study by Medawar and Herxheimer (2004) concluded that the quality 
and interpretation of data provided by health professionals in relation to ADRs associated with 
paroxetine was poor and might be considered inferior to that provided by consumers.
Summary The above evidence highlights the differences between ADR reports from patients and 
HCPs. These data demonstrate that patient reporting is important and complements ADR reports 
from health professionals. There is empirical evidence from non-UK studies that highlights the 
differences between patient and HCP reports; in particular, reports from the former may tend to 
be reported earlier and are more likely to include previously unidentified ADRs. The following 
programme of studies will explore the contribution that patients make to the YCS in the UK, 
compared with health professionals, as well as in comparison to existing schemes worldwide.
Objectives
Our objectives are to:
1. evaluate the pharmacovigilance impact of patient reporting to the YCS by analysing reports 
from patients and comparing these with reports from health professionals
2. report on patient experiences of the YCS by:
 – following up a cohort of patients reporting to the YCS
 – undertaking usability testing with patients of the different methods of reporting to 
the YCS
3. assess public awareness of being able to report to the YCS by conducting a national survey
4. offer recommendations for improvements to patient-reporting, based on our research 
findings and experience from other countries.
Methods
We plan to address our objectives by undertaking:
1. quantitative analyses of the pharmacovigilance impact of Yellow Card reports (objective 1)
2. qualitative analyses of the pharmacovigilance impact of Yellow Card reports (objective 1)
3. a questionnaire survey of patient experiences of reporting to the YCS, building on work 
already done by the MHRA (objectives 2 and 4)
4. telephone interviews to explore the experiences of patients who have reported to the YCS 
(objectives 2 and 4)
5. a national survey of public awareness of being able to report to the YCS (objective 3)
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6. usability testing and focus groups with patients to help identify recommendations for 
improvement in the Yellow Card reporting system (objectives 2 and 4)
7. a further review of the world literature on patient-reporting systems to help supplement 
recommendations for improvement to the YCS (objective 4).
Each element of our proposed methods is explained in detail below. At the end of this methods 
section we provide a table illustrating how our research methods will address the specific issues 
identified in the NCCRM call for research (RM05/JH30).
Study 1: pharmacovigilance impact of Yellow Card reports – 
quantitative analyses
This study will:
1. identify the characteristics of patients reporting to the YCS
2. identify the types of drug, types of suspected adverse reaction and seriousness of suspected 
reactions reported by patients
3. explore the time lag between ADR occurrence and reporting for patients and 
health professionals
4. investigate the factors associated with patient reports compared with those made by 
health professionals
5. explore the relative contribution of patient reporting to signal generation.
The Medicines and Healthcare Regulatory Authority (MHRA) already has around 5000 
Yellow Card reports generated by patients (Mick Foy, MHRA, London, May 2007, personal 
communication). Details from these reports are entered onto a computer database soon after they 
are received by the MHRA.
Our main analysis will be conducted on reports from October 2005 to September 2007 and we 
will ask the MHRA to provide us with a database of anonymised reports.
In addition, to allow us to undertake comparisons between patient reports and those from health 
professionals, we will ask the MHRA for an anonymised database of all reports submitted directly 
to the MHRA by health professionals over the same time period (there will be approximately 
30,000 of these on the basis of MHRA figures). From this database we will use the following 
samples of reports for subsequent analyses:
 ■ For the main analysis, either a random sample of Yellow Card reports from all health 
professionals (number to match the numbers of reports from patients) or (if resources allow) 
all reports from health professionals.
 ■ For comparison of individual health professional groups with patient reports, subsamples of 
reports from the following groups: (1) doctors; (2) nurses; or (3) pharmacists.
 ■ Reports relating to particular classes of drug and for different professional groups for 
qualitative comparison with patient reports (see Study 2, below).
Our main quantitative analysis will be based on a comparison between patient reports for the 
period October 2005 to September 2007 and reports from health professionals.
Research questions
With such large data sets it is likely that we will be able to detect a number of differences between 
the characteristics of patient reports and those from health professionals. We are particularly 
interested in answering the following research questions:
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 ■ What are the characteristics of patients who report ADRs through the YCS?
 ■ Are patients more or less likely than health professionals to report serious reactions?
 ■ What classes of drug are most commonly reported by patients?
 ■ Are patients more likely than health professionals to report suspected adverse reactions to 
particular classes of drug?
 ■ What categories of suspected adverse reaction are most commonly reported by patients?
 ■ Are patients more likely than health professionals to report particular categories of suspected 
adverse reactions?
 ■ Are there important differences in the time taken to report an ADR between patients and 
HCPs?
 ■ What are the outcomes of suspected side effects and do these differ across reporter groups?
Power calculation
The MHRA has provided us with data to do some illustrative power calculations and we have 
used differences in the proportions of Yellow Card reports graded as potentially ‘serious’ 
reactions as an example.
The MHRA has a system for coding Yellow Card reports as ‘serious’ on the basis of the 
information provided on the reports. These judgements are made in a consistent manner and the 
same approach is taken to reports from health professionals and patients. Approximately 59% of 
reports from health professionals are coded as potentially ‘serious’ reactions compared with 68% 
of reports from patients (Balall Naeem, MHRA, 2006, personal communication).
To illustrate the sample size of Yellow Card reports needed to identify both a 10% and a 
20% difference in the proportion of reports coded as ‘serious’ between patients and health 
professionals, we have provided relevant calculations in the table below for different levels of 
power and statistical significance. Note that all calculations assume a two-tailed test.
Therefore, with a sample size of over 5000 in each group we will have over 90% power to detect 
a 10% difference in the proportions of reports coded as potentially ‘serious’ between patient and 
health professional reports at the 5% significance level.
Data
The YCS database contains a large number of fields, including:
 ■ category of reporter (patient, patient’s representative, doctor, nurse or pharmacist)
TABLE 1 Sample size calculations to detect potential differences between health professionals and patients in the 
proportion of reports coded as potentially ‘serious’ reactions
Significance level Power (%)
Proportion of reports 
from health professionals 
coded as potentially 
‘serious’ reactions (%)
Proportion of reports 
from patients coded 
as potentially ‘serious’ 
reactions (%) No. needed in each group
0.05 80 60 70 376
0.05 80 60 50 408
0.01 80 60 70 550
0.01 80 60 50 597
0.05 90 60 70 496
0.05 90 60 50 538
0.01 90 60 70 695
0.01 90 60 50 754
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 ■ age of patients referred to on the Yellow Card
 ■ gender
 ■ mode of reporting: electronic, paper or telephone
 ■ numbers of drugs on each form reported as possibly causing side effects
 ■ name of drugs reported as possibly causing side effects
 ■ classification of suspected side effects (based on MHRA Medical Dictionary of Reaction 
Types)
 ■ free text used to describe suspected side effects
 ■ whether the drugs reported are new (‘black triangle’) drugs
 ■ date drug commenced
 ■ date that suspected side effect started
 ■ date that report sent to MHRA
 ■ reported seriousness of the suspected side effect
 ■ reported outcome of the suspected side effect.
Completeness of data fields will be checked and validation checks on fields will be undertaken to 
ensure that subsequent analyses are done on clean data sets.
We will create additional data fields for subsequent analyses. In some instances we will be able to 
automate this process, for example calculating the time taken to report suspected adverse events. 
In other instances it will be necessary to undertake a more detailed review of the information 
contained in the Yellow Card report. These detailed reviews will be undertaken by a researcher 
with experience in pharmacovigilance work. A 1 in 10 sample of records will be checked for 
accuracy of interpretation and data entry.
As a result of this processing and analysis of Yellow Card data we will create the following 
additional data fields:
 ■ British National Formulary (or ATC) chapter of drugs reported
 ■ British National Formulary (or ATC) subchapter of drugs reported
 ■ whether the drugs are available over the counter (OTC)
 ■ whether the ‘drugs’ reported are complementary therapies, such as herbal preparations
 ■ time taken to report the suspected adverse event (based on the difference between the date 
that the suspected adverse event started and the date that it was reported).
Analyses
Descriptive statistics will be used to provide an overview of reports from patients and health 
professionals. Categorical data will be described using frequencies and percentages. Continuous 
data will be explored using frequencies and histograms and described using means and 
standard deviations if normally distributed and medians and interquartile ranges (IQRs) if 
non-normally distributed.
A major component of these quantitiative analyses will be a comparison between patient reports 
and those from health professionals. On the basis of the descriptive analysis we will decide how 
best to categorise the different classes of drug and different types of suspected adverse reaction 
experienced by patients. We will use appropriate univariate analyses to identify potential 
differences between patient reports and those from health professionals in terms of:
 ■ age and gender of patients
 ■ classes of drug
 ■ use of other drugs (number, type)
 ■ time lag between event and reporting of ADR
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 ■ types of suspected adverse reaction
 ■ reported seriousness of the suspected adverse reaction (as coded by MHRA)
 ■ reported outcome of the suspected adverse reaction
 ■ number of words used to describe the suspected adverse reaction.
On the basis of the univariate analyses, multivariate logistic regression analyses will be 
undertaken to identify the most important factors associated with patient reports compared with 
those from those of health professionals.
As outlined above, the main analysis will be undertaken comparing all reports from patients with 
those from either the entire database of health professional reports, or a random sample of these 
(depending on the workload involved in processing all HCP reports). We will undertake similar 
analyses comparing patient reports with those from the different groups of health professionals 
(doctors, nurses and pharmacists).
Also, at the request of the commissioning panel for this research project we will make an 
assessment of the extent to which reports on the same incident have come through from 
both health professionals and patients. This assessment will be limited because we are using 
anonymised data. Nevertheless, we will look to see if there are matching cases in terms of age, 
gender and name of drug reported. We will then look in more detail at these cases to help 
determine whether they are likely to relate to the same incident, possibly enlisting the help of 
the MHRA in this. We will report the proportion of patient reports that also seem to have been 
reported by a health professional.
Signal detection analyses The MHRA already undertakes signal detection analysis of Yellow Card 
reports. It does not, however, differentiate between patient and HCP reports.
In our study we will attempt to answer the following questions:
 ■ Do patient reports add ‘weight’ to known signals or signals generated by reporting by 
professionals?
 ■ Do patient reports generate ‘new’ signals?
 ■ If they do, are these signals for events which are expected to be of more concerns to patients 
than HCPs?
 ■ Do patient reports generate new signals sooner?
 ■ For children, are the events reported directly by parents different from those reported by 
HCPs, acknowledging possible small numbers?
Having received feedback from Dr Lesley Wise from the MHRA we recognise that, for the 
purposes of signal detection analysis, the data set of patient reports does not have large numbers. 
Also, it may be influenced by ‘noise’ (e.g. effects of consumer groups). In an attempt to address 
the first of these issues we will combine drugs into drug class and/or combine ADRs into ADR 
groups if necessary.
Our proposed signal detection methods will involve screening the two groups of data from HCP 
reports and patient reports, and ranking the groups of drugs in terms of number of reports for 
ADRs/groups of ADRs. We then plan to do disproportionality analysis between HCP reports 
and patient reports for groups (classes) of drugs and ADRs (or groups of ADRs dependent on 
numbers). We also plan to investigate paediatric reports by parents as a subset, dependent on 
number of reports available.
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Study 2: pharmacovigilance impact of Yellow Card reports – 
qualitative analyses
This study will:
1. assess the extent to which patient reports are likely to capture new knowledge about ADRs 
(in terms of quantity and quality) and contribute to signal generation
2. explore the richness of patients’ descriptions of their suspected adverse reactions compared 
with health professional.
We plan to analyse several different categories of patient report based on information recorded in 
the database created for the quantitative analysis. We have budgeted to analyse in detail the text 
on at least 300 reports from health professionals and 300 reports from patients. We will create a 
sampling frame to ensure that the following categories of report are adequately covered:
 ■ patient reports by paper and internet (65% and 33% of reports, respectively: Balall Naeem, 
personal communication) (we will not focus on telephone reports as these make up less than 
2% of the total and the MHRA try to encourage patients making contact by telephone to fill 
in a paper-based or online report)
 ■ reports from different groups of health professional (including doctors, nurses and 
pharmacists)
 ■ new ‘black triangle’ drugs
 ■ drugs that can be purchased OTC
 ■ complementary therapies (acknowledging that reports may be less common from health 
professionals)
 ■ a number of specific drugs or drug groups thought to be of interest, based on the initial 
quantitative analysis, signal generation and discussions with MHRA and members of the 
study steering group.
After stratifying for the mode of reporting, we plan to take a random sample of reports from 
patients within each category and to match them, where possible, with randomly sampled reports 
from health professionals for the same drug (stratifying for types of health professional, and 
mode of reporting). This means that we will be comparing reports for the same drugs, whether 
patients or health professionals have done the report. The process of matching will be possible 
using the databases of patient and professional Yellow Card reports mentioned above.
We will undertake two distinct types of qualitative analysis on the reports.
The first, will be a detailed clinical assessment of the extent to which patient reports capture 
potentially new knowledge compared with reports from health professionals. This analysis will 
be informed by whether the reports capture problems not previously recorded on summaries of 
products characteristics or PIL. In addition, we will assess the extent to which useful information 
from patients might be lost when suspected adverse effects are coded by the MHRA.
The second, will be a comparative documentary analysis of the patients’ and professionals’ reports 
of suspected medication side effects. We will particularly examine:
 ■ the ways in which patients describe suspected side effects
 ■ the richness of patient reports compared with those of health professionals.
We will seek to identify the features that characterise the reports then use these to create a coding 
framework that will be applied to all of the data for comparative purposes. Specialist software will 
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be used as an aid to order and categorise the data. Each of three analysts will examine a subset 
of the data and generate tentative codes, which will then be discussed in team meetings. Once 
satisfied with the framework, it will be applied to the whole sample with inter-rater reliability 
coding checks carried out to ensure the consistency of coding. We will thus ensure that the data 
are fully explored and interpreted, and will identify similarities or differences between patient 
and health professional reports and the three methods of reporting.
Study 3: a questionnaire survey of patients reporting to the Yellow 
Card System
This study will obtain feedback from patients reporting to the YCS in order to address a number 
of questions raised in the call for research.
Yellow Cards currently submitted by patients usually contain their contact details, including 
postal address. The MHRA provides a reassurance to patients that their ‘personal details will not 
be passed to any person outside the MHRA without [their] permission’.
We propose, therefore, that the MHRA sent out questionnaires on our behalf with a covering 
letter explaining the involvement of the research team. We propose that patients return 
completed questionnaires to the Division of Primary Care at the University of Nottingham. 
We suggest putting code numbers on the questionnaires to allow the research team to inform 
the MHRA of non-responders. In turn, this will allow the MHRA to send out reminders to 
these patients.
To minimise recall bias it is important that we survey patients as soon as possible after they 
submit Yellow Cards. We propose, therefore, to ask the MHRA to send out requests on a weekly 
basis as reports come in.
During the time that we are collecting feedback from patients we believe that it would be best 
for the MHRA not to send out its electronic questionnaires to patients who have used internet 
reporting. This will help to avoid questionnaire fatigue in patients, which could compromise 
response rates.
Questionnaire design
We note that the MHRA already issues an electronic questionnaire to patients that have 
submitted electronic reports. We will ask the MHRA for reports on the results of these surveys to 
help inform our own questionnaire design, and, where possible, we will use similar questions to 
those already used by the MHRA.
The questionnaire will cover the following issues:
 ■ how patients found out about the YCS
 ■ how many times they have used the system
 ■ what method of reporting they used for their latest Yellow Card report (electronic, paper or 
telephone)
 ■ who did the report (the patient or the patient’s representative)?
 ■ how easy they found it to make a report
 ■ any difficulties encountered in making reports, including whether patients needed additional 
help in completing the electronic or paper-based forms
 ■ any suggestions for improvements in the reporting system
 ■ whether they informed a health professional about the suspected reaction
 ■ characteristics of respondents (age, gender, ethnicity and educational attainment).
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In addition, we propose asking patients if they would be willing to participate in a telephone 
interview to explore in more detail issues around reporting to the YCS. This will require 
participants to volunteer their contact information if they agree to be contacted directly by the 
researchers. At the time they are given the opportunity to volunteer their contact information, it 
will be explained that this information will be kept securely and will be used only for purposes of 
contacting patients for telephone interviews.
Power calculation
According to the MHRA, Yellow Card reports from patients are coming in at a rate of 100–200 
per month at present; approximately 66% of these are paper reports, 33% electronic and 2% 
reports by telephone.
As a primary outcome measure, we suggest looking for differences between patients making 
electronic or postal reports in the proportion rating it ‘easy to make a report’ (using a Likert 
scale). To detect a 10% difference in this measure between the two groups (say 50% in one group 
and 60% in the other) with a power of 80% and significance level of 5% we would need at least 
408 patients in each group (we have suggested similar numbers of patients in each group as 
the proportion of patients making electronic reports may be similar to the proportion making 
paper reports by the time of the survey). Therefore, we would aim to obtain a total of 1200 
questionnaire responses, which should be sufficient even if the ratio of paper to electronic reports 
remains at 2 : 1.
We propose to send out questionnaires to patients until the sample size is met. To increase the 
response rate we propose sending reminders to patients who have not replied within 3 weeks.
Given the current rate at which patients are reporting Yellow Cards (100–200 per month) and 
taking a conservative response rate of 50%, we estimate that it will take up to 18 months to 
complete the postal questionnaire.
Statistical analysis
Data from the questionnaires will be entered into a access database and a 1-in-10 sample 
will be checked for accuracy. If any problems are detected, data will be double entered for the 
whole sample.
Data will be exported into spss for statistical analysis. Categorical data, including many of the 
questionnaire responses, will be described using frequencies and percentages. Age of respondents 
will be described using means and standard deviations if normally distributed and medians and 
IQRs if non-normally distributed.
Appropriate univariate comparisons will be made between the types of Yellow Card report 
used by patients (electronic, paper and telephone) and their responses to the questionnaire. 
Multivariate analyses will adjust for potential confounding of factors such as age, gender and 
educational attainment.
Content analysis will be undertaken on free-text comments, such as those relating to potential 
improvements to the Yellow Card reporting system.
Study 4: telephone interview follow-up of patients reporting to the 
Yellow Card System
This study will enable us to obtain detailed feedback on current reporting systems and advice on 
how these could be improved.
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Study design
Semistructured telephone interviews will be conducted with patients selected from those who 
have completed questionnaires (Study 3) and given consent to being contacted by the research 
team. Telephone interviews will begin 3 months after the start of the questionnaire study to allow 
the interview guide to be informed by preliminary analysis of the first tranche of questionnaire 
data (see below). Interviews will be recorded digitally, if patients consent to this, and will be 
transcribed verbatim.
Sampling
We plan to use maximum variation sampling (Marshall 1996) in order to obtain a wide range of 
opinions. The factors that we will take into account in the sampling include age, gender, ethnicity, 
educational attainment of patients and the mode of reporting. In addition, we will take account of 
issues raised in the questionnaire, such as the perceived ease of reporting.
Issues to be explored in the interviews
The semistructured telephone interviews will be conducted within 6 weeks of the receipt of the 
questionnaire, using an interview guide developed by the research team. The development of the 
guide will be informed by the preliminary analysis of the first tranche of questionnaire data and a 
number of foreshadowed issues identified by the project team, which include:
 ■ exploration of any difficulties in making Yellow Card reports and suggestions for 
improvement in the reporting system
 ■ patients’ motivations for making the report and anticipated contribution of their report
 ■ patients’ expectations about what would happen to their report
 ■ patients’ satisfaction or dissatisfaction with making a report
 ■ patients’ willingness to report in future.
Analysis
Interview transcripts will be analysed by the qualitative researcher responsible for the data 
collection in collaboration with two academics with experience in qualitative analysis (one with a 
pharmacy background, the other with sociology background). The data will be analysed for both 
anticipated and emergent themes using the method of constant comparison. Analysis and data 
collection will proceed simultaneously and continue until ‘data saturation’ is reached to ensure 
that the widest possible range of experiences has been included. We anticipate that between 30 
and 50 interviews will be required to achieve this.
Study 5: national survey of public awareness of being able to report 
to the Yellow Card System
We plan to undertake a representative national survey of adults in England to assess public and 
patient awareness of being able to report suspected drug side effects using the YCS.
Survey design
We plan to cover the following issues in the survey:
 ■ whether respondents use any types of medicines regularly or have taken any types of 
medicines in the last year
 ■ whether respondents believe that they have experienced a side effect from a medicine (or 
complementary therapies) in the past and, if so, whether they told anyone about it
 ■ whether respondents have heard about the YCS for patient reporting of suspected side effects 
to medication
 ■ for those respondents who have experienced side effects from a medicine in the past and who 
had heard about the YCS for patient reporting:
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 – whether they made a report
 – if they did not make a report, why not?
 ■ in rank order, which of the following ways of reporting suspected side effects might be most 
convenient to respondents:
 – telephone
 – online
 – obtaining a paper form from a pharmacy (chemist) to fill in and post
 – obtaining a paper form from a general practice to fill in and post
 – telling a health professional about the problem so that they can decide whether to send 
in a Yellow Card.
In addition, we will obtain information on the characteristics of respondents.
Survey administration
It can be extremely time consuming, and prohibitively expensive, to undertake national surveys 
of patients given current research governance arrangements. Therefore, we propose adding our 
research questions to a representative national survey of the public. We recognise that there may 
be some disadvantages to this approach, including low response rate, but believe that these are 
outweighed by the ease and speed with which the survey can be completed, costs and the ability 
of national omnibus surveys to collect reasonably representative data.
We have worked successfully with British Market Research Bureau (BMRB) Omnibus Surveys 
in the past (www.bmrb.co.uk: Ealing Gateway, 26–30 Uxbridge Road, Ealing W5 2BP, UK) 
and suggest using them for the proposed study. This company does national surveys using 
face-to-face, telephone and on-line methods of collecting data. Following discussions with 
the company, it is likely that a telephone survey will provide the most representative sample 
for our study. BMRB national telephone surveys run from Friday to Sunday every weekend 
and interview a fresh sample of 2000 nationally representative adults aged 16+ years each 
time. Results can be delivered within a week depending on the complexity and length of the 
questionnaire and the analysis required. Results are presented in tabulated format in a database 
programme or spreadsheet, with the responses broken down by gender, age, socioeconomic 
status and geographical region. The organisation is also able to break any question against other 
demographic details available such as age at leaving education. To give an idea of costings, a ‘yes/
no’ question to 2000 people would cost £780 (+VAT) and a precoded question with up to five 
response options would cost £975 (+VAT). These are relatively low costs for a short national 
survey and would allow us to put more researcher time into other aspects of the YCS evaluation.
Statistical analysis
Data from the survey will be exported into spss and coded for subsequent analysis. Categorical 
data, including many of the questionnaire responses, will be described using frequencies and 
percentages. Age of respondents will be described using means and standard deviations if 
normally distributed and medians and IQRs if non-normally distributed.
Study 6: focus groups with patients followed by usability testing to 
help identify recommendations for improvement
We propose to combine two qualitative methods to prospectively examine patient experiences 
of using Yellow Cards: usability testing and focus groups. This study will enable us to identify 
patient views of the user friendliness, effectiveness and usability of different mechanisms of 
patient reporting, while also identifying potential ways in which the reporting system could 
be improved.
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Recruitment
We shall include patients who believe they may have experienced side effects from medications, 
but who have not previously filled in a Yellow Card report [over 10% of patients on new 
medications experience side effects (Gandhi et al. 2003)]. We plan to recruit through 
advertisements in local media, surgeries and pharmacies in Nottingham. We aim to recruit 
six groups of eight patients for this study. Each group will be heterogeneous in terms of age, 
occupational class, gender, educational level and prior experience of using the internet. Each 
group will take part in a focus group and usability testing in one 2- to 3-hour session and will be 
provided with refreshments and an inconvenience payment of £25.
Focus groups
After a short presentation on ADRs and the YCS by the group convenor, participants will be 
encouraged to discuss their readiness or otherwise to use the reporting system, to identify 
any barriers or facilitators to making use of the system and to identify their initial preferences 
for using one or other method of reporting. The focus groups will be recorded digitally and 
fully transcribed.
Usability testing
Usability testing will take place in the pharmacy practice laboratories at the University of 
Nottingham. These rooms are equipped with computers with access to the internet, telephone 
handsets and a stock of paper Yellow Card report forms will be provided.
Each user will be presented with a number of scenarios in which a patient experiences what 
may be an adverse reaction to taking a drug to treat or prevent a specified condition. These 
scenarios will be drawn from a ‘bank’, which relates to the range of drug groupings identified by 
patients in our analysis of Yellow Card reports. Users will be asked to decide, in relation to each 
scenario, whether, in their opinion, it would be appropriate to complete a Yellow Card. Three 
of the scenarios for which they deem reporting to be appropriate will then be selected and the 
user will be invited to complete a Yellow Card, using each of the three methods for one of the 
scenarios. The order in which they use the three methods will be randomly assigned to avoid 
learning effects creating bias. As they complete the tasks, the researchers will encourage them to 
‘talk aloud’ about the experience, any difficulties or uncertainties they encounter and any changes 
to the systems they would find helpful. The discussions will be digitally recorded. The researchers 
will review the recordings and identify relevant sections for selective transcription.
In order to complete each of these exercises successfully we will need at least eight researchers to 
observe patients and record their comments. These researchers would be drawn from our study 
team and we would also use PhD students at the University of Nottingham.
For the telephone reporting we will discuss with the MHRA whether we might use their own 
telephone reporting service for these exercises to help ensure that the experience of reporting 
is as close as possible to reality. Obviously, we would need to identify a way of ensuring that 
data from these telephone calls were not included in MHRA reports of suspected ADRs. If it is 
not possible to use the MHRA system, we would train researchers in the way in which MHRA 
record data from telephone contacts and use them to take calls from the patients undergoing 
usability testing.
Analysis of focus groups and usability testing
Data from the focus groups and usability testing will be analysed by a researcher at the University 
of Nottingham under the guidance of Professors Anderson and Murphy. Data will be analysed 
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for both anticipated and emergent themes, using the method of constant comparison. We are 
particularly interested in patients’ views on:
 ■ the user friendliness, effectiveness and usability of the different mechanisms of 
patient-reporting
 ■ the ways in which the Yellow Card reporting system could be improved for patients.
Study 7: literature review
The published literature on patient-reporting systems in other settings will be reviewed. Search 
strategies will be based on the findings of the study. For example, if a lack of awareness of the 
patient-reporting system is identified, the search will be focused on mechanisms used for 
addressing this problem in other countries. Where possible comparisons will be made with 
the study findings and recommendations made as necessary to amend the UK system. It is 
expected that the literature will be wider than traditional academic papers and will include policy 
documents, websites and other grey literature.
How our proposed methods will address the questions raised in the 
call for research
The call for research raised a number of research questions on the themes of patient experiences 
of reporting to the YCS and pharmacoepidemiological impact. There was a request for 
researchers to address these themes within a framework that will allow comparisons between the 
three methods of patient reporting and between reports from patients and different groups of 
health professionals. We believe that we will be able to address the questions raised in the call for 
research and we illustrate how we propose to do this below.
TABLE 2 Research themes highlighted in the call for research and how we plan to address these
Research theme Methodological approach Outcomes
Patient experience
Patient’s awareness of being able 
to report
1. National survey to assess public awareness of being 
able to report (Study 5)
1. Knowledge regarding the extent of public 
awareness of being able to report and 
on the relative effectiveness of different 
communication strategies
2. Knowledge regarding patients’ reactions 
to the reporting system and to the three 
methods of reporting
3. A detailed understanding of the benefits of 
and barriers to using the different methods 
of reporting and on the usability of the YCS
4. Recommendations for development of the 
scheme and for future communication 
strategies
The relative effectiveness of 
different communication strategies 
to encourage patient reporting
1. National survey to assess views of the public on 
options for reporting (Study 5)
2. A questionnaire survey of patients reporting to the 
YCS (Study 3)
3. Telephone interviews with patients who have 
reported to the YCS (Study 4)
4. Literature review (Study 7)
Patients’ reactions to the reporting 
system and ability to complete 
Yellow Cards without assistance
1. Questionnaire survey of patients reporting to the 
YCS (Study 3)
2. Telephone interviews with patients who have 
reported to the YCS (Study 4)
3. Focus groups (Study 6)
4. Usability testing (Study 6)
Patient’s views on the user 
friendliness, effectiveness and 
usability of different mechanisms of 
reporting
1. Focus groups (Study 6)
2. Usability testing (Study 6)
continued
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Scheduling of the studies and responsibilities of coapplicants
The Gantt chart, below, indicates the proposed timelines for the seven studies including initial 
planning and final dissemination. Responsibilities of the different centres involved in the research 
are highlighted.
Project management
Professor Avery will have overall responsibility for the successful management of the whole 
project. Areas of lead responsibility of other applicants are as follows:
 ■ University of Nottingham:
 – Dr Fortnum, liaison with the MHRA (together with Professor Avery) and coordination 
of the studies between the different sites
 – Professors Anderson and Murphy, qualitative work led by the University of Nottingham
 ■ Drug Safety Research Unit:
 – Professor Shakir, overall responsibility for analyses undertaken by the DSRU
 – Dr Marshall, supervision of work of researcher at DSRU
 – Dr Lorna Hazell, undertaking most of the analyses of Yellow Card reports that fall within 
the work remit of the DSRU
 ■ University of Aberdeen:
 – Professor Hannaford, overall responsibility for quantitative analyses undertaken by the 
University of Aberdeen
 – Dr Lee, finalisation of statistical analysis plans and supervision of quantitative analyses 
undertaken in Aberdeen
 – Dr Watson, supervising the literature review
Research theme Methodological approach Outcomes
Pharmacovigilance impact
A qualitative investigation of the 
‘richness’ of patients’ descriptions 
of their symptoms
1. Detailed analysis of the text on up to 300 reports 
from health professionals and 300 reports from 
patients (Study 2)
2. Detailed clinical assessment of the extent to which 
patient reports capture potentially new knowledge 
compared with reports from health professionals 
(Study 2)
3. A comparative documentary analysis of the patients’ 
and professionals’ reports of suspected medication 
side effects
1. A detailed evaluation of the extent to which 
patients’ reports are likely to capture new 
knowledge about ADRs and contribute to 
signal generation
2. A detailed exploration of the richness of 
patients’ descriptions of their symptoms 
compared with those from health 
professional
The time lag between ADR 
occurrence and reporting
1. Quantitative analysis of Yellow Card reports 
(Study 1)
Comparison of time lag for patient reports 
compared with reports from health professionals
The relative contribution of patient 
reporting to signal generation in 
terms of both quantity and quality
1. Quantitative analyses of Yellow Card reports 
(Study 1)
2. Qualitative analyses of Yellow Card reports 
(Study 2))
A detailed evaluation of the relative contribution 
of patient reporting to signal generation
Framework for the analyses
Comparisons between the 
three methods of reporting for 
patients and reports from patients 
and different groups of health 
professionals
1. Quantitative analyses of Yellow Card reports 
(Study 1)
2. Qualitative analyses of Yellow Card reports (Study 2)
1. Knowledge regarding the factors associated 
with different types of patient reports 
compared with different types of health 
professional reports
2. Evaluation of the pharmacovigilance impact 
of different types of these different types of 
report
TABLE 2 Research themes highlighted in the call for research and how we plan to address these (continued)
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 – Professor Bond, questionnaire design for studies 3 and 5 (with Professor Krska)
 ■ Liverpool John Moores University:
 – Professor Krska, questionnaire design for studies 3 and 5 (with Professor Bond).
Project management group
Our project management group will include all the applicants in this bid with the leads from each 
institution being required to ensure that a representative is available for all relevant meetings. 
Through previous collaborative projects we have experience of working effectively together using 
regular teleconferences and we would envisage having these every fortnight at the start of the 
project and then once a month for the duration of the studies. We would plan to have face-to-face 
meetings at the beginning, middle and end of the project, and to use the final meeting to evaluate 
our findings and agree on recommendations for any improvements in the Yellow Card Reporting 
System for patients.
Project advisory group
A project advisory group will be convened to provide advice during the course of the study and 
to contribute to making recommendations for improvements in the Yellow Card Reporting 
System for patients. The group will include representatives of the MHRA, the main professional 
groupings making reports, and patient representatives from both patient support groups and 
patient advocacy groups.
Justification for costings
In order to address the research questions raised by the NCCRD and to take maximum advantage 
of the wealth of information available, we have proposed an ambitious, but achievable, set of 
seven studies. We have costed these carefully and the total comes close to the upper limit of 
£250,000 that applicants were invited to bid for. We believe that our bid represents good value, 
given the range of outputs that we will be able to deliver.
We are requesting funding to employ four people to work solely on this project.
 ■ A research fellow with clinical skills in pharmacovigilance [0.6 whole-time equivalent (wte)] 
will be required at the DSRU for 18 months in the middle of the project to undertake initial 
analyses for study 1 and clinical assessment for study 2 under the supervision of Dr Marshall.
 ■ A research assistant with quantitative skills (0.6 wte) will be required in Aberdeen for the 
final 16 months of the project to undertake the quantitative analyses for studies 1, 3 and 5 
under the supervision of Dr Lee.
 ■ A research assistant with qualitative skills (0.8 wte) will be required in Nottingham for the 
final 18 months of the project to undertake analyses for studies 2 and 4 under the supervision 
of Professors Murphy and Anderson.
 ■ An administrator (0.5 wte) will be required in Nottingham for the duration of the project 
to provide general administrative support to the whole project but specifically to coordinate 
the questionnaire mailing and data entry in study 3, and patient recruitment and interview 
transcription from studies 4 and 6 under the supervision of Dr Fortnum.
In addition, the time of an information technology specialist (20 days) will be required at the 
DSRU in Southampton to ensure data quality.
Management of the project will be facilitated by regular team meetings. We propose to meet 
together face to face as a whole team on three occasions: at the beginning, middle and towards 
the end of the project. We request funds for travel to Nottingham and for an overnight stay 
of the final meeting. In addition, we propose to maintain management of the project via 
teleconferences: fortnightly for the first 6 months and monthly thereafter (n = 30).
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Study 3 will involve the printing and mailing of up to 2000 questionnaires for which we are 
requesting £2000.
The Omnibus survey for Study 5 will be costed per question and we estimate that we shall include 
five yes/no questions and two choice questions, at a cost of £6875.
Study 6 will involve recruitment of 48 people to focus groups and we propose to pay them an 
inconvenience allowance of £25 each. We shall also recruit local PhD students to supervise the 
sessions and have requested £885 to cover these costs for eight sessions.
The time of the coapplicants in Nottingham, Aberdeen and Liverpool is included at 6 days per 
person over the 2-year course of the project in accordance with full economic costing as applied 
at each university. In addition, an equivalent allowance has been requested for Professor Shakir 
and Dr Marshall at the DSRU.
Estate charges and indirect costs have been calculated on the basis of Transparent Approach to 
Costing methodology for each of the higher education institutions.
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